

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010913

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/559,225  
Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 12 August 2005 (12.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1352386

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*August 02, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/559,225**

**FILING DATE: *April 01, 2004***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/10913***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 961008047 US

22154 U.S. PTO  
605559225

INVENTOR(S)				
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)		
Steven	MAH	San Diego, California		
Andreas	BRAUN	San Diego, California		
Stefan M.	KAMMERER	San Diego, California		
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto				
TITLE OF THE INVENTION (500 characters max)				
METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF				
Direct all correspondence to: <b>CORRESPONDENCE ADDRESS</b>				
<input checked="" type="checkbox"/> Customer Number:		25225		
OR				
<input type="checkbox"/> Firm or Individual Name				
Address				
City	State	Zip		
Country	Telephone	Fax		
ENCLOSED APPLICATION PARTS (check all that apply)				
<input checked="" type="checkbox"/> Specification Number of Pages	138	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	1	<input checked="" type="checkbox"/> Other	Return Receipt Postcard	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 (4 pages)		(specify):		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT				
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		<b>FILING FEE AMOUNT (\$)</b> <div style="border: 1px solid black; padding: 5px; width: 100px; text-align: center;">80.00</div>		
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.				
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 03-1952				
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.				
<input checked="" type="checkbox"/> No		<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:		

[Page 1 of 2]

Respectfully submitted,

Date April 1, 2004

SIGNATURE

TYPED OR  
PRINTED NAME

Bruce D. Grant

REGISTRATION NO.  
(if appropriate)

47,608

TELEPHONE

(858) 720-7962

Docket Number:

524593009200


**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 961008047 US, in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated:

4/1/04

Signature:



(Deborah Wykes)

**Additional Page**

PTO/SB/16 (08-03)

Approved for use through 07/31/06. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 524593009200

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Matthew Roberts	NELSON	San Marcos, California
Rikard Henry	RENELAND	San Diego, California
Maria L.	LANGDOWN	San Diego, California



## METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

### Field of the Invention

[0001] The invention relates to genetic methods for identifying risk of osteoarthritis and treatments that specifically target such diseases.

### Background

[0002] Osteoarthritis (OA) is a chronic disease usually affecting weight-bearing synovial joints. There are approximately 20 million Americans affected by OA and it is the leading cause of disability in the United States. In addition to extensive human suffering, OA also accounts for nearly all knee replacements and more than half of all hip replacements in the United States. Despite its prevalence, OA is poorly understood and there are few treatments available besides anti-inflammatory drugs and joint replacement.

[0003] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0004] OA is characterized by the breakdown of cartilage in joints. Cartilage in joints cushions the ends of bones, and cartilage breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rheum. 32:241-246 (1989)).

### Summary

[0005] It has been discovered that certain polymorphic variations in human genomic DNA are associated with osteoarthritis. In particular, polymorphic variants in a locus containing a *APOL3* region in human genomic DNA have been associated with risk of osteoarthritis.

[0006] Thus, featured herein are methods for identifying a subject at risk of osteoarthritis and/or a risk of osteoarthritis in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in or around the loci described herein in a human nucleic acid sample. In an embodiment, two or more polymorphic variations are detected in two or more regions of which one is the *APOL3* region. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected.

[0007] Also featured are nucleic acids that include one or more polymorphic variations associated with occurrence of osteoarthritis, as well as polypeptides encoded by these nucleic acids. In addition, provided are methods for identifying candidate therapeutic molecules for treating osteoarthritis, as well as methods for treating osteoarthritis in a subject by identifying a subject at risk of osteoarthritis and treating the subject with a suitable prophylactic, treatment or therapeutic molecule.

[0008] Also provided are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *APOL3* nucleic acid, with a RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid designed from a *APOL3* nucleotide sequence. In an embodiment, the RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid is designed from a *APOL3* nucleotide sequence that includes one or more polymorphic variations associated with osteoarthritis, and in some instances, specifically interacts with such a nucleotide sequence. Further, provided are arrays of nucleic acids bound to a solid surface, in which one or more nucleic acid molecules of the array have a *APOL3* nucleotide sequence, or a fragment or substantially identical nucleic acid thereof, or a complementary nucleic acid of the foregoing. Featured also are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *APOL3* polypeptide, with an antibody that specifically binds to the polypeptide. In an embodiment, the antibody specifically binds to an epitope in the polypeptide that includes a non-synonymous amino acid modification associated with osteoarthritis (e.g., results in an amino acid substitution in the encoded polypeptide associated with osteoarthritis).

#### Brief Description of the Drawings

[0009] Figure 1 shows proximal SNPs in a *APOL3* region in genomic DNA. The position of each SNP in the chromosome is shown on the x-axis and the y-axis provides the negative logarithm of the p-value comparing the estimated allele to that of the control group. Also shown in the figure are exons and introns of the gene region in the approximate chromosomal positions.

#### Detailed Description

[0010] It has been discovered that a polymorphic variant in a locus containing a *APOL3* region is associated with occurrence of osteoarthritis in subjects. Thus, detecting genetic determinants associated with an increased risk of osteoarthritis occurrence can lead to early identification of a predisposition to osteoarthritis and early prescription of preventative measures. Also, associating a *APOL3* polymorphic variant with osteoarthritis has provided new targets for screening molecules useful in treatments of osteoarthritis.

### Osteoarthritis and Sample Selection

[0011] Osteoarthritis (OA), or degenerative joint disease, is one of the oldest and most common types of arthritis. It is characterized by the breakdown of the joint's cartilage. Cartilage is the part of the joint that cushions the ends of bones, and its breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rheum. 32:241-246 (1989)).

[0012] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0013] Osteoarthritis affects an estimated 20.7 million Americans, mostly after age 45, with women more commonly affected than men. Physicians make a diagnosis of OA based on a physical exam and history of symptoms. X-rays are used to confirm diagnosis. Most people over 60 reflect the disease on X-ray, and about one-third have actual symptoms.

[0014] There are many factors that can cause OA. Obesity may lead to osteoarthritis of the knees. In addition, people with joint injuries due to sports, work-related activity or accidents may be at increased risk of developing OA.

[0015] Genetics has a role in the development of OA. Some people may be born with defective cartilage or with slight defects in the way that joints fit together. As a person ages, these defects may cause early cartilage breakdown in the joint or the inability to repair damaged or deteriorated cartilage in the joint.

[0016] Inclusion or exclusion of samples for an osteoarthritis pool may be based upon the following criteria: ethnicity (e.g., samples derived from an individual characterized as Caucasian); parental ethnicity (e.g., samples derived from an individual of British paternal and maternal descent); relevant phenotype information for the individual (e.g., case samples derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic). Control samples may be selected based on relevant phenotype information for the individual (e.g., derived from individuals free of OA at several sites (knee, hand, hip etc)); and no family history of OA and/or rheumatoid arthritis. Additional phenotype information collected for both cases and controls may include age of the individual, gender, family history of OA, diagnosis with osteoarthritis (joint location of OA, date of primary diagnosis, age of individual as of primary diagnosis), knee history (current symptoms, any major knee injury, meniscectomy, knee replacement surgery, age of surgery), HRT history, osteoporosis diagnosis.

[0017] Based in part upon selection criteria set forth above, individuals having osteoarthritis can be selected for genetic studies. Also, individuals having no history of osteoarthritis often are selected for genetic studies, as described hereafter.

Polymorphic Variants Associated with Osteoarthritis

[0018] A genetic analysis provided herein linked osteoarthritis with polymorphic variant nucleic acid sequences in the human genome. As used herein, the term “polymorphic site” refers to a region in a nucleic acid at which two or more alternative nucleotide sequences are observed in a significant number of nucleic acid samples from a population of individuals. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. A polymorphic site is often one nucleotide in length, which is referred to herein as a “single nucleotide polymorphism” or a “SNP.”

[0019] Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a “polymorphic variant” or “nucleic acid variant.” Where two polymorphic variants exist, for example, the polymorphic variant represented in a minority of samples from a population is sometimes referred to as a “minor allele” and the polymorphic variant that is more prevalently represented is sometimes referred to as a “major allele.” Many organisms possess a copy of each chromosome (*e.g.*, humans), and those individuals who possess two major alleles or two minor alleles are often referred to as being “homozygous” with respect to the polymorphism, and those individuals who possess one major allele and one minor allele are normally referred to as being “heterozygous” with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

[0020] In genetic analysis that associate polymorphic variants with osteoarthritis, samples from individuals having osteoarthritis and individuals not having osteoarthritis often are allelotyped and/or genotyped. The term “allelotype” as used herein refers to a process for determining the allele frequency for a polymorphic variant in pooled DNA samples from cases and controls. By pooling DNA from each group, an allele frequency for each SNP in each group is calculated. These allele frequencies are then compared to one another. The term “genotyped” as used herein refers to a process for determining a genotype of one or more individuals, where a “genotype” is a representation of one or more polymorphic variants in a population.

**[0021]** A genotype or polymorphic variant may be expressed in terms of a “haplotype,” which as used herein refers to two or more polymorphic variants occurring within genomic DNA in a group of individuals within a population. For example, two SNPs may exist within a gene where each SNP position includes a cytosine variation and an adenine variation. Certain individuals in a population may carry one allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

**[0022]** As used herein, the term “phenotype” refers to a trait which can be compared between individuals, such as presence or absence of a condition, a visually observable difference in appearance between individuals, metabolic variations, physiological variations, variations in the function of biological molecules, and the like. An example of a phenotype is occurrence of osteoarthritis.

**[0023]** Researchers sometimes report a polymorphic variant in a database without determining whether the variant is represented in a significant fraction of a population. Because a subset of these reported polymorphic variants are not represented in a statistically significant portion of the population, some of them are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined. Methods for detecting a polymorphic variant in a population are described herein, specifically in Example 2. A polymorphic variant is statistically significant and often biologically relevant if it is represented in 5% or more of a population, sometimes 10% or more, 15% or more, or 20% or more of a population, and often 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more of a population.

**[0024]** A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5′ untranslated region (UTR), a 3′ UTR, and in DNA (*e.g.*, genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (*e.g.*, mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

**[0025]** It was determined that polymorphic variations associated with an increased risk of osteoarthritis existed in a *APOL3* region in SEQ ID NO: 1. In certain embodiments, a polymorphic variant at position rs132659 in the human genome was associated with an increased risk of osteoarthritis, and in a specific embodiment, a cytosine at position rs132659 was associated with an increased risk of osteoarthritis.

**[0026]** Polymorphic variants in and around the *APOL3* locus were tested for association with osteoarthritis. These include polymorphic variants at positions in SEQ ID NO: 1 selected from the group

consisting of 201, 425, 1095, 2201, 7879, 8395, 8461, 9503, 10304, 10695, 16300, 16444, 17591, 17988, 19116, 19358, 20300, 20669, 20891, 21451, 21978, 22785, 24248, 24770, 24844, 25066, 25096, 25309, 25344, 25529, 25537, 25554, 27963, 28134, 28356, 29648, 29986, 30217, 30267, 30315, 30585, 30724, 30897, 30931, 31080, 31246, 31373, 31463, 31467, 32188, 32288, 32520, 32594, 32657, 32677, 32764, 32784, 32830, 32872, 33121, 33348, 33952, 34184, 34361, 35026, 35192, 35600, 36033, 36289, 38869, 39629, 40530, 41621, 42379, 42802, 42865, 43644, 45051, 45828, 45829, 46257, 47286, 47427, 47963, 48013, 48229, 48282, 48376, 48404, 49900, 52699, 52897, 53414, 53487, 54112, 55492, 59766, 60307, 60701, 60952, 61401, 62379, 62870, 62879, 63499, 64284, 64408, 64760, 65230, 66127, , 6634, 66686, 66694, 67113, 67257, 67403, 67609, 68418, 68610, 69629, 70024, 70848, 71428, 71553, 71633, 71768, 71769, 73039, 73325, 73412, 73547, 73769, 73806, 74467, 74472, 74473, 74482, 74494, 74592, 74670, 74672, 74714, 74723, 74749, 74861, 74892, 74893, 75176, 75705, 75989, 76027, 77949, 77974, 78167, 78310, 78415, 78575, 78590, 78709, 78875, 79864, 81316, 81320, 81409, 81737, 81843, 82102, 82833, 83461, 83624, 83660, 83701, 83708, 83782, 85707, 85717, 86486, 86833, 87115, 87234, 87479, 87561, 87604, 87674, 87958, 87992, 88019, 88074, 88079, 88115, 88118, 88120, 88135, 88142, 88143, 88149, 88340, 88344, 88512, 88521, 88650, 88827, 89230, 89236, 90754, 90984, 91110, 92026, 92954, 93375, 93794, 94937, 95068, 96188, 97092 and 98812. Polymorphic variants at the following positions in SEQ ID NO: 1 in particular were associated with an increased risk of osteoarthritis: 20300, 46257, 87958, 89236, 30267, 32657, 36289, 38869, 45051, 54112, 60307, 63499, 20891, 52699, 71768, with specific embodiments directed to position 46257. In particular, the following polymorphic variants in SEQ ID NO: 1 were associated with risk of osteoarthritis: an adenine at position 20300, a thymine at position 46257, an adenine at position 89236, a guanine at position 30267, an adenine at position 32657, a cytosine at position 36289, a guanine at position 38869, a thymine at position 45051, a guanine at position 54112, an adenine at position 60307, a thymine at position 63499, a guanine at position 20891, a guanine at position 52699, and a cytosine at position 71768.

**[0027]** Based in part upon analyses summarized in Figure 1, a region with significant association has been identified in a locus associated with osteoarthritis. Any polymorphic variants associated with osteoarthritis in a region of significant association can be utilized for embodiments described herein. For example, polymorphic variants in a region approximately 5000 nucleotides in length and spanning chromosome positions 34828750 and 34833750 in a APOL3 locus have significant association (chromosome positions are within NCBI's Genome build 34)

#### Additional Polymorphic Variants Associated with Osteoarthritis

**[0028]** Also provided is a method for identifying polymorphic variants proximal to an incident, founder polymorphic variant associated with osteoarthritis. Thus, featured herein are methods for identifying a polymorphic variation associated with osteoarthritis that is proximal to an incident

polymorphic variation associated with osteoarthritis, which comprises identifying a polymorphic variant proximal to the incident polymorphic variant associated with osteoarthritis, where the incident polymorphic variant is in a *APOL3* nucleotide sequence. The nucleotide sequence often comprises a polynucleotide sequence selected from the group consisting of (a) a polynucleotide sequence of SEQ ID NO: 1-7; (b) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1-7; and (c) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7 or a polynucleotide sequence 90% or more identical to the polynucleotide sequence of SEQ ID NO: 1-7. The presence or absence of an association of the proximal polymorphic variant with osteoarthritis then is determined using a known association method, such as a method described in the Examples hereafter. In an embodiment, the incident polymorphic variant is a polymorphic variant associated with osteoarthritis described herein. In another embodiment, the proximal polymorphic variant identified sometimes is a publicly disclosed polymorphic variant, which for example, sometimes is published in a publicly available database. In other embodiments, the polymorphic variant identified is not publicly disclosed and is discovered using a known method, including, but not limited to, sequencing a region surrounding the incident polymorphic variant in a group of nucleic samples. Thus, multiple polymorphic variants proximal to an incident polymorphic variant are associated with osteoarthritis using this method.

**[0029]** The proximal polymorphic variant often is identified in a region surrounding the incident polymorphic variant. In certain embodiments, this surrounding region is about 50 kb flanking the first polymorphic variant (*e.g.* about 50 kb 5' of the first polymorphic variant and about 50 kb 3' of the first polymorphic variant), and the region sometimes is composed of shorter flanking sequences, such as flanking sequences of about 40 kb, about 30 kb, about 25 kb, about 20 kb, about 15 kb, about 10 kb, about 7 kb, about 5 kb, or about 2 kb 5' and 3' of the incident polymorphic variant. In other embodiments, the region is composed of longer flanking sequences, such as flanking sequences of about 55 kb, about 60 kb, about 65 kb, about 70 kb, about 75 kb, about 80 kb, about 85 kb, about 90 kb, about 95 kb, or about 100 kb 5' and 3' of the incident polymorphic variant.

**[0030]** In certain embodiments, polymorphic variants associated with osteoarthritis are identified iteratively. For example, a first proximal polymorphic variant is associated with osteoarthritis using the methods described above and then another polymorphic variant proximal to the first proximal polymorphic variant is identified (*e.g.*, publicly disclosed or discovered) and the presence or absence of an association of one or more other polymorphic variants proximal to the first proximal polymorphic variant with osteoarthritis is determined.

**[0031]** The methods described herein are useful for identifying or discovering additional polymorphic variants that may be used to further characterize a gene, region or loci associated with a

condition, a disease (*e.g.*, osteoarthritis), or a disorder. For example, allelotyping or genotyping data from the additional polymorphic variants may be used to identify a functional mutation or a region of linkage disequilibrium. In certain embodiments, polymorphic variants identified or discovered within a region comprising the first polymorphic variant associated with osteoarthritis are genotyped using the genetic methods and sample selection techniques described herein, and it can be determined whether those polymorphic variants are in linkage disequilibrium with the first polymorphic variant. The size of the region in linkage disequilibrium with the first polymorphic variant also can be assessed using these genotyping methods. Thus, provided herein are methods for determining whether a polymorphic variant is in linkage disequilibrium with a first polymorphic variant associated with osteoarthritis, and such information can be used in prognosis/diagnosis methods described herein.

#### Isolated Nucleic Acids

**[0032]** Featured herein are isolated *APOL3* nucleic acid variants depicted in SEQ ID NO: 1-7, and substantially identical nucleic acids thereof. A nucleic acid variant may be represented on one or both strands in a double-stranded nucleic acid or on one chromosomal complement (heterozygous) or both chromosomal complements (homozygous).

**[0033]** As used herein, the term “nucleic acid” includes DNA molecules (*e.g.*, a complementary DNA (cDNA) and genomic DNA (gDNA)) and RNA molecules (*e.g.*, mRNA, rRNA, siRNA and tRNA) and analogs of DNA or RNA, for example, by use of nucleotide analogs. The nucleic acid molecule can be single-stranded and it is often double-stranded. The term “isolated or purified nucleic acid” refers to nucleic acids that are separated from other nucleic acids present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term “isolated” includes nucleic acids which are separated from the chromosome with which the genomic DNA is naturally associated. An “isolated” nucleic acid is often free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term “gene” refers to a nucleotide sequence that encodes a polypeptide.

**[0034]** Also included herein are nucleic acid fragments. These fragments often have a nucleotide sequence identical to a nucleotide sequence of SEQ ID NO: 1-7, a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence that is complementary to



the foregoing. The nucleic acid fragment may be identical, substantially identical or homologous to a nucleotide sequence in an exon or an intron in a nucleotide sequence of SEQ ID NO: 1-7, and may encode a domain or part of a domain of a polypeptide. Sometimes, the fragment will comprises one or more of the polymorphic variations described herein as being associated with osteoarthritis. The nucleic acid fragment is often 50, 100, or 200 or fewer base pairs in length, and is sometimes about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 3000, 4000, 5000, 10000, 15000, or 20000 base pairs in length. A nucleic acid fragment that is complementary to a nucleotide sequence identical or substantially identical to a nucleotide sequence in SEQ ID NO: 1-7 and hybridizes to such a nucleotide sequence under stringent conditions is often referred to as a “probe.” Nucleic acid fragments often include one or more polymorphic sites, or sometimes have an end that is adjacent to a polymorphic site as described hereafter.

**[0035]** An example of a nucleic acid fragment is an oligonucleotide. As used herein, the term “oligonucleotide” refers to a nucleic acid comprising about 8 to about 50 covalently linked nucleotides, often comprising from about 8 to about 35 nucleotides, and more often from about 10 to about 25 nucleotides. The backbone and nucleotides within an oligonucleotide may be the same as those of naturally occurring nucleic acids, or analogs or derivatives of naturally occurring nucleic acids, provided that oligonucleotides having such analogs or derivatives retain the ability to hybridize specifically to a nucleic acid comprising a targeted polymorphism. Oligonucleotides described herein may be used as hybridization probes or as components of prognostic or diagnostic assays, for example, as described herein.

**[0036]** Oligonucleotides are typically synthesized using standard methods and equipment, such as the ABI™3900 High Throughput DNA Synthesizer and the EXPEDITE™ 8909 Nucleic Acid Synthesizer, both of which are available from Applied Biosystems (Foster City, CA). Analogs and derivatives are exemplified in U.S. Pat. Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WO 00/56746; WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above and in U.S. Pat. Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; in WO 00/75372; and in related publications.

**[0037]** Oligonucleotides may also be linked to a second moiety. The second moiety may be an additional nucleotide sequence such as a tail sequence (*e.g.*, a polyadenosine tail), an adapter sequence (*e.g.*, phage M13 universal tail sequence), and others. Alternatively, the second moiety may be a non-nucleotide moiety such as a moiety which facilitates linkage to a solid support or a label to facilitate detection of the oligonucleotide. Such labels include, without limitation, a radioactive label, a

fluorescent label, a chemiluminescent label, a paramagnetic label, and the like. The second moiety may be attached to any position of the oligonucleotide, provided the oligonucleotide can hybridize to the nucleic acid comprising the polymorphism.

#### Uses for Nucleic Acid Sequence

[0038] Nucleic acid coding sequences may be used for diagnostic purposes for detection and control of polypeptide expression. Also, included herein are oligonucleotide sequences such as antisense RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to inhibit translation of a polypeptide. Antisense techniques and RNA interference techniques are known in the art and are described herein.

[0039] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ribozyme molecules may be engineered that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences corresponding to or complementary to *APOL3* nucleotide sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0040] Antisense RNA and DNA molecules, siRNA and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0041] DNA encoding a polypeptide also may have a number of uses for the diagnosis of diseases, including osteoarthritis, resulting from aberrant expression of a target gene described herein. For example, the nucleic acid sequence may be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (*e.g.*, Southern or Northern blot analysis, in situ hybridization assays).

[0042] In addition, the expression of a polypeptide during embryonic development may also be determined using nucleic acid encoding the polypeptide. As addressed, *infra*, production of functionally impaired polypeptide is the cause of various disease states, such as osteoarthritis. *In situ* hybridizations using polypeptide as a probe may be employed to predict problems related to osteoarthritis. Further, as indicated, *infra*, administration of human active polypeptide, recombinantly produced as described herein, may be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with dysfunctional polypeptide.

#### Expression Vectors, Host Cells, and Genetically Engineered Cells

[0043] Provided herein are nucleic acid vectors, often expression vectors, which contain a *APOL3* nucleotide sequence, or a substantially identical sequence thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

[0044] A vector can include a *APOL3* nucleotide sequence in a form suitable for expression of an encoded target polypeptide or target nucleic acid in a host cell. A “target polypeptide” is a polypeptide encoded by a *APOL3* nucleotide sequence, or a substantially identical nucleotide sequence thereof. The recombinant expression vector typically includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term “regulatory sequence” includes promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. Expression vectors can be introduced into host cells to produce target polypeptides, including fusion polypeptides.

[0045] Recombinant expression vectors can be designed for expression of target polypeptides in prokaryotic or eukaryotic cells. For example, target polypeptides can be expressed in *E. coli*, insect cells (*e.g.*, using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

[0046] Expression of polypeptides in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion

polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant polypeptide; 2) to increase the solubility of the recombinant polypeptide; and 3) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith & Johnson, *Gene* 67: 31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0047] Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for target polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector is used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (*e.g.*, six (6) weeks).

[0048] Expressing the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide is often used to maximize recombinant polypeptide expression (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California 185: 119-128 (1990)). Another strategy is to alter the nucleotide sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, *Nucleic Acids Res.* 20: 2111-2118 (1992)). Such alteration of nucleotide sequences can be carried out by standard DNA synthesis techniques.

[0049] When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors are often capable of directing expression of the nucleic acid in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include an albumin promoter (liver-specific; Pinkert *et al.*, *Genes Dev.* 1: 268-277 (1987)), lymphoid-specific promoters (Calame & Eaton, *Adv. Immunol.* 43: 235-275 (1988)), promoters of T cell receptors (Winoto & Baltimore, *EMBO J.* 8: 729-733 (1989)) promoters of immunoglobulins (Banerji *et al.*, *Cell* 33: 729-740 (1983); Queen & Baltimore, *Cell* 33: 741-748 (1983)), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne & Ruddle, *Proc. Natl. Acad. Sci. USA* 86: 5473-5477 (1989)), pancreas-specific promoters (Edlund *et al.*, *Science* 230: 912-916 (1985)), and mammary

gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel & Gruss, *Science* 249: 374-379 (1990)) and the  $\alpha$ -fetopolypeptide promoter (Campes & Tilghman, *Genes Dev.* 3: 537-546 (1989)).

**[0050]** A *APOL3* nucleic acid also may be cloned into an expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a *APOL3* nucleic acid cloned in the antisense orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) (1986).

**[0051]** Also provided herein are host cells that include a *APOL3* nucleotide sequence within a recombinant expression vector or a fragment of such a nucleotide sequence which facilitate homologous recombination into a specific site of the host cell genome. The terms “host cell” and “recombinant host cell” are used interchangeably herein. Such terms refer not only to the particular subject cell but rather also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a target polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

**[0052]** Vectors can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DEAE-dextran-mediated transfection, lipofection, or electroporation.

**[0053]** A host cell provided herein can be used to produce (*i.e.*, express) a target polypeptide or a substantially identical polypeptide thereof. Accordingly, further provided are methods for producing a target polypeptide using host cells described herein. In one embodiment, the method includes culturing host cells into which a recombinant expression vector encoding a target polypeptide has been introduced in a suitable medium such that a target polypeptide is produced. In another embodiment, the method further includes isolating a target polypeptide from the medium or the host cell.

**[0054]** Also provided are cells or purified preparations of cells which include a *APOL3* transgene, or which otherwise misexpress target polypeptide. Cell preparations can consist of human or non-human

cells, *e.g.*, rodent cells, *e.g.*, mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a *APOL3* transgene (*e.g.*, a heterologous form of a *APOL3* gene, such as a human gene expressed in non-human cells). The transgene can be misexpressed, *e.g.*, overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpress an endogenous target polypeptide (*e.g.*, expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or mis-expressed alleles or for use in drug screening. Also provided are human cells (*e.g.*, a hematopoietic stem cells) transfected with a *APOL3* nucleic acid.

[0055] Also provided are cells or a purified preparation thereof (*e.g.*, human cells) in which an endogenous *APOL3* nucleic acid is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene. The expression characteristics of an endogenous gene within a cell (*e.g.*, a cell line or microorganism) can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (*e.g.*, a gene which is “transcriptionally silent,” not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, *e.g.*, Chappel, US 5,272,071; WO 91/06667, published on May 16, 1991.

#### Transgenic Animals

[0056] Non-human transgenic animals that express a heterologous target polypeptide (*e.g.*, expressed from a *APOL3* nucleic acid or substantially identical sequence thereof) can be generated. Such animals are useful for studying the function and/or activity of a target polypeptide and for identifying and/or evaluating modulators of the activity of *APOL3* nucleic acids and encoded polypeptides. As used herein, a “transgenic animal” is a non-human animal such as a mammal (*e.g.*, a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (*e.g.*, a chicken or a turkey), an amphibian (*e.g.*, a frog, salamander, or newt), or an insect (*e.g.*, *Drosophila melanogaster*), in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (*e.g.*, a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, and other transgenes can reduce expression (*e.g.*, a knockout). Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a *APOL3* nucleic acid has been altered by homologous recombination between the endogenous gene and an

exogenous DNA molecule introduced into a cell of the animal (*e.g.*, an embryonic cell of the animal) prior to development of the animal.

[0057] Intronic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a *APOL3* nucleotide sequence to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of a *APOL3* nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a *APOL3* nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

[0058] Target polypeptides can be expressed in transgenic animals or plants by introducing, for example, a *APOL3* nucleic acid into the genome of an animal that encodes the target polypeptide. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, *e.g.*, a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

#### Target Polypeptides

[0059] Also featured herein are isolated target polypeptides, which are encoded by a *APOL3* nucleotide sequence (*e.g.*, SEQ ID NO: 1-7), or a substantially identical nucleotide sequence thereof. Examples of *APOL3* polypeptides are set forth in SEQ ID NO: 8-10. The term “polypeptide” as used herein includes proteins and peptides. An “isolated” or “purified” polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, the language “substantially free” means preparation of a target polypeptide having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-target polypeptide (also referred to herein as a “contaminating protein”), or of chemical precursors or non-target chemicals. When the target polypeptide or a biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, specifically, where culture medium represents less than about 20%, sometimes less than about 10%, and often less than about 5% of the volume of the polypeptide preparation. Isolated or purified target polypeptide preparations are sometimes 0.01 milligrams or more or 0.1 milligrams or more, and often 1.0 milligrams or more and 10 milligrams or more in dry weight. In certain embodiments, the *APOL3* polypeptide or polypeptide fragment has *APOL3* biological activity, for example, apolipoprotein activity.

[0060] Further included herein are target polypeptide fragments. The polypeptide fragment may be a domain or part of a domain of a target polypeptide. The polypeptide fragment may have increased,

decreased or unexpected biological activity. The polypeptide fragment is often 50 or fewer, 100 or fewer, or 200 or fewer amino acids in length, and is sometimes 300, 400, 500, 600, 700, or 900 or fewer amino acids in length. The polypeptide fragment sometimes is amino acids 90-396; amino acids 19-325; or amino acids 1-196.

**[0061]** Substantially identical target polypeptides may depart from the amino acid sequences of target polypeptides in different manners. For example, conservative amino acid modifications may be introduced at one or more positions in the amino acid sequences of target polypeptides. A “conservative amino acid substitution” is one in which the amino acid is replaced by another amino acid having a similar structure and/or chemical function. Families of amino acid residues having similar structures and functions are well known. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Also, essential and non-essential amino acids may be replaced. A “non-essential” amino acid is one that can be altered without abolishing or substantially altering the biological function of a target polypeptide, whereas altering an “essential” amino acid abolishes or substantially alters the biological function of a target polypeptide. Amino acids that are conserved among target polypeptides are typically essential amino acids. In certain embodiments, the polypeptide includes one or more non-synonymous polymorphic variants associated with osteoarthritis.

**[0062]** Also, target polypeptides may exist as chimeric or fusion polypeptides. As used herein, a target “chimeric polypeptide” or target “fusion polypeptide” includes a target polypeptide linked to a non-target polypeptide. A “non-target polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to the target polypeptide, which includes, for example, a polypeptide that is different from the target polypeptide and derived from the same or a different organism. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire target polypeptide or a fragment thereof. The non-target polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

**[0063]** Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide), and a nucleotide sequence in SEQ ID NO: 1-7, or a substantially identical nucleotide sequence thereof, can be cloned into an



expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (*e.g.*, an IgG constant region or human serum albumin).

**[0064]** Target polypeptides can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Administration of these target polypeptides can be used to affect the bioavailability of a substrate of the target polypeptide and may effectively increase target polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a target polypeptide; (ii) mis-regulation of the gene encoding the target polypeptide; and (iii) aberrant post-translational modification of a target polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify target polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a target polypeptide with a substrate.

**[0065]** In addition, polypeptides can be chemically synthesized using techniques known in the art (See, *e.g.*, Creighton, 1983 Proteins. New York, N.Y.: W. H. Freeman and Company; and Hunkapiller et al., (1984) Nature July 12 -18;310(5973):105-11). For example, a relative short fragment can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

**[0066]** Polypeptides and polypeptide fragments sometimes are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; and the like. Additional post-translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical

moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

**[0067]** Also provided are chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (*see e.g.*, U.S. Pat. No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

**[0068]** The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term “about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (*e.g.*, the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

**[0069]** The polymers should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (*e.g.*, EP 0 401 384 (coupling PEG to G-CSF) and Malik et al. (1992) *Exp Hematol.* September;20(8):1028-35 (pegylation of GM-CSF using tresyl chloride)). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

**[0070]** Proteins can be chemically modified at the N-terminus. Using polyethylene glycol as an illustration of such a composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (*i.e.*, separating this moiety from other monopegylated moieties if

necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

#### Substantially Identical Nucleic Acids and Polypeptides

**[0071]** Nucleotide sequences and polypeptide sequences that are substantially identical to a *APOL3* nucleotide sequence and the target polypeptide sequences encoded by those nucleotide sequences, respectively, are included herein. The term “substantially identical” as used herein refers to two or more nucleic acids or polypeptides sharing one or more identical nucleotide sequences or polypeptide sequences, respectively. Included are nucleotide sequences or polypeptide sequences that are 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (each often within a 1%, 2%, 3% or 4% variability) identical to a *APOL3* nucleotide sequence or the encoded target polypeptide amino acid sequences. One test for determining whether two nucleic acids are substantially identical is to determine the percent of identical nucleotide sequences or polypeptide sequences shared between the nucleic acids or polypeptides.

**[0072]** Calculations of sequence identity are often performed as follows. Sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is sometimes 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70% or more, 80% or more, 90% or more, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or polypeptide positions, respectively, are then compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the nucleotides or amino acids are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

**[0073]** Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS* 4: 11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Also, percent identity between two amino acid

sequences can be determined using the Needleman & Wunsch, *J. Mol. Biol.* 48: 444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at the http address [www.gcg.com](http://www.gcg.com)), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http address [www.gcg.com](http://www.gcg.com)), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blossum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0074] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As use herein, the term "stringent conditions" refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. , 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. More often, stringency conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0075] An example of a substantially identical nucleotide sequence to a nucleotide sequence in SEQ ID NO: 1-7 is one that has a different nucleotide sequence but still encodes the same polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO: 1-7. Another example is a nucleotide sequence that encodes a polypeptide having a polypeptide sequence that is more than 70% or more identical to, sometimes more than 75% or more, 80% or more, or 85% or more identical to, and often more than 90% or more and 95% or more identical to a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7.

[0076] Nucleotide sequences in SEQ ID NO: 1-7 and amino acid sequences of encoded polypeptides can be used as "query sequences" to perform a search against public databases to identify other family members or related sequences, for example. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.*, *J. Mol. Biol.* 215: 403-10 (1990). BLAST nucleotide

searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleotide sequences in SEQ ID NO: 1-7. BLAST polypeptide searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to polypeptides encoded by the nucleotide sequences of SEQ ID NO: 1-7. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, *Nucleic Acids Res.* 25(17): 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see* the http address [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).

**[0077]** A nucleic acid that is substantially identical to a nucleotide sequence in SEQ ID NO: 1-7 may include polymorphic sites at positions equivalent to those described herein when the sequences are aligned. For example, using the alignment procedures described herein, SNPs in a sequence substantially identical to a sequence in SEQ ID NO: 1-7 can be identified at nucleotide positions that match (*i.e.*, align) with nucleotides at SNP positions in each nucleotide sequence in SEQ ID NO: 1-7. Also, where a polymorphic variation results in an insertion or deletion, insertion or deletion of a nucleotide sequence from a reference sequence can change the relative positions of other polymorphic sites in the nucleotide sequence.

**[0078]** Substantially identical nucleotide and polypeptide sequences include those that are naturally occurring, such as allelic variants (same locus), splice variants, homologs (different locus), and orthologs (different organism) or can be non-naturally occurring. Non-naturally occurring variants can be generated by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product). Orthologs, homologs, allelic variants, and splice variants can be identified using methods known in the art. These variants normally comprise a nucleotide sequence encoding a polypeptide that is 50% or more, about 55% or more, often about 70-75% or more or about 80-85% or more, and sometimes about 90-95% or more identical to the amino acid sequences of target polypeptides or a fragment thereof. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions to a nucleotide sequence in SEQ ID NO: 1 or a fragment of this sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of a nucleotide sequence in SEQ ID NO: 1-7 can further be identified by mapping the sequence to the same chromosome or locus as the nucleotide sequence in SEQ ID NO: 1-7.

**[0079]** Also, substantially identical nucleotide sequences may include codons that are altered with respect to the naturally occurring sequence for enhancing expression of a target polypeptide in a particular expression system. For example, the nucleic acid can be one in which one or more codons are

altered, and often 10% or more or 20% or more of the codons are altered for optimized expression in bacteria (*e.g.*, *E. coli.*), yeast (*e.g.*, *S. cerevisiae*), human (*e.g.*, 293 cells), insect, or rodent (*e.g.*, hamster) cells.

#### Methods for Identifying Risk of osteoarthritis

[0080] Methods for prognosing and diagnosing osteoarthritis are included herein. These methods include detecting the presence or absence of one or more polymorphic variations in a nucleotide sequence associated with osteoarthritis, such as variants in or around the loci set forth herein, or a substantially identical sequence thereof, in a sample from a subject, where the presence of a polymorphic variant described herein is indicative of a risk of osteoarthritis. Determining a risk of osteoarthritis sometimes refers to determining whether an individual is at an increased risk of osteoarthritis (*e.g.*, intermediate risk or higher risk).

[0081] Thus, featured herein is a method for identifying a subject who is at risk of osteoarthritis, which comprises detecting an aberration associated with osteoarthritis in a nucleic acid sample from the subject. An embodiment is a method for detecting a risk of osteoarthritis in a subject, which comprises detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-7; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising the polymorphic site; whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject. In certain embodiments, polymorphic variants at the positions described herein are detected for determining a risk of osteoarthritis, and polymorphic variants at positions in linkage disequilibrium with these positions are detected for determining a risk of osteoarthritis. As used herein, "SEQ ID NO: 1-7" refers to individual sequences in SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, each sequence being separately applicable to embodiments described herein.

[0082] Risk of osteoarthritis sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. Risk often is based upon the presence or absence of one or more polymorphic variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (*see, e.g.*, Agresti, *Categorical Data Analysis*, 2nd Ed. 2002. Wiley). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic

method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations.

**[0083]** In certain embodiments, determining the presence of a combination of two or more polymorphic variants associated with osteoarthritis in one or more genetic loci (e.g., one or more genes) of the sample is determined to identify, quantify and/or estimate, risk of osteoarthritis. The risk often is the probability of having or developing osteoarthritis. The risk sometimes is expressed as a relative risk with respect to a population average risk of osteoarthritis, and sometimes is expressed as a relative risk with respect to the lowest risk group. Such relative risk assessments often are based upon penetrance values determined by statistical methods, and are particularly useful to clinicians and insurance companies for assessing risk of osteoarthritis (e.g., a clinician can target appropriate detection, prevention and therapeutic regimens to a patient after determining the patient's risk of osteoarthritis, and an insurance company can fine tune actuarial tables based upon population genotype assessments of osteoarthritis risk). Risk of osteoarthritis sometimes is expressed as an odds ratio, which is the odds of a particular person having a genotype has or will develop osteoarthritis with respect to another genotype group (e.g., the most disease protective genotype or population average). In related embodiments, the determination is utilized to identify a subject at risk of osteoarthritis. In an embodiment, two or more polymorphic variations are detected in two or more regions in human genomic DNA associated with increased risk of osteoarthritis, such as a locus containing a *APOL3*, for example. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected in the sample. In specific embodiments, polymorphic variants are detected in a *APOL3* region, for example. In certain embodiments, polymorphic variants are detected at other genetic loci (e.g., the polymorphic variants can be detected in *APOL3* in addition to other loci or only in other loci), where the other loci include but are not limited to those described in concurrently-filed patent applications having attorney docket number 524593008700, 524593008800, 524593008900, 524593009000 or 524593009100, each of which is incorporated herein by reference in its entirety.

**[0084]** Results from prognostic tests may be combined with other test results to diagnose osteoarthritis. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to osteoarthritis, the patient sample is analyzed, and the results of the analysis may be utilized to diagnose osteoarthritis. Also osteoarthritis diagnostic method can be developed from studies used to generate prognostic methods in which populations are stratified into subpopulations having different progressions of osteoarthritis. In another embodiment, prognostic results may be gathered, a patient's risk factors for developing osteoarthritis (e.g., age, weight, race, diet) analyzed, and a patient sample may be ordered based on a determined predisposition to osteoarthritis.

**[0085]** The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and

biopsy tissue. The nucleic acid sample can be isolated from a biological sample using standard techniques, such as the technique described in Example 2. As used herein, the term “subject” refers primarily to humans but also refers to other mammals such as dogs, cats, and ungulates (*e.g.*, cattle, sheep, and swine). Subjects also include avians (*e.g.*, chickens and turkeys), reptiles, and fish (*e.g.*, salmon), as embodiments described herein can be adapted to nucleic acid samples isolated from any of these organisms. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (*e.g.*, frozen) for a period of time before being subjected to analysis.

**[0086]** The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample from a subject having a copy of each chromosome is useful for determining the zygosity of an individual for the polymorphic variant (*i.e.*, whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (*e.g.*, U.S. Pat. Nos. 5,891,625 and 6,013,499), PCR-based assays (*e.g.*, TAQMAN<sup>®</sup> PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used.

**[0087]** Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP<sup>®</sup> Systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon a *APOL3* nucleotide sequence using knowledge available in the art.

**[0088]** Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. As used herein, the term “adjacent” refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic



acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144, and a method often utilized is described herein in Example 2.

**[0089]** A microarray can be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330; 5,695,940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microarray may comprise one or more oligonucleotides complementary to a polymorphic site set forth herein.

**[0090]** A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit often comprises one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of SEQ ID NO: 1-7 or a substantially identical sequence thereof, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to a *APOL3* nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it also often comprises chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dITP, provided that such analogs are substrates for a thermostable nucleic acid polymerase and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP, and the like. In an embodiment, the kit comprises one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

[0091] An individual identified as being at risk of osteoarthritis may be heterozygous or homozygous with respect to the allele associated with a higher risk of osteoarthritis. A subject homozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively high risk of osteoarthritis, a subject heterozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively intermediate risk of osteoarthritis, and a subject homozygous for an allele associated with a decreased risk of osteoarthritis is at a comparatively low risk of osteoarthritis. A genotype may be assessed for a complementary strand, such that the complementary nucleotide at a particular position is detected.

[0092] Also featured are methods for determining risk of osteoarthritis and/or identifying a subject at risk of osteoarthritis by contacting a polypeptide or protein encoded by a *APOL3* nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with increased risk of osteoarthritis in the polypeptide.

#### Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

[0093] Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype as a particular treatment regimen may exert a differential effect depending upon the subject's genotype. For example, based upon the outcome of a prognostic test described herein, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (*e.g.*, the treatment has no therapeutic effect and/or the subject experiences adverse side effects).

[0094] The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant interaction with a major allele and a comparatively weak interaction with a minor allele (*e.g.*, an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the minor allele, and sometimes not administered to a subject genotyped as being heterozygous for the minor allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a major allele but is comparatively toxic when administered to subjects heterozygous or homozygous for a minor allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the minor allele.

[0095] The methods described herein are applicable to pharmacogenomic methods for preventing, alleviating or treating osteoarthritis. For example, a nucleic acid sample from an individual may be subjected to a prognostic test described herein. Where one or more polymorphic variations associated

with increased risk of osteoarthritis are identified in a subject, information for preventing or treating osteoarthritis and/or one or more osteoarthritis treatment regimens then may be prescribed to that subject.

[0096] In certain embodiments, a treatment or preventative regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing osteoarthritis assessed by the methods described herein. Thus, provided are methods for identifying a subject predisposed to osteoarthritis and then prescribing a therapeutic or preventative regimen to individuals identified as having a predisposition. Thus, certain embodiments are directed to a method for reducing osteoarthritis in a subject, which comprises: detecting the presence or absence of a polymorphic variant associated with osteoarthritis in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-7; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (d) a fragment of a polynucleotide sequence of (a), (b), or (c); and prescribing or administering a treatment regimen to a subject from whom the sample originated where the presence of a polymorphic variation associated with osteoarthritis is detected in the nucleotide sequence. In these methods, predisposition results may be utilized in combination with other test results to diagnose osteoarthritis.

[0097] Certain preventative treatments often are prescribed to subjects having a predisposition to osteoarthritis and where the subject is diagnosed with osteoarthritis or is diagnosed as having symptoms indicative of an early stage of osteoarthritis. The treatment sometimes is preventative (*e.g.*, is prescribed or administered to reduce the probability that osteoarthritis arises or progresses), sometimes is therapeutic, and sometimes delays, alleviates or halts the progression of osteoarthritis. Any known preventative or therapeutic treatment for alleviating or preventing the occurrence of osteoarthritis is prescribed and/or administered. For example, the treatment often is directed to decreasing pain and improving joint movement. Examples of OA treatments include exercises to keep joints flexible and improve muscle strength. Different medications to control pain, including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs, *e.g.*, Voltaren); cyclooxygenase-2 (COX-2) inhibitors (*e.g.*, Celebrex, Vioxx, Mobic, and Bextra); monoclonal antibodies (*e.g.*, Remicade); tumor necrosis factor inhibitors (*e.g.*, Enbrel); or injections of glucocorticoids, hyaluronic acid or chondroitin sulfate into joints that are inflamed and not responsive to NSAIDs. Orally administered chondroitin sulfate also may be used as a therapeutic, as it may increase hyaluronic acid levels and viscosity of synovial fluid, and decrease collagenase levels in synovial fluid. Also, glucosamine can serve as an OA therapeutic as delivering it into joints may inhibit enzymes involved in cartilage degradation and enhance the

production of hyaluronic acid. For mild pain without inflammation, acetaminophen may be used. Other treatments include: heat/cold therapy for temporary pain relief; joint protection to prevent strain or stress on painful joints; surgery to relieve chronic pain in damaged joints; and weight control to prevent extra stress on weight-bearing joints.

**[0098]** As therapeutic approaches for treating osteoarthritis continue to evolve and improve, the goal of treatments for osteoarthritis related disorders is to intervene even before clinical signs first manifest. Thus, genetic markers associated with susceptibility to osteoarthritis prove useful for early diagnosis, prevention and treatment of osteoarthritis.

**[0099]** As osteoarthritis preventative and treatment information can be specifically targeted to subjects in need thereof (*e.g.*, those at risk of developing osteoarthritis or those in an early stage of osteoarthritis), provided herein is a method for preventing or reducing the risk of developing osteoarthritis in a subject, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying a subject with a predisposition to osteoarthritis, whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject; and (c) if such a predisposition is identified, providing the subject with information about methods or products to prevent or reduce osteoarthritis or to delay the onset of osteoarthritis. Also provided is a method of targeting information or advertising to a subpopulation of a human population based on the subpopulation being genetically predisposed to a disease or condition, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; and (c) providing information only to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition.

**[0100]** Pharmacogenomics methods also may be used to analyze and predict a response to osteoarthritis treatment or a drug. For example, if pharmacogenomics analysis indicates a likelihood that an individual will respond positively to osteoarthritis treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regimen (*e.g.*, exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based

upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

**[0101]** The tests described herein also are applicable to clinical drug trials. One or more polymorphic variants indicative of response to an agent for treating osteoarthritis or to side effects to an agent for treating osteoarthritis may be identified using the methods described herein. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

**[0102]** Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variation which is associated with a positive response to the treatment or the drug, or at least one polymorphic variation which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains said polymorphic variation associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said polymorphic variation associated with a negative response to the treatment or the drug. In addition, the methods described herein for selecting an individual for inclusion in a clinical trial of a treatment or drug encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination. The polymorphic variation may be in a sequence selected individually or in any combination from the group consisting of (i) a nucleotide sequence of SEQ ID NO: 1-7; (ii) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7; (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-7; and (iv) a fragment of a polynucleotide sequence of (i), (ii), or (iii) comprising the polymorphic site. The including step (c) optionally comprises administering the drug or the treatment to the individual if the nucleic acid sample contains the polymorphic variation associated with a positive response to the treatment or the drug and the nucleic acid sample lacks said biallelic marker associated with a negative response to the treatment or the drug.

**[0103]** Also provided herein is a method of partnering between a diagnostic/prognostic testing provider and a provider of a consumable product, which comprises: (a) the diagnostic/prognostic testing provider detects the presence or absence of a polymorphic variation associated with osteoarthritis at a

polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) the diagnostic/prognostic testing provider identifies the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; (c) the diagnostic/prognostic testing provider forwards information to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition; and (d) the provider of a consumable product forwards to the diagnostic test provider a fee every time the diagnostic/prognostic test provider forwards information to the subject as set forth in step (c) above.

#### Compositions Comprising Osteoarthritis-Directed Molecules

**[0104]** Featured herein is a composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and one or more molecules specifically directed and targeted to a nucleic acid comprising a *APOL3* nucleotide sequence or amino acid sequence. Such directed molecules include, but are not limited to, a compound that binds to a *APOL3* nucleotide sequence or amino acid sequence referenced herein; a RNAi or siRNA molecule having a strand complementary or substantially complementary to a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); an antisense nucleic acid complementary or substantially complementary to an RNA encoded by a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); a ribozyme that hybridizes to a *APOL3* nucleotide sequence (e.g., hybridizes to a *APOL3* nucleotide sequence under conditions of high stringency); a nucleic acid aptamer that specifically binds a polypeptide encoded by *APOL3* nucleotide sequence; and an antibody that specifically binds to a polypeptide encoded by *APOL3* nucleotide sequence or binds to a nucleic acid having such a nucleotide sequence. In specific embodiments, the osteoarthritis directed molecule interacts with a nucleic acid or polypeptide variant associated with osteoarthritis, such as variants referenced herein. In other embodiments, the osteoarthritis directed molecule interacts with a polypeptide involved in a signal pathway of a polypeptide encoded by a *APOL3* nucleotide sequence, or a nucleic acid comprising such a nucleotide sequence.

**[0105]** Compositions sometimes include an adjuvant known to stimulate an immune response, and in certain embodiments, an adjuvant that stimulates a T-cell lymphocyte response. Adjuvants are known, including but not limited to an aluminum adjuvant (e.g., aluminum hydroxide); a cytokine adjuvant or adjuvant that stimulates a cytokine response (e.g., interleukin (IL)-12 and/or gamma-interferon cytokines); a Freund-type mineral oil adjuvant emulsion (e.g., Freund's complete or incomplete adjuvant); a synthetic lipid compound; a copolymer adjuvant (e.g., TitreMax); a saponin; Quil A; a liposome; an oil-in-water emulsion (e.g., an emulsion stabilized by Tween 80 and pluronic polyoxyethylene/polyoxypropylene block copolymer (Syntex Adjuvant Formulation); TitreMax; detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) in 2% squalene (Ribi

Adjuvant System)); a muramyl dipeptide; an immune-stimulating complex (ISCOM, e.g., an Ag-modified saponin/cholesterol micelle that forms stable cage-like structure); an aqueous phase adjuvant that does not have a depot effect (e.g., Gerbu adjuvant); a carbohydrate polymer (e.g., AdjuPrime); L-tyrosine; a manide-oleate compound (e.g., Montanide); an ethylene-vinyl acetate copolymer (e.g., Elvax 40W1,2); or lipid A, for example. Such compositions are useful for generating an immune response against osteoarthritis directed molecule (e.g., an HLA-binding subsequence within a polypeptide encoded by a *APOL3* nucleotide sequence). In such methods, a peptide having an amino acid subsequence of a polypeptide encoded by a *APOL3* nucleotide sequence is delivered to a subject, where the subsequence binds to an HLA molecule and induces a CTL lymphocyte response. The peptide sometimes is delivered to the subject as an isolated peptide or as a minigene in a plasmid that encodes the peptide. Methods for identifying HLA-binding subsequences in such polypeptides are known (see e.g., publication WO02/20616 and PCT application US98/01373 for methods of identifying such sequences).

[0106] The cell may be in a group of cells cultured *in vitro* or in a tissue maintained *in vitro* or present in an animal *in vivo* (e.g., a rat, mouse, ape or human). In certain embodiments, a composition comprises a component from a cell such as a nucleic acid molecule (e.g., genomic DNA), a protein mixture or isolated protein, for example. The aforementioned compositions have utility in diagnostic, prognostic and pharmacogenomic methods described previously and in therapeutics described hereafter. Certain osteoarthritis directed molecules are described in greater detail below.

### Compounds

[0107] Compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (see, e.g., Zuckermann et al., J. Med. Chem. 37: 2678-85 (1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; "one-bead one-compound" library methods; and synthetic library methods using affinity chromatography selection. Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, (1997)). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90: 6909 (1993); Erb et al., Proc. Natl. Acad. Sci. USA 91: 11422 (1994); Zuckermann et al., J. Med. Chem. 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2059 (1994); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2061 (1994); and in Gallop et al., J. Med. Chem. 37: 1233 (1994).

**[0108]** Libraries of compounds may be presented in solution (e.g., Houghten, *Biotechniques* 13: 412-421 (1992)), or on beads (Lam, *Nature* 354: 82-84 (1991)), chips (Fodor, *Nature* 364: 555-556 (1993)), bacteria or spores (Ladner, United States Patent No. 5,223,409), plasmids (Cull et al., *Proc. Natl. Acad. Sci. USA* 89: 1865-1869 (1992)) or on phage (Scott and Smith, *Science* 249: 386-390 (1990); Devlin, *Science* 249: 404-406 (1990); Cwirla et al., *Proc. Natl. Acad. Sci.* 87: 6378-6382 (1990); Felici, *J. Mol. Biol.* 222: 301-310 (1991); Ladner *supra.*).

**[0109]** A compound sometimes alters expression and sometimes alters activity of a polypeptide target and may be a small molecule. Small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

Antisense Nucleic Acid Molecules, Ribozymes, RNAi, siRNA and Modified Nucleic Acid Molecules

**[0110]** An “antisense” nucleic acid refers to a nucleotide sequence complementary to a “sense” nucleic acid encoding a polypeptide, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand, or to a portion thereof or a substantially identical sequence thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence (e.g., 5' and 3' untranslated regions in SEQ ID NO: 1).

**[0111]** An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence (e.g., SEQ ID NO: 1), and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or noncoding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described hereafter, can be designed to target a *APOL3* nucleotide sequence, often a variant associated with osteoarthritis, or a substantially identical sequence thereof. Among the variants, minor alleles and major alleles can be targeted, and those associated with a higher risk of osteoarthritis are often designed, tested, and administered to subjects.



**[0112]** An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

**[0113]** When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

**[0114]** Antisense nucleic acid molecules sometimes are alpha-anomeric nucleic acid molecules. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15: 6625-6641 (1987)). Antisense nucleic acid molecules can also comprise a 2'-O-methylribonucleotide (Inoue et al., Nucleic Acids Res. 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215: 327-330 (1987)). Antisense nucleic acids sometimes are composed of DNA or PNA or any other nucleic acid derivatives described previously.

**[0115]** In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a *APOL3* nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach, Nature 334: 585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA is sometimes utilized in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Also, target mRNA sequences

can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see e.g., Bartel & Szostak, *Science* 261: 1411-1418 (1993)).

[0116] Osteoarthritis directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a *APOL3* nucleotide sequence, or a substantially identical sequence thereof, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a nucleotide sequence referenced herein or a substantially identical sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (see e.g., Helene, *Anticancer Drug Des.* 6(6): 569-84 (1991); Helene et al., *Ann. N.Y. Acad. Sci.* 660: 27-36 (1992); and Maher, *Bioassays* 14(12): 807-15 (1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a so-called “switchback” nucleic acid molecule. Switchback molecules are synthesized in an alternating 5’-3’, 3’-5’ manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0117] Osteoarthritis directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al., US Patent Number 6,506,559; Tuschl et al. PCT International Publication No. WO 01/75164; Kay et al. PCT International Publication No. WO 03/010180A1; or Boshier JM, Labouesse, *Nat Cell Biol* 2000 Feb;2(2):E31-6. This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that “switched off” genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (see, e.g., Caplen et al. *Proc Natl Acad Sci U S A.* 2001 Aug 14;98(17):9742-7 and Elbashir et al. *Methods* 2002 Feb;26(2):199-213). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. Patent Application No. US2001000993183; Caplen et al. *Proc Natl Acad Sci U S A.*; and Abderrahmani et al. *Mol Cell Biol* 2001 Nov21(21):7256-67).

[0118] An “siRNA” or “RNAi” refers to a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is delivered to or expressed in the same cell as the gene or target gene. “siRNA” refers to short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In

one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

**[0119]** When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al., *Methods* 26:199-213 (2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA(N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C-content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA(N21). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence-specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR(N17)YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters often is efficient when the first transcribed nucleotide is a purine.

**[0120]** The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, sometimes about 20-30 nucleotides in length or about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are well known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

**[0121]** Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al., *Bioorganic & Medicinal Chemistry* 4 (1): 5-23 (1996)). As used herein, the terms "peptide

nucleic acid” or “PNA” refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al., (1996) supra and Perry-O’Keefe et al., Proc. Natl. Acad. Sci. 93: 14670-675 (1996).

**[0122]** PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as “artificial restriction enzymes” when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup et al., (1996) supra; Perry-O’Keefe supra).

**[0123]** In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across cell membranes (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. USA 86: 6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci. USA 84: 648-652 (1987); PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., Bio-Techniques 6: 958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res. 5: 539-549 (1988) ). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

**[0124]** Also included herein are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a *APOL3* nucleotide sequence, or a substantially identical sequence thereof, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al., U.S. Patent No. 5,854,033; Nazarenko et al., U.S. Patent No. 5,866,336, and Livak et al., U.S. Patent 5,876,930.

#### Antibodies

**[0125]** The term “antibody” as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab’)<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody sometimes is a polyclonal, monoclonal, recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g.,

murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

**[0126]** A full-length polypeptide or antigenic peptide fragment encoded by a nucleotide sequence referenced herein can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence referenced herein, or substantially identical sequence thereof, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

**[0127]** Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides described herein.

**[0128]** Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al International Application No. PCT/US86/02269; Akira, et al European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al European Patent Application 173,494; Neuberger et al PCT International Publication No. WO 86/01533; Cabilly et al U.S. Patent No. 4,816,567; Cabilly et al European Patent Application 125,023; Better et al., Science 240: 1041-1043 (1988); Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443 (1987); Liu et al., J. Immunol. 139: 3521-3526 (1987); Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218 (1987); Nishimura et al., Canc. Res. 47: 999-1005 (1987); Wood et al., Nature 314: 446-449 (1985); and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559 (1988); Morrison, S. L., Science 229: 1202-1207 (1985); Oi et al., BioTechniques 4: 214 (1986); Winter U.S. Patent 5,225,539; Jones et al., Nature 321: 552-525 (1986); Verhoeyan et al., Science 239: 1534; and Beidler et al., J. Immunol. 141: 4053-4060 (1988).

**[0129]** Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar, Int. Rev. Immunol. 13: 65-93 (1995); and U.S.

Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, CA) and Medarex, Inc. (Princeton, NJ), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al., *Bio/Technology* 12: 899-903 (1994).

**[0130]** An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al., *Ann. N Y Acad. Sci.* 880: 263-80 (1999); and Reiter, *Clin. Cancer Res.* 2: 245-52 (1996)). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

**[0131]** Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region).

**[0132]** Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

**[0133]** Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, gamma-interferon, alpha-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or

other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, for example.

**[0134]** An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ . Also, an antibody can be utilized as a test molecule for determining whether it can treat osteoarthritis, and as a therapeutic for administration to a subject for treating osteoarthritis.

**[0135]** An antibody can be made by immunizing with a purified antigen, or a fragment thereof, e.g., a fragment described herein, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

**[0136]** Included herein are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with osteoarthritis.

#### Methods for Identifying Candidate Therapeutics for Treating Osteoarthritis

**[0137]** Current therapies for the treatment of osteoarthritis have limited efficacy, limited tolerability and significant mechanism-based side effects, and few of the available therapies adequately address underlying defects. Current therapeutic approaches were largely developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Therefore, provided are methods of identifying candidate therapeutics that target biochemical pathways related to the development of osteoarthritis.

[0138] Thus, featured herein are methods for identifying a candidate therapeutic for treating osteoarthritis. The methods comprise contacting a test molecule with a target molecule in a system. A “target molecule” as used herein refers to a *APOL3* nucleic acid, a substantially identical nucleic acid thereof, or a fragment thereof, and an encoded polypeptide of the foregoing. The methods also comprise determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate osteoarthritis therapeutic. The interaction between the test molecule and the target molecule may be quantified.

[0139] Test molecules and candidate therapeutics include, but are not limited to, compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by a *APOL3* nucleotide sequence, or a substantially identical sequence or fragment thereof, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A “modulator” may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post-translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro-polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (e.g., effecting progression of osteoarthritis).

[0140] As used herein, the term “system” refers to a cell free *in vitro* environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism. A system is “contacted” with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. As used herein, the term “interaction” refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

[0141] There are many standard methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrametric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.



[0142] Test molecule/target molecule interactions can be detected and/or quantified using assays known in the art. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ , which can be detected by direct counting of radioemission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product. In addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell, H. M. *et al.*, *Science* 257: 1906-1912 (1992)).

[0143] In cell-based systems, cells typically include a *APOL3* nucleic acid, an encoded polypeptide, or substantially identical nucleic acid or polypeptide thereof, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (*e.g.*, cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton<sup>®</sup> X-100, Triton<sup>®</sup> X-114, Thesit<sup>®</sup>, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0144] An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (*see, e.g.*, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos *et al.* U.S. Patent No. 4,868,103). A fluorophore label on a first, “donor” molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, “acceptor” molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the “donor” polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the “acceptor” molecule label may be differentiated from that of the “donor”. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the

“acceptor” molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

[0145] In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (*see, e.g.*, Sjolander & Urbanicz, *Anal. Chem.* 63: 2338-2345 (1991) and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5: 699-705 (1995)). “Surface plasmon resonance” or “biomolecular interaction analysis (BIA)” can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0146] In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In an embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels discussed herein.

[0147] It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non-covalent (*see, e.g.*, U.S. Patent No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a bead (*see, e.g.*, Lam, *Nature* 354: 82-84 (1991)) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are well known (*see, e.g.*, U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0148] In an embodiment, target molecule may be immobilized to surfaces via biotin and streptavidin. For example, biotinylated target polypeptide can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/target polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivitized microtiter plates, which are then combined with a test molecule

under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

**[0149]** In an embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, *e.g.*, by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.*, a labeled anti-Ig antibody.

**[0150]** In another embodiment, an assay is performed utilizing antibodies that specifically bind target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be derivitized to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

**[0151]** Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (*see, e.g.*, Rivas, G., and Minton, *Trends Biochem Sci Aug; 18(8): 284-7 (1993)*); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (*see, e.g.*, Ausubel *et al.*, eds. *Current Protocols in Molecular Biology*, J. Wiley: New York (1999)); and immunoprecipitation (*see, e.g.*, Ausubel *et al.*, eds., *supra*). Media and chromatographic techniques are known to one skilled in the art (*see, e.g.*, Heegaard, *J Mol. Recognit. Winter; 11(1-6): 141-8 (1998)*; Hage & Tweed, *J. Chromatogr. B Biomed. Sci. Appl. Oct 10; 699 (1-2): 499-525 (1997)*). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

**[0152]** In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or target polypeptide is evaluated relative to the level of expression of target mRNA or target

polypeptide in the absence of the candidate compound. When expression of target mRNA or target polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or target polypeptide expression. Alternatively, when expression of target mRNA or target polypeptide is less (*e.g.*, less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or target polypeptide expression. The level of target mRNA or target polypeptide expression can be determined by methods described herein.

**[0153]** In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extracellular macromolecules, such as polypeptides *in vivo*, and these interacting molecules are referred to herein as “binding partners.” Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity *in vivo* and thereby treat osteoarthritis.

**[0154]** Binding partners of target molecules can be identified by methods known in the art. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos *et al.*, *Cell* 72:223-232 (1993); Madura *et al.*, *J. Biol. Chem.* 268: 12046-12054 (1993); Bartel *et al.*, *Biotechniques* 14: 920-924 (1993); Iwabuchi *et al.*, *Oncogene* 8: 1693-1696 (1993); and Brent WO94/10300). A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a *APOL3* nucleic acid (sometimes referred to as the “bait”) is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner (sometimes referred to as the “prey”) is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a *APOL3* nucleic acid can be fused to the activation domain. If the “bait” and the “prey” molecules interact *in vivo*, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

**[0155]** In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The

test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo. Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule agonizes target molecule/binding partner complex formation. In another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (*e.g.*, amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

[0156] The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, *e.g.*, molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

[0157] In a heterogeneous assay embodiment, the target molecule or the binding partner is anchored onto a solid surface (*e.g.*, a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; *e.g.*, by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

[0158] In another embodiment, the reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (*e.g.*, using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

[0159] In an alternate embodiment, a homogeneous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (*e.g.*, U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target molecule/binding partner complexes can be identified.

[0160] Candidate therapeutics for treating osteoarthritis are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (*e.g.*, agonize or antagonize) a function associated with the target molecule (*e.g.*, DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information described herein can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

#### Therapeutic Formulations

[0161] Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method described above. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may comprise a target polypeptide or fragment thereof in combination with a pharmaceutically acceptable carrier, where the polypeptide or fragment sometimes has an *APOL3* biological activity (*e.g.*, apolipoprotein activity), and sometimes includes all or part of an apolipoprotein domain.

[0162] As used herein, the term “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be

incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

**[0163]** A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

**[0164]** Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, *e.g.*, gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

**[0165]** Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens,

chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0166] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0167] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[0168] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0169] In one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0170] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete



units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0171] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Molecules which exhibit high therapeutic indices are preferred. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0172] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0173] As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

[0174] With regard to polypeptide formulations, featured herein is a method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject with a first polypeptide, where the subject comprises a second polypeptide having one or more polymorphic

variations associated with cancer, and where the first polypeptide comprises fewer polymorphic variations associated with cancer than the second polypeptide. The first and second polypeptides are encoded by a nucleic acid which comprises a nucleotide sequence in SEQ ID NO: 1-7; a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence referenced in SEQ ID NO: 1-7; a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-7 and a nucleotide sequence 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-7. The subject often is a human.

[0175] For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (*e.g.*, into the brain). A method for lipidation of antibodies is described by Cruikshank *et al.*, *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193 (1997).

[0176] Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0177] For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is

understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0178] With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent 5,328,470) or by stereotactic injection (*see e.g.*, Chen *et al.*, (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (*e.g.*, retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

#### Therapeutic Methods

[0179] A therapeutic formulation described above can be administered to a subject in need of a therapeutic for inducing a desired biological response.. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

[0180] As used herein, the term "treatment" is defined as the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect osteoarthritis, symptoms of osteoarthritis or a predisposition towards osteoarthritis. A therapeutic formulation includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of osteoarthritis, such that osteoarthritis is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

[0181] As discussed, successful treatment of osteoarthritis can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')<sub>2</sub> and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

**[0182]** Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

**[0183]** Another method by which nucleic acid molecules may be utilized in treating or preventing osteoarthritis is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (*see, e.g., Osborne, et al., Curr. Opin. Chem. Biol.* 1(1): 5-9 (1997); and Patel, D. J., *Curr. Opin. Chem. Biol. Jun;1(1): 32-46 (1997)*).

**[0184]** Yet another method of utilizing nucleic acid molecules for osteoarthritis treatment is gene therapy, which can also be referred to as allele therapy. Provided herein is a gene therapy method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-7). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allele therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes polymorphic variants associated with osteoarthritis.

**[0185]** In another allele therapy embodiment, provided herein is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-7). Genomic DNA in the subject comprises a

second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleic acid has a nucleotide sequence identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human.

**[0186]** For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of osteoarthritis.

**[0187]** In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (*see, e.g., Herlyn, Ann. Med.*; 31(1): 66-78 (1999); and Bhattacharya-Chatterjee & Foon, *Cancer Treat. Res.*; 94: 51-68 (1998)). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to osteoarthritis also may be generated in this fashion.

**[0188]** In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (*see, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA* 90: 7889-7893 (1993)).

**[0189]** Modulators can be administered to a patient at therapeutically effective doses to treat osteoarthritis. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of osteoarthritis. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.,* for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Modulators that exhibit large therapeutic indices are preferred. While modulators that exhibit toxic side effects can be used, care

should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0190] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the  $ED_{50}$  with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the  $IC_{50}$  (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0191] Another example of effective dose determination for an individual is the ability to directly assay levels of “free” and “bound” compound in the serum of the test subject. Such assays may utilize antibody mimics and/or “biosensors” that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or “imprinting molecule”, to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated “negative image” of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell *et al.*, *Current Opinion in Biotechnology* 7: 89-94 (1996) and in Shea, *Trends in Polymer Science* 2: 166-173 (1994). Such “imprinted” affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, *et al.*, *Nature* 361: 645-647 (1993). Through the use of isotope-labeling, the “free” concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of  $IC_{50}$ . Such “imprinted” affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual  $IC_{50}$ . An example of such a “biosensor” is discussed in Kriz *et al.*, *Analytical Chemistry* 67: 2142-2144 (1995).

[0192] The examples set forth below are intended to illustrate but not limit the invention.

### Examples

[0193] In the following studies a group of subjects was selected according to specific parameters relating to osteoarthritis (OA). Nucleic acid samples obtained from individuals in the study group were subjected to genetic analysis, which identified associations between osteoarthritis and a polymorphism in the *APOL3* gene on chromosome twenty-two. The polymorphism was genotyped again in two replication cohorts consisting of individuals selected for OA. In addition, SNPs proximal to the incident polymorphism were identified and allelotyped in OA case and control pools. Methods are described for producing *APOL3* polypeptide and *APOL3* polypeptide variants *in vitro* or *in vivo*, *APOL3* nucleic acids or polypeptides and variants thereof are utilized for screening test molecules for those that interact with *APOL3* molecules. Test molecules identified as interactors with *APOL3* molecules and *APOL3* variants are further screened *in vivo* to determine whether they treat osteoarthritis.

#### Example 1

##### Samples and Pooling Strategies

##### Sample Selection

[0194] Blood samples were collected from individuals diagnosed with knee osteoarthritis, which were referred to as case samples. Also, blood samples were collected from individuals not diagnosed with knee osteoarthritis as gender and age-matched controls. A database was created that listed all phenotypic trait information gathered from individuals for each case and control sample. Genomic DNA was extracted from each of the blood samples for genetic analyses.

##### DNA Extraction from Blood Samples

[0195] Six to ten milliliters of whole blood was transferred to a 50 ml tube containing 27 ml of red cell lysis solution (RCL). The tube was inverted until the contents were mixed. Each tube was incubated for 10 minutes at room temperature and inverted once during the incubation. The tubes were then centrifuged for 20 minutes at 3000 x g and the supernatant was carefully poured off. 100-200 µl of residual liquid was left in the tube and was pipetted repeatedly to resuspend the pellet in the residual supernatant. White cell lysis solution (WCL) was added to the tube and pipetted repeatedly until completely mixed. While no incubation was normally required, the solution was incubated at 37°C or room temperature if cell clumps were visible after mixing until the solution was homogeneous. 2 ml of protein precipitation was added to the cell lysate. The mixtures were vortexed vigorously at high speed for 20 sec to mix the protein precipitation solution uniformly with the cell lysate, and then centrifuged for 10 minutes at 3000 x g. The supernatant containing the DNA was then poured into a clean 15 ml tube, which contained 7 ml of 100% isopropanol. The samples were mixed by inverting the tubes gently until

white threads of DNA were visible. Samples were centrifuged for 3 minutes at 2000 x g and the DNA was visible as a small white pellet. The supernatant was decanted and 5 ml of 70% ethanol was added to each tube. Each tube was inverted several times to wash the DNA pellet, and then centrifuged for 1 minute at 2000 x g. The ethanol was decanted and each tube was drained on clean absorbent paper. The DNA was dried in the tube by inversion for 10 minutes, and then 1000 µl of 1X TE was added. The size of each sample was estimated, and less TE buffer was added during the following DNA hydration step if the sample was smaller. The DNA was allowed to rehydrate overnight at room temperature, and DNA samples were stored at 2-8°C.

[0196] DNA was quantified by placing samples on a hematology mixer for at least 1 hour. DNA was serially diluted (typically 1:80, 1:160, 1:320, and 1:640 dilutions) so that it would be within the measurable range of standards. 125 µl of diluted DNA was transferred to a clear U-bottom microtitre plate, and 125 µl of 1X TE buffer was transferred into each well using a multichannel pipette. The DNA and 1X TE were mixed by repeated pipetting at least 15 times, and then the plates were sealed. 50 µl of diluted DNA was added to wells A5-H12 of a black flat bottom microtitre plate. Standards were inverted six times to mix them, and then 50 µl of 1X TE buffer was pipetted into well A1, 1000 ng/ml of standard was pipetted into well A2, 500 ng/ml of standard was pipetted into well A3, and 250 ng/ml of standard was pipetted into well A4. PicoGreen (Molecular Probes, Eugene, Oregon) was thawed and freshly diluted 1:200 according to the number of plates that were being measured. PicoGreen was vortexed and then 50µl was pipetted into all wells of the black plate with the diluted DNA. DNA and PicoGreen were mixed by pipetting repeatedly at least 10 times with the multichannel pipette. The plate was placed into a Fluoroskan Ascent Machine (microplate fluorometer produced by Labsystems) and the samples were allowed to incubate for 3 minutes before the machine was run using filter pairs 485 nm excitation and 538 nm emission wavelengths. Samples having measured DNA concentrations of greater than 450 ng/µl were re-measured for conformation. Samples having measured DNA concentrations of 20 ng/µl or less were re-measured for confirmation.

#### Pooling Strategies – Discovery Cohort

[0197] Samples were derived from the Nottingham knee OA family study (UK) where index cases were identified through a knee replacement registry. Siblings were approached and assessed with knee x-rays and assigned status as affected or unaffected. In all 1,157 individuals were available. In order to create same-sex pools of appropriate sizes, 335 unrelated female individuals with OA from the Nottingham OA sample were selected for the case pool. The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St.



Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The female case samples and female control samples are described further in Table 1 below.

[0198] A select set of samples from each group were utilized to generate pools, and one pool was created for each group. Each individual sample in a pool was represented by an equal amount of genomic DNA. For example, where 25 ng of genomic DNA was utilized in each PCR reaction and there were 200 individuals in each pool, each individual would provide 125 pg of genomic DNA. Inclusion or exclusion of samples for a pool was based upon the following criteria: the sample was derived from an individual characterized as Caucasian; the sample was derived from an individual of British paternal and maternal descent; case samples were derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic. Control samples were derived from individuals free of OA, family history of OA, and rheumatoid arthritis. Also, sufficient genomic DNA was extracted from each blood sample for all allelotyping and genotyping reactions performed during the study. Phenotype information from each individual was collected and included age of the individual, gender, family history of OA, general medical information (e.g., height, weight, thyroid disease, diabetes, psoriasis, hysterectomy), joint history (previous and current symptoms, joint-related operations, age at onset of symptoms, date of primary diagnosis, age of individual as of primary diagnosis and order of involvement), and knee-related findings (crepitus, restricted passive movement, bony swelling/deformity). Additional knee information included knee history, current symptoms, any major knee injury, meniscectomy, knee replacement surgery, age of surgery, and treatment history (including hormone replace therapy (HRT)). Samples that met these criteria were added to appropriate pools based on disease status.

[0199] The selection process yielded the pools set forth in Table 1, which were used in the studies that follow:

TABLE 1

	Female case	Female control
<b>Pool size</b> (Number)	335	335
<b>Pool Criteria</b> (ex: case/control)	control	case
<b>Mean Age</b> (ex: years)	57.21	69.95

## Example 2

### Association of Polymorphic Variants with Osteoarthritis

[0200] A whole-genome screen was performed to identify particular SNPs associated with occurrence of osteoarthritis. As described in Example 1, two sets of samples were utilized, which included samples from female individuals having knee osteoarthritis (osteoarthritis cases), and samples from female individuals not having knee osteoarthritis (female controls). The initial screen of each pool was performed in an allelotyping study, in which certain samples in each group were pooled. By pooling DNA from each group, an allele frequency for each SNP in each group was calculated. These allele frequencies were then compared to one another. Particular SNPs were considered as being associated with osteoarthritis when allele frequency differences calculated between case and control pools were statistically significant. SNP disease association results obtained from the allelotyping study were then validated by genotyping each associated SNP across all samples from each pool. The results of the genotyping then were analyzed, allele frequencies for each group were calculated from the individual genotyping results, and a p-value was calculated to determine whether the case and control groups had statistically significant differences in allele frequencies for a particular SNP. When the genotyping results agreed with the original allelotyping results, the SNP disease association was considered validated at the genetic level.

### SNP Panel Used for Genetic Analyses

[0201] A whole-genome SNP screen began with an initial screen of approximately 25,000 SNPs over each set of disease and control samples using a pooling approach. The pools studied in the screen are described in Example 1. The SNPs analyzed in this study were part of a set of 25,488 SNPs confirmed as being statistically polymorphic as each is characterized as having a minor allele frequency of greater than 10%. The SNPs in the set reside in genes or in close proximity to genes, and many reside in gene exons. Specifically, SNPs in the set are located in exons, introns, and within 5,000 base-pairs upstream of a transcription start site of a gene. In addition, SNPs were selected according to the following criteria: they are located in ESTs; they are located in Locuslink or Ensembl genes; and they are located in Genomatix promoter predictions. SNPs in the set were also selected on the basis of even spacing across the genome, as depicted in Table 2.

[0202] A case-control study design using a whole genome association strategy involving approximately 28,000 single nucleotide polymorphisms (SNPs) was employed. Approximately 25,000 SNPs were evenly spaced in gene-based regions of the human genome with a median inter-marker distance of about 40,000 base pairs. Additionally, approximately 3,000 SNPs causing amino acid substitutions in genes described in the literature as candidates for various diseases were used. The case-

control study samples were of female Caucasian origin (British paternal and maternal descent) 670 individuals were equally distributed in two groups: female controls and female cases. The whole genome association approach was first conducted on 2 DNA pools representing the 2 groups. Significant markers were confirmed by individual genotyping.

TABLE 2

<u>General Statistics</u>		<u>Spacing Statistics</u>	
Total # of SNPs	25,488	Median	37,058 bp
# of Exonic SNPs	>4,335 (17%)	Minimum*	1,000 bp
# SNPs with refSNP ID	20,776 (81%)	Maximum*	3,000,000 bp
Gene Coverage	>10,000	Mean	122,412 bp
Chromosome Coverage	All	Std Deviation	373,325 bp
		<i>*Excludes outliers</i>	

#### Allelotyping and Genotyping Results

[0203] The genetic studies summarized above and described in more detail below identified an allelic variant in the APOL3 gene that is associated with osteoarthritis.

#### Assay for Verifying, Allelotyping, and Genotyping SNPs

[0204] A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0205] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which were used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension primers used for analyzing polymorphisms. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl<sub>2</sub> (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

**TABLE 3: PCR Primers**

SNP Reference	Forward PCR primer	Reverse PCR primer
rs132659	ACGTTGGATGGGCCCAGTAGTGGGTCATAAC	ACGTTGGATGGTGGGGTGAGTGCCCCAAAAG

[0206] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0207] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 4, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

**TABLE 4: Extension Primers**

SNP Reference	Extend Probe	Termination Mix
rs132659	AGAACTCCCCAAATCGTCCT	ACG

[0208] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0209] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and

SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

#### Genetic Analysis

[0210] Minor allelic frequencies for the polymorphisms set forth in Table A were verified as being 10% or greater using the extension assay described above in a group of samples isolated from 92 individuals originating from the state of Utah in the United States, Venezuela and France (Coriell cell repositories).

[0211] Genotyping results are shown for female pools in Table 5. In Table 5, “AF” refers to allelic frequency; and “F case” and “F control” refer to female case and female control groups, respectively.

**TABLE 5: Genotyping Results**

SNP Reference	AF F case	AF F control	p-value
rs132659	C = 0.675 T = 0.325	C = 0.589 T = 0.411	0.0015

[0212] The single marker alleles set forth in Table A were considered validated, since the genotyping data agreed with the allelotyping data and each SNP significantly associated with osteoarthritis. Particularly significant associations with osteoarthritis are indicated by a calculated p-value of less than 0.05 for genotype results.

#### Example 3

##### Association of Polymorphic Variants with Osteoarthritis in Replication Cohorts

[0213] The single marker polymorphism set forth in Table A was genotyped again in two replication cohorts consisting of individuals selected for OA.

##### Sample Selection and Pooling Strategies – Replication Sample 1

[0214] A second case control sample (replication sample #1) was created by using 100 Caucasian female cases from Chingford, UK, and 148 unrelated female cases from the St. Thomas twin study. Cases were defined as having Kellgren-Lawrence (KL) scores of at least 2 in at least one knee x-ray. In addition, 199 male knee replacement cases from Nottingham were included. (For a cohort description, see the Nottingham description provided in Example 1). The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age.

The replication sample 1 cohort was used to replicate the initial results. Table 6 below summarizes the selected phenotype data collected from the case and control individuals.

**TABLE 6**

<b>Phenotype</b>	<b>Female cases (n=248): median (range)/ (n,%)</b>	<b>Male cases (n=199): median (range)/ (n,%)</b>	<b>Female controls (n=313): mean (range)/ (n,%)</b>
Age	59 (39- 73)	66 (45- 73)	55 (50- 72)
Height (cm)	162 (141- 178)	175 (152- 198)	162 (141- 176)
Weight (kg)	68 (51- 123)	86 (62- 127)	64 (40- 111)
Body mass index (kg/m <sup>2</sup> )	26 (18- 44)	29 (21- 41)	24 (18- 46)
Kellgren-Lawrence* left knee	0 (63, 26%), 1 (20, 8%), 2 (105, 43%), 3 (58, 23%), 4 (1, 0%)	NA	NA
Kellgren-Lawrence* right knee	0 (43, 7%), 1 (18, 7%), 2 (127, 52%), 3 (57, 23%), 4 (1, 0%)	NA	NA
KL* >2 both knees	No (145, 59%), Yes (101, 41%)	NA	NA
KL* >2 either knee	No (0, 0%), Yes (248, 100%)	NA	NA

\* 0: normal, 1: doubtful, 2: definite osteophyte (bony protuberance), 3: joint space narrowing (with or without osteophyte), 4: joint deformity

#### Sample Selection and Pooling Strategies – Replication Sample 2

[0215] A third case control sample (replication sample #2) was created by using individuals with symptoms of OA from Newfoundland, Canada. These individuals were recruited and examined by rheumatologists. Affected joints were x-rayed and a final diagnosis of definite or probable OA was made according to American College of Rheumatology criteria by a single rheumatologist to avoid any inter-examiner diagnosis variability. Controls were recruited from volunteers without any symptoms from the musculoskeletal system based on a normal joint exam performed by a rheumatologist. Only cases with a diagnosis of definite OA were included in the study. Only individuals of Caucasian origin were included. The cases consisted of 228 individuals with definite knee OA, 106 individuals with definite hip OA, and 74 individuals with hip OA.

**TABLE 7**

<b>Phenotype</b>	<b>Case</b>	<b>Control</b>
Age at Visit	62.7	52.5
Sex (Female/Male)	227/119	174/101
Knee OA Xray: No	35% (120)	80% (16)

Unknown	1% (4)	0% (0)
Yes	64% (221)	20% (4)
Hip OA Xray: No	63% (215)	80% (16)
Unknown	2% (7)	0% (0)
Yes	35% (121)	20% (4)

#### Assay for Verifying, Allelotyping, and Genotyping SNPs

[0216] Genotyping of the replication cohorts described in Tables 6 and 7 was performed using the same methods used for the original genotyping, as described herein. A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0217] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which were used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension probes used for analyzing (*e.g.*, genotyping) polymorphisms in the replication cohorts. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl<sub>2</sub> (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

[0218] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0219] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs)

used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 7, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

[0220] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0221] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

#### Genetic Analysis

[0222] Genotyping results for replication cohorts #1 and #2 are provided in Tables 8 and 9, respectively.

**TABLE 8**

rsID	Replication #1 (Mixed Male/Female cases and Female controls)				Meta-analysis Disc. + Rep #1
	AF OA Con	AF OA Cas	Delta	P-value	P-value
rs132659	0.38	0.34	0.04	0.128	0.0077

**TABLE 9**

rsID	Replication #2 (Newfoundland) (Male/Female cases and controls)				Meta-analysis Disc. + Rep #2
	AF OA Con	AF OA Cas	Delta	P-value	Not Done
rs132659	0.36	0.36	-0.001	0.973	



[0223] To combine the evidence for association from multiple sample collections, a meta-analysis procedure was employed. The allele frequencies were compared between cases and controls within the discovery sample, as well as within the replication cohort #1 using the DerSimonian-Laird approach (DerSimonian, R. and N. Laird. 1986. Meta-analysis in clinical trials. *Control Clin Trials* 7: 177-188.)

[0224] The absence of a statistically significant association in one or more of the replication cohorts should not be interpreted as minimizing the value of the original finding. There are many reasons why a biologically derived association identified in a sample from one population would not replicate in a sample from another population. The most important reason is differences in population history. Due to bottlenecks and founder effects, there may be common disease predisposing alleles present in one population that are relatively rare in another, leading to a lack of association in the candidate region. Also, because common diseases such as arthritis-related disorders are the result of susceptibilities in many genes and many environmental risk factors, differences in population-specific genetic and environmental backgrounds could mask the effects of a biologically relevant allele. For these and other reasons, statistically strong results in the original, discovery sample that did not replicate in one or more of the replication samples may be further evaluated in additional replication cohorts and experimental systems.

#### Example 4

##### APOL3 Region Proximal SNPs

[0225] It has been discovered that SNP rs132659 in *APOL3* is associated with occurrence of osteoarthritis in subjects. *APOL3* belongs to the high density lipoprotein family that plays a central role in cholesterol transport. The cholesterol content of membranes is important in cellular processes such as modulating gene transcription and signal transduction both in the adult brain and during neurodevelopment. It has been shown that the *APOL1*-*APOL4* gene cluster on chromosome 22 exists only in primates (humans and African green monkeys) and not in dogs, pigs, or rodents, suggesting that this gene cluster has arisen recently in evolution (Monajemi et. al., *Genomics* 79: 539-546, 2002). Six transcript variants encoding three different isoforms have been identified.

[0226] Expression of this gene is upregulated by tumor necrosis factor-alpha in endothelial cells lining the normal and atherosclerotic iliac artery and aorta (Horrevoets et. al., *Blood* 93: 3418-3431, 1999). *APOL3* is genetically linked to OA and may play a role in the pathophysiology of OA brought about by inflammation. *APOL3* is likely inhibited by a small molecule inhibitor or by specific antibodies. *APOL3* activity may be increased in a subject by administering *APOL3* recombinant protein or a functional fragment thereof.

[0227] Two hundred-nineteen additional allelic variants proximal to rs132659 were identified and subsequently allelotyped in osteoarthritis case and control sample sets as described in Examples 1 and 2.

The polymorphic variants are set forth in Table 10. The chromosome positions provided in column four of Table 10 are based on Genome “Build 34” of NCBI’s GenBank.

**TABLE 10**

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs3888818	22	201	34781551	c/t
rs2010605	22	425	34781775	a/g
rs743919	22	1095	34782445	g/t
rs1008134	22	2201	34783551	a/c
rs132607	22	7879	34789229	a/g
rs1476029	22	8395	34789745	c/t
rs1476030	22	8461	34789811	c/t
rs2413380	22	9503	34790853	c/t
rs2051609	22	10304	34791654	g/t
rs2413381	22	10695	34792045	c/t
rs1894604	22	16300	34797650	a/g
rs1894605	22	16444	34797794	g/t
rs132609	22	17591	34798941	c/t
rs132610	22	17988	34799338	-/a
rs132611	22	19116	34800466	-/t
rs132612	22	19358	34800708	c/t
rs1008790	22	20300	34801650	a/g
rs23085	22	20669	34802019	a/t
rs105161	22	20891	34802241	a/g
rs132613	22	21451	34802801	c/t
rs132614	22	21978	34803328	c/t
rs132615	22	22785	34804135	c/g
rs132617	22	24248	34805598	c/t
rs3865724	22	24770	34806120	c/t
rs2019657	22	24844	34806194	a/g
rs3865725	22	25066	34806416	g/t
rs2019364	22	25096	34806446	c/t
rs2008383	22	25309	34806659	a/g
rs3986002	22	25344	34806694	a/c
rs3888942	22	25529	34806879	a/t
rs3888943	22	25537	34806887	a/g
rs3888944	22	25554	34806904	a/c
rs132618	22	27963	34809313	a/t
rs132619	22	28134	34809484	g/t
rs3827346	22	28356	34809706	a/g
rs132620	22	29648	34810998	-/a
rs132621	22	29986	34811336	a/g
rs80575	22	30217	34811567	g/t
rs80576	22	30267	34811617	a/g
rs80577	22	30315	34811665	a/g
rs80578	22	30585	34811935	c/t
rs80579	22	30724	34812074	a/c
rs80580	22	30897	34812247	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132622	22	30931	34812281	c/t
rs132623	22	31080	34812430	g/t
rs132624	22	31246	34812596	c/t
rs132625	22	31373	34812723	a/t
rs132626	22	31463	34812813	a/g
rs132627	22	31467	34812817	a/g
rs1807672	22	32188	34813538	g/t
rs132628	22	32288	34813638	c/t
rs132629	22	32520	34813870	a/t
rs132630	22	32594	34813944	a/c
rs132631	22	32657	34814007	a/c
rs132632	22	32677	34814027	a/g
rs132633	22	32764	34814114	c/t
rs132634	22	32784	34814134	a/g
rs132635	22	32830	34814180	c/t
rs132636	22	32872	34814222	c/t
rs129603	22	33121	34814471	a/c
rs132637	22	33348	34814698	g/t
rs3788518	22	33952	34815302	c/g
rs132638	22	34184	34815534	c/g
rs132639	22	34361	34815711	a/t
rs132640	22	35026	34816376	a/g
rs132641	22	35192	34816542	a/g
rs132642	22	35600	34816950	a/t
rs132643	22	36033	34817383	c/t
rs132644	22	36289	34817639	c/t
rs132645	22	38869	34820219	a/g
rs2017329	22	39629	34820979	a/t
rs739198	22	40530	34821880	c/t
rs132647	22	41621	34822971	c/t
rs2097465	22	42379	34823729	c/t
rs2105915	22	42802	34824152	c/t
rs132648	22	42865	34824215	t/c
rs132649	22	43644	34824994	a/g
rs132650	22	45051	34826401	c/t
rs132651	22	45828	34827178	a/c
rs132652	22	45829	34827179	a/t
rs80584	22	46257	34827607	c/t
rs132653	22	47286	34828636	a/c
rs916334	22	47427	34828777	c/t
rs132654	22	47963	34829313	c/t
rs132655	22	48013	34829363	c/t
rs132656	22	48229	34829579	c/t
rs3834684	22	48282	34829632	-/a
rs132657	22	48376	34829726	-/g
rs916335	22	48404	34829754	a/g
rs132659	22	49900	34831250	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132660	22	52699	34834049	g/t
rs132661	22	52897	34834247	a/g
rs132662	22	53414	34834764	a/g
rs132663	22	53487	34834837	a/t
rs132664	22	54112	34835462	g/t
rs132667	22	55492	34836842	a/g
rs132670	22	59766	34841116	c/t
rs132671	22	60307	34841657	a/g
rs132672	22	60701	34842051	a/g
rs132673	22	60952	34842302	a/g
rs132674	22	61401	34842751	c/t
rs132675	22	62379	34843729	c/t
rs80585	22	62870	34844220	c/t
rs80586	22	62879	34844229	a/g
rs132676	22	63499	34844849	a/t
rs132677	22	64284	34845634	-/a
rs132678	22	64408	34845758	a/g
rs132680	22	64760	34846110	a/g
rs132681	22	65230	34846580	a/g
rs132683	22	66127	34847477	a/g
rs2269594	22	66634	34847984	c/t
rs132684	22	66686	34848036	a/g
rs132685	22	66694	34848044	c/g
rs132686	22	67113	34848463	a/g
rs132687	22	67257	34848607	a/g
rs132688	22	67403	34848753	a/g
rs132689	22	67609	34848959	a/g
rs132690	22	68418	34849768	-/a
rs132691	22	68610	34849960	c/g
rs132692	22	69629	34850979	c/t
rs132693	22	70024	34851374	a/g
rs132694	22	70848	34852198	a/g
rs132695	22	71428	34852778	c/g
rs1966266	22	71553	34852903	c/t
rs1966267	22	71633	34852983	a/g
rs106808	22	71768	34853118	a/c
rs132696	22	71769	34853119	a/g
rs2239829	22	73039	34854389	a/g
rs2285154	22	73325	34854675	a/g
rs2239830	22	73412	34854762	a/c
rs2239831	22	73547	34854897	c/t
rs3865722	22	73769	34855119	a/t
rs3865723	22	73806	34855156	a/g
rs3985996	22	74467	34855817	c/t
rs3985997	22	74472	34855822	c/t
rs3985998	22	74473	34855823	a/g
rs3985999	22	74482	34855832	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs3986000	22	74494	34855844	a/c
rs2413382	22	74592	34855942	a/g
rs2413383	22	74670	34856020	g/t
rs2413384	22	74672	34856022	g/t
rs2413385	22	74714	34856064	g/t
rs2413386	22	74723	34856073	a/t
rs1894606	22	74749	34856099	a/g
rs916336	22	74861	34856211	c/g
rs916337	22	74892	34856242	c/t
rs916338	22	74893	34856243	c/t
rs132697	22	75176	34856526	a/g
rs12781	22	75705	34857055	a/g
rs1053983	22	75989	34857339	a/g
rs1053982	22	76027	34857377	a/g
rs2227167	22	77949	34859299	a/g
rs2227168	22	77974	34859324	c/t
rs132700	22	78167	34859517	c/t
rs3075364	22	78310	34859660	-/ct
rs2227169	22	78415	34859765	c/t
rs2097466	22	78575	34859925	c/t
rs2097467	22	78590	34859940	c/t
rs2413387	22	78709	34860059	c/t
rs132701	22	78875	34860225	c/t
rs132702	22	79864	34861214	c/t
rs132703	22	81316	34862666	c/t
rs2269595	22	81320	34862670	a/g
rs2269596	22	81409	34862759	c/t
rs132704	22	81737	34863087	c/t
rs2007468	22	81843	34863193	a/g
rs132705	22	82102	34863452	c/t
rs2007706	22	82833	34864183	c/t
rs132706	22	83461	34864811	c/t
rs132707	22	83624	34864974	c/t
rs132708	22	83660	34865010	c/g
rs132709	22	83701	34865051	a/t
rs132710	22	83708	34865058	a/g
rs132711	22	83782	34865132	c/t
rs132712	22	85707	34867057	a/g
rs132713	22	85717	34867067	a/g
rs132714	22	86486	34867836	c/t
rs132716	22	86833	34868183	a/g
rs132717	22	87115	34868465	c/t
rs132718	22	87234	34868584	a/g
rs132719	22	87479	34868829	g/t
rs132720	22	87561	34868911	a/g
rs132721	22	87604	34868954	a/g
rs132722	22	87674	34869024	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs132723	22	87958	34869308	a/g
rs132724	22	87992	34869342	-/g
rs132725	22	88019	34869369	a/g
rs132726	22	88074	34869424	c/g
rs132727	22	88079	34869429	c/g
rs132728	22	88115	34869465	a/g
rs132729	22	88118	34869468	c/g
rs132730	22	88120	34869470	a/g
rs132731	22	88135	34869485	-/ctcat
rs132732	22	88142	34869492	g/t
rs132733	22	88143	34869493	g/t
rs140575	22	88149	34869499	aca/tg
rs132734	22	88340	34869690	a/g
rs132735	22	88344	34869694	g/t
rs80587	22	88512	34869862	c/g
rs132736	22	88521	34869871	c/t
rs132737	22	88650	34870000	c/g
rs132738	22	88827	34870177	c/t
rs1807673	22	89230	34870580	a/g
rs2014700	22	89236	34870586	a/g
rs132739	22	90754	34872104	g/a
rs1812023	22	90984	34872334	a/g
rs1812024	22	91110	34872460	a/g
rs2005590	22	92026	34873376	c/t
rs132740	22	92954	34874304	c/t
rs3986001	22	93375	34874725	-/ttgc
rs2413390	22	93794	34875144	c/t
rs132743	22	94937	34876287	c/g
rs132744	22	95068	34876418	c/t
rs2413391	22	96188	34877538	a/g
rs132749	22	97092	34878442	c/t
rs132750	22	98812	34880162	c/t
rs132741	22	not mapped	not mapped	a/c
rs2413388	22	not mapped	not mapped	a/t
rs2413389	22	not mapped	not mapped	c/g

#### Assay for Verifying and Allelotyping SNPs

[0228] The methods used to verify and allelotype the 219 proximal SNPs of Table 10 are the same methods described in Examples 1 and 2 herein. The primers and probes used in these assays are provided in Table 11 and Table 12, respectively.

**TABLE 11**

dbSNP rs#	Forward PCR primer	Reverse PCR primer
--------------	-----------------------	-----------------------

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3888818	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGCCATGCCAGCTAATTTTCG
rs2010605	ACGTTGGATGTGTGCTTTTTATGTCTTAGG	ACGTTGGATGGACTTTTAGAAGAAAAGTAC
rs743919	ACGTTGGATGTTCTTCACCAAGCCCTCTTC	ACGTTGGATGCCCAACACACACAAAGATGG
rs1008134	ACGTTGGATGACATATCCGGGCATCTTTTC	ACGTTGGATGCATCCACAGGATGCAATATC
rs132607	ACGTTGGATGTAGTTTGCAGGTCACAAGGG	ACGTTGGATGGGAAGGAAGACCCAAACAGC
rs1476029	ACGTTGGATGTGGGTGACAGAGATCCTTAC	ACGTTGGATGAAACTCAGGGAAACGGACTC
rs1476030	ACGTTGGATGATCCTAGCACTGGGATTTGG	ACGTTGGATGCGTTTCCCTGAGTTTCACTG
rs2413380	ACGTTGGATGATGATACTGAGTCCAGGAGG	ACGTTGGATGAAAGGCTACTTCTTGCTCAC
rs2051609	ACGTTGGATGTAATCCCAGCACTTTGGGAG	ACGTTGGATGACAGACGGGGTTTCATCATG
rs2413381	ACGTTGGATGAGGGCTGCAGTAGAAAAGCG	ACGTTGGATGACGATGCGTGTGCCGACAG
rs1894604	ACGTTGGATGAAGTGCTGCTGCAAAAAGAG	ACGTTGGATGTTCTCCACTTCCATTCTGTG
rs1894605	ACGTTGGATGTGATGAGAGATGCAGATCGC	ACGTTGGATGTATTCAGAATTCAGCCTGCG
rs132609	ACGTTGGATGGCATTGAAAGGTCCGTATC	ACGTTGGATGCCCAAATCTGTCTTTAGCC
rs132610	ACGTTGGATGTTCTACAAGAGCTAGGGACC	ACGTTGGATGGATCTATTGCTGCTTAGGCC
rs132611	ACGTTGGATGGCCTTCTTTACTCTGTCTC	ACGTTGGATGGGTTTTCTTTCAGGTCTCC
rs132612	ACGTTGGATGAAAAATCTTCCCGCTACCTC	ACGTTGGATGTTCTGTGAGCTTCTCTCTG
rs1008790	ACGTTGGATGGTGAGGTCCCTTTTATGATG	ACGTTGGATGATAACAGCCCCTGACAGATG
rs23085	ACGTTGGATGAAACCGTGCCAGCTGAGGAT	ACGTTGGATGGTCGGCAAGGAAGAGGAATC
rs105161	ACGTTGGATGAAGGAGCGGGAAATCTTTTG	ACGTTGGATGGTAGGAGGCTGAAATGCTAG
rs132613	ACGTTGGATGATGTAAAACCAATGGCCCTCC	ACGTTGGATGAAGCTTCAGATTGTTCACCC
rs132614	ACGTTGGATGCAAGAGCCCTGCTTTGTGAG	ACGTTGGATGTCCTGCACCAGCAGAGATGA
rs132615	ACGTTGGATGAAATCTGGAGGCTTGGTGAC	ACGTTGGATGTGAGCATTACATGGGACAG
rs132617	ACGTTGGATGGAGAAGAAGAGTGTGTGTGC	ACGTTGGATGACAGCCACCTGAATTTGTGC
rs3865724	ACGTTGGATGTTCTCTGGATAATTCCCATTC	ACGTTGGATGGCTGGATCACTGAAGAAGTA
rs2019657	ACGTTGGATGACGCCAGAACATTGTGTTTC	ACGTTGGATGGTGCCAGAAACATTCAAAGC
rs3865725	ACGTTGGATGAATATAGAAGTCTGGGCGC	ACGTTGGATGTGACTTAGGAGAGGTTCTGG
rs2019364	ACGTTGGATGTGACTTAGGAGAGGTTCTGG	ACGTTGGATGAATATAGAAGTCTGGGCGC
rs2008383	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGACATGGGTGACCCTATCAAG
rs3986002	ACGTTGGATGCTTCTGTCTTCTCTGTGTC	ACGTTGGATGCAGGCAGAGGATTTGTTTGG
rs3888942	ACGTTGGATGCTGGGCTTTTGTGCTAAGAG	ACGTTGGATGGGGCCAATTTGCCCCATAAA
rs3888943	ACGTTGGATGCTGGGCTTTTGTGCTAAGAG	ACGTTGGATGTTGGGCAATTTGCCCCATA
rs3888944	ACGTTGGATGATACAGCCCTTGCCACTATG	ACGTTGGATGTTGAAGACATGGAAGCAGGG
rs132618	ACGTTGGATGAATCCGTGCCATCAGGCAAG	ACGTTGGATGCCTGCAATCGTTCTCTCTGC
rs132619	ACGTTGGATGTCATCAGCAGAAGCTGAAGC	ACGTTGGATGGGTGTGATGTCACGCATAAC
rs3827346	ACGTTGGATGAAGAGGTCCACAGAGGCTG	ACGTTGGATGAAAACAAGACCAGCAAGGGA
rs132620	ACGTTGGATGTCACATTAGATCAGGAAGCC	ACGTTGGATGTTAGGCCAGTTTAGCAGAAA
rs132621	ACGTTGGATGCTTCAAATCTGCAACTGGTG	ACGTTGGATGGATAGCTTAAGGACTCAGAG
rs80575	ACGTTGGATGGCTGCACATGAAGTCTCAAG	ACGTTGGATGTGACATGTGACAGTGAGACC
rs80576	ACGTTGGATGTGAAGCTGTACCTGCTAAG	ACGTTGGATGAACTCTCAAGCCACTTGACG
rs80577	ACGTTGGATGAGTCCATAAGAGGTTCCATG	ACGTTGGATGAACTAATGCCTTAGCAGGTG
rs80578	ACGTTGGATGACTGTTTCCCTGACAGCATG	ACGTTGGATGTGTAGAACAGAAGAGGGTCC
rs80579	ACGTTGGATGTGGGAGTAGGGTGAGAAGAG	ACGTTGGATGACTCACTGGTCTCTGCAAG
rs80580	ACGTTGGATGTTCAATCAGATGGGCGTGTG	ACGTTGGATGGATGGCATCATGCTACTTGG
rs132622	ACGTTGGATGTATGTCTTGAGACTGGGAC	ACGTTGGATGACCTGCTGTTTATTCTCAGG
rs132623	ACGTTGGATGAGCTCTGTCCAAGTCCATTC	ACGTTGGATGCTGAGGAACTGCACAAACAC
rs132624	ACGTTGGATGTGCTGGGATTACAGGCATGA	ACGTTGGATGTCAAAGAAAGTCTGCTGGG
rs132625	ACGTTGGATGTTTACGCCATTCTCCTGCC	ACGTTGGATGCGATGAAACCCCGTCTGTAC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132626	ACGTTGGATGTGGAGTGCAGTGGCATGATC	ACGTTGGATGGCAGGAGAATGGCGTGAAAC
rs132627	ACGTTGGATGAGGAGAATGGCGTGAAACCG	ACGTTGGATGAGACAGAGTCTTGCTTGTC
rs1807672	ACGTTGGATGGTGTGCTACAGCCTAAATGG	ACGTTGGATGAATACCCCATGTGACAGCTG
rs132628	ACGTTGGATGTATAGACTGAGTTGTGTGCC	ACGTTGGATGTCCTTAAAGGCTCAATCTCC
rs132629	ACGTTGGATGCTCTCTCCCTGTCTCTCTTT	ACGTTGGATGTGTGTCCTCACATGGCCTTC
rs132630	ACGTTGGATGTTCCAAGGTGAAGGTGCCAG	ACGTTGGATGAAGGCCATGTGAGGACACAG
rs132631	ACGTTGGATGGGTGGCTCCAACAACCTGATG	ACGTTGGATGATCAACCCTGCTGGCACCTT
rs132632	ACGTTGGATGCTTGGAATTTTTGCCTCCAG	ACGTTGGATGTCAGGATGCCTTAGTAAAC
rs132633	ACGTTGGATGAGAAGAGTGATTACCCAGGG	ACGTTGGATGGGAAAGCTCACTTTCTGGTG
rs132634	ACGTTGGATGAAGTGCCATGGTGCTTTGTG	ACGTTGGATGGAAAGCATGGTGGAAAGCTC
rs132635	ACGTTGGATGAATAGGCACATGGCAGAAGG	ACGTTGGATGCACCAGAAAGTGAGCTTTCC
rs132636	ACGTTGGATGAAGCGTTTGACAATAGGCAC	ACGTTGGATGAAAGTGAGCTTTCCACCATG
rs129603	ACGTTGGATGGTGTCTATATTGACACAGATTG	ACGTTGGATGAGGGTGTATATATATATACCC
rs132637	ACGTTGGATGGCATCTTAGTACACAGCAGG	ACGTTGGATGTTCCCAAATCCCTGCAAACC
rs3788518	ACGTTGGATGAATCCTTCAGAAGGGCTTGG	ACGTTGGATGGCCGCGTTATTAAACCACAG
rs132638	ACGTTGGATGCATCCTTTTCAGTGAAGGAGG	ACGTTGGATGTTGCCAAGGCAACTCAGTGA
rs132639	ACGTTGGATGACACCTGGGCAAACAAAAGC	ACGTTGGATGAAGTTCCTCATAGTTGGCAG
rs132640	ACGTTGGATGTAAGAAGCTCCAGGTGACAC	ACGTTGGATGAAAAGAGTGACTCAGCGTCC
rs132641	ACGTTGGATGAGGGTCAGCTGGGAGCAGA	ACGTTGGATGAGGGCTGAGAGAGGAGGTTG
rs132642	ACGTTGGATGAAGAAGCAAGCCTACCTGAG	ACGTTGGATGAAACGAACCCTTCAGTCAG
rs132643	ACGTTGGATGATCACAGACACCCAGTACAC	ACGTTGGATGACGTTCTGACAATGACCTGG
rs132644	ACGTTGGATGGCATAGAGTGCAAGACACAG	ACGTTGGATGGGGCTCCACTCCCTTAAATA
rs132645	ACGTTGGATGTGAAGGCCAAACAGTACAAGA	ACGTTGGATGAAGTTAACCAAGTGTTTAC
rs2017329	ACGTTGGATGCCTTCCCAATTTAAAGCAGC	ACGTTGGATGGGGCAACAAGAGTGAAATTC
rs739198	ACGTTGGATGAAACTTTGGTCTCCACAACC	ACGTTGGATGTGAGTTTGTCTAAAGACCGG
rs132647	ACGTTGGATGCCTCACTACAGAAACCATGG	ACGTTGGATGAACTCAACTGGTTCAACCAC
rs2097465	ACGTTGGATGGAATTGACCAAACCTGCAGGC	ACGTTGGATGAGGGTTGAAGCTGGATACTG
rs2105915	ACGTTGGATGAACCCAGGAGTTTCAGGACAA	ACGTTGGATGGGGAACCTACAAGTGCATCAC
rs132648	ACGTTGGATGGTGGCTCAGGGCTGTAATTC	ACGTTGGATGTGTCCTGAACTCCTGGGTTT
rs132649	ACGTTGGATGGTCCTCCCCAGTCTTATTAC	ACGTTGGATGATTTCAGAGGTTAGCTGGCTC
rs132650	ACGTTGGATGAAAGTGCTGGGATTACAGGC	ACGTTGGATGCTAAATCTCCTGCCATAGGG
rs132651	ACGTTGGATGAGGTCAGGTGTTGACCTTCC	ACGTTGGATGAGCAGGGTAGGGCATCCTAA
rs132652	ACGTTGGATGAGCAGGGTAGGGCATCCTAAC	ACGTTGGATGAGGTCAGGTGTTGACCTTCC
rs80584	ACGTTGGATGCATGGAGTCCTGTGATCTAC	ACGTTGGATGAACTGAGGCCATGGGAGAT
rs132653	ACGTTGGATGCAGCCGTGCATCTGCATAAT	ACGTTGGATGCACTTTCCCTTTTGGGTTCC
rs916334	ACGTTGGATGAAACAGGATGCTTCCAGCC	ACGTTGGATGCTGCTCTTGATCAGCAGGA
rs132654	ACGTTGGATGTAAGGAAGTGCCAGAAGCC	ACGTTGGATGAAATGATCCTCCTGCCTCAG
rs132655	ACGTTGGATGACTTTTCCAGGTGAAGGTAG	ACGTTGGATGTTGTGCAACGCCATACCTGT
rs132656	ACGTTGGATGTCACTAGAAGCAAGGAACCC	ACGTTGGATGCCAGGTTGACTGAACAAAG
rs3834684	ACGTTGGATGAGCCCTTGTTCCTAGAAAGC	ACGTTGGATGGGTGGATGTGGGAGTAAAG
rs132657	ACGTTGGATGGGCTGACTGACAATTACCTG	ACGTTGGATGAGGGCTCTGAGCTTTTCAAG
rs916335	ACGTTGGATGGATGACGAGAAAAGGTGGG	ACGTTGGATGATTTGAAGGATGCAGTCTTG
rs132659	ACGTTGGATGGGCCCATAGTGGGTCATAAC	ACGTTGGATGGTGGGGTGAGTGCCCAAAAG
rs132660	ACGTTGGATGTACATGTGGTTGTACCCTCC	ACGTTGGATGCTGGCATGGTTTATCCCATC
rs132661	ACGTTGGATGCTTCGAGAAATCATTCCGC	ACGTTGGATGCCAAAATGCAAGCTCAAGGC
rs132662	ACGTTGGATGCATCTCTTAAATGGGCCAGG	ACGTTGGATGTTGAAAGCCACAGCCTCATG
rs132663	ACGTTGGATGCCACTAAACGGATTGAGATC	ACGTTGGATGTGGCTTTCAACCAGCAACTC



dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132664	ACGTTGGATGATCATGCCACTGCAATCCAG	ACGTTGGATGGCATATGTGACTGCTTCCTC
rs132667	ACGTTGGATGCTGGAGAAATCAAATAGAGAG	ACGTTGGATGTGTACAGCTTTTGACAGTTG
rs132670	ACGTTGGATGTAAGGTCGGGAGTTCAAGAC	ACGTTGGATGACGCCCCGGCTGATTTTGTAT
rs132671	ACGTTGGATGGTGAGCCATACCATCACATC	ACGTTGGATGCTGTAGTAAAGGTCTGGTCG
rs132672	ACGTTGGATGCTCCCCAATAAGCTCAACAC	ACGTTGGATGCTGTTAGGGCAATGAAAGGC
rs132673	ACGTTGGATGTGAGTAGTTGGTGTGAGTGG	ACGTTGGATGCAATGGATGAAGCTGATCCC
rs132674	ACGTTGGATGAACTGTAGTCCCAGCTACTC	ACGTTGGATGTAGCTCTATCACTCATGCTG
rs132675	ACGTTGGATGGTAGAGCAGATGTGCAATGG	ACGTTGGATGTCCTAACCATCTGCCTTGTG
rs80585	ACGTTGGATGCTGTTGTTCCAACACTTCAC	ACGTTGGATGGGTCTGCTACTAGAATTGAG
rs80586	ACGTTGGATGGTAAGTGTAAAGAAGGTCTGC	ACGTTGGATGCAAGGCATAATATTCTGACC
rs132676	ACGTTGGATGCAAACATTCTGCAGAAAGCG	ACGTTGGATGAAGCGTGTGCTGAGAAATG
rs132677	ACGTTGGATGCTCTGTTACAAAATGAAGGG	ACGTTGGATGGCTATCTAGGCTAAAAATCCC
rs132678	ACGTTGGATGAAGGCACTGAAAATGCCTAG	ACGTTGGATGGGAATCCAGATGCTTACATG
rs132680	ACGTTGGATGGCCTTAGCTATCATGTTCTC	ACGTTGGATGGCGTGTTTAAGGCAATTCTC
rs132681	ACGTTGGATGTACTGAAGCCTGAGACTAGC	ACGTTGGATGCTAGCAGAACTAACCGAGC
rs132683	ACGTTGGATGTTACCCTATGTTAATGGCAG	ACGTTGGATGACTGATTAGTACAGGAAGGG
rs2269594	ACGTTGGATGTGGCATGGCTAAAAGGACAG	ACGTTGGATGGATTGTTCTGATGCCAGTG
rs132684	ACGTTGGATGCCTTTTAGCCATGCCATTG	ACGTTGGATGTCAGTGTAACAGTGCCACC
rs132685	ACGTTGGATGTCAGTGTAACAGTGCCACC	ACGTTGGATGCCTTTTAGCCATGCCATTG
rs132686	ACGTTGGATGCAGAAATATCCACGTCAGGTG	ACGTTGGATGGACAGCTTAGGACTATGTGC
rs132687	ACGTTGGATGCAACTGTAAGCAGCCATTG	ACGTTGGATGCTGACGGTGCAATGGATAC
rs132688	ACGTTGGATGAGTACTACAGGACGTGCTTG	ACGTTGGATGGGTCGCCTCATATATGGTAG
rs132689	ACGTTGGATGTACTGGGACAGTCTGCTTTC	ACGTTGGATGACTTACAGTGCTGGAGCAG
rs132690	ACGTTGGATGTGTTTGTCTTTCGCTCTCC	ACGTTGGATGTCTGCAACCAACTCTTTGGG
rs132691	ACGTTGGATGGTCAAAGCCAGGCATTTGTC	ACGTTGGATGCTGTCATCTTGTGGAAAGGG
rs132692	ACGTTGGATGGAATCTAAGCCAGCTGTTGG	ACGTTGGATGGGAGCATCATGTGGATTCTT
rs132693	ACGTTGGATGGCCAGAAGAAAAGAGTGTGG	ACGTTGGATGATTCTGCATGTGGAACGTCC
rs132694	ACGTTGGATGATAGAGACTGAGAGCTGCAG	ACGTTGGATGCAGAACAAAGCAGGAAGCTC
rs132695	ACGTTGGATGGCCTCTCTCTATGACTACAC	ACGTTGGATGTTACAGCAGGGAACCTTTC
rs1966266	ACGTTGGATGTGATTGTACAAGGCAGACCC	ACGTTGGATGTGTAAGCACCTGCATTGAGC
rs1966267	ACGTTGGATGTAAGTACAGACCATGAGGG	ACGTTGGATGGGAGGAAAGCACAGCAGAAT
rs106808	ACGTTGGATGAACAAGGCAGATCCTTCCCG	ACGTTGGATGATGGTTCCTGAAGAGCAGTG
rs132696	ACGTTGGATGATGGTTCCTGAAGAGCAGTG	ACGTTGGATGAACAAGGCAGATCCTTCCCG
rs2239829	ACGTTGGATGTGTCTTTGTGCTTCGGATGG	ACGTTGGATGAAAGAGCGAAACTCCGTCTC
rs2285154	ACGTTGGATGTGAAGTCAAATGATCCGCCC	ACGTTGGATGAAGAACCCTTTTCGACTGGG
rs2239830	ACGTTGGATGAAACCCTAATGGGAAGCCTC	ACGTTGGATGTGTGGTAGCAAGCAGTTGAC
rs2239831	ACGTTGGATGAGAACAGTCACTGACCCAAG	ACGTTGGATGGCTCCACACACTTTGATTCC
rs3865722	ACGTTGGATGCCACTGTACTGCTAGTATTG	ACGTTGGATGACCTGCTCTAGTTTTCATCC
rs3865723	ACGTTGGATGCCTGCATTTGATGCAATTCC	ACGTTGGATGGTTTCTGTTTCTGTTGCTTGC
rs3985996	ACGTTGGATGACATGGGTGACCCTATCAAG	ACGTTGGATGTGATTCTAGGAGCAGGACTG
rs3985997	ACGTTGGATGCAAGAATTTCTCCCGGCATC	ACGTTGGATGTGATTCTAGGAGCAGGACTG
rs3985998	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGCAAGAATTTCTCCCGGCATC
rs3985999	ACGTTGGATGTGATTCTAGGAGCAGGACTG	ACGTTGGATGCAAGAATTTCTCCCGGCATC
rs3986000	ACGTTGGATGCAGGCAGAGGATTTGTTTGG	ACGTTGGATGCTTCTGTCTTCTCTGTGTC
rs2413382	ACGTTGGATGAAACAAATCCTCTGCCTGGG	ACGTTGGATGAAAAGCCCAGAGCCTTCATG
rs2413383	ACGTTGGATGCTGGGCTTTTGTGCTAAGAG	ACGTTGGATGGGGCCAAGTTGACCCATAAA
rs2413384	ACGTTGGATGCTGGGCTTTTGTGCTAAGAG	ACGTTGGATGGGGCCAAGTTGACCCATAAA

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs2413385	ACGTTGGATGAATGGTCTTCGCTGATACAC	ACGTTGGATGATGGAAGCCGGTGTTCGATG
rs2413386	ACGTTGGATGTTTTATGGGTCAACTTGGCC	ACGTTGGATGTTCCAAAATGGTCTTCGCTG
rs1894606	ACGTTGGATGTTTTATGGGTCAACTTGGCC	ACGTTGGATGAGACTCCTGCAAAAGCTTCC
rs916336	ACGTTGGATGGGATGAGGGTATTTGCTGTC	ACGTTGGATGGGCCTGTATGTAGGTTGAAG
rs916337	ACGTTGGATGAGATCAGAAGGGCCTGTATG	ACGTTGGATGATTTGCTGTCTGGCTGTCTC
rs916338	ACGTTGGATGATTTGCTGTCTGGCTGTCTC	ACGTTGGATGAGATCAGAAGGGCCTGTATG
rs132697	ACGTTGGATGCATGAGGAAGAGAAGTCAGG	ACGTTGGATGACACTGACTGATGACTGAGC
rs12781	ACGTTGGATGTTACACACAGGGCACTCAGC	ACGTTGGATGGAGCCAGAAAATTAAGTAAAA GC
rs1053983	ACGTTGGATGCCATCATCAAGAAGCCACTG	ACGTTGGATGTGCTTACCAGCATCCACTC
rs1053982	ACGTTGGATGGGAGAGTGGATGCTGGTAAG	ACGTTGGATGCGGTTGAATGTCTTCCAAG
rs2227167	ACGTTGGATGCTCCTGAGTGTATGGACATC	ACGTTGGATGGGCATTAAGGGACATTCTGC
rs2227168	ACGTTGGATGCCAATTGGAGGCATTAAGGG	ACGTTGGATGCTCCTGAGTGTATGGACATC
rs132700	ACGTTGGATGAATGTGGTGTCTGGCTCCAC	ACGTTGGATGCTCAGCCCTGCTGTAAATGG
rs3075364	ACGTTGGATGGAACAGCAGTTTAGGGAGTG	ACGTTGGATGCGAAGCCTTTCTATGGACTC
rs2227169	ACGTTGGATGAGGTAAGTAAGCTGCCTTTC	ACGTTGGATGTTCAAGCCTTCATAGAGAGC
rs2097466	ACGTTGGATGCTGGGATTACAAGCATGAGC	ACGTTGGATGCTGCATAAATCACAGAGCTG
rs2097467	ACGTTGGATGATCTCCTGACCTTGTGATCC	ACGTTGGATGATTCTTTCAAGGCCGGGCG
rs2413387	ACGTTGGATGAAGTAGCTGGGACTACAGGC	ACGTTGGATGTAACACGGTGAAACCCCGTC
rs132701	ACGTTGGATGGTGGCATATCTATGTTGTAC	ACGTTGGATGGCGAGACTCCATCTCAAAAA
rs132702	ACGTTGGATGGAAGCTCACCCAGTTAAGGA	ACGTTGGATGCCCTGTAAACAACATCCTG
rs132703	ACGTTGGATGCTTGACCTGATCAATGTGTG	ACGTTGGATGTTTGTGCAGTTCCTCAGAAG
rs2269595	ACGTTGGATGAGAAGTTTCAGGAAAAGGGCC	ACGTTGGATGCAGCAGGACTTTCTTTGGGA
rs2269596	ACGTTGGATGAGGTGCTCAGTTAGCGTTAC	ACGTTGGATGTCCCAAAGAAAGTCCTGCTG
rs132704	ACGTTGGATGATATTCTTCCTGCACTGCTG	ACGTTGGATGATCTCCCCGGGCTAGTTTTT
rs2007468	ACGTTGGATGAGGTTACCTGGGCAATTCAG	ACGTTGGATGGAAAATCCTGCTGACTAGCG
rs132705	ACGTTGGATGTTTTGATGGAGGCACCAAGTG	ACGTTGGATGTCTCCAAATACGGTCACTGG
rs2007706	ACGTTGGATGCCCAGGAATTTACATAAGGG	ACGTTGGATGTTGAACATAGCAAGAGTGAG
rs132706	ACGTTGGATGAAGGATCAGTGCTGAGGGTC	ACGTTGGATGATTCTCCTGCTGGTCATGG
rs132707	ACGTTGGATGAATCCTTAGGAAGGGCTGGG	ACGTTGGATGAGCTGGCCCCGTTAGTAAAC
rs132708	ACGTTGGATGTCTTGTTTCAGAGGGAGAGC	ACGTTGGATGTCTCAGCCAATCCCAGAATC
rs132709	ACGTTGGATGTGAGTCCTGTCCAAGATGAG	ACGTTGGATGAGCCCTTCCTAAGGATTCTG
rs132710	ACGTTGGATGTGAGTCCTGTCCAAGATGAG	ACGTTGGATGCCTAAGGATTCTGGGATTGG
rs132711	ACGTTGGATGTCATCTTGACAGGACTCAG	ACGTTGGATGTTGCCATGGCAACCAAGTCA
rs132712	ACGTTGGATGGTCTTCAAGGCTGAGTGAGC	ACGTTGGATGACTCCACGTGGCCTCTCTTG
rs132713	ACGTTGGATGAAGGCTGAGTGAGCCCCAAC	ACGTTGGATGACTCCACGTGGCCTCTCTT
rs132714	ACGTTGGATGACACGGTGAAACCCCTTCTC	ACGTTGGATGAGTAGCTGGGACTACAGGTG
rs132716	ACGTTGGATGTGGATTGCAATGAGGAGTC	ACGTTGGATGTCAATGACTGTGCTCTACTC
rs132717	ACGTTGGATGAATGTGGGCAGTTTTACGTG	ACGTTGGATGGATGGACCTTAGGGTGTTC
rs132718	ACGTTGGATGTCAGAGGGTATCAACATCTC	ACGTTGGATGTGGGCATCTTCATATACTGC
rs132719	ACGTTGGATGATACCTCAGTTGTACCCAG	ACGTTGGATGCTGAACAAAGGAGAAGGAGG
rs132720	ACGTTGGATGATACTGGGTACAAGTGAAGG	ACGTTGGATGCCTCTCCACCTTTTCTAAC
rs132721	ACGTTGGATGCAGCTACAAAGTTGCTAATGG	ACGTTGGATGTCTTATTTGTACCCTCCCTC
rs132722	ACGTTGGATGACAATGGTAATGCTTGGAGC	ACGTTGGATGGGGAGGGTACAAATAAGATG
rs132723	ACGTTGGATGACACAGATGTCTGTCTTCTG	ACGTTGGATGATACTCCCCTGGTGAATGCT
rs132724	ACGTTGGATGCCCCATGCAACAAGGGTAAA	ACGTTGGATGTGTCCCTTACAGCAAGAAGC
rs132725	ACGTTGGATGCCCCATGCAACAAGGGTAAA	ACGTTGGATGTGTCCCTTACAGCAAGAAGC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs132726	ACGTTGGATGGGGTCACACAGTGAACAAAG	ACGTTGGATGTTCTTGCTGTAAGGGACAGG
rs132727	ACGTTGGATGGGGTCACACAGTGAACAAAG	ACGTTGGATGTTCTTGCTGTAAGGGACAGG
rs132728	ACGTTGGATGAGTTCTACTGGCTCATGGTG	ACGTTGGATGTTGCGCTTCTTCCTGCTTTG
rs132729	ACGTTGGATGAGTTCTACTGGCTCATGGTG	ACGTTGGATGTTGCGCTTCTTCCTGCTTTG
rs132730	ACGTTGGATGTTGCGCTTCTTCCTGCTTTG	ACGTTGGATGAGTTCTACTGGCTCATGGTG
rs132731	ACGTTGGATGTTTGTTCACTGTGTGACCCC	ACGTTGGATGTCCTGGTCTCCAGTTCTA
rs132732	ACGTTGGATGGCCAAGGCAACCATCTCAAC	ACGTTGGATGTGCAGCTCATCACAAGCGTC
rs132733	ACGTTGGATGGCCAACCATCTCAACACCATG	ACGTTGGATGTGCAGCTCATCACAAGCGTC
rs140575	ACGTTGGATGTGCAGCTCATCACAAGCGTC	ACGTTGGATGCCATCTCAACACCATGAGCC
rs132734	ACGTTGGATGGGATACTGACTGTTAGCCTC	ACGTTGGATGCGGAATTGACCAACTGGTAG
rs132735	ACGTTGGATGGGATACTGACTGTTAGCCTC	ACGTTGGATGCGGAATTGACCAACTGGTAG
rs80587	ACGTTGGATGTCTGAGCCAAGCTCACCAGA	ACGTTGGATGTTTTCTGCCAAGGAGGAG
rs132736	ACGTTGGATGTTTTCTGCCAAGGAGGAG	ACGTTGGATGAAGCTCACCAGATGCAGACG
rs132737	ACGTTGGATGTCTAGGCAGCAATGAGCTAG	ACGTTGGATGTGCTCCTCCTGAGAAATCAC
rs132738	ACGTTGGATGTGAAGCCTGTAATCCAGTG	ACGTTGGATGCATAGAGACAGCATCTCCTG
rs1807673	ACGTTGGATGTTGCAGTGAGCAGAGATTGC	ACGTTGGATGGTGAAATCTGAGTCGTGGTC
rs2014700	ACGTTGGATGTTGCAGTGAGCAGAGATTGC	ACGTTGGATGGTGAAATCTGAGTCGTGGTC
rs132739	ACGTTGGATGGGAATCAAAGAAGGTGGAGG	ACGTTGGATGTGTTGTGGCCAGACCATAA
rs1812023	ACGTTGGATGAGCAGGAGGGAGGGAGCAAT	ACGTTGGATGGACCTCCCTCCATCTCCTTA
rs1812024	ACGTTGGATGTGTCAGAGGAAGATCCCTTG	ACGTTGGATGCCTCATAGAGCTATTGCGAG
rs2005590	ACGTTGGATGGGAGGCAATGCCTGATTTTG	ACGTTGGATGTGCTCCACCACCTGGAAAA
rs132740	ACGTTGGATGTTCACTTCTTGTGCACAG	ACGTTGGATGCTTGACTGGTACCTAACAATG
rs3986001	ACGTTGGATGTTTTCTGACTTGGCATCACC	ACGTTGGATGCACAAAGTATTCCACCTTCC
rs2413390	ACGTTGGATGATAAATTCGTGGCTGAGCTC	ACGTTGGATGATCTTGTGGCATAAGGAGTC
rs132743	ACGTTGGATGACAGGGAGAAAGTGAGGAAG	ACGTTGGATGCATCCTGTTTCCCCTAAAGG
rs132744	ACGTTGGATGGGGTCTGTTTCAGGAGCATG	ACGTTGGATGTCTATGGCTGATGGCCACAG
rs2413391	ACGTTGGATGGGGCAAAGCAGAAATACTG	ACGTTGGATGCCCTCAAACCCTGTTTTCTG
rs132749	ACGTTGGATGCCATGCACTCTCTAGTACTC	ACGTTGGATGTGTGGCCTTGGGGAAATGAT
rs132750	ACGTTGGATGTCCTGTGCCTGTGGAAACTC	ACGTTGGATGGGTTCTCCAGGTGGCAAAAG
rs132741	ACGTTGGATGCTACAATTTATCCGCACTAG	ACGTTGGATGGCCAAGTCAGAAAAATGAGAG
rs2413388	ACGTTGGATGTACAGAATTCAGACCAACCC	ACGTTGGATGGCCCTGAGATTTGATTTTCC
rs2413389	ACGTTGGATGGCTAGAATCTCATAACAGACG	ACGTTGGATGGCGTCCTACTATGATTTGTC

TABLE 12

dbSNP rs#	Extend Primer	Term Mix
rs3888818	TGAGACCAGCCTAGCCAAC	ACT
rs2010605	TGGTCCCAAGATATTCTATAGA	ACT
rs743919	CTCACCTAAGGACTGCCTCT	ACT
rs1008134	CCGGGCATCTTTTCTTCCATC	ACT
rs132607	GCAGGCAGGACAGCATGTG	ACT
rs1476029	CTTAGAGGCTATATTAAGACCA	ACG
rs1476030	TTTGGCAATACTGGCCTATTCT	ACT
rs2413380	TCCAGGAGGGAAGACAACC	ACT
rs2051609	CGCTTGAGGTCAGGACCAG	CGT

dbSNP rs#	Extend Primer	Term Mix
rs2413381	GCGTGTGCGCAACAGCCTC	ACT
rs1894604	AAATGGGAGGGAATGTTGGC	ACG
rs1894605	TGCAGATCGCAACTGAGCG	ACT
rs132609	GTTTCTCAGAGGATCAGGGA	ACT
rs132610	GGTGTGAGATTTGGAGACTTT	ACG
rs132611	CTCTGTCTCTAGCCCC	ACT
rs132612	ATCTTCCCGCTACCTCAAGAGT	ACT
rs1008790	CATAATCACAAGTCCTATGATTA	ACT
rs23085	AGGATGACCATGGCAAGGAA	CGT
rs105161	GGCCCTGGCAGGAAACAG	ACG
rs132613	CCAATGGCCTCCACTGGC	ACT
rs132614	CGGCCACAGCGCTGCC	ACG
rs132615	GCTTTCAGAACAACGGTAGAA	ACT
rs132617	AAGAGTGTGTGTGCAGTAGCAAG	ACG
rs3865724	TCACTTAAGCTTTGAATGTTTCTG	ACT
rs2019657	GCCAGAACATTGTGTTTCATTTGT	ACG
rs3865725	GGCAAGAGATACAGAATGCACA	CGT
rs2019364	GTATCTCTTGCCCCTGCTC	ACG
rs2008383	GAAGGACAGAAGGCTGATGC	ACG
rs3986002	TCCTTCTCTGTGTCACTCCT	CGT
rs3888942	ACATGGAAGCAGGGGTTTGA	CGT
rs3888943	AGCAGGGGTTTGATGAAATCT	ACT
rs3888944	CATCCTCCACATTGGGCCAA	ACT
rs132618	AATCTCAGCTGGAAGTGG	CGT
rs132619	TGCAACCAGCATTGACCG	CGT
rs3827346	GAGGCTGCACCATCTCCAA	ACG
rs132620	GGAAGCCTTTATTCAGGATTGT	ACT
rs132621	TCAAATCTGCAACTGGTGTGAGAA	ACT
rs80575	GAAGCTCTCAAGCCACTTGAC	ACT
rs80576	GCTAAGGCATTAGTTTGGCTGG	ACG
rs80577	TGAAATTGCACATGGCATTGG	ACG
rs80578	ATGCCTGGGAAGTGGGGC	ACT
rs80579	GGGAGGCACTGAGGGCATGAAA	ACT
rs80580	CTGAGAATGAACAGCAGGTCA	ACT
rs132622	ATAGTAGTTCAATCAGATGGGC	ACT
rs132623	ATTCCAGCCTCTCTGTGTTCTG	ACT
rs132624	ACAGGCATGAGCCGCTGC	ACT
rs132625	GGCCACCGCATCCGGCTA	CGT
rs132626	AGTGGCATGATCTCGGCCAC	ACG
rs132627	GAGGCGGAGGTTGCGGTG	ACT
rs1807672	CATTGAGAATAAGGTGGTTCTGA	ACT
rs132628	CCTCCAAATTCATATACTGAGACC	ACG
rs132629	TCTCTCTCTCTCACACAC	CGT
rs132630	CTGCTCCTGGCTTACAGAG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132631	TCACAGTTCTGGAGGCAAAAA	ACT
rs132632	TGGAATTTTTCCTCCAGAACTGT	ACT
rs132633	AGTGATTCACCAGGGAAGTGCCA	ACG
rs132634	GGTGCTTTGTGGAGGAACC	ACT
rs132635	ATTTCCCGTACATGGGGAGAAA	ACT
rs132636	TGACAATAGGCACATGGCAG	ACT
rs129603	GCTGCCATCCTAAACACATCTA	ACT
rs132637	ACACAGCAGGATTACTGCCCAGA	ACT
rs3788518	TGGGAGGCTCAAGGAAGAACTCT	ACT
rs132638	GGAAAAAATAAAAGCAAAATACCC	ACT
rs132639	AAAGCAAACAGGCCTTCAGAA	CGT
rs132640	GGTGACACAGAGAAGACGTGGC	ACT
rs132641	GGGAGGTCAGAGGTCGGG	ACT
rs132642	GTCAGTGAAGAGACTTTCC	CGT
rs132643	GACACCCAGTACACACTGGCT	ACT
rs132644	TTTGAATGAGGAGTCATTTACA	ACT
rs132645	CTCAACAGTAAGCAAGATTTAAA	ACT
rs2017329	TGATGTTCAAGTTTTCCTTTTTT	CGT
rs739198	TGGTCTCCACAACCTCTTATC	ACT
rs132647	AAACCATGGAAGTCTCTAGAGTCA	ACT
rs2097465	CAAAGTGCAGGCTTGCCCAG	ACT
rs2105915	CAAGCCTGGGCAGCATAGCAC	ACT
rs132648	AATTCCTGTGCTAATGCACG	ACT
rs132649	CAGTCTTATTACTTTTGTACGAGG	ACT
rs132650	CATGAGCCACCGTGCCAG	ACT
rs132651	CCTCAGGGTTTTTCACCTGCCT	ACT
rs132652	AGGGCATCCTAACCCCCTA	CGT
rs80584	ATCTACCTGCTCAACTTCCTGA	ACG
rs132653	AATAACCAGACACGTTCTCCAG	ACT
rs916334	GTCCAGCAGCACCCCTTGGT	ACG
rs132654	CGACAAGAGCAGGTCTGGAAC	ACT
rs132655	CAGAAGAACCCACATAAGGAA	ACT
rs132656	TCTTTGTCTTTTACTCCCACATCC	ACT
rs3834684	CACTAGAAGCAAGGAACCCCC	ACT
rs132657	TACCTGACAATCACCCCCC	CGT
rs916335	TCAGGTAATTGTCAGTCAGCC	ACT
rs132659	AGAACTCCCCAAATCGTCCT	ACG
rs132660	CCCCAGAGTGGGCTTTTCT	ACT
rs132661	CCGCTCTCCCTCTGAGAGT	ACT
rs132662	TGATCTGAGTTTACAGGTGAG	ACT
rs132663	TGAGATCTGTCTCAGACGCA	CGT
rs132664	CTGGGCTAGAGAGGGAGAC	ACT
rs132667	CTTTAACTTTTGTCTACAAGAGT	ACT
rs132670	AGACCAGCCTGATCAACATG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132671	ACATCAATAGGCCTAAAAATCGTT	ACT
rs132672	GAAACTTGAAATTCCTTGAGAAAT	ACT
rs132673	GTGTGAGTGGGAAGCCTCC	ACG
rs132674	GGAGTTGGAGGCTGTAGTAA	ACT
rs132675	AGATGTGCAATGGAATTTGCAA	ACT
rs80585	AGGCATAATATTCTGACCATTAAAG	ACG
rs80586	GGTCTGCTACTAGAATTCAGAA	ACG
rs132676	ATCCCTTAATATTGCATAGGAC	CGT
rs132677	GGGTTGAAGTACTATGCTAGT	CGT
rs132678	AGGTTAGTTCATGTAAGTCCAT	ACT
rs132680	TTTTATTTTAGCTTGAGCTTTTCA	ACG
rs132681	CTAGCTCTAAATCACATTCTGC	ACG
rs132683	CAGGCCCATACCCAAAATATGCT	ACT
rs2269594	TGGCTAAAAGGACAGATAGAG	ACT
rs132684	GACACTAAGAGCGGTGAGAC	ACT
rs132685	CGTGCCACCCAACTGGAGA	ACT
rs132686	TGTGCATCTTATGGTGTACCA	ACG
rs132687	TCGTTACCCCCATTCTATCC	ACT
rs132688	ACAGGACGTGCTTGAAAGAG	ACG
rs132689	TGGCGATGGCCTCTGCTC	ACT
rs132690	GCTCTCCTTGCTTCAAAAAAAAAA	CGT
rs132691	TGACCTATCCTGCTTCAGGT	ACT
rs132692	CGAAGTGTGTTAGCTCATGAC	ACT
rs132693	GAGTGTGGACACCAGGTCA	ACT
rs132694	CACCTTAGGAATGGCAGCTTC	ACG
rs132695	TATGACTACACATGCTGGCAAAC	ACT
rs1966266	GCAGACCCCTAACTCTAATTTG	ACG
rs1966267	CACTGAGTTATGAGTACTCAAC	ACT
rs106808	GATCCTTCCCGAGGACACC	ACT
rs132696	CAGGCTGCCTGGAAGGAGA	ACT
rs2239829	GATGGCTGGATTACATAACAGGTAA	ACT
rs2285154	AGTGCTGGGATTACAGGCAT	ACT
rs2239830	CAGTCACCTGAATTTGTGCTTATT	ACT
rs2239831	GTCAGTACCCAAGCTATCCTC	ACG
rs3865722	CAATTGCAAGCAACAGAAACAGAA	CGT
rs3865723	TCCACTGTACTGCTAGTATTG	ACG
rs3985996	AGAATTTCTCCCGGCATCAG	ACG
rs3985997	TCTCCCGGCATCAGCCTTC	ACG
rs3985998	GGGAGGAGTGACACAGAGAAGGA	ACG
rs3985999	GGGGTACTGGGAGGAGTGACAC	ACT
rs3986000	GCAGGACTGGGGTACTGG	ACT
rs2413382	CAGGGGAACTCAGGCCACA	ACT
rs2413383	AGCCATTGAAGACATGGAAGCC	ACT
rs2413384	ATTGAAGACATGGAAGCCGG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2413385	GGCCAGCTCTTCCTCCAC	CGT
rs2413386	CTTGCCCCAATGTGGAGGA	CGT
rs1894606	CCTAGCGGCAAGGGCTGT	ACT
rs916336	AGGGTATTTGCTGTCTGGCTGTCT	ACT
rs916337	AAGGGCCTGTATGTAGGTTGAA	ACT
rs916338	CCCTCTATGTCTCATGGATTTTCC	ACG
rs132697	CCTAGGGGAGCCCATATATCA	ACT
rs12781	AGACAGCTCGAGAGATCC	ACT
rs1053983	GCTGACTCAGATACACCCC	ACG
rs1053982	GATGCTGGTAAGACAGGG	ACG
rs2227167	CGTCAAATCAAGTGCAA	ACT
rs2227168	CATTAAGGGACATTCTGC	ACT
rs132700	ATCCTGTCTGTCATTGGCGTT	ACT
rs3075364	GTTTAGGGAGTGGTTTTTGAAG	CGT
rs2227169	TGTCCTTTATTGGTACAGGGAAGA	ACT
rs2097466	TACAAGCATGAGCCACCGC	ACT
rs2097467	TCCCAAAGTGCTGGGATTACA	ACT
rs2413387	TACAGGCACTCACCACCAC	ACT
rs132701	TGTACAAAACATATTTAACCTTGA	ACT
rs132702	CACCCAGTTAAGGAAAAATTCCT	ACT
rs132703	GATCAATGTGTGTTCCCGGA	ACT
rs2269595	GCCCCAGACAGCATCTCC	ACT
rs2269596	TTGCTGGCAAGAGACCAGG	ACT
rs132704	GGGCTGCCTGGAGGAGG	ACG
rs2007468	TGGGCAATTCAGCCACACGCAC	ACT
rs132705	TATAGACTGAATTGTGTGCC	ACG
rs2007706	GGAATTTACATAAGGGTCTATAG	ACT
rs132706	GAACCCCTCCACTGCCC	ACT
rs132707	GCTCTCCCTCTGAAACAAGATG	ACT
rs132708	GAGAGCTTCTTCCTTGCC	ACT
rs132709	CAGGGAAGATTAGAAGCTGAGAGC	CGT
rs132710	GGGCAGGGAAGATTAGAAGC	ACG
rs132711	TTTGCTGTCCAGGGCGGC	ACG
rs132712	AACCCAGACGGAGGTGGC	ACG
rs132713	GCCCCAACGGAACCCAGA	ACG
rs132714	CCCCTTCTCTACTGAAAATACAAA	ACT
rs132716	TGAGGAGTCATTTACCATGAG	ACG
rs132717	GCAGTTTTACGTGAAGGAGG	ACT
rs132718	GTTTTATACCTAGAGCCACACT	ACT
rs132719	TACCCAGTATTTCTTAACCTCC	CGT
rs132720	CAGCTACAAAGTTGCTAATGG	ACT
rs132721	ATGTTAGGAAAAGGTGGAGAG	ACT
rs132722	CCTAACTGGGATGGGCCTGAA	ACT
rs132723	TTCTGGGGCCCCCATGCA	ACT

dbSNP rs#	Extend Primer	Term Mix
rs132724	ACCCAGTCCTGGGCAGCA	ACT
rs132725	GGGAGTATGCAGAGGGGC	ACT
rs132726	CAGTGAACAAAGCAGGAAGAAGG	ACT
rs132727	GTCACACAGTGAACAAAGCAGGAA	ACT
rs132728	CATGGTGTTGAGATGGTTGCC	ACG
rs132729	GCTCATGGTGTGAGATGGTT	ACT
rs132730	GTGACCCCCTAGGCCAAGGCA	ACT
rs132731	GGCAACCATCTCAACACCAT	ACT
rs132732	AACCATCTCAACACCATGAGCCA	ACT
rs132733	ATCTCAACACCATGAGCCAG	ACT
rs140575	GCTCTCTCCTGGTCCTCC	ACG
rs132734	AGCCTCAACTAGGACACA	ACT
rs132735	TCAACTAGGACACAGTGC	ACT
rs80587	GCCAAGCTCACCAGATGCAGA	ACT
rs132736	AGGGAGCTGCTTTGCTGAAA	ACT
rs132737	CCTGCAGCCTGGGTGACA	ACT
rs132738	GGCCAGGAGTTCAAGACAGCCTG	ACT
rs1807673	GGGCAACAGAGCGAGACTCC	ACT
rs2014700	GAGCGAGACTCCATCTCA	ACT
rs132739	GGGAGGTGACCTGGAGCC	ACG
rs1812023	GCAATCAGACTCAAGCCTGG	ACT
rs1812024	GGGATGGTGTGACCTCCC	ACG
rs2005590	CAATGCCTGATTTTGTCACTGAAC	ACT
rs132740	GGCATATGTGCATTTGTCTGAG	ACG
rs3986001	TCCTTTTTCTAAACCCCTGCAA	ACT
rs2413390	GGCTGAGCTCAAGGTTTTAAA	ACT
rs132743	GGAGAAAGTGAGGAAGAAAATTA	ACT
rs132744	TGGGGTTACAGTTGGTCATAACC	ACT
rs2413391	TGATATGTTTCAGCGGTGCAC	ACT
rs132749	TCTTGATGTTTCTCCTATCCC	ACG
rs132750	CCTGTGGAAACTCAGCAGC	ACG
rs132741	GCACTAGATATTGAATTCTTTCC	ACT
rs2413388	CAACCCCGTGAAGGAGATTTC	CGT
rs2413389	TTTCTCTCTCTAGTACTCTATTT	ACT

### Genetic Analysis

[0229] Allelotyping results from the discovery cohort are shown for cases and controls in Table 13. The allele frequency for the A2 allele is noted in the fifth and sixth columns for osteoarthritis case pools and control pools, respectively, where “AF” is allele frequency. The allele frequency for the A1 allele can be easily calculated by subtracting the A2 allele frequency from 1 (A1 AF = 1-A2 AF). For example, the SNP rs2010605 has the following case and control allele frequencies: case A1 (A) = 0.19; case A2



(G) = 0.81; control A1 (A) = 0.18; and control A2 (G) = 0.82, where the nucleotide is provided in paranthesis. Some SNPs are labeled “untyped” because of failed assays.

TABLE 13

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.81	0.82	0.782
rs743919	1095	34782445	G/T	0.10	0.11	0.502
rs1008134	2201	34783551	A/C			
rs132607	7879	34789229	A/G	0.11	0.11	0.813
rs1476029	8395	34789745	C/T	0.15	0.15	0.983
rs1476030	8461	34789811	C/T	0.36	0.37	0.708
rs2413380	9503	34790853	C/T	0.29	0.29	0.900
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.08	0.08	0.759
rs1894605	16444	34797794	G/T	0.08	0.09	0.468
rs132609	17591	34798941	C/T	0.68	0.67	0.777
rs132610	17988	34799338	-/A			
rs132611	19116	34800466	-/T	0.14	0.15	0.863
rs132612	19358	34800708	C/T	0.23	0.23	0.951
rs1008790	20300	34801650	A/G	0.03	0.10	0.007
rs23085	20669	34802019	A/T	0.31	0.32	0.738
rs105161	20891	34802241	A/G	0.76	0.77	0.826
rs132613	21451	34802801	C/T	0.80	0.81	0.619
rs132614	21978	34803328	C/T	0.16	0.14	0.434
rs132615	22785	34804135	C/G	0.32	0.31	0.740
rs132617	24248	34805598	C/T	0.35	0.36	0.825
rs3865724	24770	34806120	C/T	0.65	0.65	0.940
rs2019657	24844	34806194	A/G	0.20	0.20	0.857
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.40	0.39	0.767
rs2008383	25309	34806659	A/G	0.18	0.17	0.665
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.43	0.43	0.934
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.84	0.84	0.976
rs132620	29648	34810998	-/A	0.29	0.29	0.879
rs132621	29986	34811336	A/G	0.32	0.31	0.867
rs80575	30217	34811567	G/T	0.27	0.27	0.948
rs80576	30267	34811617	A/G	0.26	0.25	0.443
rs80577	30315	34811665	A/G	0.26	0.23	0.191
rs80578	30585	34811935	C/T	0.49	0.48	0.548
rs80579	30724	34812074	A/C	0.23	0.25	0.574
rs80580	30897	34812247	C/T	0.31	0.31	0.878
rs132622	30931	34812281	C/T	0.29	0.30	0.943
rs132623	31080	34812430	G/T	0.60	0.59	0.806
rs132624	31246	34812596	C/T	0.36	0.37	0.772
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.89	0.84	0.082
rs132627	31467	34812817	A/G	0.12	0.11	0.836
rs1807672	32188	34813538	G/T	0.30	0.30	0.974
rs132628	32288	34813638	C/T	0.25	0.24	0.691
rs132629	32520	34813870	A/T	0.04	0.06	0.250

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132630	32594	34813944	A/C	0.75	0.75	0.978
rs132631	32657	34814007	A/C	0.72	0.73	0.509
rs132632	32677	34814027	A/G	0.66	0.65	0.798
rs132633	32764	34814114	C/T	0.34	0.33	0.796
rs132634	32784	34814134	A/G	0.45	0.42	0.317
rs132635	32830	34814180	C/T	0.41	0.40	0.772
rs132636	32872	34814222	C/T	0.41	0.44	0.192
rs129603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.09	0.09	0.628
rs3788518	33952	34815302	C/G	0.17	0.19	0.297
rs132638	34184	34815534	C/G	0.56	0.58	0.509
rs132639	34361	34815711	A/T	0.13	0.12	0.561
rs132640	35026	34816376	A/G	0.32	0.30	0.388
rs132641	35192	34816542	A/G	0.48	0.51	0.287
rs132642	35600	34816950	A/T	0.15	0.14	0.732
rs132643	36033	34817383	C/T	0.44	0.46	0.360
rs132644	36289	34817639	C/T	0.53	0.58	0.075
rs132645	38869	34820219	A/G	0.19	0.18	0.572
rs2017329	39629	34820979	A/T	0.39	0.40	0.915
rs739198	40530	34821880	C/T	0.70	0.70	0.878
rs132647	41621	34822971	C/T	0.23	0.23	0.957
rs2097465	42379	34823729	C/T	0.54	0.51	0.344
rs2105915	42802	34824152	C/T	0.57	0.56	0.468
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.21	0.22	0.579
rs132650	45051	34826401	C/T	0.34	0.31	0.248
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs80584	46257	34827607	C/T	0.81	0.75	0.043
rs132653	47286	34828636	A/C	0.17	0.15	0.312
rs916334	47427	34828777	C/T	0.34	0.36	0.345
rs132654	47963	34829313	C/T	0.54	0.56	0.439
rs132655	48013	34829363	C/T	0.41	0.41	0.838
rs132656	48229	34829579	C/T	0.37	0.36	0.813
rs3834684	48282	34829632	-/A	0.21	0.22	0.480
rs132657	48376	34829726	-/G	0.49	0.50	0.719
rs916335	48404	34829754	A/G	0.38	0.36	0.509
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.37	0.38	0.754
rs132661	52897	34834247	A/G	0.27	0.29	0.291
rs132662	53414	34834764	A/G	0.61	0.58	0.186
rs132663	53487	34834837	A/T	0.26	0.29	0.167
rs132664	54112	34835462	G/T	0.25	0.29	0.098
rs132667	55492	34836842	A/G	0.35	0.36	0.559
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.49	0.53	0.145
rs132672	60701	34842051	A/G	0.23	0.22	0.716
rs132673	60952	34842302	A/G	0.41	0.37	0.184
rs132674	61401	34842751	C/T	0.32	0.31	0.476
rs132675	62379	34843729	C/T	0.38	0.35	0.188
rs80585	62870	34844220	C/T	0.28	0.27	0.525
rs80586	62879	34844229	A/G	0.66	0.66	0.966
rs132676	63499	34844849	A/T	0.26	0.23	0.177
rs132677	64284	34845634	-/A	0.69	0.69	0.873
rs132678	64408	34845758	A/G	0.46	0.48	0.395
rs132680	64760	34846110	A/G	0.20	0.20	0.995
rs132681	65230	34846580	A/G	0.24	0.24	0.901

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132683	66127	34847477	A/G	0.19	0.19	0.851
rs2269594	66634	34847984	C/T	0.70	0.67	0.332
rs132684	66686	34848036	A/G	0.21	0.20	0.756
rs132685	66694	34848044	C/G	0.30	0.28	0.553
rs132686	67113	34848463	A/G	0.46	0.48	0.398
rs132687	67257	34848607	A/G	0.96	0.96	0.767
rs132688	67403	34848753	A/G	0.24	0.23	0.553
rs132689	67609	34848959	A/G	0.61	0.63	0.564
rs132690	68418	34849768	-/A	0.16	0.17	0.672
rs132691	68610	34849960	C/G	0.52	0.52	0.976
rs132692	69629	34850979	C/T	0.63	0.62	0.800
rs132693	70024	34851374	A/G	0.58	0.58	0.868
rs132694	70848	34852198	A/G	0.17	0.16	0.583
rs132695	71428	34852778	C/G	0.23	0.22	0.616
rs1966266	71553	34852903	C/T	0.49	0.47	0.413
rs1966267	71633	34852983	A/G	0.40	0.41	0.773
rs106808	71768	34853118	A/C	0.68	0.67	0.617
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.34	0.36	0.510
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.49	0.50	0.841
rs2239831	73547	34854897	C/T	0.52	0.50	0.564
rs3865722	73769	34855119	A/T	0.57	0.56	0.861
rs3865723	73806	34855156	A/G	0.59	0.58	0.722
rs3985996	74467	34855817	C/T	0.30	0.29	0.861
rs3985997	74472	34855822	C/T	0.89	0.90	0.527
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.19	0.19	0.968
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.61	0.59	0.618
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.70	0.944
rs2413386	74723	34856073	A/T	0.70	0.71	0.816
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			
rs916338	74893	34856243	C/T	0.40	0.40	0.939
rs132697	75176	34856526	A/G	0.59	0.61	0.418
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.42	0.43	0.848
rs1053982	76027	34857377	A/G	0.69	0.69	0.981
rs2227167	77949	34859299	A/G	0.35	0.37	0.392
rs2227168	77974	34859324	C/T	0.38	0.38	0.797
rs132700	78167	34859517	C/T	0.25	0.25	0.729
rs3075364	78310	34859660	-/CT	0.42	0.42	0.879
rs2227169	78415	34859765	C/T	0.38	0.37	0.619
rs2097466	78575	34859925	C/T	0.52	0.52	0.962
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.23	0.951
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T	0.52	0.52	0.995
rs2269595	81320	34862670	A/G	0.19	0.18	0.464
rs2269596	81409	34862759	C/T	0.40	0.40	0.753
rs132704	81737	34863087	C/T	0.65	0.66	0.906
rs2007468	81843	34863193	A/G	0.40	0.40	0.987

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132705	82102	34863452	C/T	0.30	0.30	0.944
rs2007706	82833	34864183	C/T	0.32	0.32	0.944
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.26	0.28	0.540
rs132708	83660	34865010	C/G	0.30	0.29	0.506
rs132709	83701	34865051	A/T	0.45	0.46	0.538
rs132710	83708	34865058	A/G	0.62	0.60	0.310
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.84	0.84	0.693
rs132713	85717	34867067	A/G	0.29	0.30	0.911
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.48	0.49	0.647
rs132718	87234	34868584	A/G	0.68	0.69	0.453
rs132719	87479	34868829	G/T	0.59	0.54	0.078
rs132720	87561	34868911	A/G	0.12	0.13	0.607
rs132721	87604	34868954	A/G	0.73	0.73	0.919
rs132722	87674	34869024	C/T	0.22	0.22	0.985
rs132723	87958	34869308	A/G	0.03	NA	0.033
rs132724	87992	34869342	-/G	0.12	0.12	0.830
rs132725	88019	34869369	A/G	0.69	0.64	0.097
rs132726	88074	34869424	C/G	0.10	0.13	0.240
rs132727	88079	34869429	C/G	0.68	0.67	0.865
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.37	0.38	0.656
rs132734	88340	34869690	A/G	0.46	0.44	0.522
rs132735	88344	34869694	G/T	0.85	0.85	0.781
rs80587	88512	34869862	C/G	0.40	0.42	0.493
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.32	0.33	0.824
rs132738	88827	34870177	C/T	0.78	0.80	0.327
rs1807673	89230	34870580	A/G	0.28	0.28	0.969
rs2014700	89236	34870586	A/G	0.89	0.92	0.036
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.70	0.70	0.997
rs1812024	91110	34872460	A/G	0.68	0.69	0.755
rs2005590	92026	34873376	C/T	0.71	0.73	0.252
rs132740	92954	34874304	C/T	0.09	0.08	0.370
rs3986001	93375	34874725	-/TTGC	0.51	0.54	0.302
rs2413390	93794	34875144	C/T	0.37	0.41	0.103
rs132743	94937	34876287	C/G	0.07	0.07	0.985
rs132744	95068	34876418	C/T	0.73	0.78	0.078
rs2413391	96188	34877538	A/G	0.39	0.40	0.938
rs132749	97092	34878442	C/T	0.47	0.50	0.329
rs132750	98812	34880162	C/T	0.67	0.67	0.710
rs132741	not mapped	not mapped	A/C	0.29	0.30	0.608
rs2413388	not mapped	not mapped	A/T	0.31	0.31	0.967
rs2413389	not mapped	not mapped	C/G	0.30	0.28	0.393

[0230] The *APOL3* proximal SNPs were also allelotyped in the replication cohorts using the methods described herein and the primers provided in Tables 11 and 12. The replication allelotyping results for replication cohort #1 and replication cohort #2 are provided in Tables 14 and 15, respectively.

**TABLE 14**

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.79	0.80	0.664
rs743919	1095	34782445	G/T	0.11	0.11	0.982
rs1008134	2201	34783551	A/C			
rs132607	7879	34789229	A/G	0.10	0.11	0.589
rs1476029	8395	34789745	C/T	0.16	0.13	0.177
rs1476030	8461	34789811	C/T	0.33	0.38	0.149
rs2413380	9503	34790853	C/T	0.26	0.30	0.174
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.07	0.08	0.476
rs1894605	16444	34797794	G/T	0.07	0.09	0.269
rs132609	17591	34798941	C/T	0.68	0.67	0.687
rs132610	17988	34799338	-/A			
rs132611	19116	34800466	-/T	0.14	0.14	0.992
rs132612	19358	34800708	C/T	0.22	0.22	0.799
rs1008790	20300	34801650	A/G	0.03	0.06	0.358
rs23085	20669	34802019	A/T	0.31	0.30	0.868
rs105161	20891	34802241	A/G	0.75	0.80	0.058
rs132613	21451	34802801	C/T	0.82	0.81	0.725
rs132614	21978	34803328	C/T	0.15	0.15	0.914
rs132615	22785	34804135	C/G	0.32	0.32	0.885
rs132617	24248	34805598	C/T	0.36	0.37	0.706
rs3865724	24770	34806120	C/T	0.66	0.64	0.473
rs2019657	24844	34806194	A/G	0.21	0.21	0.898
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.41	0.39	0.480
rs2008383	25309	34806659	A/G	0.17	0.16	0.721
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.42	0.45	0.522
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.85	0.84	0.703
rs132620	29648	34810998	-/A	0.29	0.28	0.917
rs132621	29986	34811336	A/G	0.32	0.31	0.864
rs80575	30217	34811567	G/T	0.27	0.27	0.909
rs80576	30267	34811617	A/G	0.30	0.22	0.007
rs80577	30315	34811665	A/G	0.24	0.23	0.853
rs80578	30585	34811935	C/T	0.49	0.49	0.884
rs80579	30724	34812074	A/C	0.24	0.25	0.761
rs80580	30897	34812247	C/T	0.30	0.30	0.815
rs132622	30931	34812281	C/T	0.29	0.28	0.884
rs132623	31080	34812430	G/T	0.62	0.63	0.633
rs132624	31246	34812596	C/T	0.36	0.35	0.769
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.92	NA	NA
rs132627	31467	34812817	A/G	0.10	0.10	0.844
rs1807672	32188	34813538	G/T	0.29	0.29	0.954

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132628	32288	34813638	C/T	0.24	0.25	0.796
rs132629	32520	34813870	A/T	0.03	0.06	0.345
rs132630	32594	34813944	A/C	0.75	0.72	0.388
rs132631	32657	34814007	A/C	0.70	0.77	<b>0.017</b>
rs132632	32677	34814027	A/G	0.67	0.63	0.275
rs132633	32764	34814114	C/T	0.34	0.32	0.558
rs132634	32784	34814134	A/G	0.44	0.41	0.435
rs132635	32830	34814180	C/T	0.39	NA	0.409
rs132636	32872	34814222	C/T	0.42	0.46	0.179
rs129603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.08	0.10	0.462
rs3788518	33952	34815302	C/G	0.19	0.19	0.855
rs132638	34184	34815534	C/G	0.54	0.60	0.114
rs132639	34361	34815711	A/T	0.13	0.09	0.153
rs132640	35026	34816376	A/G	0.31	0.32	0.767
rs132641	35192	34816542	A/G	0.46	0.53	0.074
rs132642	35600	34816950	A/T	0.16	0.12	0.101
rs132643	36033	34817383	C/T	0.42	0.48	0.081
rs132644	36289	34817639	C/T	0.50	0.62	<b>-0.0001</b>
rs132645	38869	34820219	A/G	0.21	0.15	<b>0.027</b>
rs2017329	39629	34820979	A/T	0.40	0.38	0.737
rs739198	40530	34821880	C/T	0.74	NA	0.697
rs132647	41621	34822971	C/T	0.21	0.24	0.430
rs2097465	42379	34823729	C/T	0.54	0.52	0.670
rs2105915	42802	34824152	C/T	0.57	0.55	0.582
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.20	0.23	0.213
rs132650	45051	34826401	C/T	0.36	0.29	<b>0.033</b>
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs80584	46257	34827607	C/T	0.81	0.75	<b>0.043</b>
rs132653	47286	34828636	A/C	0.18	0.13	0.060
rs916334	47427	34828777	C/T	0.32	0.38	0.064
rs132654	47963	34829313	C/T	0.55	0.54	0.769
rs132655	48013	34829363	C/T	0.42	0.39	0.390
rs132656	48229	34829579	C/T	0.38	0.35	0.429
rs3834684	48282	34829632	-/A	0.21	0.23	0.416
rs132657	48376	34829726	-/G	0.47	0.53	0.089
rs916335	48404	34829754	A/G	0.39	0.33	0.153
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.39	0.36	0.227
rs132661	52897	34834247	A/G	0.25	0.31	0.086
rs132662	53414	34834764	A/G	0.63	0.57	0.083
rs132663	53487	34834837	A/T	0.25	0.31	0.051
rs132664	54112	34835462	G/T	0.23	0.29	<b>0.037</b>
rs132667	55492	34836842	A/G	0.34	0.32	0.546
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.49	0.55	<b>0.041</b>
rs132672	60701	34842051	A/G	0.24	0.20	0.211
rs132673	60952	34842302	A/G	0.40	0.36	0.284
rs132674	61401	34842751	C/T	0.32	0.29	0.453
rs132675	62379	34843729	C/T	0.38	0.33	0.178
rs80585	62870	34844220	C/T	0.29	0.24	0.164
rs80586	62879	34844229	A/G	0.65	0.69	0.212
rs132676	63499	34844849	A/T	0.26	0.20	<b>0.034</b>
rs132677	64284	34845634	-/A	0.69	0.72	0.438
rs132678	64408	34845758	A/G	0.48	0.50	0.572

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132680	64760	34846110	A/G	0.20	0.18	0.429
rs132681	65230	34846580	A/G	0.25	0.22	0.362
rs132683	66127	34847477	A/G	0.19	0.17	0.449
rs2269594	66634	34847984	C/T	0.70	0.65	0.234
rs132684	66686	34848036	A/G	0.21	0.18	0.349
rs132685	66694	34848044	C/G	0.30	0.28	0.528
rs132686	67113	34848463	A/G	0.46	0.50	0.207
rs132687	67257	34848607	A/G	0.95	0.98	0.217
rs132688	67403	34848753	A/G	0.26	0.23	0.367
rs132689	67609	34848959	A/G	0.60	0.63	0.353
rs132690	68418	34849768	-/A	0.16	0.15	0.901
rs132691	68610	34849960	C/G	0.51	0.53	0.573
rs132692	69629	34850979	C/T	0.62	0.64	0.566
rs132693	70024	34851374	A/G	0.58	0.62	0.227
rs132694	70848	34852198	A/G	0.17	0.14	0.195
rs132695	71428	34852778	C/G	0.24	0.22	0.560
rs1966266	71553	34852903	C/T	0.49	0.46	0.389
rs1966267	71633	34852983	A/G	0.40	0.43	0.304
rs106808	71768	34853118	A/C	0.66	0.70	0.243
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.34	0.38	0.264
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.49	NA	0.490
rs2239831	73547	34854897	C/T	0.52	0.48	0.254
rs3865722	73769	34855119	A/T	0.57	0.56	0.739
rs3865723	73806	34855156	A/G	0.58	0.57	0.819
rs3985996	74467	34855817	C/T	0.30	0.31	0.799
rs3985997	74472	34855822	C/T	0.88	0.89	0.941
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.20	0.20	0.871
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.61	0.58	0.311
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.68	0.509
rs2413386	74723	34856073	A/T	0.71	0.70	0.807
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			
rs916338	74893	34856243	C/T	0.41	0.39	0.465
rs132697	75176	34856526	A/G	0.58	0.63	0.101
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.41	0.45	0.301
rs1053982	76027	34857377	A/G	0.66	0.66	0.959
rs2227167	77949	34859299	A/G	0.35	0.39	0.313
rs2227168	77974	34859324	C/T	0.39	0.35	0.234
rs132700	78167	34859517	C/T	0.26	0.24	0.652
rs3075364	78310	34859660	-/CT	0.42	0.45	0.287
rs2227169	78415	34859765	C/T	0.40	0.36	0.293
rs2097466	78575	34859925	C/T	0.52	0.49	0.376
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.21	0.499
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T	0.52	0.52	0.995
rs2269595	81320	34862670	A/G	0.20	0.17	0.210
rs2269596	81409	34862759	C/T	0.42	0.37	0.172

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132704	81737	34863087	C/T	0.64	0.67	0.398
rs2007468	81843	34863193	A/G	0.39	0.42	0.354
rs132705	82102	34863452	C/T	0.29	0.28	0.834
rs2007706	82833	34864183	C/T	0.29	0.27	0.546
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.26	0.29	0.252
rs132708	83660	34865010	C/G	0.29	0.28	0.584
rs132709	83701	34865051	A/T	0.46	0.47	0.748
rs132710	83708	34865058	A/G	0.62	0.60	0.477
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.82	0.82	0.984
rs132713	85717	34867067	A/G	0.31	0.33	0.416
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.48	NA	NA
rs132718	87234	34868584	A/G	0.67	0.71	0.237
rs132719	87479	34868829	G/T	0.56	0.52	0.254
rs132720	87561	34868911	A/G	0.12	0.14	0.416
rs132721	87604	34868954	A/G	0.72	0.71	0.626
rs132722	87674	34869024	C/T	0.23	0.24	0.791
rs132723	87958	34869308	A/G	NA	NA	
rs132724	87992	34869342	-/G	0.12	0.12	0.830
rs132725	88019	34869369	A/G	0.60	NA	0.691
rs132726	88074	34869424	C/G	0.09	0.15	0.103
rs132727	88079	34869429	C/G	0.68	0.66	0.536
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.43	0.44	0.792
rs132734	88340	34869690	A/G	0.45	0.41	0.263
rs132735	88344	34869694	G/T	0.83	0.82	0.629
rs80587	88512	34869862	C/G	0.42	0.47	0.152
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.33	0.35	0.631
rs132738	88827	34870177	C/T	0.74	0.79	0.131
rs1807673	89230	34870580	A/G	0.30	0.32	0.583
rs2014700	89236	34870586	A/G	0.85	0.90	0.043
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.70	NA	0.704
rs1812024	91110	34872460	A/G	0.66	0.68	0.563
rs2005590	92026	34873376	C/T	0.72	0.75	0.268
rs132740	92954	34874304	C/T	0.10	0.06	0.085
rs3986001	93375	34874725	-/TTGC	0.49	0.53	0.341
rs2413390	93794	34875144	C/T	0.35	0.40	0.143
rs132743	94937	34876287	C/G	0.06	0.05	0.608
rs132744	95068	34876418	C/T	0.72	0.78	0.069
rs2413391	96188	34877538	A/G	0.37	0.39	0.544
rs132749	97092	34878442	C/T	0.48	0.51	0.311
rs132750	98812	34880162	C/T	0.65	0.67	0.678
rs132741	not mapped	not mapped	A/C	0.28	0.30	0.509
rs2413388	not mapped	not mapped	A/T	0.32	0.32	0.908
rs2413389	not mapped	not mapped	C/G	0.32	0.29	0.480



TABLE 15

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3888818	201	34781551	C/T			
rs2010605	425	34781775	A/G	0.84	0.84	0.924
rs743919	1095	34782445	G/T	0.08	0.11	0.294
rs1008134	2201	34783551	A/C			
rs132607	7879	34789229	A/G	0.13	0.10	0.297
rs1476029	8395	34789745	C/T	0.13	0.18	0.126
rs1476030	8461	34789811	C/T	0.40	0.35	0.214
rs2413380	9503	34790853	C/T	0.33	0.28	0.163
rs2051609	10304	34791654	G/T			
rs2413381	10695	34792045	C/T			
rs1894604	16300	34797650	A/G	0.09	0.08	0.726
rs1894605	16444	34797794	G/T	0.09	0.09	0.834
rs132609	17591	34798941	C/T	0.67	0.67	0.950
rs132610	17988	34799338	-/A			
rs132611	19116	34800466	-/T	0.14	0.15	0.749
rs132612	19358	34800708	C/T	0.23	0.24	0.780
rs1008790	20300	34801650	A/G	untyped	0.16	NA
rs23085	20669	34802019	A/T	0.32	0.35	0.395
rs105161	20891	34802241	A/G	0.78	0.71	0.037
rs132613	21451	34802801	C/T	0.78	0.82	0.245
rs132614	21978	34803328	C/T	0.17	0.13	0.167
rs132615	22785	34804135	C/G	0.31	0.30	0.691
rs132617	24248	34805598	C/T	0.35	0.35	0.862
rs3865724	24770	34806120	C/T	0.64	0.67	0.384
rs2019657	24844	34806194	A/G	0.17	0.18	0.745
rs3865725	25066	34806416	G/T			
rs2019364	25096	34806446	C/T	0.38	0.39	0.702
rs2008383	25309	34806659	A/G	0.18	0.18	0.853
rs3986002	25344	34806694	A/C			
rs3888942	25529	34806879	A/T			
rs3888943	25537	34806887	A/G			
rs3888944	25554	34806904	A/C			
rs132618	27963	34809313	A/T	0.44	0.40	0.330
rs132619	28134	34809484	G/T			
rs3827346	28356	34809706	A/G	0.84	0.85	0.568
rs132620	29648	34810998	-/A	0.30	0.31	0.665
rs132621	29986	34811336	A/G	0.32	0.32	0.955
rs80575	30217	34811567	G/T	0.26	0.27	0.812
rs80576	30267	34811617	A/G	0.22	0.29	0.024
rs80577	30315	34811665	A/G	0.27	0.21	0.072
rs80578	30585	34811935	C/T	0.50	0.46	0.263
rs80579	30724	34812074	A/C	0.22	0.24	0.639
rs80580	30897	34812247	C/T	0.32	0.32	0.976
rs132622	30931	34812281	C/T	0.30	0.32	0.701
rs132623	31080	34812430	G/T	0.57	0.52	0.224
rs132624	31246	34812596	C/T	0.36	0.39	0.393
rs132625	31373	34812723	A/T			
rs132626	31463	34812813	A/G	0.86	0.84	0.723
rs132627	31467	34812817	A/G	0.14	0.12	0.672
rs1807672	32188	34813538	G/T	0.31	0.31	0.940
rs132628	32288	34813638	C/T	0.26	0.23	0.307
rs132629	32520	34813870	A/T	0.05	0.07	0.493
rs132630	32594	34813944	A/C	0.76	0.80	0.269
rs132631	32657	34814007	A/C	0.74	0.67	0.058
rs132632	32677	34814027	A/G	0.64	0.68	0.316
rs132633	32764	34814114	C/T	0.33	0.34	0.757

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132634	32784	34814134	A/G	0.45	0.43	0.574
rs132635	32830	34814180	C/T	0.42	-0.01	
rs132636	32872	34814222	C/T	0.40	0.40	0.856
rs129603	33121	34814471	A/C			
rs132637	33348	34814698	G/T	0.09	0.09	0.882
rs3788518	33952	34815302	C/G	0.15	0.19	0.133
rs132638	34184	34815534	C/G	0.58	0.55	0.324
rs132639	34361	34815711	A/T	0.13	0.16	0.210
rs132640	35026	34816376	A/G	0.34	0.28	0.075
rs132641	35192	34816542	A/G	0.49	0.47	0.539
rs132642	35600	34816950	A/T	0.14	0.19	0.079
rs132643	36033	34817383	C/T	0.47	0.45	0.565
rs132644	36289	34817639	C/T	0.57	0.51	0.156
rs132645	38869	34820219	A/G	0.17	0.23	0.076
rs2017329	39629	34820979	A/T	0.39	0.42	0.531
rs739198	40530	34821880	C/T	0.64	0.05	
rs132647	41621	34822971	C/T	0.25	0.22	0.339
rs2097465	42379	34823729	C/T	0.54	0.50	0.311
rs2105915	42802	34824152	C/T	0.58	0.56	0.667
rs132648	42865	34824215	T/C			
rs132649	43644	34824994	A/G	0.21	0.19	0.471
rs132650	45051	34826401	C/T	0.31	0.34	0.365
rs132651	45828	34827178	A/C			
rs132652	45829	34827179	A/T			
rs80584	46257	34827607	C/T			
rs132653	47286	34828636	A/C	0.15	0.18	0.404
rs916334	47427	34828777	C/T	0.36	0.33	0.383
rs132654	47963	34829313	C/T	0.53	0.60	0.090
rs132655	48013	34829363	C/T	0.39	0.44	0.150
rs132656	48229	34829579	C/T	0.36	0.39	0.507
rs3834684	48282	34829632	-/A	0.21	0.21	0.956
rs132657	48376	34829726	-/G	0.51	0.45	0.112
rs916335	48404	34829754	A/G	0.36	0.40	0.245
rs132659	49900	34831250	C/T			
rs132660	52699	34834049	G/T	0.33	0.41	0.044
rs132661	52897	34834247	A/G	0.29	0.27	0.624
rs132662	53414	34834764	A/G	0.59	0.59	0.998
rs132663	53487	34834837	A/T	0.27	0.26	0.792
rs132664	54112	34835462	G/T	0.28	0.28	0.934
rs132667	55492	34836842	A/G	0.36	0.42	0.054
rs132670	59766	34841116	C/T			
rs132671	60307	34841657	A/G	0.50	0.49	0.839
rs132672	60701	34842051	A/G	0.21	0.25	0.297
rs132673	60952	34842302	A/G	0.42	0.40	0.525
rs132674	61401	34842751	C/T	0.33	0.32	0.909
rs132675	62379	34843729	C/T	0.38	0.36	0.722
rs80585	62870	34844220	C/T	0.27	0.30	0.405
rs80586	62879	34844229	A/G	0.68	0.62	0.113
rs132676	63499	34844849	A/T	0.25	0.27	0.442
rs132677	64284	34845634	-/A	0.69	0.64	0.147
rs132678	64408	34845758	A/G	0.43	0.45	0.620
rs132680	64760	34846110	A/G	0.19	0.23	0.258
rs132681	65230	34846580	A/G	0.23	0.28	0.201
rs132683	66127	34847477	A/G	0.19	0.21	0.493
rs2269594	66634	34847984	C/T	0.68	0.69	0.866
rs132684	66686	34848036	A/G	0.21	0.24	0.487
rs132685	66694	34848044	C/G	0.29	0.29	0.888

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132686	67113	34848463	A/G	0.45	0.44	0.708
rs132687	67257	34848607	A/G	0.96	0.93	0.210
rs132688	67403	34848753	A/G	0.22	0.23	0.917
rs132689	67609	34848959	A/G	0.63	0.62	0.839
rs132690	68418	34849768	-/A	0.16	0.19	0.295
rs132691	68610	34849960	C/G	0.53	0.50	0.441
rs132692	69629	34850979	C/T	0.64	0.59	0.223
rs132693	70024	34851374	A/G	0.57	0.52	0.191
rs132694	70848	34852198	A/G	0.17	0.20	0.413
rs132695	71428	34852778	C/G	0.23	0.23	0.928
rs1966266	71553	34852903	C/T	0.49	0.49	0.881
rs1966267	71633	34852983	A/G	0.41	0.38	0.400
rs106808	71768	34853118	A/C	0.71	0.63	0.030
rs132696	71769	34853119	A/G			
rs2239829	73039	34854389	A/G	0.35	0.33	0.665
rs2285154	73325	34854675	A/G			
rs2239830	73412	34854762	A/C	0.51	-0.02	
rs2239831	73547	34854897	C/T	0.51	0.53	0.577
rs3865722	73769	34855119	A/T	0.56	0.57	0.887
rs3865723	73806	34855156	A/G	0.61	0.60	0.837
rs3985996	74467	34855817	C/T	0.30	0.27	0.501
rs3985997	74472	34855822	C/T	0.89	0.92	0.287
rs3985998	74473	34855823	A/G			
rs3985999	74482	34855832	C/T	0.18	0.17	0.691
rs3986000	74494	34855844	A/C			
rs2413382	74592	34855942	A/G	0.60	0.62	0.642
rs2413383	74670	34856020	G/T			
rs2413384	74672	34856022	G/T			
rs2413385	74714	34856064	G/T	0.70	0.72	0.433
rs2413386	74723	34856073	A/T	0.70	0.72	0.510
rs1894606	74749	34856099	A/G			
rs916336	74861	34856211	C/G			
rs916337	74892	34856242	C/T			
rs916338	74893	34856243	C/T	0.39	0.43	0.334
rs132697	75176	34856526	A/G	0.60	0.57	0.463
rs12781	75705	34857055	A/G			
rs1053983	75989	34857339	A/G	0.43	0.39	0.279
rs1053982	76027	34857377	A/G	0.74	0.74	0.852
rs2227167	77949	34859299	A/G	0.35	0.35	0.998
rs2227168	77974	34859324	C/T	0.38	0.42	0.226
rs132700	78167	34859517	C/T	0.25	0.25	0.989
rs3075364	78310	34859660	-/CT	0.41	0.37	0.252
rs2227169	78415	34859765	C/T	0.36	0.38	0.520
rs2097466	78575	34859925	C/T	0.52	0.57	0.255
rs2097467	78590	34859940	C/T			
rs2413387	78709	34860059	C/T			
rs132701	78875	34860225	C/T	0.23	0.27	0.255
rs132702	79864	34861214	C/T			
rs132703	81316	34862666	C/T			
rs2269595	81320	34862670	A/G	0.18	0.19	0.672
rs2269596	81409	34862759	C/T	0.39	0.43	0.258
rs132704	81737	34863087	C/T	0.67	0.64	0.391
rs2007468	81843	34863193	A/G	0.41	0.37	0.247
rs132705	82102	34863452	C/T	0.32	0.33	0.785
rs2007706	82833	34864183	C/T	0.36	0.41	0.226
rs132706	83461	34864811	C/T			
rs132707	83624	34864974	C/T	0.27	0.26	0.598

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs132708	83660	34865010	C/G	0.31	0.30	0.754
rs132709	83701	34865051	A/T	0.43	0.45	0.627
rs132710	83708	34865058	A/G	0.63	0.60	0.482
rs132711	83782	34865132	C/T			
rs132712	85707	34867057	A/G	0.87	0.86	0.667
rs132713	85717	34867067	A/G	0.28	0.24	0.293
rs132714	86486	34867836	C/T			
rs132716	86833	34868183	A/G			
rs132717	87115	34868465	C/T	0.47	0.49	0.533
rs132718	87234	34868584	A/G	0.68	0.66	0.705
rs132719	87479	34868829	G/T	0.62	0.57	0.223
rs132720	87561	34868911	A/G	0.12	0.11	0.727
rs132721	87604	34868954	A/G	0.75	0.77	0.495
rs132722	87674	34869024	C/T	0.21	0.20	0.630
rs132723	87958	34869308	A/G			
rs132724	87992	34869342	-/G			
rs132725	88019	34869369	A/G	0.69	0.00	
rs132726	88074	34869424	C/G	0.12	0.10	0.509
rs132727	88079	34869429	C/G	0.68	0.70	0.583
rs132728	88115	34869465	A/G			
rs132729	88118	34869468	C/G			
rs132730	88120	34869470	A/G			
rs132731	88135	34869485	-/CTCAT			
rs132732	88142	34869492	G/T			
rs132733	88143	34869493	G/T			
rs140575	88149	34869499	ACA/TG	0.30	0.29	0.903
rs132734	88340	34869690	A/G	0.47	0.49	0.571
rs132735	88344	34869694	G/T	0.88	0.90	0.595
rs80587	88512	34869862	C/G	0.37	0.33	0.365
rs132736	88521	34869871	C/T			
rs132737	88650	34870000	C/G	0.31	0.29	0.686
rs132738	88827	34870177	C/T	0.82	0.81	0.773
rs1807673	89230	34870580	A/G	0.26	0.23	0.356
rs2014700	89236	34870586	A/G	0.93	0.96	0.324
rs132739	90754	34872104	G/A			
rs1812023	90984	34872334	A/G	0.71	-0.01	
rs1812024	91110	34872460	A/G	0.70	0.70	0.888
rs2005590	92026	34873376	C/T	0.69	0.70	0.719
rs132740	92954	34874304	C/T	0.08	0.09	0.442
rs3986001	93375	34874725	-/TTGC	0.53	0.55	0.563
rs2413390	93794	34875144	C/T	0.40	0.43	0.365
rs132743	94937	34876287	C/G	0.07	0.09	0.436
rs132744	95068	34876418	C/T	0.74	untyped	
rs2413391	96188	34877538	A/G	0.43	0.41	0.611
rs132749	97092	34878442	C/T	0.47	0.48	0.858
rs132750	98812	34880162	C/T	0.70	0.67	0.285
rs132741	not mapped	not mapped	A/C	0.30	0.30	0.999
rs2413388	not mapped	not mapped	A/T	0.30	0.30	0.989
rs2413389	not mapped	not mapped	C/G	0.28	0.26	0.555

[0231] Allelotyping results were considered particularly significant with a calculated p-value of less than or equal to 0.05 for allelotype results. These values are indicated in bold. The allelotyping p-values were plotted in Figure 1 for the discovery cohort. The position of each SNP on the chromosome is presented on the x-axis. The y-axis provides the negative logarithm (base 10) of the p-value comparing

the estimated allele in the case group to that of the control group. The minor allele frequency of the control group for each SNP designated by an X or other symbol on the graph in Figure 1 can be determined by consulting Table 13. For example, the left-most X on the left graph is at position 34781551. By proceeding down the Table from top to bottom and across the graphs from left to right the allele frequency associated with each symbol shown can be determined.

[0232] To aid the interpretation, multiple lines have been added to the graph. The broken horizontal lines are drawn at two common significance levels, 0.05 and 0.01. The vertical broken lines are drawn every 20kb to assist in the interpretation of distances between SNPs. Two other lines are drawn to expose linear trends in the association of SNPs to the disease. The light gray line (or generally bottom-most curve) is a nonlinear smoother through the data points on the graph using a local polynomial regression method (W.S. Cleveland, E. Grosse and W.M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole.). The black line provides a local test for excess statistical significance to identify regions of association. This was created by use of a 10kb sliding window with 1kb step sizes. Within each window, a chi-square goodness of fit test was applied to compare the proportion of SNPs that were significant at a test wise level of 0.01, to the proportion that would be expected by chance alone (0.05 for the methods used here). Resulting p-values that were less than  $10^{-8}$  were truncated at that value.

[0233] The exons and introns of the genes in the covered region are plotted below each graph at the appropriate chromosomal positions. The gene boundary is indicated by the broken horizontal line. The exon positions are shown as thick, unbroken bars. An arrow is placed at the 3' end of each gene to show the direction of transcription.

#### Example 5

##### *In Vitro* Production of Target Polypeptides

[0234] cDNA is cloned into a pIVEX 2.3-MCS vector (Roche Biochem) using a directional cloning method. A cDNA insert is prepared using PCR with forward and reverse primers having 5' restriction site tags (in frame) and 5-6 additional nucleotides in addition to 3' gene-specific portions, the latter of which is typically about twenty to about twenty-five base pairs in length. A Sal I restriction site is introduced by the forward primer and a Sma I restriction site is introduced by the reverse primer. The ends of PCR products are cut with the corresponding restriction enzymes (*i.e.*, Sal I and Sma I) and the products are gel-purified. The pIVEX 2.3-MCS vector is linearized using the same restriction enzymes, and the fragment with the correct sized fragment is isolated by gel-purification. Purified PCR product is ligated into the linearized pIVEX 2.3-MCS vector and *E. coli* cells transformed for plasmid amplification. The newly constructed expression vector is verified by restriction mapping and used for protein production.

[0235] *E. coli* lysate is reconstituted with 0.25 ml of Reconstitution Buffer, the Reaction Mix is reconstituted with 0.8 ml of Reconstitution Buffer; the Feeding Mix is reconstituted with 10.5 ml of Reconstitution Buffer; and the Energy Mix is reconstituted with 0.6 ml of Reconstitution Buffer. 0.5 ml of the Energy Mix was added to the Feeding Mix to obtain the Feeding Solution. 0.75 ml of Reaction Mix, 50 µl of Energy Mix, and 10 µg of the template DNA is added to the *E. coli* lysate.

[0236] Using the reaction device (Roche Biochem), 1 ml of the Reaction Solution is loaded into the reaction compartment. The reaction device is turned upside-down and 10 ml of the Feeding Solution is loaded into the feeding compartment. All lids are closed and the reaction device is loaded into the RTS500 instrument. The instrument is run at 30°C for 24 hours with a stir bar speed of 150 rpm. The pIVEX 2.3 MCS vector includes a nucleotide sequence that encodes six consecutive histidine amino acids on the C-terminal end of the target polypeptide for the purpose of protein purification. Target polypeptide is purified by contacting the contents of reaction device with resin modified with Ni<sup>2+</sup> ions. Target polypeptide is eluted from the resin with a solution containing free Ni<sup>2+</sup> ions.

#### Example 6

##### Cellular Production of Target Polypeptides

[0237] Nucleic acids are cloned into DNA plasmids having phage recombination sites and target polypeptides are expressed therefrom in a variety of host cells. Alpha phage genomic DNA contains short sequences known as attP sites, and *E. coli* genomic DNA contains unique, short sequences known as attB sites. These regions share homology, allowing for integration of phage DNA into *E. coli* via directional, site-specific recombination using the phage protein Int and the *E. coli* protein IHF. Integration produces two new att sites, L and R, which flank the inserted prophage DNA. Phage excision from *E. coli* genomic DNA can also be accomplished using these two proteins with the addition of a second phage protein, Xis. DNA vectors have been produced where the integration/excision process is modified to allow for the directional integration or excision of a target DNA fragment into a backbone vector in a rapid *in vitro* reaction (Gateway™ Technology (Invitrogen, Inc.)).

[0238] A first step is to transfer the nucleic acid insert into a shuttle vector that contains attL sites surrounding the negative selection gene, ccdB (e.g. pENTER vector, Invitrogen, Inc.). This transfer process is accomplished by digesting the nucleic acid from a DNA vector used for sequencing, and to ligate it into the multicloning site of the shuttle vector, which will place it between the two attL sites while removing the negative selection gene ccdB. A second method is to amplify the nucleic acid by the polymerase chain reaction (PCR) with primers containing attB sites. The amplified fragment then is integrated into the shuttle vector using Int and IHF. A third method is to utilize a topoisomerase-mediated process, in which the nucleic acid is amplified via PCR using gene-specific primers with the 5'

upstream primer containing an additional CACC sequence (*e.g.*, TOPO® expression kit (Invitrogen, Inc.)). In conjunction with Topoisomerase I, the PCR amplified fragment can be cloned into the shuttle vector via the attL sites in the correct orientation.

**[0239]** Once the nucleic acid is transferred into the shuttle vector, it can be cloned into an expression vector having attR sites. Several vectors containing attR sites for expression of target polypeptide as a native polypeptide, N-fusion polypeptide, and C-fusion polypeptides are commercially available (*e.g.*, pDEST (Invitrogen, Inc.)), and any vector can be converted into an expression vector for receiving a nucleic acid from the shuttle vector by introducing an insert having an attR site flanked by an antibiotic resistant gene for selection using the standard methods described above. Transfer of the nucleic acid from the shuttle vector is accomplished by directional recombination using Int, IHF, and Xis (LR clonase). Then the desired sequence can be transferred to an expression vector by carrying out a one hour incubation at room temperature with Int, IHF, and Xis, a ten minute incubation at 37°C with proteinase K, transforming bacteria and allowing expression for one hour, and then plating on selective media. Generally, 90% cloning efficiency is achieved by this method. Examples of expression vectors are pDEST 14 bacterial expression vector with att7 promoter, pDEST 15 bacterial expression vector with a T7 promoter and a N-terminal GST tag, pDEST 17 bacterial vector with a T7 promoter and a N-terminal polyhistidine affinity tag, and pDEST 12.2 mammalian expression vector with a CMV promoter and neo resistance gene. These expression vectors or others like them are transformed or transfected into cells for expression of the target polypeptide or polypeptide variants. These expression vectors are often transfected, for example, into murine-transformed adipocyte cell line 3T3-L1, (ATCC), human embryonic kidney cell line 293, and rat cardiomyocyte cell line H9C2.

#### Nucleotide and Amino Acid Sequence Embodiments

**[0240]** Table A includes information pertaining to the incident polymorphic variant associated with osteoarthritis identified herein. Public information pertaining to the polymorphism and the genomic sequence that includes the polymorphism are indicated. The genomic sequences identified in Table A may be accessed at the http address [www.ncbi.nih.gov/entrez/query.fcgi](http://www.ncbi.nih.gov/entrez/query.fcgi), for example, by using the publicly available SNP reference number (*e.g.*, rs132659). The chromosome position refers to the position of the SNP within NCBI's Genome Build 34, which may be accessed at the following http address: [www.ncbi.nlm.nih.gov/mapview/map\\_search.cgi?chr=hum\\_chr.inf&query=](http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr=hum_chr.inf&query=). The "Contig Position" provided in Table A corresponds to a nucleotide position set forth in the contig sequence (see "Contig Accession No."), and designates the polymorphic site corresponding to the SNP reference number. The sequence containing the polymorphisms also may be referenced by the "Nucleotide Accession No." set forth in Table A. The "Sequence Identification" corresponds to cDNA sequence that

encodes associated target polypeptides (e.g., APOL3) of the invention. The position of the SNP within the cDNA sequence is provided in the "Sequence Position" column of Table A. If the SNP falls within an exon, the corresponding amino acid position (and amino acid change, if applicable) is provided as well. Also, the allelic variation at the polymorphic site and the allelic variant identified as associated with osteoarthritis is specified in Table A. All nucleotide and polypeptide sequences referenced and accessed by the parameters set forth in Table A are incorporated herein by reference.

Table A

RS_ID	Chromosome	Chrom Position	Contig Accession No. [1]	Contig Position	Nucleotide Accession No. [2]	Sequence Position	Amino Acid Position	Locus	Locus ID	A [3]	Allelic Variability	OA Assoc. Allele
rs132659	22	34831250	Hs22_11677_34: 9	15897265	NM_014349	mna-utr		APOL3	80833	F	[C/T]	C

[1] Contig Accession Number which can be found in the NCBI Database:  
http address: [www.ncbi.nih.gov/entrez/query.fcgi](http://www.ncbi.nih.gov/entrez/query.fcgi)

[2] Sequence Identification or Nucleotide Accession Number which can be found in the NCBI Database:  
http address: [www.ncbi.nih.gov/entrez/query.fcgi](http://www.ncbi.nih.gov/entrez/query.fcgi)

[3] "A" column is the sequence orientation ("F" is forward, "R" is reverse).

[0241] The following is a genomic nucleotide sequence for an *APOL3* region. The following nucleotide representations are used throughout: "A" or "a" is adenosine, adenine, or adenylic acid; "C" or "c" is cytidine, cytosine, or cytidylic acid; "G" or "g" is guanosine, guanine, or guanylic acid; "T" or "t" is thymidine, thymine, or thymidylic acid; and "I" or "i" is inosine, hypoxanthine, or inosinic acid. Exons are indicated in italicized lower case type, introns are depicted in normal text lower case type, and polymorphic sites are depicted in bold upper case type. SNPs are designated by the following convention: "R" represents A or G, "M" represents A or C; "W" represents A or T; "Y" represents C or T; "S" represents C or G; "K" represents G or T; "V" represents A, C or G; "H" represents A, C, or T; "D" represents A, G, or T; "B" represents C, G, or T; and "N" represents A, G, C, or T.

#### APOL3 Genomic Sequence (SEQ ID NO: 1)

>22:34781351-34880400

```

1      tacacttttt tttttttttt tgagacagag tcttgctcta ttgccaggc tggagtgcag
61     tggcactatc tcagctgact gcaacgcctc ctgggttcaa gctattttca tacctcagcc
121    tcccaagtag ctgggattac aggtgtgtgc caccatgcc agctaatttt cgttttttaa
181    gtagagacag ggttccacca Ygttggttag gctggttcta aactcctgac ctcaagtgat
241    cctcctgcct tggcctccga aagtgtctgg attacaggcg tgagccacca aaccggcct
301    gatacacaat tgtctatggg agaagcacag tgaatgcact ctgatttagc aatcttattc
361    tcttgaatgg tttgtgcttt ttatgtctta ggaaaccttc cttggtccca agatattcta
421    tagaRacttt attttgtact tttcttctaa aagtcttttc tttttttttt ttttttgaga

```



481	cagagtctca	ctccggttgc	caggctggag	tgcagtggca	cgatcttggc	tcactgcaac
541	ctccgcctcc	tcggttcaag	cgattctcct	gcctcagcct	ccagagtagc	tgggactaca
601	ggcatgcgcc	accacgcctg	gctaattatt	gtatttttag	tagagacggg	gtttcaccat
661	attggccagg	ctagtcttga	actcctgagc	tcaagtgatc	tgcccatctc	ggcctcccaa
721	agtgcaggga	ttacaggcgt	gagccaccac	gcccagcctc	taaaagtctt	aacgttttgc
781	ctttcacatt	tacatctgga	attgattttg	ttatgcggtg	aggaaaagaat	ctttttattt
841	ttctcttttg	ggactcacc	cccactccat	ttgcaggcct	gttgggaggt	aggctcatct
901	tagaggaaca	gaccctgggc	aggctgtgac	acagggtctc	agcaacaagc	cgcagaagcg
961	gaactcataa	catgtggcat	tggcattccc	taccattact	gattcaatgc	cattccacgg
1021	tggccctggg	tcattggacca	gctcatgttg	ggctaattgtc	ccaacacaca	caaagatggt
1081	aggtttgact	aagcMagagg	cagtccttag	gtgaggttgc	agggagaggg	aagagggctt
1141	ggtgaagaat	agaagaccca	tgaagaaggg	gtgtggtctt	ggtgaccacg	tgatcccata
1201	gtattcccat	agacactcaa	gacagctggt	aaattgagct	gctccccaga	ggaggccaac
1261	agacaggctg	gacaatgact	gggtctctgag	cagagacccc	gtctcccttc	tgctgcacct
1321	gctgcagctt	aacattgact	agactaccag	gctcagcctc	agcaaggccc	ccacctggct
1381	ctgggcctgg	tgaccaggga	aggtgggaag	agagggggct	catcacttcc	tacagaagga
1441	agctcagact	tccaatttctg	tgtggcataa	gagcatgggc	tctgggcaac	actgcctgga
1501	ttagtattca	gctcggggccc	tactcgtggt	ataactggga	gtcactaatt	ttatctctgg
1561	gcttcactat	aaatgggatc	ctaattggcag	tctacccaaag	cagggtattg	tgaggcctag
1621	agatgatgag	gcaaacagtt	ggttctcaat	acaagaaaga	aatttatcat	ttgcatgtag
1681	ctgcatagct	gataagccca	tgacagtttt	cccataacct	gttttcatgg	cctttatttc
1741	cgcaactctg	tctattttcag	ctacgtggaa	ccactcctgt	gtactgtgac	agtctaattgt
1801	tgggatctgg	ttaaatatat	tatggcccat	ccaggcgagg	tggctcacgc	ctgtaacccc
1861	agcactttga	gaggccaaga	caggcggaatc	accctgaggt	caggagtctg	agaccagctt
1921	ggccaagatg	gtgaaacccc	gtctctacta	aaaatacaaa	aattagctga	gtgtggtggt
1981	gcctgcctgt	aatcccagct	actcgggagg	ctgaggcagg	agaattgctt	tgaacccggg
2041	agggtggaggt	tgcattgagc	caagattgca	ccactgcact	ccaacttggg	cgacagacag
2101	agagagactc	ggtctcaaaa	aaaaaaaaaa	aaaaagtta	ggcccatcca	caggatgcaa
2161	tatcatatag	ccatttaaaa	gaatgggcta	catctgaacc	Mgatggaaga	aaagatgccc
2221	ggatatgtta	ttaatgggat	gaggcaacgt	gtagaacctg	tgtaaaatag	gatttttttt
2281	ctgagatgga	ctcttgctct	gtcaccagg	ctggagtga	ttgggtgcat	ctctctcac
2341	tgcaacctct	gcctcctggg	ttcaagcgat	tctcctgcct	cagcctccca	agtagctggg
2401	attataggag	cccgcaccca	catctggcta	gtttttgtat	ttttagtaga	gacgaggttt
2461	caccatgttg	gccaggctgg	tcttgaactc	ctgatctcag	gtgatccacc	cacctcggcc
2521	tcccaaagtg	ctgggattac	aggtgtgagc	caccacgcct	ggccaagtag	gatgtcttta
2581	tgccatattt	aaaagaatcc	acagggagct	gttaatgctg	atacttttgg	ggaaagggct
2641	cagtggagca	gctaagcttt	tgcttttctt	tttgttctct	tctgtggaat	tggcattgcc
2701	taccaacact	gattcagtg	cattccacgg	tggccctggg	gcattggtgt	ttttttcatg
2761	gatcagctct	gcctgacacc	accatgcagc	aggctgtact	gtgagcctca	ttttgcaggt
2821	gagagaagca	aggcacagag	aggttacgta	acttgcttaa	agacatgtga	caagtaagag
2881	gtggagctgg	gattcaaaact	caggcagtg	aggtctggag	tccctatttt	tagctactac
2941	atgacactgt	ctcccaatat	attattttta	tctattttaa	aattcaaagc	agttttctgt
3001	gttatagact	attttttact	tcttcacatg	cttaaaaaca	aacaaaacaa	aaaaaataaa
3061	acagaggcca	ggcacgggtg	ctcacgcctg	taatcccagc	actttggaag	gccgaggaag
3121	gtggattacc	tgaggctcag	agttcgagac	cagcctggcc	aacatggtga	aacctgtct
3181	ttactaaaaa	tacaaaaaat	agccaagtgt	ggtggcatgc	gcctgtagtc	ccagctactc
3241	gggaggctga	agcaggagaa	tcgcttgaac	ctgggagaca	gagtttgag	tgagctgaga
3301	ttgtgtcatt	gtactccagc	ctgggagaca	gagagacttc	atctcaaaaa	aacaaaacaa
3361	aacaaaacaa	aacaaaaaaa	aacaggaaca	atgcatagcc	catgatgaat	tgttttatta
3421	tctgtgactc	ttattgttca	ttggttgctt	ctgtccctct	ctgaccacag	cctgatggga
3481	ggcacaggcg	agggaagaac	gtggcttttg	gagcaggggg	accctcattc	tcattcccagc
3541	tctgcacgaa	ctgcggcatg	accttgccca	ggcccttcc	cttcttggc	ctcagcctcc
3601	atctgtagag	ctgggccaat	gccggagcca	atgacctctg	cgggcccctc	tgcacaagga
3661	ttctctccct	ctttctgac	tatttttgcc	tgacgcctct	cccagggggc	tgtgggctctg
3721	agctaatttt	cctggctggc	cccagtcag	gcagctcag	tgagagcgc	caagctaagt
3781	aggccaaggt	catggtccag	ttagcatctc	tcggaggaac	cgtggctttt	cagcagact
3841	gtagctccct	gaccagtcac	tgcgctcagg	tagaggcggg	ccctagagga	gaggacaata
3901	gcaaagctgg	atcctgcaag	tcagcatttc	cagtaggagc	tgctcagggc	ccagggccca
3961	gatacccttt	gtgactgcag	ggcagcatgt	ccaggctcac	atcaacatac	caggatgatt
4021	caaggagctg	gtacgttggg	ggttagggag	aggaccaggt	ggatcaccaa	gtgctgcaa
4081	gtacccccac	acctgtcaag	tcaggagaat	gagaaccaat	tctaccttta	aatctaagc
4141	agattgggag	gccgaggcag	gaggatcacc	tgaggtcagg	agtttgagac	cagcgtgacc
4201	aacatggtga	aaccccatct	ctactaaaaa	tataaaaatt	agccaggcat	ggtggcggg
4261	gccacctccc	agctactcag	gaggctgtgg	cgtgagaatc	gcttgaacct	gggaggcgaa

4321	gggtgcattg	agccaagatc	atgccattgc	actccagcct	gggggataga	gcgagactct
4381	gtctcaaaaa	acaaaacaaa	acaaaacaaa	caatctatat	ctatatctat	atctatctat
4441	ctatctatct	atctatctat	ctatctatct	atctatataa	agcagacagc	atgtccacat
4501	tctctcaagg	tgacccccct	tttctaacat	cagaactttc	cttttttcta	catgaggcat
4561	ttccaccact	tttaaatacag	atgtaagaca	gagtaagcct	tcctctttta	cctgccacga
4621	ggggccaggg	ttgtctgttc	cttctctact	acatcccccg	cacctagacc	catgccctgg
4681	gtacctacac	taggagctca	gtcaatattg	ttgagcgaat	caaataacca	ctgttccaga
4741	atgaggctgc	agactgcctt	tgaacggaca	cagtattgcc	agtgggtttg	actcagtttt
4801	gttcaaatat	ttcaattttct	ttttttgggt	tgtttttctg	agggagtctc	actctgttgc
4861	ccaggctggc	gtgcagtagc	gtgatctcgg	tcggctcact	gcaacctcca	cctcctgggt
4921	tcaggcgatt	ctcctgcctc	agcctcccaa	gtagctgggg	ctacaagcat	gcgccaccac
4981	acctggctaa	tatttttgta	tttttagtag	atacagggtt	tcaccatgtt	ggtcaggctg
5041	gtctcaaact	actgacctca	aatgatccac	ctgcctcagt	ctccgaaagt	gctgggatca
5101	caggcgtgag	tcaccgtgcc	tggcctcaga	tgcttctatt	tcaacgagtc	tggtgaagct
5161	tgttatattag	agagtaatat	gtgaatgctc	tagaaaaagc	aattctcctg	tctcagcctc
5221	ccaagtagct	ggcactacag	gtgccaccca	ccatgcctgg	ttaagttttt	gattttttact
5281	agagacaagg	ttttaccatg	ttggccaggc	tggtctcgaa	ctcctgactt	caagtgatct
5341	accctccttg	gcctcccaaa	gtgctgggat	tagaggaatg	agccaccaca	cttgcccaaa
5401	ttattccttt	tacaatctgc	tacaaccccc	tgatttgaac	attttgcaaa	tttgaatgtt
5461	ctcatttaggt	tttcgattca	gttcagttaa	tgtttattat	taagtattgt	tattatatta
5521	ttattcatta	ttgttattat	ttaataagaa	taattgagtt	cttaccataa	gccagacttt
5581	gggttaaaca	cataacatgt	agatttagtt	aattttcatg	acaaatctat	aagatgggca
5641	ctactgctat	cctactttac	agatgagaaa	actgaggcag	acagaggtta	agtaaattgc
5701	tcaaccccac	atgaatagta	agtctcggag	ccaggagtca	aacttcagag	cctacactcc
5761	taatcacagc	taagtgtgct	cttcaggacg	tactttacat	gcaagtacag	taactgtcta
5821	caaggcactg	gtgattaaaa	aatgaacaaa	gcctttaaca	ggtgaatggt	taagcagact
5881	gtggcacatc	cacatcatgg	aacacaattc	agcaacagca	cggaatgaac	actattgatg
5941	cacacagtaa	cctgaatgac	tctccagaga	attatgccaa	ctgcgaaaag	gcaatccgca
6001	agagttacgt	actctatgat	gccattttact	tatttttttt	gagacctagt	ctcgctctgt
6061	caaccaagct	ggagtgcagt	ggcatgatct	cggctcactg	taacctccgc	ctctgggtg
6121	caagcgattt	tcctgcctca	gctttccaa	tagctgggac	tacaggcgctg	caccaccacg
6181	cccagctaata	ttttgtattt	ttagttagaga	cagggtttta	ccatgttggc	cgggctgggtc
6241	tcgaacttct	gacctcaaat	gatccgccct	ccttggcctc	ccaaagtgtc	gggattacag
6301	gcgtgagcca	ccgtgcctgg	aaaattattt	atttttaaga	tttgtaagt	gtagtcatga
6361	gaagcgggaa	agagtagaac	aaggagtttt	atctgctgtg	actgaacaat	caattgagat
6421	aacgcggcac	cttcggatca	gctgattcca	tttatctaac	attcttaaat	ggaccactt
6481	atagacatga	agaatagatt	agcaattgcc	aaggctaaag	tagggatcag	ggtgggagag
6541	aagtgggtga	ggctataaaa	ggacaacaag	agggattcct	gtggtgatag	aaatattcta
6601	tatcttgatt	atatcaatgc	caatatcctg	gttgtgatat	tgaagaggct	aaagctgcat
6661	ttggtacaat	aaaatacaat	tagcagccta	taaccccaaa	ggagaaaaact	ggccagtgtg
6721	gtattaaatc	tttgtgtgtt	tgcattatgt	acatttaaat	gcttaattta	tatgccaaca
6781	tttagcattt	ttccaagatg	ttactattaa	cggaaactga	gtaaagggtg	catgggatct
6841	ctctggatta	ctttgtacaa	atgcaataaa	aaatgttaat	ttaaaaaaac	agaatgaggc
6901	caggtagcgt	ggttcatgcc	tgtaatccca	gagctttggg	agaccaaggt	gggaggatcg
6961	attgaggcca	ggagtccaag	accagcctgg	ccaaccagca	agaccccatc	tctacaaaaa
7021	attaaaaaat	tcagctgggc	atggtggcgt	atgcctgtag	tcctagctac	tgcagaggct
7081	gaggcaggaa	aatcacttga	gactgagagg	tcgaggctgc	agtgagcaat	gatggtgcca
7141	ctatactcta	gcctgggcaa	cagggcaaga	gaatgaggca	gacaggagcc	cagcctggca
7201	ggaaagggag	gttgtattag	tcagggttct	ccagagagac	agagctaata	ggaatagatt
7261	atatatgcag	gggagtttat	taaggagtat	tgactcacac	gaacacaagg	tgaagtccca
7321	caacaggctg	ttttcaagct	gattagcaaa	gaagccagcc	agagtctcaa	aacctcaaaa
7381	gtaggggaag	tgacagcgca	gcttttagtc	tgtggccgga	ggcctgagag	cccctggcaa
7441	accactggtg	taagtccaag	agtcacaaa	ctgaagaact	tggagtctga	tgttcaaggg
7501	caggaagcat	ccagcacggg	agaaagacca	tggaaaggag	tgaaggctgg	aagactcagc
7561	aagtctagtc	cttccaagtt	cttctgcctg	cttaattcta	gccgtgttgg	cagctgatta
7621	gatggtgccc	accagatttg	agggtgcgtc	tgccctctcc	aggccactga	ttcaaatgtt
7681	aatctccttt	ggccacaccc	tcacagacac	acccagggaac	aatactttgc	atccttcaat
7741	ccaatcaagt	tgacactcaa	tattaaactat	cacagagggc	ttccaatgca	gtgacagttg
7801	acatgagtcc	tcaaggtttag	tttgcagggt	acaagggaga	gaaggacagg	aggcctgagg
7861	caggcaggac	agcatgtgRt	agtgggctgt	ttgggtcttc	cttcccaaaa	gtcatctggg
7921	gatggtgaga	tctccggcca	ttcattccat	tgcaagaggg	cattcatgca	ggctacctcc
7981	caacttggtc	ataaaaaatgt	taagtgatgg	acaaaaataat	gtctttacat	ttttcttaaa
8041	cgtttggttc	ctgctgctgc	ttatctggta	gagaggctca	tcagaggaga	aaatgaagga
8101	agattccctt	gtcaaacatc	acaacagaga	gcaagcatct	ttgttcagcc	tgtcaggatc

8161	atcttttcaca	ttcaatttag	aaaaatggca	gatgttaatg	tttttcctgt	taagagataa
8221	tttctttttta	aaatgtttgt	tttttttttc	cccttactat	gcctagtccct	gctttttata
8281	tgataacagc	ctaggagtgg	aaagaatgag	agtttggtg	acagagatcc	ttacatttga
8341	atctcaattc	cacttagagg	ctatggctcat	gacttagagg	ctatattaag	accaYttaga
8401	ggctatggtc	atgaccttga	gtccgtttcc	ctgagtttca	ctgcctcaga	ctaatacatc
8461	Ygaataggcc	agtattgcca	aatcccagtg	ctaggatggg	gattaatgag	aaaacatttg
8521	ccaaaaaacc	tagtatacct	tgtgtaatac	ctgacacgta	gtaggtgctc	aataagtgat
8581	actcattgat	ttattttttt	attttattta	ttttattttt	ttgagaccga	gtcttactct
8641	gtcaccagc	ctagagtgc	gaggcggtgat	ttcgacttac	tgcaacctct	acctcctggg
8701	ttcaaagtat	tctcctgcct	gggcctccc	agtagctggg	ataacaggcg	tgtgccacca
8761	cacctggcta	atttttatat	ttttagttaa	gacagggttt	caccatgttg	gccaggctgg
8821	tcttgaactc	ctgacctcag	gtgatccgcc	tgcctcagcc	tcccaaagt	ctgagattac
8881	agttgtgagc	caccacgcct	ggtcaataag	tgatactcat	tgtaataaac	aattctagtt
8941	catctaagga	tttaaagctg	tgtacctttc	atagtgttct	acaaacagct	tcctgatttc
9001	cagcagcttt	gcttatatca	gccaggatag	tctaggttat	gctgcagtaa	aaaacaagcc
9061	cctaggctgg	gcacgggtgg	tcacgcctgt	aatcccagca	ctttgggagg	ccgaggcggg
9121	cggatcacct	gaggtcagga	gtttgagacc	agcctgacca	acgtggtgaa	cccctgtctc
9181	tattaaaaat	tcaaaattag	ccgggcatgg	tggtgcacgc	ctgtagtcct	agctagttgg
9241	gaggctgagg	caggagaatc	gcttgaacct	gggaggtgga	gcttgacagt	agccaagatc
9301	gcgccattgc	actccagcct	gggctactag	agcgaaactc	tgtctcaaaa	aacaaaacaa
9361	aactaaacaa	aacaaaaaaa	caaaccaaac	aaacaaacaa	aaaccaccaa	aaagcaagcc
9421	ccgatctca	gtggttcaca	acagcaaagg	ctacttcttg	ctcacgctac	atgtccatca
9481	tggggcaggt	gcctctctgc	tcYggttgct	ttccctcctg	gactcagtat	catggagcaa
9541	ccactttctg	gaagattgct	ggttgccaca	gtagaggaaa	agggctcttat	atcagcattc
9601	attgctgtgg	cttagaaatg	acacatatta	tttccattca	aaactctttt	gtccagaact
9661	ggttacatat	acctacccaa	ccataaggag	accagggaaga	ataatccac	tgtgcattctg
9721	gaaaggggaa	aagccagaca	aatgtggcca	acagccccag	tgactaccac	cacagtgcct
9781	ttgaaaacca	ctgcccagag	ccagaaggat	ggaggatcag	catggcggtg	ggagggaagg
9841	agaagccaga	ggggaatgag	gaggagccgg	ggtgcctggt	atggaggggc	atccatcctt
9901	ggcgaatgtg	cagggtggtg	gccagaggaa	ggctgggcgc	ctttctcatc	tggaccagaa
9961	ttcaatagca	ccccggggcc	attcgtttct	gcaggcaaac	aagccagtcc	tgtagcaatg
10021	tggcagtcac	aggttttcaa	catggaagg	ggagctgcct	ggacgctgtg	ttttttttct
10081	gtttgttttt	ttgagacgga	gtcttgctct	gtcaccagag	ctggagtgc	gtggcatgat
10141	ctgggctgat	tgccgctcgg	caaaatctcg	gctgacttgc	ctcccgggtt	caagcgattc
10201	tcctgcttca	gcctcccag	tagttgagat	tacaggcgcg	caccaccacg	cccggtcaat
10261	ttctgtattt	ttagtacaga	cgggttttca	tcattgttgg	cacKctggtc	ctgacctcaa
10321	gcgatccgcc	cgcccaggcc	tcccaaagt	ctgggattac	aggaataagc	caccgcgcc
10381	ggccagacgc	tgtgttttcc	tggcactcca	cttcatgagc	aaaactgtca	cagagtagta
10441	tttccctggc	tccacccctc	cggcgctgct	ggattcctga	acctattcac	ttcttctgaa
10501	gtgctctcaa	cttggcctcc	ctggctcctt	cctggtgcag	acatttactc	ttcctgtctc
10561	ggctttgtgc	ctctgtaaaa	ctgctgacgt	caccagcagc	ggctccgacc	gectgtctc
10621	caaggtcccg	ggctgctggc	gcgcagcgcc	gacagcacga	tgcgtgtgcc	gacagcgcca
10681	cctcctggct	ctgcYgaggg	tgttggaac	acgcagggct	cgcatgtgcg	ccgcttttct
10741	actgcagccc	tcaaaattca	gcacgaggtc	tggctagggg	agcttgagt	gctgacactg
10801	tggtctggtt	agtttccatt	ctgaccatg	ctagccgtct	ttcagattct	agaactcagt
10861	tcttctccgg	acctccctcc	cagccacaag	tctttgaata	tgcggcctgc	agctgggctc
10921	ccctcatccc	cgctcttctc	cccaaccttc	ttcatcatcc	cttggccgat	cttgaagact
10981	tagcggaggc	agggcgcaat	ggcttacgcc	tgtaatccca	gcacttaggg	aggccgaggc
11041	gggagcatca	cttgagggtca	ggagtttgag	accagtctgg	ccaacatggt	ggaactttgt
11101	ctctactaaa	aatacaaaaa	ttagctgggc	gtggtggcgg	gcacctgtac	tcccagctac
11161	tggggagggt	gaggtaggag	aatcgcttgt	acccgggagg	cagagggtgc	tgtgagccag
11221	gattgagcca	ctgcaactcca	gcctgggcaa	cagagcgaga	tcctgtctca	aaggaaaaaa
11281	aaagtcttag	ctgaaacgtc	acttcctcga	ctcctcaaat	ttagtcaagc	ccccgtgcta
11341	tgagatctct	ccccttcttg	ctggacgggt	tggcaatgct	ggaggatctt	gaaagaggaa
11401	ctcatctggg	tcaagagcat	ttcctaagag	cgaacagagg	tttcagaatc	ctcatgagca
11461	tcggtgtctc	cttctgtgga	cgtgctcac	acactttgtg	atcctcagag	gtgagtgca
11521	ggcctattaa	acacgctggc	cttggtgaga	aagcctctgt	gggtttcctg	tttatcccaa
11581	taagctgatt	caggaaagga	gacatctcct	tccttctctg	tttgccatgg	aggactcaca
11641	cctttcttgt	ccccaggaca	gtggacatct	gtttgccaat	gcagacctcg	tgctcactgg
11701	aggctgggag	aggcacgctc	aagaaacgtt	caaggcatga	cagctacca	gaaggcctct
11761	agtgccccaa	gagctgctca	tcagccccat	tttcttccca	atattattta	aaaattttaa
11821	gaaattcagt	gaaagtgtaa	gcatacaggg	ataggtagta	ggtaaaactag	aattcactct
11881	tgctggggga	ataccaccca	gggtttgaaa	agatacagaa	ggcaaaaagaa	actgcattta
11941	gtataataaa	atacaattag	gcagagcacg	gtggctcatg	cctgtaattc	cagcactttg

12001	ggaggccgag	gaaggcggat	tacctgagct	ctggagtttg	agaccagcct	gggcaacatg
12061	gtgaaacccc	gtctctacaa	acatacaaca	attagttagt	cttgggtggt	catgccagtc
12121	atcccagtta	tttgctgggc	tgggctggga	tgggaggact	gtttgggctc	aggaggtcaa
12181	ggctgcaatg	agctgtgttc	acgccactgc	actccagcct	gggtgacaaa	gcaagaccat
12241	gtctagaaaa	aataaaaaaa	ttagcagcct	ataattccaa	agcagaaaaa	cagctggctg
12301	gctatgcact	aaatctgacc	agccattgtg	tgtaaggcgt	gtgtgtgcaa	atgtgtgttt
12361	gcatgtatat	cgtttaaata	gttactttat	ttaccaacat	ttacatttaa	ggaaatttca
12421	catcaaataa	tctataattc	tagaatcttc	ttaaacatga	gggtgggcaac	atgagacccc
12481	cactttctatc	agtatccatc	ctgactggac	ccaagtggac	agcttgagtt	tccagttcaa
12541	tccagttcct	gcctggcctc	tgctggcctc	tgggtttgca	atcccaactc	cctaccaccg
12601	ccactactgc	tgagagcatc	ccctctacag	tactcagaac	ctcactggct	gcctgcaacc
12661	ctgggggcatc	agcagaagag	actctaagcc	catctatcag	gtaaaaaacc	tgaggcccag
12721	agagggaaag	tgacttacct	agggacacac	agctcttagt	aaacagagtg	gaggccaact
12781	ccactccaac	tcagtctcat	tcccactctg	agatttaaga	aaaaaaaaatg	tgattttaaa
12841	aatcccaaa	ttgtttcctt	cctccctccc	tccctccctt	cctccctctc	cctcccttcc
12901	ttcctccctc	tccctccctt	ccttccctcc	tctccctcct	ttcctccctt	ccttccctcc
12961	ctttccctcc	ttcctctccc	tcctttcatt	ccttccctcc	cctccttttc	ttccttccct
13021	tccctccctt	tcttccctcc	tctccctcct	tttcttccct	cctctccctc	cttttcttcc
13081	ttcctctccc	tccttttctt	ccttccctcc	cctccttttc	ttccttccct	tccttccctt
13141	tcttccctcc	tctccctcct	ttcctccctt	ccttccctcc	cttttcttcc	ttccttccct
13201	tccttttctt	ccttccctcc	ccttccctcc	ttccttccct	tccttccctt	ccttccctcc
13261	tctccctcct	ttccttccct	ccttccctcc	tccttccctc	ccttcttccc	tccttccctc
13321	ttccttccct	ccctcccttg	ccctccctcc	ctcccttctt	tccttccctc	ctttgtttct
13381	tccttccctc	ttcccttccct	ccctctctct	ccttccctcc	tctctttctc	tctctctctc
13441	tctctttctt	tttcccccct	tctctctttc	tttctttctt	ttgacagggt	ctcagtcctc
13501	actctgtcac	caaggctaga	gaaccagcag	gtgatcatgg	ctcactgtag	cttctacctc
13561	ctcgggttga	agggagcctc	ccacctcagc	ttccccagta	gctggaacca	cagtcacgag
13621	ccacaatgcc	tggctaattt	tttgatattt	ttgtagagat	gggggtttcac	gttggtgccc
13681	aggtgtgtct	caaactcctg	ggctcaagca	gtcctcttgc	cttggcctcc	ggaagtgtct
13741	ggattacagc	catgagccac	cgcgcgcggc	caatcgcaaa	gtttctaaa	taggaaatgg
13801	gactctatct	catccccaac	taattgtccc	caaccactgg	tagcagcctg	tagctgtctc
13861	gcttcgacaa	acacagaggt	ctaagctcac	actctcaaa	ttacactcac	atgtctacag
13921	tttggtcttc	tctcttttac	tttttttaaa	atttattttc	tatttgtttt	cccatgaca
13981	tagctccagg	agatcctgag	aacatgtccc	ctacagtttg	gcttttaatc	ttatgattgc
14041	aaagctggga	tcagtctgca	aacaccactc	tgcaacgtat	ccttcccacc	aacccagcgc
14101	ccacacaacc	ccctcagtg	ggccactctt	tccctttcag	gacacacagc	acagtcctct
14161	tcttccctca	tcacctcaca	ggcctgaaca	gagggccaga	gaggtggagt	cctgcaattt
14221	acctgtctag	tctcccatca	caggaccctg	gacaagtcac	tcctctctca	gagcctcagt
14281	ttccctgcag	gaaagaggag	gtgctcagag	acaaggtgga	tgaacaattt	tctgggcttc
14341	ttgtatctca	aaagaaatcc	tcttctctgt	gccgggcgcg	gtggctcttg	cctttaatcc
14401	cagcactttg	ggaggctgag	gcaggcggat	cacctgaggt	caggagatcc	ccgtcaggag
14461	atccatgacc	atcatggaga	aaccccgctc	ctactaaaa	tacaaaatta	gctgggcatg
14521	gtggtgcatg	cctgtaatcc	cagctactca	ggaggctgag	gcaggagaat	cgcttgaacc
14581	tggcaagcgg	aggttgtggt	gagccgagat	cgcgccattg	cactccagcc	taggcaacaa
14641	gagcaaaaact	ctgtctcaaa	aaaaaaaaaa	aaaatcctct	tcccctgtca	ggccttagta
14701	gcagcatcct	aggggtagcc	tagacggggg	cagattcctg	gggggtggtc	taaccacat
14761	cacattaatg	atgccaccca	agtccattcc	catggcacca	ggctactggg	acaaagggcc
14821	aggtctccag	tcttccatgt	ctgacctcta	cctcctttgc	ttcctccaaa	gtgccagag
14881	aaatgcacgt	ggccccagcc	tgctgccttc	tgaggtcacc	tggccatacc	ccaagtatgc
14941	tgggaaccca	tgctgagcct	ggagaatcct	cactctccca	cctctccctc	cattcctcag
15001	gggaacaagg	actccaaaag	agccgtcgga	taaacctggg	tttggatcca	ggctttctac
15061	cttggacaag	ttacctaaac	ctcctgcac	tcggtttctt	cttcgtcaaa	tggggacaat
15121	acttctttct	ttaaaggctt	tactttgagg	atgaggtgag	agggaagcca	tcctcctccg
15181	tacccacaa	ggatcacagg	ccagttagat	ccagctatta	tcacctctgg	tgatgtgtgt
15241	cgccaacaac	ccaaggacc	ctgttactga	gctctaacca	gacctccct	ctagtatcca
15301	acacatactc	tcaaggga	cagaaatcac	acagaagagg	ccaggcaggc	gcagtggctc
15361	acgcctgtaa	tcttagcatt	ttgggaggca	gaggcgggtg	gatcacctga	ggtcaggagt
15421	ttgagaccag	cctggccaac	atggtgaaac	cctgtctcta	ctaaaagcac	aaaattagcc
15481	gggcgtggtg	gcacacactt	gtaatcccag	ctactcagga	ggctgaggca	ggagaatcgc
15541	ttgaaccggg	gaggcaagg	ttgcagttag	ccaagatcgt	gccactgcac	tcaagcctgg
15601	gcaacaagag	cgaaactctg	tctcaaaaaa	aaaaaataaa	gaaagaaatc	acatagaggga
15661	aataaatttg	ctggttctat	tctcaacctc	agctccgctg	ctccactggc	taactcagag
15721	gacagcccca	gtccagccat	gacccactgt	ccagcctcct	ttcctgcagg	gaaccagctt
15781	gggtttccag	gacgacacac	tggcccgaag	tcttactccc	agtcgccact	gcactcctgc

15841	ctgggcaaca	acagtgaac	tccatctcaa	aaaaaaaaa	aaaaaaaaa	atgatacaac
15901	ggactctggg	aactcacggg	gaagggttga	aaggccaggt	atgcggggatg	gtattggcaa
15961	ggacacatat	agagacacag	agaaggagca	tcgtaggggg	tatgggggaag	ctatgcacat
16021	ttcaaagtat	tagtagagca	caaggaagag	gctgggacag	ggggaggatg	aacttggaga
16081	agccatgact	ggaagcctgt	gtcccatggc	attgtcatct	gtgtgtgtgc	cccatcttga
16141	ctttgagctc	cacacaggac	aggactctga	ctcatctttg	ttatagatct	cagtgaagtgc
16201	aaggcacgaa	gaagaagggg	tgtcaatgag	tgcttcataa	atgaatgatt	ggatgaatga
16261	atgaatcatc	tgtttctcca	cttccattct	gtggtctccR	gccaacattc	cctcccattt
16321	acctctcatt	aaactctttt	tgcagcagca	ctttctctta	gttcttctctg	tcatttgcga
16381	gacttcagct	ttgtgatctt	tgggtcagac	accatgatga	gagatgcaga	tcgcaactga
16441	gcgKcattta	aatattcaga	agagctgagg	ctccgcaggc	tgaattctga	atatgcagat
16501	aattcagaaa	acactggagc	aatagacttg	ttgaattcaa	actcgagggtg	gagcagacga
16561	gggtacagct	cggcttaggt	gacccatcgt	ccccatcagc	tgctccttcc	caaagctacg
16621	gctccctcgg	cctttgagct	ttcaagcctc	agcctcgtgt	gttgcttcag	tggcagctgg
16681	aacattcctc	cctgcagcct	gtcctcaga	cgttatctc	accccatagg	gccctgtctc
16741	atctcagttc	tgatgggggt	tagcagtggt	ttctggatca	aagtagcttc	tttctttgtg
16801	ctgtatttaa	actttgtggc	gtaggcatca	gtttccctaa	tgctctgtgt	atccatcttg
16861	cagggtctaca	gtattgagag	acagaaagtc	aagaagttct	ggacctgcca	ggaattccca
16921	ctgtggaaac	aaatccaccc	tccttacttc	ctggagaggg	gcaattcctt	caggaaggtc
16981	ttccatgagc	cttacatcag	actttgtcct	gaactccacc	cacagctccc	ctgtctgagc
17041	gtgtcccat	ttctctggac	ctcttccatc	tccagtccca	gaccagcatc	ctcctgcatg
17101	tgcttctgaa	agtacaggcc	actcctgcac	cccttctata	cctgggtcgc	caggaaactc
17161	acggatccac	ttttgacgca	gtctgttctg	ctctcccttc	tcaaactctgc	ccagatctca
17221	gctgtccccc	atgggtcctta	tcaaactccc	atctacagcc	tctagaaagt	gacttctgat
17281	catttctctc	atcgtggccc	tgaatggcag	tcacatgtac	ccttcatctg	tttggctctt
17341	gccccctgcc	agacccagca	gcaattccat	gcccctgtct	ttctggatct	cagctcgaga
17401	ggagtttgag	gtgcgtggct	tgattttcgc	ccatcattct	gtcctgtctg	gcttgcagtc
17461	cttacctttt	cttcacagga	aatcccatca	ttcaatccac	atgttgcttt	tccatgtacc
17521	aatattagat	tttccctagt	attcttttct	gatagtaagt	cccaaactctg	tcttttagcc
17581	aatcttatcc	Ytccctgatc	ctctgagaaa	ccagactcct	agatacggac	ctttcaaagt
17641	cttctttgct	tttgggcttt	taataatccc	cctgagatta	ttcaccagct	aaaggatgtg
17701	ggggacagaa	cagcacttga	ctgataaagg	cccccatcct	cctgggtctgt	cactctcaca
17761	tcccaccggt	ccctggggta	ccccctggag	gccagcacac	gacctctcca	gatccctgtt
17821	gacaccactt	gttggggaaa	ggcagctcga	gcatcccatg	gacatccgtc	tgaagggttg
17881	gcccgaatct	ggttcccttc	ttgatggagg	acgacattaa	aagaagacaa	aggagagaat
17941	ttggggtgac	tgatctattg	ctgcttaggc	caagtctaac	cattgaaNgt	ctocaaatct
18001	cacacctaag	ggtccctagc	tctttagtaa	caccacagag	attttccagt	tcaagggtttt
18061	ggtctatcac	acgatgggag	aaagctggca	agaagaaaac	aagctgtggg	aatcaacaat
18121	tgttttactc	accaaaagatt	aggaaagcctg	aataacaaca	tcacctcttt	tgagtacagc
18181	ctcacataga	actgaactga	atagaaatca	tctcatttta	caatcatcag	acatctgtct
18241	ttgccccagt	cctggctgct	gcacctcac	tacgagccct	ggattgccac	gtcgtccctt
18301	ggttcccaaa	tcctagccccg	tggatataca	tttcttatcc	taagagtcac	cctactatgt
18361	gaggggttctg	ggagcagctt	tgttcctggg	aatctgcagg	caccttctctg	ccttctctgt
18421	gtggctcgcca	ggcacaagga	aagaagaag	ggtctcgctt	attacagtag	ggaaaacatg
18481	cgatgaattc	tcttctaacc	ctggtgcaga	aattctccta	atgagtcctg	gggtgaaacg
18541	caggcctgga	agcgagggtga	ggctcctccc	caccagcatc	taaaaagccg	gctccctgga
18601	gccacaggat	ttttccaatc	agccatggga	ccagggcagc	ccaccagcct	ccccagctgc
18661	cagacgctgg	tagagagacc	tgagacagag	ggcaggtgaa	tggagcggga	gaggaggaga
18721	gaagggacac	cagatgggggt	ctgaggaaga	aagaagggaag	aaaaaaagat	accttgatgg
18781	ggaaggggaa	agccttaatc	tgcttctcaa	tcgcgaagta	ggtctgcttc	tcaattcatg
18841	agttagggagt	gaaaagcaca	ggtggggctt	ttgaggctca	ggcactccac	ccaccaggac
18901	aatgctggacc	ccatgactgc	agagcctagg	ctctgcaggg	agcagctagg	gagacactag
18961	taagggagggt	gggcaggggg	cagaggcccc	tttcccccac	tgctccacag	gggatgagga
19021	gggggcttcc	gaaaaggccc	aggtttagggg	gcctgcctgc	tcagctcaca	tccccctggt
19081	gtgacagtgc	cttctttact	ctgtcctcta	gccccNggga	cccatctgag	tcttccccct
19141	ggaaattgga	ggacctgaaa	gaaaaccctt	ggaggcagca	ggcagtgga	ctgagggctt
19201	gagtgtagct	cggtccctac	cgctgagagc	cctgaggctt	tctgggtccc	tgggtcttccc
19261	taagcctggt	tttaaaaaat	gtgcacgcac	gcccaccac	ccaaggattt	ctttaattct
19321	gtgagctttc	tctctggatc	attcaaatat	atgcctcYac	tcttgaggta	gcgggaagat
19381	tttttaagat	ttttcatttg	ttttgtttt	tgcatttgct	tttgtcttg	tttgtcttg
19441	cttatgttcta	cttgcaccca	aagggctcta	cctaatagaa	aaattggcac	caaagggttg
19501	gttgcagacc	acaaagcctc	aggataattg	gtacaggtag	aatcatgttt	tgtgttgaga
19561	ggtggacaga	gcaatagtga	acccttctca	ccccctcat	tctggggagc	acctgtctc
19621	agcttgtgga	aaggggacaa	ggaatgctgg	gacatgaagc	aggaccactc	actttggaca

19681	aaggcctttg	acattttctcc	tgaaggcgctc	caataaattg	tggctgttga	tatttttggc
19741	tgactctcct	atgaaaaaca	aattcagaaa	cgttttctat	aggtttctgg	ttacatgatg
19801	aatttcatcc	tcactagatc	ttctaagcgc	acatgagggc	cctgatgggg	acagagtggg
19861	gtgctagtag	ctctcctgct	gtaacaaagc	cctacagaca	cagtgcactg	aaccaacaca
19921	aagttgttct	cttccagtag	agttctaaaa	tcaaggcatg	ggtagagctg	cattccttgg
19981	ggaggtctcg	ggagaagcaa	ttcccttacc	ttttccagct	tttagaggca	cctgctgtcc
20041	tcagctcctg	gcttctccct	tcgtcttcaa	gccagccttg	tagcatcctc	tgatctctct
20101	cagtttctct	ccccttctat	catctcatct	ccttttctcc	ctctcaccct	actgtctccg
20161	ccttataagg	acccttgtgg	ataccctggg	cccaccagga	taatcgaga	taacctctca
20221	tctccagatc	cttgactgga	tcaacactgt	gaggtccctt	ttatgatgga	aggtgacata
20281	atcacaaagt	ctatgattaR	gacaccaca	tctgtcaggg	gctgttattt	agcctaacac
20341	aagatgtatt	cagaaaattg	caatagggat	acctgagggg	aattgaagga	tcccaactcc
20401	aagccgcctc	taaggatgct	tccgaggtgc	agctcccgtc	ggaggactct	gctccatctc
20461	tcttctctgt	tgccgctgcc	tgccctctct	tttctagaca	gccagtgttc	aagtcagtat
20521	ggccttgaga	gtgaactgca	gaatggaaa	gagtgaagat	ctgcagcagg	agaaagagct
20581	cgctgtcaaa	gctccgaaga	gctgaagacc	atttatttgc	atgggtgggt	ctgacggagg
20641	tcggcaagga	agaggaaatca	tcatttggWt	tccttgccat	ggtcacctc	agctggcacg
20701	gtttgctcca	gcagcaggct	gggattccag	ctgtgccag	tgtagccat	gccaccctca
20761	actaaatgct	gatcacttct	ttgtgacata	aaaagccaga	aattagttgg	catgatgaag
20821	aagaaggagg	actcaaagtg	tgtaggaggg	tgaaatgcta	gatttgattt	ctcaagcact
20881	tectgcccac	Rctgtttcct	gccagggccc	aaaagatttc	ccgctccttt	aacgaaga
20941	gtcaatggat	aaccaggaac	tctctataat	aggggagggg	ctgggactct	ggtctcttta
21001	gggtgggaga	aattccaaga	ggccgactgt	aggggaggca	ggtaactgcc	agaagaaaag
21061	agagtgcggg	cgccagggtca	cgcaccagga	gggcgcata	tcattggctca	agggacattt
21121	gataggaaca	aggttccaaa	atagagctgg	aagacagtcc	actgacttta	caaaaccccc
21181	aatctgggtg	gtggatacct	gtcacagggtc	atcaggctgg	atagtcctgt	ctgtgacacc
21241	aattcttagg	cctgggtcag	agggggagat	tatagggcac	aagtaattag	tgaatatcta
21301	tattogtttta	cctttgatta	agtccatcag	ggtcccaccc	tcacctgggt	atcatttttc
21361	aaattcctgg	gtggataaact	ggaaagaata	ctcttggaag	cttcagattg	ttcaccacaga
21421	cccacggacg	gggactattt	cagtgaata	Ygccagtggg	ggccattggt	tttacatacc
21481	tgccataaata	ttttactcaa	agtcacaccc	aacttcattg	aggagttaca	gttgcagttt
21541	cagagatttc	tgccatcatc	aagattttaa	gggagcagaa	gcagtgattc	ctgtgactca
21601	cctgttcacc	tctccagtgt	ggccagtcgt	caacagggaa	acaactgttt	gttttccaac
21661	cgcagaacaa	agtaggaagc	tcataaatgg	aagttgccat	tcctaagttg	ttcttggtta
21721	tgaagcaaat	aaacacagcc	tgacgtctc	agtctgtatc	aatcaggctt	cttggtcgag
21781	cagaggtacc	aactctgttt	tcttgggcca	gaaaacaaca	tgaaattcac	tggaaatgata
21841	ccagaagaac	cccacgtgtg	taggaggtcg	gaaattggct	tggaaagata	atagaagcca
21901	agacagttag	acggtatcga	aggctgagag	cacaagagcc	ctgctttgtg	aggagtgaac
21961	cggccacagc	gctgcccYgc	cacctgcgga	cgtcatctct	gctgggtgcag	gactcggtcg
22021	tcccctgtct	tattcccctc	ccgggcagtc	ctgctgctct	cactgagaat	ggatttcaag
22081	cacctgtggc	tttgccctcac	ttgtccagca	ttcaggatcc	catgtggaag	cagccaatta
22141	gccagcctag	gtcttgtcca	gaagccctgg	atgccagggt	gggggtggac	agagagtcac
22201	ctattctctt	gggcattaca	tagaaggtgg	gaccagtctt	tctctatgac	tccacatgct
22261	gggaaacccc	acaaaactag	gaagaggcga	atagatgcca	atcagctccc	tcccaggaaa
22321	ctgggagttc	attccaccca	gaggccataa	atgttgacat	gccgtctttg	agtgtagagg
22381	gaaggaagct	aactccaatt	cgcaaaatga	ctaaatagag	ataaatgact	gacagctcag
22441	aaaagaccat	gagggctgaa	ttcaggtgct	tacacagagt	catgagtact	cagcatctct
22501	caaattgtgc	tgtgctttcc	gcctggccca	cctgtccccc	ccaggtctgg	cctgctgtgg
22561	aacgcctctc	aaggacgggt	cctgaagagc	aatggagcac	acctcacagt	ccaggctgcc
22621	tggaaggagc	tgcatcctcg	gaccaggatc	tgcatgtttt	cctgggtaac	aactaaggaa
22681	ttagctggaa	tttcaacatt	ttagaaggaa	ttaatctgga	ggcttggtga	caaagatttt
22741	tagggaagag	gaacatacat	agagctttca	gaacaacggg	agaaStaaaa	aaaaatctgt
22801	cccatgtgaa	tgctcatttg	aagatgtoca	ccatcaaaaa	agactctttt	tttttttttt
22861	ttgagactgg	gtctcactgt	atcgcccagg	ctggagtcca	gtggtgcaat	ctcggtcac
22921	tgcaacctct	gctcccagg	ttcaagcaat	tctcgtgcct	cagcctccaa	agtagctggg
22981	attacaggca	cccgtcacca	tgtctgggtg	ctagtttttg	tatttctagt	agaaataggg
23041	tttcaccatg	ttgaccaggc	tggtctccaa	ctcctgactt	caactgatcc	actcgccttg
23101	gtctcccaat	gtgctgggat	tacaggcggt	agtcaccatg	cctggctcag	aggctgttaa
23161	taaacaaggg	aagaagtcac	tctttaaggc	tcaaatctcc	tctgttcccc	aggcagcctg
23221	acattttcag	aatgggtcca	ttacccaact	tgccaatgt	ggagctctat	gtaaccacac
23281	aacacggacc	ccactcatca	aggctgacca	cttggcaccc	agtgaatctc	aacccgggaa
23341	atgacagcct	taggtcccat	ggaaatggcc	caaaggggac	tcagctccat	atcagaggct
23401	gggagctgcc	cttaggatgt	gatatgtttt	gaatccatac	ccagaatttt	ccccatttcc
23461	tgtaatagcc	agaattcatg	gagctgggca	gtcagagggt	aagatgaggg	tgatagctct

23521	atggtttacc	acaataaacc	actttcaaaa	attttgttta	tgatacatat	tcctaactca
23581	cagactttta	ggtctggaag	tttcagtatc	taaggttgac	aaaagttgtt	tcagcagaaa
23641	ccatagctgg	cttctcatgc	tccctgatgt	agggatagca	atgacgtcac	tgggttgat
23701	ataatcatgc	atcatgttcc	tccagggaag	ctcatgttgt	tattacacag	caggacagga
23761	ggaattgagg	gatcccttag	gattgtctct	tgtaatactc	taaagtgtta	gagtattagt
23821	gtaaaatgtga	ataggaaatt	tcaccaactt	actgaggcca	gaccatcaag	gagcttagac
23881	accacgagaa	tgactttgcc	cataagtaag	aggaacattg	agtggaaaca	ttcaagactt
23941	ctgatggtgg	cagcaatggt	cagtagtggt	tgtagccttg	accgtacctc	tttattttct
24001	acaaatatac	acacacaaaa	attctgagac	agaagctgcc	aatggacca	aagaaaaatt
24061	gatcgtgtgc	tgaggccctc	ctcctgtgac	ataacttcag	catgcagaag	gtggagatgc
24121	tgtgtgtggc	tctcactggg	gaagaggcaa	gtgcatttgc	ctttttcctt	gggatggctg
24181	ggttcatagc	agataaggag	agttcttttt	gtttgtatga	gaagaagagt	gtgtgtgcag
24241	tagcaagYga	ttgactgtat	acaatgagca	caaattcagg	tggctgtttg	gccagaggct
24301	tccatttagg	gtttgtgtct	ctgttaccca	tccccattcc	tgataccata	gcctcactga
24361	ttagttcaag	aagagtcact	aacccaagct	attctgtcta	ctgagtatgt	gaaactttaa
24421	tcagagacac	taggaatcaa	agtgtgtgga	gctaagccag	gtgcaggcag	agccctgaaa
24481	gggcaaacca	tatatctctg	atgttggttaa	tggtctgtct	ctgtccttcc	aaattctgta
24541	gattttgttc	ttccttccat	cctctgacct	gctctagttt	tcattccaatg	aattcttctat
24601	tttgtttaag	acagatagtt	tctgtttctg	ttgcttgcaa	ttgaaaaatt	tttaacaat
24661	actagcagta	cagtggaaat	gcatacaatg	caggtagcct	gatggcattt	caactctaag
24721	tgtcagggca	aatgctggct	ggatcactga	agaagtaaat	tactcagtY	agcaaacatt
24781	caaagcttaa	gtgaaatgta	tgaaaagaat	gggaattatc	caggaattga	tgaacaattg
24841	acaRacaaat	gaaacacaat	gttctggcgt	taggcaagtc	gggtggccgt	gctctgttga
24901	cttcttcagg	aagaaataga	tgaatcaact	gaaggtcagg	gaagccttgg	ctgatggaga
24961	gttagcaggga	ctgaggcaag	tgttctgcag	gatgtcatat	aaaaaaggac	taagtaggcc
25021	ctgggtgcac	tttaacgagt	acttaggaga	ggttctgggg	tgattKtYtg	cattctgtat
25081	ctcttgcccc	tgctcYgggc	tccagctgag	gcgcccagca	gttctatatt	ctatgcattg
25141	aaatacagat	aattaatgtc	cactggggca	aggccatggg	ggacaggagc	agtggttaca
25201	ggcctccctc	tctcctccct	gtagaggaac	attctgaaga	cgctccttga	agactcctca
25261	ggaggtctcc	agtcgcccac	atgggtgacc	ctatcaagaa	tttctcccRg	catcagcctt
25321	ctgtccttct	ctgtgtcact	cctMccagta	ccccagtcct	gctcctagaa	tcacttccca
25381	aacaaatcct	ctgcctggga	gccttgccct	gggctctccc	ttcaggggaa	ctcaggccac
25441	agcagcctac	attagacagc	atgaaggctc	tgggcttttg	tgctaagagt	aataggaagc
25501	cattgaagac	atggaagcat	gggcttgaWg	aaatctRtgt	tcttacgggg	caaMttggcc
25561	cagtgtggag	gatgggcagg	gatagtggca	agggtgtgat	aacagggaa	accattctgg
25621	aagcttttgc	aggagtctgg	gtgaaatgag	agggtgact	ggatgagggt	gtttgcagac
25681	tggatgaggg	tgtttgacga	ctggatgagg	gtgtttgctg	tctggctatc	tctctctgtt
25741	cctctatttc	tcatggactt	tctctcaacc	tacacacagg	cccctctgat	tttagtcagc
25801	cttgtgtgac	ccatgtcatt	cggtggccct	ggctgctaga	tggggaccat	gcctgcactt
25861	gggccaagcc	agatgtctac	aagctttccc	tgagtgcctc	acaggccact	gggcatggg
25921	gtcgcccaga	aatgaccgac	cagaagaaca	agcagaaggg	gccatggagg	cctagctccc
25981	tgagtccctg	gaagaaggat	catgaggaag	tgaagtcagg	caccgagagc	ccaggggagc
26041	ccatccatca	gcaccacaaa	ggcacaggca	tagatcagtg	ttgcttgaa	ccagatctdc
26101	agaacacaag	aggagagagc	caggtggacc	tgagatatca	tcttgtccag	cccctctttc
26161	ccagctgatg	aggaaactga	ggctcagaga	ggcggtgtct	cttgactgca	ggctggttca
26221	tctcctcaat	gcaccacaaa	gttcttgtat	tggttctctg	catctggttt	tgcttttctc
26281	ttccttggtt	ttttttgggg	gggggacgag	ggggatggag	tctcgctctg	tctcccagac
26341	tggagtgcac	tggcgccatc	tgggtcact	gcaacctcct	cctcttgagt	tcaagcaatc
26401	cgctgcctc	agcctcctta	gtagctaaga	ttacaggcac	ccaccaccat	gcccagctaa
26461	tttttgtatt	tttagtagag	aaggggtttc	actgtgttgt	cctggctggt	ctccaactac
26521	tgacctcagg	tgatccaccc	gcctcgccct	cccaaagtgc	caggattaca	ggcctgagcc
26581	accgtgcccc	gcctcctttt	atttttcttc	acaaatcaat	gacttttcca	atacagaatt
26641	tggagtttca	ttggaatgtc	atcgttccct	cagtgtatcc	tggccccaa	cagggtgac
26701	atttgtcaag	tctcctgtct	gtctgtgac	atcatcacca	tcacctttac	cactgttcag
26761	acaaaaactt	cagacaggaa	cttgctccca	aagcgagaaa	ggagccagga	gaccaaggaa
26821	tgactcgaat	aagtccagct	tggtgtagag	gtgagtttat	taggacttac	acacagggca
26881	ctcagcagga	tggctctaga	gatccggcct	ccccagctct	ctaaactgct	tttcagttaa
26941	ttttctgtct	ctttgcctgc	tgtatatgag	taatgagact	gtttttcttg	gtaggttctc
27001	gcatactctc	caggatgttt	gggttttttag	agacacctgg	tcctcagctg	gggacaatgg
27061	caatggctca	ttacctggcc	ttcagggttc	aagcagggga	catatacccc	taaaactacc
27121	aaaggggac	catcacacta	caaccaccac	ctccaccgcc	atcatcaaga	agccactggc
27181	tgactgagat	acacttccag	gaggacaaga	cagagtggat	gctggaaaga	cagggcaggg
27241	gaccatcacc	agggaaagac	ttcattcttg	gaaggacatc	gaaccggggg	caggtcggtt
27301	gtggagccgc	tgtttcttct	gctgtatcca	aaagtcttaa	ctcttcggct	ttctgcattt

27361	tcagctctttt	cttttctctg	ccttctcatt	gctggttcct	gcacacctcc	cctctattcc
27421	tcccccaat	atattcgta	gtctaaagga	aatttcttct	tcctattccc	cacactctcc
27481	agtoocctct	cctcccttat	tccaggtcc	agcattcctg	ccttctcctt	ggtgcacttg
27541	ccatctgcat	taacccctcc	cctgctgtgc	tcagctacag	aaatgccaaa	gtcactaaca
27601	ctcagctcca	taaactttac	cttgccctct	ttatccccct	aataaaatgc	ctgcattttg
27661	tcgtggcctg	tgtatggctc	acctccctcg	ctggctgcac	tggtctgggg	tcagtggtga
27721	tggtatggat	tcagacgctg	atagatctga	gtgagctcca	ttagattctc	ctccagctcc
27781	tgagcctgcc	gcctcagctc	ctcagcagat	gcagactttg	ccccctcatg	caagtgcctt
27841	gactcgtata	caaggttgac	cacatccagt	gcaaggaaga	tgctgaagt	ggtgcgactc
27901	aggatccggg	ctcctctgct	cactgcccg	gtggtgcctg	caatcgcttct	ctctgcttga
27961	ccWccacttc	cagctgagat	tcgccagggtg	gtcacaggga	gtcggggccct	ggctctggct
28021	tgctgatgg	cacggatttc	actcccaatg	gtttgtgtgg	cttcgtaata	attattaaga
28081	agggaaagta	agttgggtgt	gatgtcacgc	ataacttctt	taaatacctt	caaKcgggtca
28141	atgctgggtg	cagtcagcct	gctggcttca	gcttctgctg	atgatgtgta	tgagtgcctc
28201	acgatgctgg	tggtgatccc	agtcacagca	gacgtgctc	ccagccctac	cccagctgca
28261	gtaagggccca	gactcgtccc	tgctgtaaat	ggtgccaaaa	caagaccagc	aagggaatg
28321	atgccagagg	cagcgccagt	ggagctggac	accacRttgg	agatgggtgca	gcctctgtgg
28381	acctcttcaa	taccattttg	aagggcacga	agcttttcta	tggaactcctg	gatcttccctc
28441	ttgacttggg	gaaactcttt	caaaaacat	tccctaaact	gctcatcttt	ctgctgcaca
28501	tattcgtcct	caatagctgc	atatgttcta	agcttcttca	gagcttcgta	gagagcatct
28561	gcctcatccc	tgtaccaata	aaggacagat	gattaagaaa	ggcagcttac	ttatctgtaa
28621	aatcagctca	ataagatctg	ttctacataa	atcacagagc	tattactatg	agtcaaatgg
28681	aaataaagct	ttaaatttta	aatggaaaaa	tttaaaataa	tttttccaag	gttaaacatg
28741	ttttgtatat	catagatatg	ccacagtact	tattctgtat	gggaataaaa	aacttaaagt
28801	catcttcaga	tgctctttag	tggtaggat	tcgataaaga	tggtctctca	agcaagagag
28861	gtcaacatca	tccttccaat	agtgtgtgga	gaggggaaat	tttgtagatg	aacaagaga
28921	agtgggttgc	gagcaaaaag	accttcattc	agaggatcat	agaacagtga	aggattaact
28981	ttattagaag	agaggtcggt	cttttgtctt	tgggccctgg	gaagggatct	ctggggccct
29041	ggaatgtcct	gcctggtagg	aacatctttg	tttccctggt	ggtttggtca	cagcacagta
29101	tagcaatggt	atgggtgatg	ggttttgagg	ctattacgta	tcctttctgc	cttccaaagg
29161	aactgggaac	taagggtggt	agacctcagg	gaggggctgg	ggactccatg	tcagccatca
29221	ggacagcttg	tgatccagcc	ccagaaagag	ctctgtacat	tgaggcatag	ggtgagaaag
29281	actttctcct	tgggccaaact	ccagtcaggc	tgctctgagc	cttttctcct	ctaggcgctg
29341	accttccatg	cccatcccg	gcttgcctgg	cctgtactgc	cccagttcag	caagaatccc
29401	ccaaggcagt	tagggagggt	cctccctcct	tgctgtctga	gcattcttgc	tgctgtatca
29461	cgggtcttcac	ccgctcctta	cctgccttta	ggtgagcagc	ttgttaggcc	agtttagcag
29521	aaacccccca	ttctgggtgc	tcagtcaga	actggtccat	ctccactcc	tcacctgggt
29581	ggtggtctg	actcccccct	tgcttttaact	atattgggag	ctgggctcag	tctccctccc
29641	ctgtaacNca	atcctgaata	aaggttctct	gatctaagt	gattcacagg	aatttttctc
29701	taactgggtg	agcttctctg	gttggaacaa	ccccatgtgt	tttgtccac	attcacacag
29761	gagaacacag	cgctcctgagg	acaacgaagc	ttcacacctg	aaacctccc	agactctgcc
29821	ctgtgtgtct	cttcccttagg	ctgatttttaa	tctgtgttct	ttccctgtga	taaaccacaa
29881	tcgtgcaata	acagttatca	gtgagttacg	taagtctttg	tagtgaaat	tcaaacctga
29941	gtgggggctt	aagaaacacc	ttcaaactctg	caactgggtg	cagaaRgaag	ggtgccttca
30001	gacattgcat	tttgactaac	tctgagctct	taagctatca	aataaaaacct	cagcttggaa
30061	gagatcacct	tgcttggtgc	gttcttctct	ccaatgccac	atgccctttg	atcttctgac
30121	tgaaggccac	tggttccagc	cactgcccc	tttgactgaa	aagtgaagg	cctggctatt
30181	agtcctggct	gcacatgaac	tctcaagcca	cttgacKgcc	tcctgacctg	gcacctccaa
30241	gcttcagggt	ctcactgtca	catgtcRcca	gccaaactaa	tgcttagca	ggtgacagct
30301	tcacctgtgt	gcatRccaat	gccatgtgca	atttcatgga	acctcttatg	gactcatgag
30361	actttgaaaa	tcatctctat	aaatcactaa	tgctgaaaag	acctgcattt	ggacaagatg
30421	atagagaaag	tgtttttctc	tttggttggg	gacttgtgag	tctcctgaga	accttcaaaa
30481	ttaccaggtt	ggcagacact	tgttccaact	ctccaagctg	gcccgaagaa	acacttccctc
30541	tactctatgt	agaacagaag	aggggtcccaa	atggcagttc	agaaYgcccc	agttcccagg
30601	catgtgtgca	gggaaacagt	cacctatggc	ccactatgcc	catcagtgat	gggactcaaat
30661	cagggaggga	agaaaatattc	ctctcccact	cactggctct	ctgcaagtcc	atggccacgt
30721	tacMtttcat	gcctcagtg	cctccctctt	ctcaccctac	tcccagcctt	ggtgcccag
30781	ccttccctgct	gctcctccaa	cccaggccca	cccctgcccc	atcctgacct	ctggctctgc
30841	ccctgaaacg	tctctctggg	tctttggatg	gcacatgct	acttggttcc	ccacctYtga
30901	cctgtgttc	attctcaggc	tttaaccaca	Ygcccactctg	attgaactac	tatttagctt
30961	ggagagatgg	caggtcccag	tctccaagac	ataaaacaac	agccccagag	ctgtgcaggg
31021	acagagccaa	gatccacccc	cagctctgtc	caactccatt	ccagcctctc	tgtgttctgK
31081	gtcagcagga	ggatcctgct	gtgtttgtgc	agttcctcag	aggtggaaga	aaagggccccc
31141	ggacagcatc	tccaggaaca	cacattgatc	aggtcaagat	ttttctggct	tttttcaaa



31201	aaagtcctgc	tgggcatcca	actctaagaa	aaacacttgg	tcgggYgcag	cggctcatgc
31261	ctgtaatccc	agcaccttgg	gaggccgagg	cgggaggatc	acgaggtcag	gagatcaaga
31321	ccatcctggc	taacacgatg	aaaccccgtc	tgtactaaaa	atacaaaaaa	aaWtagccgg
31381	atgcggtggc	cggagcctgt	agtcccagct	acttgggagg	ctggggcagg	agaatggcgt
31441	gaaaccggga	ggcggagggt	gcRgtGRgcc	gagatcatgc	cactgcactc	cagcctgggg
31501	gacaagcaag	actctgtctc	aaaaaaaaaa	aaaaaaagaa	aaaaaaagaa	aaaaaaagaa
31561	aacacttttg	gtcctgggtc	ctccccagca	atctttttta	aaggtaacat	taacggagca
31621	cctaccatgt	gtcagtcatt	atgctaaata	ctttacatgc	attagcttat	ttttctcaca
31681	ataaagctca	atggatgaag	aaagggaagg	agaaagtagt	caagtagctt	gcaaagctcc
31741	catcaccagt	agatggcaga	actgaccctg	cccttgtggg	cttcctctcc	cctcagcctg
31801	aggtcactca	ctgccagcga	aggacttggg	ggaaatatcc	ctcctggact	gctgagagg
31861	acattctcaa	gttcagcaga	gggggctgcc	tggaggagg	gtgcctgcca	gagaaaaacta
31921	gcccagggga	gatcaggatg	gcatagccgg	ggcgccccat	ggaggtaacc	ccacggagg
31981	tacctgggca	attcagccgc	agtacagaa	ctcttcagg	cttcattgtt	agtcagcagg
32041	atttgcagat	gcaactgggt	gactctctcc	cggaaagtatt	tgggtggcctc	ttcagtaaa
32101	cgtttctttt	ctacttggaa	acaaaaagca	taagattgga	agaaagtgtg	ctacagccta
32161	aatggcattg	agaataaggt	ggttcgaKgt	taatcctcct	caaccagctg	tcacatgggg
32221	tatttttggat	ggaggcatca	gtgctataga	ctgagttgtg	tgccctccaa	attcatatac
32281	tgagaccYta	aaccccagta	actatatttg	gagattgagc	ctttaaggaa	gtcattaatt
32341	taaagagagt	cgtaagggtg	gggccctaata	cctacaggac	tgggtgtctag	ttaaaagaaa
32401	aaaaagaggc	agaagatctc	tctctctctc	ctcaccctac	cccgcctctg	ctgtctctct
32461	tgccctccag	ccctctctcc	ctgtctctct	ttctctctct	ctctctctct	ctcacacacW
32521	cacacacaca	cacacacaca	cacatacacc	ccccacactg	ggaaggccat	gtgaggacac
32581	agccctgagg	cagMctctgt	aagccaggag	cagagccctc	cccagacatc	aaccctgctg
32641	gcaccttcac	cttgggMttt	ttgcctccag	aactgtRaga	aaatacatca	gttgttggag
32701	ccacccagcc	tgtggcgttt	tactaaaggca	tcctgagaag	agtgattcac	cagggaagtg
32761	ccaYgggtgct	ttgtggaggga	accRatctat	ttcagctgag	aatcaccaga	aagtgagctt
32821	tccaccatgY	tttctcccca	tgtacgggaa	atattccagt	gatcgcttcc	tYctgccatg
32881	tgccctattgt	caaacgcctt	acaccagtg	cttcaaaatc	tgagtttcga	cccatcagtg
32941	ggttatgaaa	atagttcatt	ttgtcaagag	cagcatttta	aaaagaaaag	agcattgaaa
33001	atatcagagt	gtattgaaca	cagcaagagt	gagtatctct	ttgtaagata	tttgaaatat
33061	atataatata	tatatacata	agggtgtata	tatatatacc	cttatgtaaa	ttcctgggat
33121	Mtagatgtgt	ttaggatggc	agcattttca	atctgtgtca	atatgacaca	gggtgcatat
33181	gctgtatcac	tgaccactcc	cacactgggtc	aacgctacaa	atgtttcaac	cttgtaatca
33241	aaggtacaaa	tgtttcaaca	gagaaaccaa	tgaatattca	ccttaaatgg	gatacataat
33301	attatcagta	caaagcatct	tagtacacag	caggattact	gccagaKga	gttgcccaa
33361	aaatgtgtgg	tttgcaggga	tttgggaatt	atggaactgc	agagaaggga	ctgggaagca
33421	gtatggatgt	atgtatgcac	tgggacatga	ggtaaaatcg	tttcctgccg	tggacacact
33481	tgcgaggcct	cattctcatt	tcacagaagg	agaaattgag	accagacag	cgaagacac
33541	cacccaaccc	agcaagcagg	aagctcagga	tttgactcaa	ggccagcgtt	cccttgccat
33601	tactttgaag	actccatata	ttttgaaaat	gcctgtgggt	cctgcattct	ccactgtagt
33661	atacctgtgg	gatttttaac	atttttattga	aaaagaatat	ttcaacccta	caccattgaa
33721	taaactacca	tgacacagag	attcctcctg	ctgctcatgg	gcgctctcag	atgggcagtg
33781	gaggggggtt	tttagggcgg	caggggagca	agaccctcag	cactgatccc	tgtggccctt
33841	ctgtgttacc	tctgtcctct	gcaggctggg	ctcaggggac	atggctcccc	actatcacc
33901	ctgaaccag	ctggccgctg	tattaaacca	cagatcatct	tgtttcggag	aSagagtttc
33961	ttccttgagc	ctcccagcca	agcccttctg	aaggattccg	gggttggctg	gtaggtccc
34021	gcttctaata	ttccctgccc	tctcctcatc	ttggacagga	ctcagcagag	cccagtttgc
34081	tgtccagggc	ggctcctgag	cagatgtgac	ttggttgcca	aggcaactca	gtgaggggag
34141	aaaacaggcc	ttagggaaat	gaacacagt	ctgacttggg	tgaSgggtat	tttgctttta
34201	ttttttcctc	cttcactgaa	aggatgaagg	aaaccagggt	tggatggagg	gaacctccag
34261	cactagatct	gtgtatttat	tgctgggggtg	ggagtaccag	ggtgttaaag	caaacttaaa
34321	atgaacacct	gggcaaacaa	aagcaaacag	gccttcagaa	Wggctgtaac	cccccttaaa
34381	ctgccaaact	tggggaactt	aactggagtc	gtttcagatg	ggtgcttacg	ttaggcacia
34441	acaaaactta	acttcggcca	gtcatagaca	gccagctgac	agacgggtac	acgataagg
34501	atttttccaac	aaggtaaaac	aaaaaacata	atttgacaac	tgcaacaaat	caaataatgt
34561	ccttattcca	cttccatatt	cacctataaa	atacctgcct	ctgacacttt	tccatcataa
34621	catgaaatgt	ctttcatttt	gatgtttccc	acttcatgac	ttgcttcttc	ctcaataaaa
34681	gtcttcaaaa	ttcgatttga	cctcagattt	ttctttgaca	aggggtattt	gagatcatgg
34741	gaagtgggag	ctgctgagg	cagtcactcc	tgtaagcag	gtgcttgtga	tgggcccgtg
34801	agggcaggcc	ccctggggga	caaaaagggg	cttcacactg	gaatcaacag	tggcaggtaa
34861	aggggatggg	aaccaactct	tagggaggcc	ctactgtgtg	gcaggcactg	gctgggcccag
34921	gtacccatgt	actatttgat	cctcatgacc	acatggggaa	atattatact	cgcattccag
34981	gtgaggggag	gtaagaagct	ccaggtgaca	cagagaagac	gtggcRaagg	ccagaatggg

35041	gctcagttca	gtgggacgct	gagtcactct	tttcacaggg	ccactcagag	cagaggggct
35101	ggtgcagggc	aagagctgga	gggaggggac	tggcctgtgc	tggaaacacc	ccaggggtcag
35161	ctgggagcag	agcgggaggt	cagaggtcgg	gRctgtgtgt	caacctcctc	tctcagccct
35221	ccgcacctcc	tggaccctgc	tctcccccta	ctccccgacc	ctgctgtttc	cacttcccca
35281	aggctgtggt	gccccacttg	agtcgtttgc	taggtgccag	ggcagggagg	aagtgggcac
35341	ctggggccatg	ctccccctgag	gagaggtcag	gacatagatg	cccccacaga	cccttgggtc
35401	gggggactcc	atgtggcctc	ttttggggct	caggggaagac	tcatcggcct	gcttgaccat
35461	ccgggttcct	ctggggctca	ctgagttgtg	gaaacgccac	cctccattct	aggtgctgag
35521	aggaaccagc	caggggaagag	gaagaagcaa	gcctacctga	gtccatggtg	ccagcagcca
35581	ggtcactgag	agactttccW	tggagctctc	cagtcactga	cctgactgga	aggggttcgtt
35641	ttttttctta	acccttgagg	aggagaaagc	aaattgtggg	actgaatgtg	agccacctgt
35701	ggacagaggg	aggttgagg	ggctggatct	ctgcaatccc	tttgcgtgtc	agcaaatgcc
35761	aagaccaacc	tagcccgggtg	ttttttaatc	tcctgggccc	cagccagctg	gtatttagag
35821	aaattctact	tgctccagct	ccctctgccc	tcactctcac	accaaggcag	ggtccttttg
35881	tcctgtagg	gtatgaagag	aagataatca	gaggaaggga	tggacatctg	ataatcacag
35941	aaactacaga	gtctatacac	cgaatatagag	atgggaagga	acgttctgac	aatgacctgg
36001	gcctggcaac	atgtgtgata	actaattgat	aaYagccagt	gtgtactggg	tgtctgtgat
36061	ctgcagggct	cctcatatgt	gcctcattcg	atgatcacac	acaggccagg	agatgggtgc
36121	aaccgtggct	cccattttga	aacagaagaa	acctcaaagt	ttaagcaacc	ttgccatgtt
36181	ttcacaaatg	gggtagagcc	aggacttctg	attcaaatcc	catgtcttcc	atgactgggc
36241	tccactccct	taaatatata	aaaatatgtg	ctcatgcata	catgcttaYt	gtaaatgact
36301	cctcattcca	aatctgtgtc	ttgcaactta	tgcccaagtg	tctgtcttgg	tgaattcact
36361	ggtgctgtgc	tggacaccct	ttgtccccct	tgttctgtgc	tgtatgtcct	ggctgcaagt
36421	gatgcttctg	cttcaacttc	ccaagtagtt	gtccctacag	gtacatacca	ccacgctagg
36481	cacattaaaa	aaaaattttt	tttagaaatg	tggatcttgc	tttgttgccc	agagctggtc
36541	tccaactcct	ggtttcaagc	aatcctcctg	cctgagcccc	ccaaagtccct	gcgattgcag
36601	gcatacagcca	ctacaaccag	cctaaataaa	tgtgatctt	tatacagaga	aacactcttc
36661	acattctgct	tgtgatgatc	ttgccttggg	aaatgagaaa	aaagaaagca	aatgttgatt
36721	atgttttaggc	attgttctaa	gaaggtagaa	gaacatttat	tgactatccc	ttcaagatct
36781	gactacagt	ttagtcaagg	cacttataag	tataataaca	gtcaatgaga	aataggggtg
36841	aacatttgtg	tactcgactt	tgaccacta	attgtcttaa	gatgttataa	ataataactc
36901	acagtcctct	tccaagagcc	tattaagtgg	gtaccatttg	tatttccatt	ttcagataag
36961	aaaactgaaa	cagatgttca	gcgacttgcc	caatctcaga	aatctactaa	gggtgtaaaga
37021	ctgggttccc	acccaaccag	acggactcaa	gaacacacac	actgcctctg	caccctctgc
37081	tgccaatgaa	aatgtgaatg	gaccagttgt	gggtggctcac	gccttaatcc	cagcaatttg
37141	ggagaccgag	gcaggtggat	cacgaggtca	ggagatcaag	accatgctgg	ccaacatagt
37201	gaaaccctgt	ctctactaaa	aatgcacaca	cacacacaca	cacaaattag	ctgggcgtgg
37261	tggcgtgtgc	ctgtaatccc	agttacccgg	gaggctgagg	caggagaatc	gcttgaaccc
37321	aggaggcaga	agttgcagt	agccgagatt	gggtcactgc	actccaccct	ggtgacagac
37381	tgggactctg	tctcaaaaaa	tatatacata	tgaaaatttg	aatgaggaaa	acaggagatc
37441	agagacttca	acagatattt	ggaagacaga	actggctgaa	gaagtgcaca	ctgaatagag
37501	aggggtaaag	ggatctgcaa	tccacagcaa	caccaagagc	acattcagcc	aagaattgcc
37561	tgctaagcag	agcctcagag	agggggagaag	ttcaccagcc	ccacgaccca	tacaggattc
37621	acagtagccg	tgagtctaca	ccaattggaaa	aaattagaga	cttcataact	gcactctaaag
37681	gccccagaaa	taatatcttt	gtatcctgat	gccaaaggagt	tctcatttca	tcactctaca
37741	gggaagactg	ccagtggaac	tgcccccttt	tttaatatga	atagatctag	gatcagataa
37801	agcagaaaga	caaaaaatgg	ggaaaagggtc	aagataacaa	gtaaaaaatg	agtccagaag
37861	aaatggatga	ttgcgaaaat	agaaaataat	ttttaaaaaa	tcaaaacccat	gtcctcaggg
37921	acataaaaaa	gtttttattca	taaatgagaa	cattatgtac	tgaaaaggaa	caaagatgat
37981	ggaacaaaaa	agacttcttg	agaattaaaa	ggtgattgag	aaaataaaca	actctaggac
38041	aagattcaaa	aagataggca	aggaagcttt	ccagaaaaatc	aactaaaagg	atgacagaaa
38101	aagaaaaaaa	caaaaaacaaa	aacagagcta	gatatagaat	aagaaagtta	ccatacataa
38161	taattacata	gaaagctact	tgagtctgag	catggtggct	catgcctata	accccatact
38221	ttggggagggt	aagcaggaga	attcttttag	tccaggaggt	ctagaccagt	atgggccaca
38281	tagtgacacc	ccatcattac	aaagaataca	aaaatgaacc	aggtgtgggtg	atgcatgcct
38341	ctagtcccaa	ctactctgga	agctgactgg	ggagaatctc	ttgagcccaa	gaggtcacag
38401	agcaagaccc	tgtctctgtt	aaaagaaaaa	caagtaaata	acagaaaaaga	aagttacttg
38461	agaatgagct	gtggaggctg	agaggaggaa	gaatgtgagt	gtgtgtgtgt	gtgtgcacgc
38521	acactcatgg	agaggggata	agggaaaacca	agagagaaaa	agacgtgaaa	gagaaaaatc
38581	aacccaggga	gaaggaaatg	caaggatacac	agctgggcat	gcagcaggcc	tagaaagcaa
38641	ccagtccagg	atagaataag	aaggaaaagg	ctctgtaggg	aaaggggact	cgatagaaca
38701	ttgcatataa	ttcacagttt	gagaaaaaact	gaggaaatca	tgaaggcaaa	cagtacaaga
38761	gggggaaaaa	acaaaggcaa	ttagaaacat	caggaaaaaac	taaagccgtg	cagcaaaaaa
38821	tgtgcaacca	tattgtacaa	ctcagctcaa	cagtaagcaa	gattttaaRc	gtcaccaaaa

```

38881  tgtaaacact  tgggttaactt  ttaacttttta  gaacaaaaca  gaacattttac  atatgagaac
38941  taaatctact  tgttaccagt  cagtataatt  aatgttccat  ggttaaagggtg  ggaggtgaaa
39001  cactgaagga  aggaggggga  ggattaatat  ggccattttg  taaagtgaag  agtcaagaaa
39061  tactggctac  agttaagggc  ataagaaata  aagttaaata  aactcacgtt  tagttctcac
39121  aacaaccatc  ctacgtaggc  actgttatca  tcttaatagt  tctgagggga  aaactaaagc
39181  ttggagaagt  taagtaattc  acctggagcc  cctagctagt  gacagccaga  agccaaactc
39241  aagtgcccaa  tctccagagc  atgcaactctc  actctatttc  atctgctagc  ataagaatat
39301  tatgtaaaga  aaatgattta  ctccctaaag  aaaagctggc  taggcacact  ggttcacatc
39361  tgtaatccca  gcactttagg  aagctgagggt  ggggtggatca  cctgaggttg  ggagttcgag
39421  agcagcctga  ccaacatgga  gcaactctgt  ctctactaaa  aaaatgaaaa  aattagccgg
39481  gcatggctgt  gcatgocctg  tatctcagct  actcaggagg  ctgaggcagg  agaatcgctt
39541  gaaccagga  ggtggagttt  gtggtgagcc  aagatagcta  cattgcactc  cagcctgggc
39601  aacaagagt  aaattctgtc  tcagaaaaWa  aaaaaaggaa  aatctgaaca  tcaaaattag
39661  ctgcttttaa  ttgggaaggg  agtgagtgga  gccctcttta  ttaaattgatt  tgtctgaacc
39721  gtatacactt  attaatgat  ttttttaaatt  ttttaaaaa  cagaagttac  tttatagtag
39781  ttagtaactg  ctaacctcaa  taatggtttg  gattgtggtg  ccaccacctt  aaagttgatg
39841  gagaagtgtg  agcaagtgcc  aaagagaaat  acacctgcct  cctgatggga  gaaatgtcag
39901  cttcagagaa  acctcgggtg  ctggggtaac  caagctgcta  agaaaagtac  ggatgttgtc
39961  attttatgtt  aaactgttaa  tattaacagc  ataatcagag  tgaactccta  tcttgaatca
40021  gtataatttc  cagtggcacc  ttgccactca  acatacgggc  ttctttttcca  cccaaaggaa
40081  ccaagacgtc  ttgtggggaa  ccaaatctcc  cagactgtga  tatgtgttac  cccagaaagc
40141  aaggacgctt  ccaagatgt  tcagagcagt  gttcaaagg  atgcccactg  gtcagtccca
40201  accgctgtga  acccggaaaa  tctgagactg  gtgtcagtta  atttagaaag  tttattttgc
40261  caaggttgag  gacgtatgcc  tgtgacacag  cctcaggaag  tcctgatgac  atgtgcccaa
40321  ggtggttggt  gtgtagcttg  attttataca  cttagggagc  atgagacatc  aattaagtac
40381  acttgagaaa  tacatcggtt  tggcttagaa  aggcgggaca  actcaaaagt  ggcgtttcca
40441  ggctacaggt  aaattgaaac  gttttctggt  tgacaattgg  ttgagtttgt  ctaaagaccg
40501  gagatcaata  ggaaggaatg  tttgagttgY  gataagaggt  tgtggagacc  aaagttttat
40561  cctgcagatg  aagctttcag  ctgacaggct  tcacagagaa  acaggctgta  aaatgtttct
40621  tcttagactg  aaagcctgtg  ttgatattaa  tgccagagag  gcataatgaa  gcatgtctga
40681  cccccatttc  ccttcatggc  ctgaaccagt  ctttcagggt  aaattttaag  agccctggct
40741  gaggaggaag  tccttttaaat  gagggggagg  cttagaatct  tacttttggt  ttataccgct
40801  tatattcaac  agtaataatt  gattgtgatt  attatgatca  tgtttacttg  gtccaagatg
40861  aatctgtgaa  aggccttggt  ttgatactaa  cattcaagtg  agaacatttg  agaaaagtat
40921  acagaaaagg  ctaaaacagg  gtacttgaaa  tgcaaagact  tatcgtaaca  gagaatgttt
40981  aattgttaat  tgggttttaac  aagaagagca  tcttaatata  aatggatatt  tttccttcta
41041  tttatttatg  ttctgttctg  taagtgttga  gaatgaagga  agagctgcca  cagacatttg
41101  gaagctggcg  tggactccca  gaagggctgt  gttattctcc  tatggacaga  aataatgtca
41161  cagaatagta  accacacaca  gggtgactct  gagattgtga  gcaaattgaa  cagagcaatt
41221  agacttcata  atactgtcta  agtatagaca  gaaactgagt  ctctgctcca  cccacaaaat
41281  accaaacact  ccctctcctg  gctaaaataga  atgcctgttt  tttctacacc  aagtcaactc
41341  taacctcttc  ctggtctccc  tctctctaga  tgagatttgc  tgagataccc  actggttagc
41401  ttgcccccca  ctttctgcaa  cacccaatcc  agagtgggct  ccatttcata  ggccctcctg
41461  ccaatcacc  agccagaacc  cagatatctt  aacaggttcc  ttctgcacc  ccttatggag
41521  gtgocgatgg  acctccacct  gtgtccctc  cactgagaag  aatgaactca  actggttcaa
41581  ccacctacag  gagtgatctg  gcagccccag  cctggaagaa  Ytgactctag  agacttccat
41641  ggtttctgta  gtgaggaggc  aacaacaagc  ccaggcagct  gtgaggtggc  cctgtcaggc
41701  ccctcaaagg  taggggttgg  ctccaagcag  gccctatct  ctttcttctt  tactgtggct
41761  tcggctgcat  ctgtttcagc  tggctcccg  gcacatccat  tccagccgct  ggtctttgct
41821  ccagacttt  atgttaacaa  cgagtggtt  cccgggaccc  cctgatgcgt  tttcatcctc
41881  aaggctcatgt  gtagaagcat  cctcatcgaa  agcctctcac  ctccctcttc  ctatttctctg
41941  cctctgtctt  agggatcttg  catccagggt  tctattgtct  ggggccccca  tgcaaccatg
42001  gtgacagtga  ggccaataga  ggcactagg  gagtgtgctg  aggggtttct  ggggtgcttct
42061  tgctgtaagg  gataaggggt  atagaaggag  ggctcccctt  ccccttcttc  atggttttgtt
42121  cagtgtgtga  cccctaggc  cagggcagct  gtctcaacat  catgagccat  caggaccagg
42181  agccagcaca  gagcagagga  gcaggagggc  agagagagct  ggggcctcag  accacacctg
42241  acacctctga  tgagctacac  ccagggtctc  gtctctctta  ggcgttgttg  gcctggctcg
42301  gaatcttgct  tggggcatcc  gctgagggtt  gaagctggat  actgcccctc  gagctgaact
42361  aggacacagc  atgtctctYc  tgggcaagcc  tgcagtttgg  tcaattcccc  gaaagggact
42421  ttagttcctg  gagaggccc  agacaggag  ccctccctc  tgcctcagct  ctgagccaa
42481  ctctccagat  gcagaggaca  gagactctca  gcaaagcagc  tccctgcaag  tggctgtggg
42541  gcctcctcct  taggcagaga  gagagggaga  gaggggtgaa  gacaccgtgc  tctcctgag
42601  gaatctttat  ttttattttc  aatatttttt  ttttttgctc  tgttaccag  gctggaacgc
42661  agtggcacca  ccataactca  ctgtagtgtt  gacgttctag  gatcaatcga  tctcctgccc

```

42721	tcattcttct	gagtagtggg	aactacaagt	gcatacctat	gtcagtcaat	ctttttattt
42781	tcattttttgc	agagatgggg	tYgtgctatg	ctgcccaggc	ttgtcctgaa	ctcctgggtt
42841	cgaggggatcc	tccctgcatta	gcctYcgtgc	attagcacgg	gaattacagc	cctgagccac
42901	aatacctagg	tctcctgagg	aatctttaa	gacctgccag	ggtcaagttc	aacccttaa
42961	ctgggcacac	gggctcctac	tttccctact	gctccctgcc	cacacagtca	ccttgggtcc
43021	aggtacacac	tgacgccctg	cttccctgcc	tcccagagcc	catctactcc	ccccactccc
43081	attcccagcc	tcaggccttt	gctcaggctg	ctccctcccc	ttggaatgcc	ttccccacct
43141	ttcccaccat	gtgcaagtca	cccatacctca	gaggctcagc	caaagctgcc	tggaccctgc
43201	agcgtccccc	agccctcccc	aggctccctg	agcactctgc	tttccggggg	cagctctacc
43261	tctgtgtggc	tcttttgggc	tctgtctccc	cgttaaacctc	tgagcatccg	gcagggaccc
43321	tgcggtgttc	ccagctgcac	cccctatgac	tgacctgggt	ggcctctgcc	ctccgtggca
43381	cagcctggct	gaaatccgag	gtgtgggagg	cagcacttgg	actaaaagca	accagcctct
43441	ggacaacatg	gcccagcttc	agtctcactt	tcagttgagg	gattgaatgt	ttttccttgc
43501	tatctagatg	ctcatctctt	tttggggaag	aacaaataag	accatgactc	tgatttctatg
43561	tacttttggg	ggctctatca	ggtttctgag	tttccattta	ttttctcccg	tgctctcccc
43621	agtctttatta	cttttgtacg	aggRgaaaga	aaaaagaaat	ttctaaaaac	acgcgagcca
43681	gctaacctct	gaatcatagc	catggtttcc	aagcctcccc	ttccccacgg	caatggccca
43741	ggcctgcatc	tgggcccagc	tccctccggg	tccatgacac	tcttatgcag	caaccaacta
43801	ctgccaggga	cttttacggg	aaagaggtca	tttcttctct	gcacttgttg	tgcttagaa
43861	tacacacaaa	aaagtcttgt	tcttctttgt	ctgtagtagg	tacctatgaa	ataggctcta
43921	cttttaaaag	aagaagaaac	aaattcttct	ccaaaaataa	gtaaatcaat	cccaaaggga
43981	tctaagtgtg	ccccagaaag	aaaaaattaa	aactatacta	gaagaaatgt	taaaaacaat
44041	gttgagttgg	gaagaccttt	cgaatcaaaa	ctcaattccc	agaagactta	aagggaaaat
44101	tgaatagagt	tttacctctt	acaaattaaa	aattagaaag	aacatcattc	aagagccaga
44161	ataaaatgaa	agaataggaa	gcacggtttg	caatacttaa	agcaaaggta	actgtccaca
44221	atccacaaga	aatgctcaaa	tcaacatgaa	aagactgaaa	tcaagtctct	aaaaatatag
44281	ccaggtgcgg	tggctcatac	ctgtaatccc	agcactttgg	caggccaagg	cgggtggatc
44341	acctgaggtc	aggagtctga	gaccagcctg	accaatatgg	tgaaactctg	actctactaa
44401	aaatatcaaa	atttgccagg	tgtggaggca	cgcgcctgta	gtcctagcta	cttgggaggc
44461	tgagacagga	gaattgcttg	aaccccgagg	gtggaggttg	cagtgagctg	agattgcgcc
44521	actgcacttc	agcctgggca	acaaagccag	actccatctc	ataaataaat	aaataataaa
44581	ataaaaattta	aaaatgggta	aaagatagga	tctgaagaaa	tagaaattaa	cgttaaccat
44641	atgaaaaggc	actcaagctc	acttttgaac	catatatgta	agtgatcaca	gagacatacg
44701	tttttgaaac	attagataag	ccaaaacctaa	agtgactaat	aatgtccact	gttagggagg
44761	taaaggtggc	acaagcccct	tcactgttga	tggagtgtga	aaggttctgg	tgctctggag
44821	gatcgctcagc	gatactcagc	acacttttaca	aagtgtcccc	acgtcatggc	acagcaccca
44881	ctcctaggtc	tcagcctcca	gggagcagag	ggcaagtgtg	cagggacagg	ggcttttagag
44941	ggtgccatgc	agcgttgttt	ctatcaacca	aaaggagaaa	atcactaaat	ctcctgccat
45001	agggagtagg	cgggtcccta	acactatgac	cattaagact	aaggaatgcg	Yctggcacgg
45061	tggctcatgc	ctgtaatccc	agcactttgg	gtggcgagg	tgggtggatc	acaaggctcag
45121	gagatcgaga	acatcctggc	taacatggtg	aaaccccgtc	tctactaaaa	atactaaaaa
45181	ttagccgggc	gtggtggcac	gcctctgtag	tcccagctac	tcaggagggt	gagctggaga
45241	atcacttgaa	cccaggaggc	ggaggggtgca	gtgagccgat	ggtgctactt	gcactccagc
45301	ctgggcgaca	gagcaagact	ccgtcagaaa	aaaaagacta	atgaatgcga	tgcttccctt
45361	aaagaaaatga	ggaggaaaag	aagctgcaca	gaatcaaaaga	cccttcgagg	ccacgacaca
45421	gaggtgagaa	acacagggct	ccatgaagtg	aaatctgaat	agcaggtgtg	agtgtgcgtg
45481	tgtgtgtgtg	tgtgtgtgtg	tgaatttgtg	agtgtgtgtg	tggcatatgc	aaggtttgcc
45541	ttttatttgg	ttgccagcat	gtcaaatgta	attgcacctg	agtttatagc	aatgtttccg
45601	tcattctgagc	tctgaggagc	caggccccacc	ctctcacctg	ctgggcatca	cctggatctg
45661	agaagcccat	gcaggcctcc	agctctcccc	actttcctgc	agccccctgca	ggcatctggg
45721	ctgcaatgtc	aactttcccc	tgactcgcac	tgccccgcct	cccacctcac	cccagatggg
45781	gtcagcagcc	tgctgggggt	cagcagggtg	gggcatccta	acccccMWg	gcaggtgaaa
45841	aaccctgagg	ctcagagagg	ggaagtgact	tccccagtgt	cacacacctc	ttggagggca
45901	gggggaaggt	caacacctga	cctcctgact	ctgacattga	agcaagaaaag	tataatgtta
45961	ataatccaaa	atcttccagg	tttgtttctg	cttctacaaa	cacagagggc	taagctcacg
46021	ctcccacagt	tatgctcacg	cttccacagt	ttgactttta	atctcatgat	tgtcaagctg
46081	ggatcatgtg	gcagacacca	ttctgcaaca	tgccgttctc	actgcccctg	tctgggccat
46141	ctttcccact	agggaaacagc	acagcttctt	tcttctctat	cacccagagg	cctgaaaagg
46201	aaccagggtga	gtgtcaggga	catggagtcc	tgtgatctac	ctgctcaact	tcctgaYatg
46261	ggaccctcag	cgagtcactc	atctccctag	gcctcagttt	acccacaggg	cctggtcaa
46321	gtaggtgctc	agagtcaggg	tgggtgaaac	aacctctggg	ttccttggtta	tctcttttctg
46381	ctctctctct	cttttttttt	tttgagacag	agtctcactc	tgtcaggagt	gcactcaggc
46441	tggagtgact	ggtgcgatct	cgactcactg	caaccttcat	cacctgggtt	caagtgattc
46501	tcatgcctca	gcctcccaag	tagctgggat	tactggcttg	tgccaccacg	cccagcta

46561	tttttgtatt	tttagtagag	gcagggtttc	tccatattgg	ccaggcaggt	ctcgaactcc
46621	taacctcaag	tgatctaccc	gtctcgccct	ctcaaagtgc	tgggattaca	ggcatgagcc
46681	accgcgcccc	gccagggttc	ttgtatctca	aaggaaatcc	tctgtcccca	tggggcctca
46741	gcagcagcac	cctggggcca	gcctcagggt	ggccaggcca	caagaaggac	aggccaggct
46801	ctggatcacc	tctgtctctc	caccttctct	ggttcctcca	aatattctaa	aggaatggac
46861	agtcccaaca	tctgccttcc	ttctgggggtc	accgggccat	gtctcacgca	ggctggaact
46921	agagctgagc	cctaggaagc	tttgtgaacc	cagctgagct	gattctgcct	ctgtctctac
46981	tgtttggggg	cccagagaga	gggagggaga	agtccagcta	aaacctgggt	gcaaattcag
47041	gctctgccat	ggaccgagat	gtgacctcag	tcagttacct	aacctctctg	agctcatcta
47101	caaaaggtga	atgacccttc	tcttatagag	ctgctgtgag	gatggggaga	tggggaaggt
47161	cagaccaccc	ctaacttacc	aaggaaagctt	ctcttgaaag	agtgtgagca	agatccagct
47221	gttctgagct	gtgtggatcc	cacctccagc	cgtgcatctg	cataataacc	agacacgttc
47281	tccagKctct	gagatatacc	ctggaaccca	aaagggaaag	tgaaagtcac	aacttggcag
47341	cagctcctga	tcaaacatgc	aaaacaggat	gcttcccagc	cccacccttg	gcccagtccc
47401	atccttgggtc	cagcagcacc	cttggtYcca	ccctcctgct	gatccaagag	cagccccaga
47461	cgctccttctt	ggccaaccca	cctgcctccc	atacttaggg	ttgggggttt	gctgtgtctt
47521	caggaagaaa	gacctaccac	tgaaagacta	tgagaccctc	cagattactc	cccacccccca
47581	ataacaccac	actccccaga	tgcccacctc	actccctcca	tgccatcagc	attaccacag
47641	tccatcacac	atgcccgggtg	gacgcttatt	gcatattgat	tgtattgctg	ttggggttat
47701	tttgtttgttt	tgttttgttt	tgtttttgag	atgggggtctg	gctctgtcac	ccaggctgga
47761	gtgcggtggc	acaataatag	ctcactgtag	cctcaaattc	cagggttcaa	atgaacctcc
47821	tgagtagctg	ggactacaag	catgagccac	tggcctggc	tacttttaaa	aaatgatttt
47881	gaaggggtga	aatcttacta	tttttaccag	gttggtttca	aactctggcc	tcaaatgatc
47941	ctcctgcctc	agcatgagcc	acYgttccag	acctgctctt	gtcgaacgcc	atacctgtgt
48001	ggcttctgga	caYttcctta	tggtgggtct	tctgccagga	gcacctgcta	ccttcacctg
48061	gaaagtcac	gctcctctat	cagaatgcaa	atctagcatt	tcctcccctg	agaagccccc
48121	tagcatectc	ttcagcagag	cccactgccc	catgttccac	tctgtggcca	cttttgttag
48181	gctgttgtaa	ttggccacag	tcccagggtg	actgaacaaa	gtggggggYg	gatgtgggag
48241	taaaagacaa	agacaaaaga	gtatattagg	aagaaggggt	cNgggggttc	cttgcttcta
48301	gtgaacaagg	gctctgagct	tttcaagctc	tctgagtta	ttaggtaaaa	gagatgacga
48361	gaaaaggtg	gggggNtgat	tgctagctaa	ttgtcagtca	gccRtttgg	tcacagcagg
48421	cttgcaagac	tgcatccttc	aaataatagg	tgctagatat	cccaacagat	aacttcaagg
48481	agcccagcac	cagggagtg	tgccctcag	gaaaccttct	ggcggcgggt	gcagtgtgag
48541	tttaccacac	tcccgcattc	atgataaaca	gtttgctgtt	tgatcatata	gcctccagtg
48601	aaatgtctg	ttggtcacaa	tccctttggc	cttttcagct	cccaacaggc	agtttaagtag
48661	acattagcag	ctgggagag	aaaagagcgc	agaaagcctg	tcactgcaac	agctcgtggc
48721	ccacctaaagt	tcagccccag	agccattcta	agacccccct	aactgatgaa	gttggtggta
48781	tagtttgtgg	ccagcacatc	ctgaagaaag	agaaactagg	gcacaggtgg	aaattcccta
48841	aaggggcaca	tgcccagtaa	catgaaactg	tgccctcagg	tcaccccaag	ttcattatac
48901	catcattata	ataaaatgtg	gttttattat	acaaaagccc	cagagtgggc	ttttctgta
48961	aaattatggg	taaaaacatg	cattgcctaa	ttttagttaa	ataaccataa	actgccaatc
49021	agatgacatc	gtcctttact	cagacacagc	cccaacctca	acttctctcc	acaaaccgca
49081	cagaagcacc	ttaaactcta	tatagagggg	ctgacttcac	ttcacagaaa	ttagcccaact
49141	gtccctctga	gagtgtctaa	ctgtgcttca	atacactttg	ctttgagctt	gcatttttga
49201	gttagcctgc	aatgttttgc	tcactctcag	aagaactgag	attactggtc	cagaactcca
49261	gctctgttaa	tctcctcagt	taaaggatcc	atcccagcgc	agaattcctg	gtaatatctt
49321	agtgtgtgta	cctggatgat	ttacgttcag	catggctttt	aatatgtgct	tgatttttagc
49381	ttggggaaact	gaaacatatt	ttgctaaaaat	gcttccttct	gctttgggtc	aagatgtttg
49441	tgctatgttt	cgctgcttgg	ctaagagaag	ttgcaatgag	tgttgtattt	gctgcattag
49501	agagggggta	tatcccccaa	catgccacca	ataactttta	gagaagggct	tagagaaatc
49561	ttctctggat	ttaggtttaa	ttagctgttt	aacgtgatta	aacaacttca	ttaggttgta
49621	gtggccattg	aagcccagag	cttgtaacaa	gcccagggaa	gctttgagag	gcaaaatggg
49681	ttcttatgct	ctggccacag	agccaggaat	cacctcaaac	tccctttaga	ctgggcattt
49741	tggtctgatg	caatttttaa	aattactgat	taagagagcc	gattgggatt	cagatcatgg
49801	agatgctctg	ataaatgcta	agtttagagg	tttacagccg	ggaacgaagg	gtaggcccat
49861	agtggtcat	aacctttgga	gaactcccca	aatcgctcctY	gcccaccctt	ttgggcactc
49921	acccccaccg	aggccccctc	cctgccacac	tgccataggc	agcagcacag	cttctgaaga
49981	tcgttttgca	attttttttc	ctttttcttt	tgaacagagc	ttcatttctt	ttctttcttt
50041	ctaaccactt	ttattcagaa	tctaggggac	aaatgttttc	agcaaggctg	tagtaccac
50101	tgtaggaagg	ggtctccatg	ctgggcacag	ccatggtcca	cacataggtg	caacttgaga
50161	gacacacaga	ctgccccagg	ggaggcggag	cctccatcta	aagagcaggg	gacactctct
50221	cctggtaaatg	gtcaaggata	ttgggatgtc	gagactacct	tgatctcagt	gctgtgtatt
50281	ctggattgcc	agctgcatcc	acactcctat	gtaaaaccac	agagggctgc	ccaaactgat
50341	gatgtctcca	cagacaaaata	cacttgtgag	acttttagtgg	acctcaagcc	tctcttttaa

50401	agactgccaa	aaaataagta	atgcccactg	actttcccta	gtgccttttt	ttaaatatta
50461	gctttaagtt	ggattgttat	agttattctc	atataatttg	agttcaattg	cctcctcctg
50521	aatgggtgaa	ataatttttt	atgctaaaat	agctgtttta	aatgcagtaa	ccaatatttt
50581	tgctttttta	actagattaa	cccttgcaat	catttctcct	aatgtttttt	tccaacaccc
50641	atatttagct	accatcaaag	aagtttttaa	accttgttta	aacacaacat	caacggactg
50701	cacaacatca	cagaaactgt	tgaatctgtg	tttacacctt	ccctagcaga	ggcttatcag
50761	ccattttccat	tctgtcttct	gagtggaatc	aatcagaaac	atttccagcc	cccacttctg
50821	ttaaccgacc	agaataagct	gtcaatccta	gggtcgagcc	cacagtcaat	tgcatactcc
50881	ttaaaagtct	ataccaacaa	acctgttaca	acctccgagg	acctgtcgtc	tatctgtaat
50941	actatctgac	taagcactcc	tttgtcttct	atcttcattg	aggatgaggc	cattacttgg
51001	attttttcct	aatattttcca	aggcttgcaa	tcacacttgt	accctatttt	ccaccaatt
51061	atgtgtcagc	ttagtactg	acaacaaaa	atgcaaacat	acctgatatt	ctaattcttc
51121	tttgtgtttt	attcatttcc	caagccccc	aacagaacca	ctatgtggaa	agaagccagc
51181	tattctggat	ctaccctttt	ccccagaccc	acaccagaat	atcattttta	acataacaac
51241	ttctggtttc	agtctcacia	cttcgggcaa	aatcattgca	aaaaactgca	gctccccata
51301	atttcacaat	attggttggg	atcccatcac	tccttctctc	aattgggctt	ttgattcctc
51361	tttcattctg	tcaagtactg	cctgtgttcc	cccattacat	gaactagcct	tgacttccac
51421	ttctgagggt	attaaagcag	acttacacag	catggaaaa	ccctacttta	gtatcactgt
51481	tgatatttgt	cttaacatga	caaatcacat	ttttgtatag	aaacaaggca	tatctctgct
51541	tgtctgctaa	ttaaacgggg	atttggccct	agttttacatc	atccccaac	tcactcttat
51601	cgatagcatt	ccctcccta	tacacgtcca	atctgttaaa	actgaaagag	gagttttaac
51661	agcactgact	ataattggcg	ttctggctgg	tattggcacg	ggaactggag	gacctcctta
51721	actccatttt	tactgccag	aaactcttct	taaaaattac	tcaacaaatt	attaatctaa
51781	ctaaccaggt	caataccctt	tcagaacaaa	ttgcttcatt	agcaagcata	gtcttatgaa
51841	attgatgagc	ttttaatttg	ctcacagcca	atcaaggggg	agcttgtgca	acacttgata
51901	aacattgctg	ttttcatcaa	ccaatcaggt	aaagtgcaaa	ccaacttaaa	aaaattacag
51961	acagggccaa	caagttaatg	gaaaaacagag	tttcaggagg	ctttgactgg	tggaatttta
52021	acaactggtc	ctggttttcc	tggttagccc	cctttcttgg	tcctaaaaa	gctttatata
52081	acttatagct	ttcaaacgat	gctcatttga	tttacaagg	tgttttgttt	cttcccacct
52141	agaatccata	aaactccaaa	tgattctaca	caaggttacc	gcgaggtctc	aacctgtct
52201	gatatctacg	tgggccctt	ggatggccac	cacttttctc	tgcccaacct	accagctaca
52261	agagagcaaa	aaagagaacc	caattattac	cactgcctct	tgctcagcag	aagtagccag
52321	attaattgtc	accgatctac	ccaaaaattt	ggcttttttt	ctctaaagg	ggaaatatta
52381	ggtagttaa	tagacattag	cagctaggag	tgggtaagaa	aagagagtag	aaaggctgac
52441	agtgaacag	ccccggccc	acctaagttt	agccccagaa	cgttcctaat	gccatcttaa
52501	tggatggagt	ttttggtaaa	gtctgtggcc	agcacatccc	aaagaaagag	aaagtaaggc
52561	acaggtggaa	gtctcctaaa	ggggcacatg	cccagtaaca	caaaaacatg	ccctcaggtc
52621	accccaagtt	cattatacca	tcattataat	aaaatttaca	tgtggttgta	ccctcctttc
52681	cccagagtgg	gcttttctKt	ataaatgatg	ggtaaaacca	tgccagttta	atttttagtta
52741	tataaccata	aactgccaat	caaatgcata	catcctgtta	ctcagacaca	acccaaacct
52801	tgactcctcc	ccacaaaccc	cataaaagca	ccttaaaccc	tgtaaaagag	ggcttatttc
52861	acttcgcaga	aatcattccg	ctctccctct	gagagtRtat	tactgtgctt	caatacactt
52921	tgctttagc	ttgcattttg	gtgttagtct	gcaattcttc	gctcactatc	agaggaactg
52981	agattgctgg	tccagagctc	cagctctggt	aatccccacc	tctgttaaga	atccatccca
53041	gtgcaggatt	attggtaaca	cttagaggga	aggggcctaa	gcccactgct	cagccacagt
53101	ccgtggcta	agaaggcgtg	ctgtcggatt	gctggcggac	ttttctgctt	tacccaggc
53161	agaagggttt	tgagaggggc	tgaacctga	ccaacatgac	cctttcactg	ggaactgttt
53221	catcctgggc	aaatgtccct	gcagcctcgt	ggccaccacc	ccatacacct	gccagatttt
53281	cagggaggaa	cagggagggtg	attacacaag	aactgtacga	tacactttga	aataataccca
53341	cttctctatt	taattggaat	ttgataacca	tctcttaaat	gggccaggag	tatgatctga
53401	gtttacagg	gagRaaactg	aggcaaggca	tgaggctgtg	gctttcaacc	agcaactcgg
53461	ggaggagcca	agatttgtaa	accaagWtgc	gtctgagaca	gatctcaatc	cgttttagtgg
53521	tttattttgt	catggttgag	gatgcccaca	ggaaaaaaa	aagagacaca	agtcacagtc
53581	ggatctgtgg	cccacaagtt	ttcaaaagag	ggttttaagg	gcttcaatat	ttcaaaggta
53641	aagagtggga	aggaggagga	gggtgaaaa	aaaaagacag	gacaggtagt	gagaagagtt
53701	gtcacatttc	tgtgaggctt	tgattgagac	ttcctgaatc	tatgtgctgc	atgtaaaagg
53761	catggataga	agaacagtaa	ttatgcattc	atctcatgct	cagtaaatgt	gtattttaca
53821	gaagataaaa	ataaacaggc	agggcttggt	ggctcatgcc	tgtaatccca	gcactttggg
53881	aggcctaggc	acttgatca	cctggagtca	ggaggtcgtg	accaacctgg	ccaacatggc
53941	aaaacctcgg	gtctactaaa	aatacaaaaa	gtagctgggc	atgggtgtgc	acgcctgtag
54001	tttcagctac	tcaggaggct	gaggcaggag	aatcgcttga	atccaggagg	tggagggtgc
54061	agtgagccgg	gatcatgcca	ctgcaatcca	gcctgggcta	gagagggaga	cKccatctca
54121	aaacaaaaca	aaacaacaac	aataaaatga	acatagatta	gaggaagcag	tcacatatgc
54181	atttgtgttg	aagtgagcag	cagggttaatt	tctagtcttg	gttttgcatt	gtacctgtca

54241	aggtaagtta	ctaatttgca	ttgtcatggt	aaaattccac	aggctctgtt	ttaaggga
54301	agatgttggg	gtcacaaagg	aattttcttg	tgggaaatcc	atgaggaaga	ccacctgggg
54361	aatatgttgc	cttctgtctt	ggcagatacc	tgttttagga	caaaaagaag	ggcagttttt
54421	tgactgattc	aatttccctg	cttaacgggt	ttctttggca	tagagagttt	ggggccctga
54481	tattttattt	tcctttgaca	ttatctctcc	cttttataaa	atctttttga	gaaagcattg
54541	gagatgcaaa	tgagtctctg	gtcatgagtt	tcactctgatt	cctgtcagat	gaagtgtctt
54601	agtttcagtc	tgtaggggtg	tcagggaagc	acggttttta	tttctgggtg	ttccgagtga
54661	gaaaaatgag	agaaagaaga	caagaatgat	gcttcttttg	agacttgagc	ccaagaaaga
54721	attcacgagc	cagcctagat	gaattttgga	caaataataa	aactggaata	caatggacaa
54781	agctagaatc	taataacagg	tattctacag	tttcttttaa	aacataattt	tttttctctt
54841	cagtcctcta	attctaccaa	agacaaatca	tggtaggact	aattttattg	aaaaataagt
54901	tgtagtctta	tgatacttgg	cctgattact	ttcataaagt	gcagtaagaa	caatgattta
54961	ccatatgggt	tcttcttaag	aaattggatt	tgctggaaca	tcttcttttt	cataaggaat
55021	ctcagattac	acctttttaa	gccttgagtt	cagccaaagta	tttatctgtg	cctgcaggtt
55081	tctgtatgaa	ttgggtgagt	tcctctcttc	ttgagattcc	aagataaact	gggggttctt
55141	aggcctgtca	gaaagtatta	tttctcttac	ttaccccaca	tcccacatca	ggaaccttgc
55201	atagttaaag	aatgaggcca	attttttgat	ggggctttca	ttggctctat	aagtcaacct
55261	ctattcctca	aagctgcctg	ctcatatgtg	aaaatatgcc	atgccagtca	aagccttgat
55321	aaaataacta	gtgtctccaa	tggtgtccta	ttgcaaaagga	aaacagattg	ttactgaact
55381	tatgcaataa	attctattgc	cataaattaa	gaaaactcac	aaatagtttc	caaattcttg
55441	agaaatcaaa	tagagagaaa	gaaatgtgct	ttactttttg	ctcacaaagag	tRtatttcat
55501	tcaactgtca	aaagctgtac	atagctcaca	agatatcaac	gtttccttga	ctctgaagaa
55561	gaaaaaaaaa	agaatcagcc	atgtttcaaa	cacaaagtca	tctaaaaaat	tatttcagtc
55621	ctctattaga	tcagtcctaa	gatagaaaaa	aatcaaaaaa	tgttattttg	gagacttgcc
55681	gccaggaaag	atttcaggat	ccattctaga	ttaaattttg	acaaataaca	aaactggaaa
55741	aacaatgcac	aaggccctaa	tctagtaca	ggtgttctat	aactcgttcc	acctgatatt
55801	gggttagcaa	tcctcatgaa	cataacaact	ttttaattag	agtctctggat	ttttttcttc
55861	tagtccaatg	gcatagcctg	tagctgacca	taaactggta	ttgagaagaa	ttaaagtaaa
55921	acagtaactg	tggtatagcaa	aagtattaga	gcagccttgg	caaacacaaa	attgacaagg
55981	aaatttggtt	atttctgtga	cacacaacaa	cttaccgtaa	aaatgattat	tattactaat
56041	aacatatatt	gctgtgtgcg	gtgtgtcaaa	cttgtaatcc	cagcactttg	cgaggctag
56101	gtgggcggtg	cacttgaggc	caacagtttg	aaaccagctg	accaacatgg	caaaatccca
56161	tctctactaa	aaatacaaaa	agcagcttgg	tgtgtgtgtg	cacacctgta	gtcccagcta
56221	ctcgggaggc	tgaggcatga	gaattgtctg	aacctaaaag	gtggcggttg	cagtgaacca
56281	agattgtgcc	attgcactcc	agcctgggtg	actgagttag	actctgtctc	aaaacaaaca
56341	aacaaacaaa	acaaaaacac	catagaggaa	gctataacag	aattatagtc	atctcataca
56401	attttggaac	acattttatt	atatataact	caaagaaagt	tacaacacca	ttttacatct
56461	gtcctgctag	accctgtgta	gacacttgca	agctcggaga	gcacagtctt	ggagagagta
56521	aagaaaagac	ttggagagag	cagatgagac	ataagcttta	ttcagggaac	ttacatacaa
56581	ggagtccagg	agcagcaggc	tggaacagaa	gcccttcaca	tttgtaaaaa	gcactgcagt
56641	tgatatgtat	ccttcccaca	gcaacctcca	cttagccacc	tccacccggc	aacctccact
56701	tagcccaaaa	caaagggcct	tggttccctc	caggacctgc	ttcccaagga	ctggggccagg
56761	ttacagggtg	tcttcatagg	tatagtgtaa	acatctggat	tggccattcc	tgggggtccat
56821	agtttagaac	aatgaacaaa	cattcaccaa	ggaacatagg	gccattctca	ggggatgctt
56881	gaattattgc	tgtctgacag	gacatgccc	ctaggcactc	cactccagta	tagcttcag
56941	tgccctctc	gtaccaagta	agatgaatat	gtctcttcaa	gacttcaggg	gacctaatat
57001	ctaaaaaatt	aatgagggtca	aaacactgga	tttgaaattt	gatttttagaa	agtttgtcaa
57061	ataccaaagg	ttgaaaacac	ttgatatac	aaaataggat	tacgctcact	ataaagtaag
57121	tcattcgtgt	ggccaaagag	ataacttaaa	tatttcaaaa	acatagaaat	gtttacacct
57181	tgagagagag	aagactcagt	ttcccacaca	ataacacctc	ataaagacag	catgggctgg
57241	gcattggcag	tcattgactgt	aatcccagca	ctatgggagg	ccaaggcaag	cggatcacct
57301	gaggtcagga	gttcgagact	ggcctggcca	acatggcgaa	accccgctct	tacttaaaat
57361	acaaaaatta	gccagacgcg	gtggtgggca	cctgtaatcc	cagctattcg	ggaggctgag
57421	gcaggggaaa	ttgctggaac	ccgggaggga	gaggtcgcag	tgagccgaga	tcacgccatt
57481	gcgctccagc	ctgagcaaca	gagtgcagct	ccaccgcaaa	aaaataaata	aacagcatga
57541	ggccagtggg	atctgtttct	ctccctacca	gcttttttgt	agttttattca	aaaagcaaac
57601	agacgtcttt	tattatcttg	taatattaca	tgaaaatctt	gttcaaagca	gcaagcccaa
57661	atttaccttt	gcttaacact	aaagttaatt	ttataatatt	agaaacaaat	ctgtcaaatt
57721	ttaattagtt	acatcttaag	gtaaaaatatt	ttataaataat	tttataacct	tttcaatttc
57781	tattaaaaag	cagatcaatg	ctccaagaaa	gccctgttat	tctcatacag	tggtctcagat
57841	tctgaccttt	catcagtggt	gtattttatat	taattttcaa	tttataggaa	aagtaaatata
57901	tccccattac	aatttttgcca	ccttgatcac	aaacaaattc	tttttacaag	aataatcttc
57961	cacacacctt	ctataatttg	ctgaaaactt	tggtttgggtc	ctgtttttca	tttaacttga
58021	aataatcctt	aaaaacttct	aaactagata	acattattat	tattattatt	attatttttt

58081	tttgagacag	agtctcgctc	tgtcgcccag	gctggagtg	agtggcacga	tctcggtcca
58141	ctgcaacctc	cgcttcccag	gttcaagtga	ttctcctgcc	ttagcctcct	gagtagctgg
58201	gactacaggg	gcgtgccacc	acaccgggt	aattttttgt	atttttagta	gagacgtgg
58261	ttcaccgtgt	ctactaaaga	tggctccat	ctcctgacct	cgtgatccac	ccacctggc
58321	ctcccaaagt	tcttggatga	caggcgtgag	ctagcacgcc	cggttaatta	cgtttaacaa
58381	aaccacatt	cctgtgcctc	ttataacggt	tttaccacaa	acacatccta	ccttttgtca
58441	cagggtataac	tgactgggac	caatattgtg	gacagtataa	taattttacc	aagacagtca
58501	tggttaaaga	aagacagatt	tattagagaa	agtacaaaga	cacattgcaa	aagtgcattg
58561	gtcagcacag	caaagaagg	acgtctgcaa	agtgtcagg	gctgaaggga	agtttcata
58621	ggttgtagct	gaggctacct	gtggaatgag	gtgcagctgg	ggctacatgc	ggagtggagt
58681	atttggaac	aggatgtcat	gctagtgggt	gtgtctgtgat	cagctgtctc	tcagaacaat
58741	tggttctccc	cacctggggc	cccttctctg	ttgttgctta	cttatcttat	taggactcca
58801	cacaaattac	tccttatcag	atttttagcca	ggacaaacag	ctgatatttc	tggcttttta
58861	actttttatac	aaaagataac	ctcctgagtg	aaaccaataa	cgcttaacta	aggtcattac
58921	tgaaccatgg	atgcatggat	tccccctggt	ctcaggctac	acactagaca	gaaagtgagc
58981	taagctattt	tcactgtatt	cttatctttg	cagggtgtaa	ctcaaccttt	tccccacggc
59041	acttctcttg	gttattctga	aagcctctgc	agtactctga	ttatcccgat	gtatatacta
59101	catgaaacac	tgtctgggtt	attagttcat	ttatctcact	aacagcaatc	atactaatac
59161	gttttttatga	cctgagaagc	ctttgcttca	aaagaagaag	tttttagtagt	tgaagtatca
59221	actacaaatc	tcaaatgact	ctacggttgc	ccaccaccat	accacacatt	tgaagaacca
59281	gcttacgtaa	aatccttgac	gagaaaggaa	ggaatcaaac	ctcctaaaac	tggttccaaa
59341	cgagcttcat	aatcactctg	actttctcaa	ttaaaatgta	ttagtataaa	taattacata
59401	actttgtcaa	agtttaactg	taggttaaaa	ttatttatct	ctttatggca	tatccattta
59461	aactaggcct	ccaagatgct	atgtcaccta	tcatagaagg	aagaactcct	tcattttcat
59521	gaccacaccc	atgtgggtcat	ttctctttct	ctgttttttt	tttttttttt	ttttttttga
59581	gacagagttt	cactcttgac	tcttggtggc	cagggtggag	agcaatggca	cgatcttggc
59641	tcaacacaa	ctccgcctac	cggttcaag	cgattctcct	acttcagcct	cccacgcagc
59701	tggtgattaca	ggcatgtgcc	accacggccg	gctgattttg	tatttttatt	agagacagga
59761	tttttYcatg	ttgatcaggc	tggcttgtaa	ctcccgacct	taggtgatcc	gcccgcctcg
59821	gcctcccaaa	gtgctgggat	tacaggcgtg	agccaccacc	gtgcctggcc	gtgatcattt
59881	ccttaattcg	ttcattagta	ctttatatata	cttccctgat	actaacaata	actattgcac
59941	aagactatag	atgcccaga	agtggagaca	atatgaacta	tggttgcttg	tagtatctta
60001	attttaattg	ttctcccatc	attatgtggt	ctaatacata	atagatgaaa	ttaataatct
60061	ctccctttct	gtcaaaaacta	tagggcatca	atgatattga	agctacaaat	atacagatta
60121	tgaagaccta	agttttgact	cctacataat	tcccacaaca	gacttaaaat	caagagagct
60181	gtggttactt	gaagttgaca	gttgagttagt	tctccctata	gaaatattaa	ttcatatggt
60241	aattttcatca	gaagatgtcc	tatatgtgtg	agccatacca	tcacatcaat	aggcctaaaa
60301	atcggttRcaa	tcccagggca	tttaaaccac	gcaaccttaa	catctatacg	accagacctt
60361	tactacagac	aatgcccaga	aatctgcaga	tccaaccatg	gctttatacc	cattgttctt
60421	gaactagtc	ccctaaagca	cttcgaaaa	tggtcagcct	ctgtatcata	atatcattgt
60481	gaagctaatt	agcattaacc	ttttatgtta	aagaccgaga	gccaggattt	ctccacatta
60541	aaatgtccca	actaaacaca	tctacattat	ttactatgg	tttatgtata	atcatatcac
60601	tctttatctt	atttcaatta	aaattctcaa	aatttatctc	cccaataagc	tcaacactaa
60661	aattctttga	atcacagaaa	cttgaaattc	cttgagaaa	Raaatgaatg	gaaatgtatt
60721	tgcctttcat	tgcccttaaca	gtaatacgaa	gaccgtagt	tataatctcc	tatttccaag
60781	tattttat	ctatcatcta	gtcacctgat	taacaactgg	ctaacttcca	ttcaacagcg
60841	actaattcaa	ctcatattaa	aacaaatgat	aataatacat	aataccaatg	gatgaagctg
60901	atcccttata	ctaatttcat	gtattctggt	tattggctca	actaatttac	tRggaggcct
60961	cccactcaca	ccaactactc	aactctcaat	aaatttaggt	atagctat	cagtatgagc
61021	aggagcagta	attactgggt	ttgtgcacaa	aacaaaagca	tcccttgctt	atttctacc
61081	acaaggaatg	cctattttaa	ttctctcttt	tctagtcatc	gtcaaaaacca	ttagcctttt
61141	cattcaacca	atagccttac	ccatatgatt	gacagccaat	attacaactg	taaatgtaa
61201	ttatacat	aactggaggt	gccatcttag	tatcaacatc	tattagccta	cccacagcct
61261	cagtcccatt	tattaccttg	attttactag	ccgttcttga	atttgccatg	gttttaatcc
61321	aagcatatgt	ttttacaatt	tttttttag	acagagtcta	gctctatcac	tcagtctgaa
61381	atgtagtgc	atgatcttg	Yttactacag	cctccaactc	ctgggctcaa	gcagtcctcc
61441	agcctagcct	ctggagtagc	tggtgactaca	gtttcatgtc	accatgtctg	actatttttt
61501	tattttttat	tttttggtta	gatgggggtt	tatcaatgtg	cccaggctgg	tctcaaactc
61561	ttaggttcaa	gcaatctacc	tgcttgggcc	tcccaaagtg	ggattatagg	tgtgagacac
61621	cataactag	ggtttttaca	cttctagtga	gcctctactc	acatgatagt	actttacgac
61681	ctacaaaacc	caagcatata	atagagtaag	cttcagccct	tggtccattca	cagggcgct
61741	cataactact	gtaacacttg	ttgaaaggca	ctcattacaa	catctgtctt	agccatagta
61801	ttccactcga	actcaattac	tctattaacc	ctaggccctag	taactaatac	attaacaatg
61861	tatcaatcat	aatgagacaa	tatcagagaa	ggcacattcc	atggccacca	cttgtcaatt



61921	gtccgaaag	gccttagata	tggaataatt	ttattttatcc	catcagaagt	agttttctct
61981	gctggattct	tctgagcatt	caagcctggt	cccaatccca	gaactcggag	gctgctgacc
62041	tccaacaggt	atttacctcc	ttaacccctt	cgaagtgcc	ctactcaaca	tatccattct
62101	ctcagctttg	ggagtatcaa	ttacctgagc	ccatcatagt	ttgaaagaag	aaaacccaaa
62161	acacatactc	caaacccttat	ccattacgat	tgccctggat	atttacttta	cactcttcca
62221	agcctcagaa	tgcttcagag	cacctttcac	cacctctcat	ggcatatatg	gctcaacatt
62281	ctctatcgct	acagacttcc	atggacttca	cgatcatcaat	ggctcaacct	tcctaaccat
62341	ctgccttggtg	catcaacgaa	aatttctactc	atcagactYt	tgccaaattc	cattgcacat
62401	ctgctctaca	atcaaagaca	ccttggtatct	aattctcctt	ctaattattac	tactcatatc
62461	agtactgttc	tcaactgacc	tattaggaga	ctcagacaat	tacactccag	caaattctct
62521	caacacacca	cccgacatta	aaccagaatg	gtgcctttca	tttgccctatg	caattctaca
62581	ttaaaccaga	aggggtgtctt	ctattttgctt	atgcaattcc	acattaaacc	acagtagtgt
62641	atttcatctt	ccaatgcaat	tccacatgaa	accagaatgg	caactttcat	ttgcctatgt
62701	aattccacat	taaaccagaa	tggtactttt	catttgctta	tgcaattcta	cactccattc
62761	ctaatagaact	aggaggcatg	ctggcccttg	tcttctccat	tcttatecta	gctgtgttct
62821	ccatcaaaaca	catatctaaa	caacaaggca	taataattctg	accattaagY	caatgtctRt
62881	tctgaattct	agtagcagac	cttcttacac	ttacatgaat	cggggggccaa	cctgttgaaac
62941	acctctttat	tattatgagc	caagcagcat	ccattgtgta	cttttccctt	atccttcttt
63001	ttataccaat	tactagccta	atcgaaaacg	agctactcaa	atgaagaagt	ccttgtagta
63061	tcattaaagt	actctggtct	gtaaaaccaa	aatggaggac	cgggctcctt	gggaccattt
63121	ccaggaagaa	gcttcttgct	ccacaaccag	cacccaaagc	tgaaattcta	cttaaacat
63181	tccttgattt	ttgtacttga	agtgaataac	atttatttta	actgctatgt	cagattggaa
63241	aatccacata	aattactggt	gcaactatgt	acatcatgca	ttcctgcttg	accccatgaa
63301	ttaacatgct	agtactagat	gtgctgatc	gtatatgtga	tatttatgta	tcgtacctta
63361	aatcttcacc	tccatgaata	tttagcagga	gtaataatgt	cacagcaacc	tgatcatacat
63421	tcatcaaaaca	ttctgcagaa	agcgattaac	atacatatat	atcatccagt	ataaataacc
63481	cttaatatgt	cataggacWt	tcagttattt	atgaatcata	gcacattcaa	gtcaaatcat
63541	ttctcagcaa	cacgcttatc	acctcctaaa	aacattctta	actaacaagc	tttgagaaat
63601	cagcagcctg	cttggaaggt	tctatccttc	ttactcccg	cccatgacac	ttgggggtaa
63661	ttagactgca	actataacctg	gcactctggt	cttccctcag	ggccatggag	actaagatcg
63721	tccacttggt	cctcttaaat	aagacacctc	aatgatttag	tgacaatcac	ctcatggcta
63781	cttgacagaag	tactgacatg	tatttggtag	tttttaaatt	gggagatgct	atgactcagc
63841	atgggtgggag	cctgaaccca	gccaaactcca	ttgtagctgg	agtttaatgg	aatattacga
63901	gtcaacacct	acaaccacaa	ggtgctaatt	tattcatgct	tgacagatat	catgaaaaga
63961	aaatgcacgt	tcaagctcac	cctttctcca	aacatgtatc	tgatttactc	ctcaaatccc
64021	ccatgccccct	tttccctgga	ctaaacctaat	tatgccaaaa	aaaattgttt	gttcttgcca
64081	agcccaaaaa	caagatatgt	ataacatcaa	tgacagccag	ggctcacact	ccaaatcaaa
64141	ttgtaatctc	aactacaatt	acatttttagc	caaactttca	attaaaccta	tttcaaaaac
64201	acatgattgt	aaaataaaaa	ccaggctatc	taggctaaaa	atcccacttt	ttatttctaa
64261	agttactaaa	tattgcccta	ataNctagca	tagtacttca	acccttcatt	ttgtaacaga
64321	gagaaaattg	tctagatccg	aattaatgta	gcttatgata	ttaaaacaag	gcactgaaaa
64381	tgcttaggtt	agttcatgta	actccatRaa	cacaaaggca	tagttctggt	ctttttattg
64441	ggtttttaata	agattacaca	tgtaagcatc	tggattccag	tgaaaacgcc	ctccagatca
64501	tctaattttca	aaaggagcag	gtactaagtg	cacagcccta	catcataaca	ccttgctcaa
64561	ccacgacccc	acgggaaaca	gcagtgtata	aaaaaaaaaa	aagcaataaa	tgaaagtttg
64621	actaagctat	actaaactat	tagggttggt	aaatttcatg	ccagctaccg	gagtcataca
64681	attaacccaa	actcacaaaa	acaagcattc	agcgtgttta	aggcaattct	cataataaag
64741	ctaaacttta	aaccgagccR	tgaaaagctc	aagctaaaaat	aaaaagaaac	tacaacaatg
64801	atttttagtat	cctgagaaca	tgatagctaa	ggcccaaact	gggactaaat	ctctcactgt
64861	gcttagccat	aaacttaaat	aatttaataa	acagaattat	ttaccagagc	actataagca
64921	atagcttaag	cctcaaagga	catggcgatg	ctttacagct	ctcgagaggg	gcctgttcta
64981	tattcaataa	gctccgatat	acctcagcat	ctcttggtta	ctcagcctgt	atactgctta
65041	aacaatctca	caggaagtca	ccccatctat	taattattct	tttatcagtc	cccttgataa
65101	gtgggtcatc	cacttttatca	tctcttattc	ttgcacaata	atctgcatga	ttgattttac
65161	catctgacc	cctgtccata	atgtaattca	tctcaacact	agcagaaact	aaccgagccc
65221	catttgaccR	gcagaatgtg	atttagagct	agtctcaggc	ttcagtatag	ttattttatt
65281	aatttttttt	ttgagacaaa	gtctcactct	gtcaccaggg	ctggagtgca	atgggtcgat
65341	ctcggcttac	tgcaacctct	gcctctgggc	tcaagcgatt	ctcgagcctc	agcctcctga
65401	gtagctggga	ttacaggtgc	acaccaccat	cctagctgat	ttttgtattt	ttaatggaga
65461	tggggtttct	ccatgttgac	tggtgtggct	ctggaactcc	tgacctcatg	tgatccacct
65521	gcactgcacct	cccaactgc	tgagattaca	ggagtggagc	attgcgccc	gcccggcttc
65581	aatgttgaat	atgctgcagg	ttcattgggt	gtttcttcat	agcagaatat	actaacatta
65641	ttataataaa	tgtcctaact	actattattt	ttccaggagt	actacatgat	gtctttatag
65701	caaaaatcta	tacaattaat	tccattacca	aactctccta	ctgagaaccc	tgtttctgtg

65761	aatcagggca	tcagacctat	gagtttgata	tgatcaactt	atgcatcttc	ccgtgaaaaa
65821	actttctatt	ccttactcta	gccctatgca	tacagaatgt	ttaaataatct	gtcctaatat
65881	ctagtattca	gccacaaaca	tgggaaatat	gtctgataag	agagttactt	tgacagagta
65941	aattacagag	gtttaaatct	tcctattttct	agaattacag	gaattgaaac	tagtcctaag
66001	aagtcaaaat	tctccatgct	atctgataca	ccatgtccta	tagtaatagc	agctaataag
66061	taagggcagc	ttaccctatg	gtaatggcag	ctaaataagt	tatcaggccc	atacccaaaa
66121	tatgctRgtt	tatacccttc	ctgtactaat	cagttctcta	atcttcctca	ctatcctatt
66181	cactattttt	atagaaactg	taattatagt	aatcgcccta	cactgtctct	taatctgaaa
66241	ggattagaaa	taaatatgct	agtcataatc	cccataaaaag	gccc aaacca	ggccgggaat
66301	ggtggctcac	acctataatc	tcaacacttt	gggtggctga	ggtgggtgga	ctgcttaagg
66361	ccaggaggtc	gagaccagcc	tcggcaacat	tcatagggag	tgaggccatg	cttggtagtg
66421	agtgactcat	tcaaagtttt	catggtttca	gggagattct	tagtctagga	cccccaagag
66481	ccatcctggg	acagtgtcta	tatgtgggtc	tttagcaggg	cactcttcca	ctgagggtctg
66541	ccccagtggt	ttacatgagc	tgtggaacct	ccagtctatg	gattgtttctg	atgcccagtg
66601	ctggaaatca	tggcccatga	aagggggccc	tgaYctctat	ctgtcctttt	agccatgcca
66661	ttcgtgacac	taagagcggg	gagacRcttc	atgStctcca	gttgggtggc	acgtttttaca
66721	ctgaaggcct	gtagtagcct	cattgttgta	tccacacagg	ttaagtcata	ccgtttccct
66781	ccgctctggg	gcgggggggc	caataaaatc	gactcgccag	tcccgcacag	gttgtagggc
66841	tcgatgtatg	tgacccgggtg	tgggaggaac	ctttctagtct	gcagccatga	acagggtccc
66901	gggttctgaa	cagctgctga	attatctgca	cagtgggcag	ggaagcctac	agtcctttgt
66961	ttggcccacc	tcatggctgc	cccctgtggg	tcgctcttat	aaggtagcca	catggcagcc
67021	tcccacaatg	ggctccagca	aacctaggga	acatgcttaa	gggcgctgc	ctcctgattt
67081	ccaggagaca	gcttaggact	atgtgcatca	acRtggtaca	ccataagatg	cacatcattc
67141	ttttgtcacc	tgacgtggat	attctgccac	atggacaggc	cctcaaaggg	gcctgcccga
67201	aacctcccaa	ctgtaagcag	cccattgact	gctttgtcgt	tacccccatt	ctatccRtat
67261	ggttgccagt	tcattttgca	ccgtcagcac	tgaccgttaag	tggttaggtgc	tctgttagtg
67321	tccatgtgtt	tgccctggcag	atatcgtaag	ggtcgccctca	tatatggtag	ttggcatggt
67381	aggtggatct	attgccatgt	ccRctcttct	aagcacgtcc	tgtagtactt	gacttaaagg
67441	actagtggac	agggcatccc	tttgttgcat	agaggcatgg	catttctgta	ggatgtgtgg
67501	ttgtgccacc	ccgggaggcg	ggcttggtcta	ggagaccttc	cattcaccct	tgtataaggt
67561	aggcagctct	tactgggaca	gtctgttttc	tgccgatggc	ctctgtctRt	tgcaatgtcc
67621	tatacatggc	caatagctgc	tgctccagca	ctgtaaagtg	agattctgct	cccttcaca
67681	gttgagactg	aaaccctaca	ggtaccattc	ctgtgggttg	catttgcgac	aaactccaac
67741	tcagggtcagt	ggcgtctcta	gtgacttcca	gtacaagagg	gtgctgtggt	catgaggctc
67801	ctgttgcttg	agcttggttc	accataattt	tgttttgtca	gaagcctctt	gctccatata
67861	tgtccagttc	catttggttc	acctttcttt	attagagtgt	ataatgggca	aaggcattgt
67921	gccaaatgag	gaatgaatat	cctccagtag	cccagtaaac	ctaggaaaac	ctgcagttgc
67981	tttactgtct	gaggaacagc	atggatgcgg	gcttgatggt	cccctggggc	ccatcggaat
68041	ctcttcccag	gaaattggag	gacctgaagg	aaaaccctta	gaggcagcag	gcagtggaag
68101	tgaggctctga	agaggagctg	gtttcccact	gctgacacc	ctgaggcttt	ccggatccct
68161	ggcttccctc	aaacctggct	ttaaaattgc	ctgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt
68221	gtgtgtgtct	gtccatacat	gtgtgtgtgc	acacccatag	atttctttat	ttattttaatt
68281	ctgtgagctt	tctctctgga	ttcttccaat	acatgtctct	actgcagagt	tagccagagg
68341	attttaaaaa	gctttctgct	cacttttgtt	cttgcatattg	cttttgactt	tgttttgctt
68401	tgcgctctcc	ttgcttcNaa	aaaaaatgtt	taactgatac	aaacattgtc	ccaaagagtt
68461	gggtgcagat	cacaggccct	cagatgattg	gcataatttg	aataagtttt	caggctgaga
68521	ggagggcaga	gcaacagtga	gccaccccca	acccagcat	tccggggagc	acctgctgtc
68581	atcttgtgga	aaggggcaag	gaacgctggS	acctgaagca	ggataggtca	cttcagacaa
68641	atgcctggct	ttgacatttt	tcctgaaggc	gtctgataaa	ttgtggctgt	tgatattttt
68701	ggctgacttt	cctatgaaaa	gcaaattctg	taggtttctg	gttacatgat	aaatttcgtc
68761	ctcgccagat	cttctaagcg	cacatgaggg	ccctgatagg	gagagagtgg	tgtgttagct
68821	cctcccctgc	tgtaacaaag	caccacagac	acagtggctc	aaaccaacac	gaagttcttc
68881	tggagctcag	aagtccctaaa	atcaagggtg	gggcagagct	gcgttccttc	tggaggctct
68941	ggaagaagaa	gccattccat	tgctctctcc	agctcttgga	ggaaactgct	ggccttggtc
69001	cctgtctcct	tcttctctct	tcaaagtcag	ccttgtagca	tctccgatc	ctctccagtc
69061	tctctccctc	tctatcatct	catctcctt	tctccctctc	accctactgt	ctctgcctta
69121	gaaggacctc	tgtggttaca	ttggaccac	ttaaagaatc	ccaaataatc	tcccatctcc
69181	agatccttat	ctggacgata	actgcaagg	cccttttatg	atggaagggtg	atataatcgc
69241	aagtcccagg	gttaggacat	gcacatctgt	agggggctgt	tattcagcct	aaaacaagtt
69301	gcatcaagaa	aattacgatg	gggatatcaa	ggagtgtgaa	gaatcccaac	tcgtagccat
69361	gtctaagggc	ttttctgagg	tacaggcccc	gctagaggaa	gctgctccaa	ctctgttctc
69421	gtctgctcct	gccccactct	ctgtttctag	acagcctgcg	ttcaagtcac	tgtggcccaa
69481	gactgaactg	cagaatggaa	aggagtggag	cgctgcagca	gaaggagctc	gctgtcaaag
69541	ctccaaagag	ccggagacca	tttgcagggt	ggggtctgag	ggagggttggc	aaggaaaggg

69601	gagcatcatg	tggatttcctt	tccatagtYg	tcattgagcta	acacacttcg	ccccaacagc
69661	tggcttagat	tctaattgtg	cccaggactg	gccatgcaac	ccttgagtaa	atgctggcca
69721	cctctctatg	acacccaaaag	gccagaaatt	acctggcatg	ataaagaaga	aggagtcaag
69781	tgtataggag	accggagggt	tagactggat	ttctcaggcg	ccttctgccc	tgactgtgtg
69841	ctgccagggc	ccaggagatt	cccctttcct	ttgatgagaa	gaatcagtgg	atattctcta
69901	gagctctcta	gaatggggga	ggggctagga	ccctggtctc	tttaggttgg	gagaaattcc
69961	aagaggcaaa	ccctagggtg	aggcagggtg	tggccagaag	aaaagagtgt	ggacaccagg
70021	tcaRgaagca	gggagggcgc	atgatctggg	ctcagggacg	ttccacatgc	agaatccagc
70081	aacagagctg	gtggacagtc	tactgacttc	gcaaaacccc	cagtctggtg	agcaggcacc
70141	tgtcacaggt	catcatgctg	gatggccctt	gcttgactac	caattctcag	gcctgactca
70201	tagcacagac	ccagagccct	tgaaggaaaag	ggaggccagg	agtctgcaaa	aggccccgtc
70261	atttcccata	agtgcagcct	gtgagcgttc	ctcctacctg	ttctccctgg	acctggagcg
70321	tcccctcaga	tcacagggga	cggcttaaag	gaaacccatc	cccaggactg	ttggatccca
70381	tccagactga	caccaattcc	tgggacccat	aatgaccag	agtgccactg	tggtgttcca
70441	gtcagagggg	gggttacagg	gaacaagtaa	tgaatgaata	tctgatttca	gtttactttt
70501	caataagctc	atcacctggg	tattattttt	taaattcctg	ggtggataac	tggaatgcat
70561	attcttggaa	gcttcagatt	gttcacgtag	acccacggat	gatgactatt	tcagtgcacg
70621	acgccggtgg	aagccgttgg	ttttacatac	ctgcctaaat	attttaatca	gagtcaacag
70681	caaattcatg	gaggagttag	agagattgct	gccatcatca	aggtttaaag	ggagcagaag
70741	cagtgtattcc	tgtgactcac	ctgttcacct	cttcaatgca	gccagtcgtc	agcagggaaa
70801	caactgtttg	tcttccaaca	gcagaaacaa	gcagggaagct	catcagtRga	agctgccatt
70861	cctaagggtg	tcttgttaat	gaagcaaaata	aacacagcct	gcagctctca	gtctctatca
70921	atcaggcttc	ttggtcaagc	agaggtacca	tctctggttt	ttaagggcag	aaaacaacat
70981	gaaattcact	ggaatcatat	cagaagagcc	ccacctgcag	aggaggctgg	agtttggtct
71041	ggaagataaa	aagaagccaa	gacagtgcac	cggatcaag	gctgcgagca	caagagccct
71101	gttttgtgag	gagtgacacg	gccacagcgc	tgccccgcca	cctgcggaca	tcactctctc
71161	agggtgcagga	ctcggctgcgc	ctcttctcta	ttctcctcct	gggcagtcct	gctgctctca
71221	ctgagaatgg	gttctaagca	ccctgggctt	tgccctcact	gctccagttt	cagaatccca
71281	tgtggaagca	gccaatagc	cagcctagct	cctggacagg	agccctggat	gccagagtgg
71341	gggttagggag	tgggagaatc	tacttgccct	agaatcacag	agggaatgg	gcccagcctc
71401	tgtctatgac	tacacatgct	ggcaaaSc	caaagttagga	agaggaaaat	agctgccgaa
71461	gagttccctg	ctgtgaaaca	agtttggttc	atctcttggg	tctaaatatt	gacatctttg
71521	attgtacaag	gcagaccctt	aactctaatt	tgYgaaaact	aaatagagat	acataactca
71581	cagaccatga	gggctgaatg	caggtgctta	cactgagtta	tgagtactca	acRtctctca
71641	aattctgctg	tgctttcctc	ctggcccacc	tgctcccacc	aggcctggcc	tgctgtggaa
71701	cacctctcag	ggatggttcc	tgaagagcag	tggagcacac	ctcacagtcc	aggctgctct
71761	gaaggagMRg	tgctcctcgg	aaggatctgc	cttggttgct	gggtaacagt	tgaggatttg
71821	gctgtaagtt	cagcattttta	gaaggaatac	gtctggaggc	ttggtgacaa	agatatttag
71881	ggaagaggta	tacagataaa	gatttttagaa	tgagcccaga	gcaaaaaaaaa	gaaagagaaa
71941	aaaactaccc	ctgtcccatt	tgaatactga	ctagaaagtc	tccactctca	agagactcat
72001	atacagggaa	gaagtcaact	ttgtggctgc	aagtctcctc	tgttcccagg	gcggcccggt
72061	atttttcagaa	tgggctccat	aaccagggtgc	gtgatgtgga	gctcgggtga	accacgcaac
72121	acggatccct	cctcaaggct	gagcacttgg	catcgtccag	tgaatctcaa	ccccggaagt
72181	cacagcctta	gagagcatgg	aaatggcccg	aaggggactc	agttccatgt	cagaggctgg
72241	gaactgcctt	taggatgtgc	tatgttttga	attcataccc	aaaatttacc	tcatttctct
72301	tgatagccag	aatttatgga	gctggacagt	aagaggttaa	gatgaggggtg	atagctctat
72361	ggttacaaac	aataagtcac	tttcaaaaat	cttggtttaca	atacccttaa	ctcagagact
72421	tttaagtcta	gaagtttcag	tatctaagggt	gggaatgcct	cctgcaaggc	tgacaaaagt
72481	ggttttcagag	gtgcccatag	ctggcttctc	atgctccctg	atgtagggat	agcaatgacg
72541	tcactgggtt	agatataatc	atggatcatg	atcatccagg	gaagctcatg	ttgttactac
72601	acagcaggac	atgaggaatc	gagggatccc	ctaggattgc	tccttgtaat	actctaacaa
72661	gttgtaaagg	tgaataggaa	atttcaccac	cttactgagg	ccagaccatc	aaggagctta
72721	gacccacaaa	gaatgacttc	gcccataagt	aagagggaaca	ttgagtggaa	cagtcaaaga
72781	cttgtgacgg	tggcagcaat	ggtcagtggt	ggttgtagcc	ttgaccgcac	ctctctgttt
72841	cctacaaaata	tacacacaga	aaatgctgag	ataggagctg	ccaatggacc	aagagaaaaa
72901	ttgacagtgt	gccgagccct	tcctcctgtg	acataacttc	agcatgcaga	agagggcgat
72961	gggtgtgtgtg	gctctctttg	gagaagaagc	aagtgcattt	gtctttgtcg	ttcggtggc
73021	tggattcata	acaggtaaRg	agagtttttt	gtttgttttt	cgagacggag	tttcgctctt
73081	tcaccaggct	ggactgcagt	ggcgtgatct	cagctcgtctg	caagctctgc	ctcccgtatt
73141	caagcaattc	tcctgcttca	gctcctgaga	tagctgggat	tacaggcatg	tatcaccatg
73201	cctggctaatt	ttttgtattt	ttagtagaga	cggggtttca	tcatgttggc	catgctggtc
73261	ttgaactcct	gaactcaaat	gatccgcccc	ctgcaaccac	gcgaagtgct	gggattacag
73321	gcgtRagcca	ctgtgcccag	tcgaaaaggg	ttctttttgt	ttgtatgaga	agaagggtac
73381	gtgtgtgtgg	tagcaagcag	ttgactatat	aMaataagca	caaattcagg	tgactgtttg

73441	gccagaggct	tcccattagg	gtttgtgtct	ctgttactca	tcgctgttcc	tgataccata
73501	gcttgactga	ttgggtcaag	aacagtcact	gacccaagct	atcctcYcat	ttgagaatgt
73561	gaaactttaa	tcagagacac	taggaatcaa	agtgtgtgga	gctaagccag	gtgcaggcag
73621	agccctgaaa	gggcaaacca	tatattcctg	atgttggttaa	tggtctgctc	ctgtccttcc
73681	aaattctgta	gattttgttc	ttccttccat	cctctgacct	gctctagttt	tcattccaatg
73741	aatcttctat	tttggtttaag	acagatagWt	tctgtttctg	ttgcttgcaa	ttgaaaaatt
73801	tttaaRcaat	actagcagta	cagtgggaatt	gcatcaaatg	caggtagcct	gatggcattt
73861	caactctaag	tgtcagggca	aatgctggct	ggatcactga	agaagtaaat	tactcagtgc
73921	cagaaacatt	caaagcttaa	gtgaaatgta	tgaaaagaat	gggaattatc	caggaattga
73981	tgaacaattg	acagacaaat	gaaacacaat	gttctggcgt	taggcaagtc	ggtggccgtt
74041	agtgggtaca	ggcctccctc	aagaaataga	tgaatcaact	gaaggtcagg	gaagccttgg
74101	ctgatggaga	gttacaggga	ctgaggcaag	tgttctgcag	gatgctacat	aaaaaaggac
74161	taagtaggcc	ctgggtgcac	tttacgagtg	acttaggaga	ggttctgggg	tgattttgtg
74221	cattctgtat	ctcttgcccc	tgctctgggc	tccagctgag	gcgcccagca	gttctatatt
74281	ctatgcatgg	aaatacagat	aattaatgtc	cactggggca	aggccatggg	ggacaggagc
74341	agtgggtaca	ggcctccctc	tctcctccct	gtagaggaaac	attctgaaga	cgctccttga
74401	agactcctca	ggaggtctcc	agtcgcccac	atgggtgacc	ctatcaagaa	tttctcccg
74461	catcagYctt	cYRtcttct	cYgtgtcact	cctMccagta	ccccagtcct	gctcctagaa
74521	tcacttccca	aacaaatcct	ctgcctggga	gccttgccca	gggctctccc	ttcaggggaa
74581	ctcagggccac	aRcagcctac	attagacagc	atgaaggctc	tgggcttttg	tgtaagagt
74641	aataggaagc	cattgaagac	atggaagccK	gKgtttgatg	aaatctgtgt	ttttatgggt
74701	caacttggcc	caaKgtggag	gaWgagctgg	cctagcggca	agggctgtRt	atcagcgaag
74761	accatttttg	aagcttttgc	aggagtctgg	gcgaagtgag	aaggctgact	ggatgaggg
74821	gtttgcagac	tggatgaggg	tatttgctgt	ctggctgtct	Stctctgtcc	ctctatgtct
74881	catggatttt	cYYtcaacct	acatacagc	ccttctgac	ttagcctcat	gtgacctatg
74941	tcaatccttg	gccctggctg	ctagatcagg	accacgcctg	tactagagcc	aagccagaag
75001	tctacaagtt	ttccctgagt	gcttcagggg	ccactgggca	ctgggttcgc	agagaaatga
75061	gcagtctgga	gagtaagcag	aaggggccat	ggaggcctag	ctccctgaga	gcctggaaga
75121	agaatcatga	ggaagagaag	tcaggcaccc	agagcctagg	ggagcccata	tatcaRcaca
75181	caaaggctca	gtcatcagtc	agtgttgctt	gaacacaagt	ctctagaaca	caagagaaga
75241	gggccagggtg	gatgtgagat	atcatcttgt	ccagccccc	tttcccagct	ttgagggaaa
75301	ctgaggctca	gagagatggg	gtctcttgac	tgaggctgg	ttcatctcct	caatgcacca
75361	caacattcct	tgacttgttc	ctggcatctg	gttttgcttt	tatttttctt	cacacatcaa
75421	cgtttccaat	atagcatttg	gagtttcatt	gaaatgtcat	cggtcctcct	gtgtacgctg
75481	gccccaaagca	gggcccagcc	catgtcaagt	cctcttgctg	tctgtcgaca	tcaccacaat
75541	gccttttacc	actgttagga	caaaaacttg	agacaggaaac	ttgccctcaa	agcgggaaag
75601	gagccatgag	accaaggaat	gacttaaaca	agtccagctt	ggcgagtagc	taagtttatt
75661	aggacttaca	cacagggcac	tcagaagac	agctcgagag	atccRgcctc	ccccaatgtc
75721	taaactgctt	ttcagttaat	tttctggctc	tttgtctact	atatatgagc	aacgagactt
75781	ttacttggtt	ggttctcaga	tactctcag	gatgtttgga	ttctcagaga	cactggttcc
75841	tcagctgggc	accatggaaa	tggctcatta	cccggccttc	agggttcaag	caggggacat
75901	gcacccttaa	ataacctaaa	ggggacctgt	cacactacaa	ccaccaccac	catcatcaag
75961	aagccactgg	ctgactcaga	tacaccccYg	ggaggacaaag	ggagagtgga	tgctggtaag
76021	acagggYgag	agaccatcac	cagggaaagga	ttccattctt	ggaaggacat	ccaaccgggg
76081	ggcgggtctt	tagtggagcc	gctgtttctt	ctcctgtatc	caacagttct	aactgtggct
76141	ttctccattt	tcagctcttt	cttttctctg	tcttctcatt	gcttgttcct	acgtgtctcc
76201	ctctcttctt	cccccaatat	actctttagt	ctagagtaaa	ctgcttcttt	ccattcccca
76261	cactctccag	tccctctctc	tcccttattc	caggcccccag	catttctgcc	ttctccttgg
76321	cgcacttgcc	atcttgagta	accctctccc	tgctgtgctc	agctacagat	gccaaagttc
76381	ctaacactga	gttcataaaa	ctttacctcg	ccctctttat	tcccttaaaa	aatgtctgcg
76441	ttttgtcccc	gcctgtgtct	ggctcacctt	ccctgggtggc	tgactgctc	tggggtcatt
76501	gggtatcggg	gaacctgccc	cgatggtcac	gtaggttctt	ttctattttc	cctaagtgtt
76561	ggccggtttg	agaaataaag	gcacagagta	caaaaagagag	aaatttttaa	gctaggtgtc
76621	caggggagac	atcacacatc	ggtaggttcc	gtgatgcctc	acaagccgca	aaaccagcaa
76681	gtttttatta	gggactttca	aaaggggagg	gagtgtatga	atagggtgtg	ggtgtgggtc
76741	acaaagatca	cctacttcac	aaggttaatag	aatatcacaa	ggcaagtgga	ggcagggcga
76801	gatcacagga	acacaggacc	ggggagaaat	taaaattgct	aatgaggttt	cgggcaccat
76861	tgtcattgat	aacatcttat	caggagacag	ggttttgaga	gcaaccggtc	tgaccaaaat
76921	ttattaggcg	ggaatttctt	cttccctaata	agcctgggag	cgctatggga	gactgggggt
76981	tattttatcc	ctacagtctc	gacctatgaa	gatggccaca	cccaaggagg	ccattttatag
77041	accacacctc	aggggtgcac	tctctttctc	agggatgttc	cttgctgaga	aaaagaattc
77101	agcgatatatt	ctcccatttg	cttttgaaag	aagagaaata	tgactctgtt	ccaccagggt
77161	cactgttggg	cagagtttaa	ggttatctct	cttattccct	gaacaattgc	tgttatcctg
77221	ttcttttttc	aaggtgcccc	gatttcatat	tgttcaaaca	cacatgctct	acaatttgtg

77281	cagtttaacgc	aattatcaca	tggctcctgag	gtgacatata	tcctcctcag	ctgacaggat
77341	taggagatta	aagtaaagac	aggcataaga	aatcacaaag	gtattgattg	gggaagtgat
77401	cagtgtccat	gaaatcttca	caatttgtgt	ttagagattg	cggtaaagac	aggcatagga
77461	aattataaaa	gtattaattt	ggggaactaa	taaatgtcca	tgaatcttcc	acaatccacg
77521	ttcttctgcc	atggcttccag	ccagtcctcc	cgtttgggtg	ccctgacttc	ccgcaacaat
77581	tgggcctagc	ctgcttttag	actctgatgg	atatgggtga	gctcattgag	attctcctcc
77641	agctcctgag	cccactgcct	cagcgactca	gcagactcgg	atthttgcccc	cttgtgcaag
77701	tccagtgaag	cttgacacaag	gttgactaca	tccagcacaa	caaggacacc	tgaagtggcc
77761	ttgcccagg	tccggggtac	ttttctcact	atccgggtgg	gggccccacg	tggtctcagt
77821	gtctcaacaa	catttatag	tacatatcgc	caagcaatca	aagggtcgct	aacagtggct
77881	ttagatctcc	tgagtgtatg	gacatcattc	gcaatcattt	ttgtggcttc	gtcaaaatca
77941	agtgcaaaRg	aaagcacatt	gggtgtgatg	tcaYgcagaa	tgtcccttaa	tgccctcaat
78001	tggctcagtgc	ttgttgagct	cagcctgctg	gctgtgagtt	ctgctgacct	tggtgtatgtg
78061	ttctccacga	tgctggaggc	gatcccagcc	gtggcagatg	ctattcccag	ccctacccca
78121	gctgcagtaa	tgctcaggct	cagccctgct	gtaaatgggtg	ccaacaYaac	gccaatgaca
78181	gacaggatgc	cagtgaggcc	agacaccaca	ttggcgatga	cgcagcctct	gtggaccttt
78241	tcaatctcat	ttgcaatgac	acgaagcctt	tctatggact	cctgaatctt	ccatctgatt
78301	tgaggaaacN	ttcaaaaacc	actccctaaa	ctgctgttct	ttttgctgca	tgcttttgct
78361	ctcaatagcc	acatatgggtg	taagattcct	cagagcttca	tagagagcat	ctgcYtcttc
78421	cctgtaccac	taaaggacag	atgattaaga	aaggcagctt	acttacctgt	aaaatgagct
78481	caataagatc	tattctgcat	aaatcacaga	gctgtttcta	taagtcaaat	ggaagtaaa
78541	ttctaaaaa	taaataattc	ttttcaaggc	cgggYgcggg	ggctcatgcY	tgtaatccca
78601	gcactttggg	aggccgagat	gggtggatca	caaggtcagg	agatcgagac	catcctagct
78661	aacacgggtg	aaccccgctc	ctactaaaaa	tacaaaaaat	tagccaggYg	tggtgggtgag
78721	tgctctgagt	cccagctact	tggtggagctg	aggcaggaga	atggcatgaa	tccaggaggt
78781	ggagcttgca	gtgagccgag	atcgccgac	tgactccag	cctgggagac	agagcgagac
78841	tccatctcaa	aaaaaaataa	taataataat	tctaYtcaag	gttaaatatg	ttttgtacaa
78901	catagatatg	ccacagtact	tattcagtat	gggaaaaaat	aagttaaagt	catcttccga
78961	tgctctttag	tggtctatgtg	tttgataaa	atggctcctc	atgcaaggga	ggtcaatgcc
79021	atcactacca	gggtgtgtgg	agaggggaaa	ctttgtagaa	aaacaaagag	aagtgggttc
79081	agagcaaaaa	gaccttcatt	cagaggatca	tagaacagtg	atgaattaac	ttatttagaa
79141	gagagcatat	ccctttgtcc	tccggccctg	gaaagggatc	tctggggccc	tggaatgtcc
79201	tgctctggtg	gaacgtcttt	gtttccctgg	tggtttgggt	acaggccagt	atagcaatgt
79261	gatgggtgat	gggcgttttag	ggctattagg	tgctctcatc	gccttccaga	ggaactgagg
79321	tgtaaaagg	ttagaccctg	gggaagggtc	ggagactcca	tgcttgccat	gacggcagct
79381	actgatccag	cccaggaag	agctctgcat	tgctcatgag	taagaaagac	ttactcttg
79441	gcaaaacttc	agttgggagg	ttctgagcct	cttctcctct	agacattgac	cttggccttc
79501	catgcccac	ccgtgcttgc	tggtgctgca	ccgccccagc	tcagcaagaa	tccccaaa
79561	tcaattttag	gaggatcccc	ccagcttgct	gtctgagcac	acttgctctc	tgatcacgg
79621	cttaccctac	tcatttgata	agcgactgtc	tgacctgcct	ttaggagca	tcctgttag
79681	cagttttagc	aggaaccccc	cactctgggtg	tctcctgtca	gtcctgttcc	atctgcggcc
79741	ctttaccctg	gtgttggtg	tgactcccc	tctgacttta	ctgtattggg	agctgggctc
79801	agtctccctc	ccctgttaaca	acaatcctga	ataaaggctt	ccttccctgat	ttaatgtgat
79861	tcaYaggaat	ttttccttaa	ctgggtgagc	ttccctgggt	ggcaacaccc	catgtgtttt
79921	gttccacatt	gacacaggag	aacacagcct	cctgaggaca	atgaagcttc	acaactgaaa
79981	ccctctcaga	ctctgcccctg	tatgtctctt	ccttaatctg	tgttctttcc	ctgtgataaa
80041	ccacaatcgt	gcaataacag	ttatcagtga	gttacgtgag	tccttgtagt	gaattatcca
80101	acctgagggg	ggcttaagaa	agccctcaa	gtttgcaact	ggtgtcagaa	gtaagggtgc
80161	actcgaacgt	tgcaagttcac	ctaaatctga	gtccttaaga	attcaaacac	aacctcagac
80221	tagaagggtg	caatttgctt	ggcatgttct	ctcttccaat	gcctcatgac	ctttgacgtt
80281	ctgactaaag	gccactgggt	ccagccactg	ccacctatga	ctgaaaagtg	gaagacctgg
80341	ctattagctc	tggtgtgaca	caaactctca	agccacctta	ctgcctcctg	acctggcacc
80401	tccaaacttc	agggtctcac	tctcacatgt	caccagccaa	actaatgcct	tagcagggtg
80461	cagcttcatg	tgtatacagg	tcaaggccct	gtacaatttc	atggaagctc	ttgaggactc
80521	atgaggactt	tgaaaatcat	ctctataaat	cactaatgct	gaaaagacct	gcatttgac
80581	aagatggtag	agaaagtgtt	tttctctttg	gttggggact	tgtagtctt	ccgagaaccc
80641	ttcaaattac	accagttgaa	gccactcgtc	cccactctgg	aagttggcct	gaagaaacat
80701	tgctcttact	ctatgtagaa	cagaagaagg	tttcaaatgg	cagcccagaa	ctccccat
80761	cccaggcatg	gtgtcgggga	aacagtcacc	catggccac	tatgcccac	agtgatggga
80821	tcaaactcag	gaggggaagaa	atatccctct	cctactcag	ggtcttctgc	aagctcatga
80881	ccatgttaca	tttcatgctc	tcagtgtctc	ccttctctca	ccctcctccc	agccttgatg
80941	ctccagcctt	cctgctgctc	ctccaatcta	ggtccacccc	tgccccatcc	tgacccctgg
81001	ctctgcccct	ggcaatgtct	ctctgggtct	ttgggaggca	tcatgtctatt	tggttcccca
81061	cctttgacct	ggagttcatt	ctaaggcctt	caccacactc	ccatctgatt	gaattactaa

81121	tagcattgga	cagacggcag	gtcccagtc	ccaagacata	aaccaacagc	cccagagctg
81181	tgcagggaca	gagccaggat	ccacccagc	tctgtccaac	tccattccag	cctctctgtg
81241	tcttgggtca	gcagaaggat	tctgtgtgt	ttgtgcagtt	cctcagaagt	tcaggaaaag
81301	ggccccagac	agcatYtccR	ggaacacaca	ttgatcagg	caagattttt	ctgacttttc
81361	ccaaagaaag	tcttgtctgg	cttccatctc	taagaaaaag	acttttggYc	ctggctctct
81421	gccagcaagt	tttgtaaaa	gtaacgctaa	ctgagcacct	actgtgtgtc	agtcattatg
81481	ctaaatactt	tacatgcatt	atcttatttt	tctcacaata	aagctcaatg	gatgaagaaa
81541	ggaaagcaga	aagtagtcaa	gtagcttgca	aagctcccat	caccagtaga	tggcagaact
81601	gaccctgccc	ttgtgggctt	cttctccctt	cagcctgagg	tcactactg	ccagcgaagc
81661	acttggagga	aataattctt	ctgcaactgt	gagagggaca	tcctcaagcc	cagcagaggg
81721	ggctgcctgg	aggaggYgtg	cctgccagag	aaaactagcc	cggggagatc	tgggtggcat
81781	caccgggggtg	ccccaaaggag	gtaaccccat	ggaggttacc	tgggcaattc	agccacacgc
81841	acRaatctct	tccaggcttc	atcgctagtc	agcaggattt	tcagatgcac	tgggctaact
81901	ttcttctgga	agtattcaat	gacttcttca	gtgaagcggt	tcttttctag	ttggaaacaa
81961	aaaggataag	attggaagaa	agtttgctac	cacataaatg	gcattgagta	taaggtgggt
82021	cggtgttaat	cctcctgaac	cagctgtcac	atgggtattt	tttgatggag	gcaccagtgc
82081	tatagactga	attgtgtgcc	cYccaaattc	aaatactgag	gctctaaacc	ccagtgaccg
82141	tatttggaga	ttgagccttt	aaggaaagtc	ttaatttaaa	gggagtcata	agagtaggga
82201	cctactccta	taggactgg	gtccaattaa	aagaaaaaaa	agagacagat	gatctctctc
82261	tctctctctc	tctctctctc	tctctcacac	acacacacac	acacacacac	acacacacac
82321	acacaccact	gtgaaggcca	tgtagggaca	cagccctgag	gcagcctctg	taagccagga
82381	gcagagccct	ccccagacat	caaccctgct	ggcaccttca	ccttggtactt	cttgccctca
82441	gaactgtgag	aaaatacgtc	agttgttgaa	gccaccagc	ttgtggcatt	ttactaaggc
82501	atcctgagaa	gagtgattca	ccagggaagt	gccacgatgc	tttgtggagg	aaccaatcta
82561	tttcagctga	gaatcaccag	aaagtgaagt	ttccaccatg	ttttctcccc	atgtacggga
82621	aataattccag	tgatogcttc	ctcctgccat	gtgcctattg	tcaaacactt	tacaccagtg
82681	tcttcaaaat	ctgaattttg	acccatcagt	gggttatgac	aatagttcat	tgtgtcaaga
82741	gcagcatttt	aaaaagaaaa	gagcattgaa	aatatcagag	tatattgaac	atagcaagag
82801	tgagtattct	tttgtaagat	acttgaataa	taYctataga	cccttatgta	aattcctggg
82861	atctagatgt	gtttaggatg	gcagcatttt	caatcttcta	gaaggacag	aggggtgcata
82921	tggtttatca	ctgaccactc	ccagcaggga	ctgggcccc	ccttgtaatc	ccaggtacaa
82981	atgtttcaac	caggaaacca	atgaatatct	accttaagt	gcatacataa	tattatcact
83041	acaaagcatc	ttagtacaca	gcaggattac	tgcccagatg	agttgcccc	aaaatgtgtg
83101	gtttgcaggg	atttgggaat	tatggaactc	cagagaaggg	gctgggaacc	agtttgtatt
83161	tcattgatgc	ctgggacatg	atgtataatt	gtttcctgct	gtgctcatal	gtgagaggcc
83221	tatttctcat	ttcacagaag	gagaaattga	gacccagaca	gcgagagaca	ccacccaacc
83281	cagcaagcag	gaagctcagg	atttgactca	aggccagcgt	tcccttgcca	ttactttgaa
83341	gactccatat	atttaaaaaa	tgctgtgtgt	ttctgcattc	tcccctgtag	tatacctgtg
83401	gggttttaaa	catttttatt	gcacagagga	ttcctcctgc	tggctatggg	ctctctcaga
83461	Yggggcagtg	aggggggtct	ttaggtgggc	aggggagtg	gaccctcagc	actgactcct
83521	tgggccccct	cggtgtgcct	ctgtccccct	caggctgggc	tcagggtaca	cggctcccc
83581	ctggcacctc	tgaacccagc	tgggccccgt	agtaaaccac	agaYcatctt	gtttcagagg
83641	gagagcttct	tccttggccc	ccagcccgag	cccttcctaa	ggattctggg	attggctgag
83701	WgctctcRgc	ttctaattct	ccctgccctc	ccctcatctt	ggacaggact	cagcacagcc
83761	cagtttgctg	tccagggcgg	cYcctgagca	gagctgactt	ggttgccatg	tgaactctgt
83821	aaggggagga	agccctcctg	aggaaatggg	gcttagggaa	atgaacgcag	gtctgacttg
83881	gctgggcgag	ggattgtctt	gttttttctt	tttcttctt	cacccaaaagg	agggaaggaaa
83941	ctcagggttg	gatggaggga	acctccagca	ctaaatttgt	gttttattga	tgggggtggg
84001	atggtgaata	ttaaagcaaa	attaaaataa	aaaccagacc	tgaacattc	ccgggcaaac
84061	aaaaccaacc	agaccttcag	aacagctgta	acccccatg	aaactgcaag	ctatgaatct
84121	gaactgggg	catatcagat	gggcgcttct	gtcagacaca	aacacagctt	aacctcggcc
84181	agtcatgagc	agccagctga	cagagggcca	tgctgagatg	tggatactgg	gaggtcacag
84241	aaagaacaag	aactccaggc	agcaggttca	cataatggac	acagaaggag	ctgctgtaac
84301	cagctgttagg	gacaggggga	ggggatgggc	ccagaggacc	ctgacaaaac	ggaagtggcc
84361	aatctggcta	agaccagtaa	gatctaactc	agcactgggt	ctgaccacc	tttcacccca
84421	gactcaatca	tacctcctt	gtcccacacc	cacctgtgcc	acagaagttc	catgcttgca
84481	acaaaactgc	gtggcccccc	agttccaaga	aatccccgcc	tcttcccata	aatccttatg
84541	cttactctgc	cccttaactt	agtaaaccac	caaagtcaga	aaccccaaac	cccactgggc
84601	ccgactggct	cttctgagtc	cgcctgcact	cccaccctg	agcctgcgct	tctgtcttgc
84661	aataaaagct	aatttgcttt	ggctttgcct	caaattcttt	ctctcttcgt	tgtcagaatc
84721	ctggacaagg	ctaaggtccg	gtctcacctg	cattcagaga	cctccctaaa	cccaccggca
84781	tcaacatgac	caggaatttt	ccaacaagg	aaagcaaac	aggcagtttt	atcactggaa
84841	ctaatacaat	aatgtcctaa	ttgcacttcc	atattcaccc	gataaacact	tgtcttccac
84901	agtttttcat	cataacacaa	aacctcctcc	agtttgggtt	tctctattta	tgaactcctt

84961	cttatttcaga	taaatgttgt	tgtgcctcag	atgtttcttt	gacaaggggt	actttcga
85021	attggactca	gcccagataa	agagggtgct	gtgacaggca	gtgcaggggt	gggtgccctaa
85081	cacagctcgg	gaaggggggt	gcttccactt	acaatcaaca	ggggtcaggt	agaggggatg
85141	ggaaccaccc	cttagggagg	ccgtactgtg	tggcaggcac	tggctggccc	aggtacccat
85201	gtaatgtttg	atcctcatga	caacatgggc	aaatatccta	gtgggtgcagg	tgaggaggag
85261	taaggagctc	caggtcacac	agaggggaca	tggccaagac	cagaatgggg	tccagttcag
85321	tgggaagctg	ggtcactcta	cccacagggc	cactcagagc	agaggggctg	gtgcagggca
85381	agagctggag	ggaggggacc	ggcctctgct	ggaacacccc	cagggtcagc	caggagcaga
85441	gagggaggtg	agaggtcagg	gctgtctggt	aacctcctct	cccacccctc	cgctactcct
85501	tgccaaccct	caaaagccaa	cctgtctgtt	tccatttccc	caaggctgtc	ctgccccact
85561	taagtcatth	gctaggtgtc	agggtaggga	ggaagtgggc	acctggggcca	tgacccgctg
85621	aggagaggtc	aggatgcaga	tgccccccag	aacctgggtg	caggggactc	cacgtggcct
85681	ctcttggggc	ttggggcagc	ctcatcRgcc	acctccRtct	gggttccgtt	ggggctcact
85741	cagccttgaa	gacaccaccc	tccattctag	ctgtgggtag	gaaccagcca	gggaagagga
85801	ggcgagccta	ccagcagcca	ggtctctgaa	aggcttacct	tggaaactgtc	cagccactgt
85861	ccagcctgga	tggttttgct	gcaccttgga	ggaagagaaa	acaaattgtg	ggattgaatg
85921	tgagccacct	atggggcaag	ggaggcttga	acagctgggc	ctctgcagat	ccctctgagg
85981	tggcagcaaa	tgccaagacc	aacctaaccc	agattctttc	tctatcacca	agtccccatc
86041	atctgctatt	tacagacact	caactcattc	cagctccctc	tcccctcact	ctcacaccaa
86101	ggaaaagtcc	gcttgtcctg	ttggagaatg	aggagaagat	aatcagagga	ggggcagcca
86161	tctgatcatt	acagaaacta	cacagcttat	acgcagaaat	agagatggga	aggaacgttc
86221	taacaatgac	cggaaacatg	tgtgacaact	aattgatgat	agccagtctg	tattgagtgt
86281	ctgtgatgtg	cagggcttct	ttttttatth	ttatttttat	ttattttatat	tttttgagac
86341	ggagtctcgc	tctgtcgtcc	agggtggagt	cagtggcgcg	atctcggctc	actgcaagcg
86401	ccgcctccca	ggttcacgcc	attctctttg	ctcagcctct	cgagtagctg	ggactacagg
86461	tgcccgctgc	cacattcggc	taattYtttg	tattttcagt	agagaagggg	tttcaccgtg
86521	ttagccagga	tggtctcgat	ctcctgacct	catgatcagc	ccgtctcggc	ctcccaaagt
86581	gctgggatta	caggcgtgag	cggtcgcgcc	gggcctgtga	tgtgcagggc	ttctgacatg
86641	tgtctcattc	aatgatcaca	cacagcccg	gagatgggta	ccactttccc	atttgaacac
86701	agaggaattc	acaaaagtta	gggaacttgc	cagtgttttc	tattgctaga	gccaggactt
86761	ctgcttcaac	ctcatgtctt	caatgactgt	gctctactcc	cttaaatata	caatatttag
86821	tcatgtatac	acRctcatgg	taaatgactc	ctcattgcaa	atccatgtct	cacactccgt
86881	gctcaactth	tctgtcttgg	gaattcactg	gtgctgcagt	ggacagcctg	tgtccccctt
86941	gcttctctaa	gatcctttgt	cccacaaaga	cctggatcct	gccagatgcc	ggcctagccc
87001	ctgctgtggc	tgccgagccc	tcctggcgct	gccctgttcc	ctctgctgtc	ctcccttagc
87061	tgatggacct	taggggtgth	ctaattcttc	atgtaaaatta	tgctacaaa	aacaYcctcc
87121	ttcacgtaaa	actgcccaca	tttgatttta	tttccttaag	atatttgtag	gagtagaatg
87181	actaggtcag	agggtatcaa	catctcaaaa	tgttttatac	ctagagccac	actRcatgca
87241	aattgtacca	attcacactc	aaactagcag	tatatgaaga	tgcccattct	ttcagtccta
87301	ctggctctca	gtagtctctt	tatcaggaca	aaaaatatat	acacaacatg	taaatttgag
87361	aactaaatat	cttggttatca	ataccaatta	gtacaaactt	taaggcacga	aggtagcagt
87421	tgagatgtga	agcactgaac	aaaggagaag	gaggattaat	attgtcattt	tttaaagaKg
87481	gaagttaaga	aatactgggt	acaactgagg	gtataagaaa	gttgtaagta	aattgtttac
87541	agctacaaag	ttgctaattg	Ragacataaa	actggtgata	gaatgttagg	aaaaggtgga
87601	gagRagagat	agagggaggg	tacaaaataag	atgaaaatga	ctaataatga	tactataaat
87661	aataacaata	ccaYttcagg	cccatccag	ttaggggcgg	ctccaagcat	taccattgtt
87721	cttttctcac	cgtgtgtctc	tgcgcactcc	ctggcacacc	cacttccagc	agctgggtct
87781	tgtttgacag	ctttattttta	acagctcagt	ggttcccggg	ccccctgatg	gggttccatc
87841	ctccagctct	catactaaa	ccccctcctc	aaaagccact	cgctccctc	tttccctttc
87901	ctgcctttgt	ctcagggttc	agacacacag	atgtctgtct	tctggggccc	ccatgcaRca
87961	agggtaaaa	gggggaccag	tcctgggcag	cNttcaccag	gggagtatgc	agaggggcRt
88021	ctgggcgctt	cttgcgtgta	gggacagggg	tgacaggaga	ggggcatccc	ttcSccttSt
88081	tcctgctttg	ttcactgtgt	gaccccttag	gccaRggSaR	ccatctcaac	accaNgagcc
88141	aKKagaacNg	ggaggaccag	gagagagcag	aggagcagga	gggcagagag	ctggggcctc
88201	ggactcacc	gacgcttggt	atgagctgca	cccaggatcc	catcctcctt	ggctattgtt
88261	ggcctggctc	agacgtgat	ctggggcctc	tgctgaatgt	tgaggctgga	tactgactgt
88321	tagcctcaac	taggacacaR	tgcKtcccc	ctaggcgagt	ctaccagttg	gtcaattccg
88381	ggaagtgatt	ttggttccta	gaaaaaccca	catggctcct	ggcccagccc	aagccctgcc
88441	caattgtgca	gcccagacag	ggagccctcc	ctcccaccte	agggtctgta	gccaagctca
88501	ccagatgcag	aSgacaaa	Ytttcagcaa	agcagctccc	tccatgtcgc	tgccgggcct
88561	cctccttggg	caggaaaaga	ggggttgaga	cagtgtgctc	ctcctgagaa	atcaccttt
88621	tcattttcatt	tttaataaac	cgttttgctS	tgtcaccacg	gctgcagggc	tttgacgcca
88681	tcctagctca	ttgctgccta	gatctgctgg	gctcaagtga	tcttccctct	tcaaccttct
88741	gagtagctgg	gactacaggt	gcacgctacc	atgctgggct	aattttgttaa	tttttgattt

88801	catagagaca	gcatactcctg	tgttttYcag	gctgtcttga	actcctggcc	tcaagtgatc
88861	ttcccgcttc	tgccctccac	agcactggga	ttacaggctt	cagctatagt	gctttctatc
88921	ttgatgggca	tctctttttg	gtgaagaaaa	atcaggccgg	gagcgggtgg	tcacgcctgt
88981	aatcccagca	ctttggggagg	ccgaggcagg	cagatcacaa	ggtcaggaga	tggagaccat
89041	cctgggctaac	atgggtgaaac	cccatactcta	ctaaaaatac	aaaaattagc	cgagtgtagt
89101	ggcggggcgcc	tgtagtccca	gctactcggg	aggctgaggc	aggagaatgg	tgtgaacccg
89161	ggaggcgagg	cttgacagtga	gcagagattg	cgccactgca	ctccagcctg	ggcaacagag
89221	cgagactccR	tctcaRaaaa	aagaaaaaaa	aaaaaaagaa	aagaaaaata	agaccacgac
89281	tcagattttca	cagaaattac	ccccttgatt	tcattggactt	ttggcagctc	tatcagggtt
89341	ctgagagggg	aaaatcttag	gctgggaggg	gaggtgactt	gcccagagtc	gcacagctct
89401	tggagagcag	acgggaagcc	aacatctgcc	cttgtgactc	tgctattgaa	gaaaaacggg
89461	tgatttttagt	aatccaacag	tgtccagggt	tgattctgct	tctacaaaca	cagagatcta
89521	agctctcact	cctgtagtta	cactcacaa	tccacaggtg	gcttttgaat	ctcatgatta
89581	caaagctggc	gtcatgccac	aggcaccatt	ctgcaatgcg	accttctcac	tcccctgtct
89641	cagccatggt	tcctattgcg	ggaatctggc	agcagccccc	agtgcacagg	ggctctctct
89701	ttgctcctag	gcggtacggc	aggttgagaa	ataatagaca	cacacaagat	agtgaagct
89761	gggtccaggg	gggtcacccg	cttctgggtca	acaatgcact	ggatatacca	gcatttatta
89821	ttcagtttag	tgaggggcgg	ggtagggttag	tgagggattt	agggtcattt	gattacgagg
89881	tgggatggtc	acatggggat	gaagtaattc	tttaacataa	cattcgtatg	tagaagtaca
89941	tggtcatttgt	atgtagaagt	acagtataca	gagataagaa	tttacaatat	agtggtgtgc
90001	tcagtaatttt	ctaacagagc	cttaaaacag	aaacacaatc	tttccataac	ctatgattag
90061	caagatatta	atcagcagta	acaattgcaa	caaaagctgg	ttactgacaa	tccatggaaa
90121	caggacgtga	agctagataa	ccggttagac	tagaaattct	cagaaggagg	tatacctgaa
90181	ccctaaagat	gcctagaaga	gccacggcaa	gatgatagca	tttatagccc	tagcttgtcc
90241	atatggacag	gcgccccctt	gcataccattc	ataggctctc	tgccagggga	agcacatcac
90301	tgctgtgttg	ttcgttctgg	cagttccaacc	tggtcttgtc	tttacacaat	cctgcattga
90361	attttgtatt	tacaataatc	aggagcattt	catcttttat	tccgtagcaa	tagtttcagg
90421	gggtctccct	acagtttccc	attagggaca	cagcacagcc	tgtttcttct	ccatcaccct
90481	agaggtctga	acagagggac	agaggtgagg	gccacagaca	tggagtcccta	tgatctacct
90541	ccacagctc	ctgacactgg	accctggggc	agtcactccc	ctcccagggc	ctcagtttcc
90601	ggcagggccc	tggcacaagt	aggtgctcag	actcaggggtg	gggtgagatga	cctctagggt
90661	ccttggtatct	caaaagaaat	ctcttgccctc	atcaggccctc	agcagccgca	ccccggggcc
90721	agcctgggtg	tggccagacc	ataaggacag	accRggctcc	aggtcacctc	cccacctcca
90781	ccttctttga	ttccttcaaa	tttcccaaag	agatgggcac	ccccaacaca	aaccttccct
90841	ctggggctac	ctggccatgt	ctcagcagtc	taaaacagag	ctgagcccag	agagctttgt
90901	gaacccatct	gagctatttc	cccacctctc	tctacggttt	aagggccag	caggagggag
90961	ggagcaatca	gactcaagcc	tggRtgcaaa	tcccggctct	accactgctt	tcctgtctga
91021	tctgaacgag	ttacctaac	tctccgagct	tatctacaaa	agctgaatga	tccttccctc
91081	atagagctat	tgcgagaata	aggagatggR	gggaggtcac	accatcccca	acttaccacg
91141	ggatcttccct	ctgacagaga	ctgagcaaga	tccagctggt	ctgagctgtg	tggatctcac
91201	tccagctgt	gcacctatat	aataaacaga	cacgtcctcc	agcccccaag	atataccag
91261	gaattcgaaa	ggtaaaatga	aagtcacaac	ttcccagcag	ctcacaatca	agcacagcaa
91321	acacgctgct	ccccagcacc	tcttgcagtc	cagccccacc	ctccttgctg	ctgcgcttag
91381	aggagcagcc	tgagaccaga	cctccaggtc	tctttcatcc	aaccacctg	cctggcatcc
91441	tcgggggttg	gggtctgcta	tagtcttcag	gaagaaagac	ctgccactga	catactgtgg
91501	gacctttcag	attactcccc	gtctcccggt	gcttccacat	tcccctgatg	cctgccttac
91561	tcctgcccac	accatcagca	tttgacagct	ctcctacaca	tgccaagtgg	atccttattg
91621	tatatattatt	gtaaggccat	tgggggttatt	ttggttttgt	tctggagaca	gggtctcact
91681	ctgtagccaa	ggctgaagtg	caccgccaca	gtcatagtgc	actgcagttt	caaacccttg
91741	ggctcaagcc	atcctcccac	ctgagcctcc	tgagttagctg	tttctacagg	catcagccaa
91801	ccaccagct	aatttttaaa	aaagtatat	tagagatggg	gtctcactat	attgactggg
91861	ctactcttga	actccaggcc	tcaagtgate	ctcccacctt	ggcatgagcc	accgcaccag
91921	gcctgctctt	gttgaaggcc	atggcttggtg	gcttctagat	atttgcttat	gtggggctct
91981	ctgccgggat	ccccgtcttc	caccacctgg	aaaaatcatg	ctcatYgttc	agtgacaaaa
92041	tcaggcattg	cctcctgtca	gagatcccc	agcatcctcc	caagcagagg	cactgcctcc
92101	gtgttccact	cccgaggcac	acaggggtgga	gggactagag	accactgctc	agccacactt
92161	ctatggctaa	gaagtcatgc	aaccagattg	ctattggact	tttgtgcttt	gccccaggca
92221	gaagggcctc	aaagacagct	gaacctcaga	agccaacctg	acccttccat	gggggcctat
92281	ttcatcctga	gcaaacatcg	ctggggggcat	cgtggccacc	tccccccacc	catagcaca
92341	cacaccagct	tttgagacag	gaacagaaag	gtgattacac	agggactgca	caatacactt
92401	tgcaatacat	tccatttgca	aatgctttctc	catttgattg	aattttataa	tcacccctc
92461	aatgggcccag	gatttatgatc	taagtttttca	aatgaggaaa	ctgaggcaag	gggagaggaa
92521	gttgcttttca	tccagcaact	cagggaggag	ccaagacttg	tcaaccaaa	aggggtctggg
92581	acacgtctca	gtcagtttag	aggtttactc	tgccaaggtt	gaggatgcac	ccaggaaaaa



92641	gacacgcaag	tcacaggaag	atctggggcc	cactcattat	tcccagaggg	ttttgagggc
92701	ttcaacattt	aaatgtgtaa	aatcaggcag	gcgtggaagg	aggggaaggaa	aaaagacagg
92761	ataggtaagt	agctgagtgg	tcacattttt	gtgaggcttt	gatcggccct	ccctgaatcc
92821	ataggttcca	tgtgaaaggg	ggttagagga	acagtccatt	attcattctt	cttgtgcaca
92881	gttaatctac	attttctata	agataaaaa	aaacagaaag	tagaggaagt	aggcatatgt
92941	gcatttgtct	gagYgtgggc	agaagggcca	cttccactct	tgtcattgtt	aggtaccagt
93001	caagataagt	tgccagtttg	cattgtcaca	gtgaaattat	acaaagtctg	tctcaggggtg
93061	aaaatttggg	gacctacaag	gattttcttt	gtgaggaatt	tgtgaggcag	gccaactggg
93121	gtatatgttg	ccttccatct	ttgcaaatat	ctgttttagaa	acaaaaacaa	aggcaggttc
93181	tggagtgact	ctgtttccag	gcttaactgg	ttccactggt	atagtgaatt	tggggccctg
93241	agatttgatt	ttcctttcac	attttctctt	tgtttttcaa	tatcttttgg	agaaaacagt
93301	gtagaagcaa	aagaatctcc	agtcacgggg	ttggtctgaa	ttctgtaaca	caaagtattc
93361	caccttccgt	ttgcNtgcag	gggttttagaa	aaaggacagt	tttgatttct	ggtgatgcca
93421	agtcagaaaa	atgagagaaa	aacaaaagga	atatgttagt	ttggagactt	gtagccagga
93481	aagaattcaa	tatctagtgc	ggataaattg	tagacaaata	ataaagctgg	aaaacaattg
93541	acaaagctag	aatctcataa	cagacgtttt	atagtttctt	ttaaaaacaca	ttttctctct
93601	ctagtactct	atttctacca	aagacaaatc	atagtaggac	gcattttatt	gcaaaataag
93661	tttttagtctt	ctaatacttg	gcctgattat	ttgcataaag	tgcagaagaa	taatcttgtg
93721	gcataaggag	tcttttttaa	aatttgactt	tgctaggcca	ttttcgtatt	cataagctat
93781	ctcagagtga	gccYtttaaa	accttgagct	cagccacgaa	tttatgtttg	cctgcagata
93841	cctgtatgaa	ttgggtgagt	tcctttcttc	tcgaggcccc	atgatcactt	ggggttctctg
93901	ggcctgtcag	aaagtgtat	tctttattta	ccacagttca	ggaacctgt	aaaggaactc
93961	tataggcaaa	ggacttaata	aaggactgaa	attaatttca	gtcctttagt	aattcagctc
94021	catgtaatta	ccttcttcca	tttgatattg	gcttagcaac	cttccctgac	acatcagctt
94081	tttttttttt	tttccagttt	tgctgtcagg	gcccagggga	gggagaataa	ggagttatgg
94141	cttgctggat	acaaagtttc	cattttgcga	gaagaaaagt	tctgtggtg	atagcggttg
94201	cacacacaat	tgaatgtaat	tccactgaac	tgtacaccta	aaaatggtta	aatgatcaa
94261	cttttaggtta	ggaatatatt	accacaattt	aatttttgtt	tgtttgtttg	tttgcttgtt
94321	tgttttgaga	tggagtcttg	ctctgtcacc	caggctggag	tgcagtggcg	caatctcggc
94381	tcactgcaac	ctccacctcc	caggttcaag	caattctcct	gcctcatctt	ccccagcagc
94441	tggaactaca	ggtgcatgcc	accacgtcca	gctaattttt	tgtattttca	gtagagacag
94501	ggtttcacca	tgtttagccag	gatggtttca	atctcctgat	gttgatgcc	acctgccttg
94561	gcctcccaaa	gtgctgagat	gacaggagtg	agccactgca	ccaggcccaa	ttaaaaaagt
94621	ttttaaaatc	cttgaaaacc	cacctttgca	gaaaaaaaaa	taatagcacc	tgagcctttt
94681	ctggtttgct	aaacattttt	acacacataa	tcatacaagt	ttcaacaaca	gcctgtgat
94741	gaaaacattt	tcttcctagc	ctcgtttccc	agaagagaaa	acaaagggtt	aatgtgggtg
94801	aaatgagtta	ctcagaaaaga	ggcagagctg	ggctgttagc	tggacctttc	tggttcttgt
94861	tttgtttcat	tttctggacc	atcctgtttc	ccctaaagga	aatgatttcc	tgaattttct
94921	caagtattct	gaaaatStaa	ttttcttctt	cactttctcc	ctgttggtcc	aagatgaatc
94981	acaaaactcc	aaataccatc	agaatgtggt	gcccaggtcc	cacctgttct	atggctgatg
95041	gccacaggga	gctgggtatg	gctgggcYgg	ttatgaccac	ctgtaacccc	atcaaggatt
95101	aacatgctcc	tgaacagac	cccattgtcca	gaaatttgca	aaacctaccc	tgaatgtttg
95161	acatcataga	gtgtgcccc	atgtcctgtc	cagatttctg	tccctcccat	gagctggaga
95221	ggatatattg	catcagacag	ctggaaatca	ctttccccag	tttttggtct	catgactcag
95281	ttttcttgct	tgtagaataa	agctaattcat	agaatttacc	tctcagaatt	cctaagagaa
95341	taaatttcagg	caggggtggg	aatatgcattg	gcataatagta	gatgctcatt	aaacaagaat
95401	caatatattct	gagcactcac	tctgtataca	gggcagttag	caatcatgat	gtctgcatta
95461	tctccatttg	taactgaaga	aaagtccagc	tgctcactgc	ttgcaaaggc	aatgaacaa
95521	ggatgagaag	cagtgaagg	aaagtgactt	cattccaaaa	gcccatatct	ggggatgagg
95581	tcaggctagt	gccttagaga	aaccatttca	gattttgaac	tgagggcagg	tgtttcaaaa
95641	ggaaaacttg	atatgaaagg	catgcaagag	tggtgaagaa	gtgccagtct	acatgacttg
95701	tccaatgacc	atcttgagtt	attgccccat	cgggtgtatg	gactggggac	atctccagga
95761	tagccaggtt	gaaaattcaa	tgtagccttg	aggcaattct	gtagcttctt	ggatggtttc
95821	aagatttctt	ctactggggg	aacacactcc	caacatttca	atggaggttc	tttctatttt
95881	ccataaatgt	tgccagctg	agaaataaag	agagacagta	caaagagagg	aattttacag
95941	ctgggtgctg	gggggtgaca	tcacataatca	gcaggactgt	gatgccacc	tgaattctcag
96001	atcagcaagt	ttttattcag	ggttttaaaa	aggggagggg	gtgtaagaac	agggagttagg
96061	tacaaagatc	acatgcttca	aagggcaaaa	agcagaacta	ctaataaggg	tctaacaaag
96121	atcacatgct	tctgagggaa	caggacaaag	ggcaaaagca	gaaataactga	tatgttcagc
96181	ggtgcacRta	ttgtcttgat	aaacatttca	aacaacagaa	aacagggttt	gagggtagag
96241	aaccggtctg	accacaaatt	taccagggtg	gactttttcc	ccaccctaatt	aagcctgagg
96301	gtactgcagg	agaccagggc	atatctcagt	ccttatctca	accgcataag	acagacatcc
96361	ccagagcggc	cgtttataga	cctcccccca	gaaatgcatt	cctttccag	ggtattaata
96421	ttaatatctc	ttgctgggaa	aagaatttgg	caatatcttc	cctacttgcc	catctgttta

```

96481 taggctctct gcaagaagaa aagtatagct ctttttgccc gaccctgcag gcagtcagac
96541 cttatggttg tcttcccttg ttcctataaa tcgctgttat tctgttcttt ttcaagggtg
96601 actgatttca tattgttcaa ccacacatgt tttacaatca atttgtacag ttcacataat
96661 tatcactgtg gtccctgagg gacgtacatc ctcagcttag gaagataaca ggattaagag
96721 attaaagtaa agacaggcat aagaaattat aaaagtatta tttgggaact gataaatgtc
96781 catgaaatct tcacaattta tgttcctctg ctgcggtccc agccggtccc tccattcggg
96841 ctccctgact tccctgcaaca tcttccctgg aatttctaag caatctaaca tgattaaata
96901 aaatacagtg catgggaggg gagttcctag tagaaaagga gaacaaagat tcacacatta
96961 ctaaaagcaa aacaagaaat ggacaaagag aggagaccag aaacaaacaa acaaaaaata
97021 aaatgggata cttggttaca ttttcatctt ctccatgcac tctctagtac tcttgatgtt
97081 tctcctatcc cYatgtacag accagaaaaca gactcagaaa ataaaaatcat ttccccaagg
97141 ccacacaact ggccttggtt tctttttttg ttagagacag gatctcactc tgttgcccag
97201 gctgggggtg agcagcagat caaacgtctg ggctcaagtg atccccccac tgcagggaacc
97261 caagcagctg aaactacagg catgtgccac catgtctggc taatttttta actttcttgg
97321 tagagatgag gtctcatgat gttgccagg ctggtcttaa actcctagcc tcaagtaacc
97381 cttctgcttc agcctcccaa tgtactggag ttgtaatcga gtaaccagc attgaaatgt
97441 actttaacat tatttttctt tctgtcttaa tctcagaatg tagctttaaa atgtacttca
97501 aaattccttt ccctccctt tctcaccaag ctctcttctg cacagtgtc acttatctaa
97561 tgatgtgggt gcatagaaat tcaaggagtg aattttgaaa aaaaaacagg cagagaaacc
97621 caggtgcaaa attctccggc ttagggggag ttaccaacaa ttaatccacc accaacaggg
97681 taaagtccaa atgatgccaa ttggactctc tgacgggcta cttctcaaga cagccattgg
97741 aacaagacac agacctgcac cctcctgcac cactcccaca cacctccaat tccaattttc
97801 cttttctaaa ccctctctc cagcctaag tagaaatgat cttttaagag catgagcctg
97861 atcattcccc cactgtgagc acttgaatga agctgcttcc ccttcaccgc aactcacttc
97921 ctgtgttttt ggccactgag tggtagcag ctggacttga gccagttata gcattacagg
97981 agggagccaa tgcacccagc atggcttccc tttttcacct actgatcctc acgattcagt
98041 gcttaaatat tagaaatttt ttcatttcta agacaaataa tgatagactc acaagacaaa
98101 acagcacagc tggaaaaata gttgcaaac tagcacagag aggccttgca gactctttgc
98161 ccagtttccc ccaacggtcc tccagttcat ctgatgtagg agctggactg ggctgggtctg
98221 gaaactcagt ctcagctgcc tgaagtggc acttatccat gcgctccctt agaggggatg
98281 acaaggctct aggagaagtc aacatcaaag ccacctccaa gctgtggtca gcccgaagga
98341 gatggtcaca aaggcagaat tcagaaggag gaagagactt agagccaagg gtggagatgg
98401 aacctagggg tgggccttga gttacttagg tcaccgatgc caagctgcc taacaaagag
98461 ctcccaatta ccgatatatt caatcaatga tataggagat tgctgaactg agacattcac
98521 accaacgttg ctaggcagtt tcagtggcag gtggttttgc tcccgaaggt cgaccagggg
98581 ttgccactca gagggagttg ttgttttcca cgtggaagct ggcgcttacc catacatccc
98641 agcccaaaga acagaagagg acacaaaaca caggaatctt ccccttaaga gaaacaccta
98701 caagttgcag acatcactgc tctcaccttc cattggccac aatttaggaa gaagacccca
98761 tggagttgcc agggatactg ggcagtcctg tgctgttgg aactcagcag cYtgatgatc
98821 aaagacgaaa aaaaagagag gaaataaaaa cgggtaaaat gctcaatttt ataactttta
98881 aattttcatc ttttgccacc tggagaacct gaaatggaaa cgaaaagtca caacttctca
98941 gcagctcgtg atcacgcaaa ccactaaac aactgtctcc ccggcaccac cttcagcccg
99001 gtcccaccct ccttgctgct gcacttacag gagcaacccc agaccagtg

```

[0242] The following cDNA sequences 1-6 show human cDNA structure for transcript variants 1-6 of APOL3. cDNA sequence 1 encodes the longest isoform (1), which is shown in amino acid sequence 1. cDNA sequence 2 differs in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2, which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 3 has multiple differences in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2, which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 4 differs in the coding region but maintains the reading frame compared to the variant in cDNA sequence 1. This variant encodes isoform 2 (amino acid sequence 2), which is shorter and which contains a unique N-terminus compared to isoform 1. cDNA sequence 5 differs in the 5' UTR and

coding region compared to the variant in cDNA sequence 1. This results in translation initiation from a downstream ATG and an isoform 3 (amino acid sequence 3) with a shorter N-terminus compared to isoform 1. cDNA sequence 6 differs in the 5' UTR and coding region compared to the variant in amino acid sequence 1. This results in translation initiation from a downstream ATG and an isoform (3) with a shorter N-terminus compared to isoform 1.

#### APOL3 cDNA SEQUENCE 1 (SEQ ID NO: 2)

NM\_145640 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/d, mRNA

```

1 agcaggaggg tgggaccaag ggtgctgctg gaccaaggat gggactgggc caaggggtggg
61 gctgggaagc atcctgtttt gcatgtttga tcaggagctg ctgccaaagt gtgactttca
121 ctttcccttt tgggttccag ggtatatctc agagcctgga gaacgtgtct gggtattatg
181 cagatgcacg gctggaggtg ggatccacac agctcagaac agctggatct tgctcacact
241 ctttcaagag aagcttctct gaaaagaaac gctttactga agaggccacc aaatacttcc
301 gggagagagt cagcccagtg catctgcaaa tcctgctgac taacaatgaa gcctggaaga
361 gattcgtgac tgcgctgaa ttgcccaggg atgaggcaga tgctctctac gaagctctga
421 agaagcttag aacatatgca gctattgagg acgaatatgt gcagcagaaa gatgagcagt
481 ttagggaatg gtttttgaaa gagtttcccc aagtcaagag gaagatccag gagtccatag
541 aaaagcttct tgccttgca aatggtattg aagaggtcca cagaggctgc accatctcca
601 atgtggtgtc cagctccact ggcgctgcct ctggcatcat gtcccttgct ggtcttggtt
661 tggcaccatt tacagcaggg acgagctctg cccttactgc agctggggta gggctgggag
721 cagcgtctgc tgtgactggg atcaccacca gcatcgtgga gcactcatac acatcatcag
781 cagaagctga agccagcagg ctgactgcaa ccagcattga ccgattgaag gtatttaagg
841 aagtattgct tgacatcaca cccaacttac tttcccttct taataattat tacgaagcca
901 cacaaccat tgggagtga atccgtgcca tcaggcaagc cagagccagg gcccgactcc
961 ctgtgaccac ctggcgaatc tcagctggaa gtggtggtca agcagagaga acgattgcag
1021 gcaccaccgg ggcagtgagc agaggagccc ggatcctgag tgcgaccact tcaggcatct
1081 tccttgcact ggatgtggtc aaccttgat acgagtcaaa gcacttgcat gagggggcaa
1141 agtctgcac tgctgaggag ctgaggcggc aggtcagga gctggaggag aatctaattg
1201 agctactca gatctatcag cgtctgaatc catgccatac cactgacct cagaccagt
1261 cagccagcag gggaggtgag ccatacacag gccacgacaa aatgcaggca ttttattagg
1321 gggataaaga gggcaaggta aagtttatgg agctgagtgt tagtgacttt ggcatttctg
1381 tagctgagca cagcagggga ggggttaatg cagatggcaa gtgcaccaag gagaaggcag
1441 gaatgctgga gcctggaata agggaggaga ggggactgga gagtgtgggg aataggaaga
1501 agaaatttcc tttagactaa cgaatatatt ggggggagga atagagggga ggtgtgcagg
1561 aaccagcaat gagaaggcca ggaaaagaaa gagctgaaaa tgcagaaagc cgaagagtta
1621 gaacttttgg atacagcaga agaaacagcg gctccactac cgacctgcc ccggttcgat
1681 gtccctccaa gaatgaagtc tttccctggt gatgggtccc tgccctgtct tccagcatc
1741 cactctgtct tgtcctctct gaagtgtatc tcagtcagcc agtggcttct tgatgatggc
1801 ggtggagggt gtggtgtgag tgtgatggat cccctttagg ttatttaggg gtatatgtcc
1861 cctgcttgaa ccctgaaggc caggtaatga gccatggcca ttgtccccag ctgaggacca
1921 ggtgtctcta aaaacccaaa catcctggag agtatgagc aacctaccaa gaaaaacagt
1981 ctcatctact atatacagca ggcaaaagaga cagaaaatta actgaaaagc agtttagaga
2041 ctgggggagg ccgatctct agagccatcc tgctgagtgc cctgtgtgta agtcctaata
2101 aactcaccta ctcaccaa

```

#### APOL3 cDNA SEQUENCE 2 (SEQ ID NO: 3)

NM\_014349 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/a, mRNA

```

1 agcaggaggg tgggaccaag ggtgctgctg gaccaaggat gggactgggc caaggggtggg
61 gctgggaagc atcctgtttt gcatgtttga tcaggagctg ctgccaaagt gtgactttca
121 ctttcccttt tgggttccag ggtatatctc agagcctgga gaacgtgtct gggtattatg
181 cagatgcacg gctggaggtg ggatccacac agctcagaac agctggatct tgctcacact

```

```

241 ctttcaagag aagcttcctt ggacaaaagg accctgcctt ggtgtgagag tgagggcaga
301 gggagctgga gcaagtagaa tttctctaaa taccagctgg ctggggccca ggagattaaa
361 aaacaccggg ctaggttggg cttggcattt gctgacacgc aaagggattg cagagatcca
421 gcccctccaa cctccctctg tccacagggt gctcacattc agtcccacaa tttgctttct
481 cctcctcaag ggttaagaaa aaaaacgaac ccttccagtc aggtcagtga ctggagagct
541 ccatggaaag tctctcagtg acctggctgc tggcaccatg gactcagaaa agaaaacgctt
601 tactgaagag gccaccaa atctccggga gagagtcagc ccagtgcac tgc aaatcctt
661 gctgactaac aatgaagcct ggaagagatt cgtgactgcy gctgaattgc ccagggatga
721 ggcagatgct ctctacgaag ctctgaagaa gcttagaaca tatgcagcta ttgaggacga
781 atatgtgcag cagaaagatg agcagtttag ggaatggttt ttgaaagagt ttcccaagt
841 caagagggaag atccaggagt ccatagaaaa gcttcgtgcc cttgcaaatg gtattgaaga
901 ggtccacaga ggctgcacca tctccaatgt ggtgtccagc tccactggcg ctgcctctgg
961 catcatgtcc cttgctggtc ttgttttggc accatttaca gcagggacga gtctggccct
1021 tactgcagct ggggttagggc tgggagcagc gtctgctgtg actgggatca ccaccagcat
1081 cgtggagcac tcatacacat catcagcaga agctgaagcc agcaggctga ctgcaaccag
1141 cattgaccga ttgaaggat ttaaggagt tatgctgac atcacacca acttactttc
1201 cttcttaaat aattattacg aagccacaca aaccattggg agtgaaatcc gtgccatcag
1261 gcaagccaga gccaggcccc gactccctgt gaccacctgg cgaatctcag ctggaagtgg
1321 tggtaagca gagagaacga ttgcaggcac caccggggca gtgagcagag gagccccgat
1381 cctgagtgcg accattctag gcatcttctt tgcactggat gtgggtcaacc ttgtatacga
1441 gtcaaagcac ttgcatgagg gggcaaagtc tgcactgtct gaggagctga ggcggcaggc
1501 tcaggagctg gaggagaatc taatggagct cactcagatc tatcagcgtc tgaatccatg
1561 ccataccccc tgaccccaga ccagtgcagc cagcagggga ggtgagccat acacaggcca
1621 cgacaaaatg caggcatttt attaggggga taaagagggc aaggtaaagt ttatggagct
1681 gactgttagt gactttggca tttctgtagc tgagcacagc aggggagggg ttaatgcaga
1741 tggcaagtgc accaaggaga aggcaggaa gctggagcct ggaataaggg aggagagggg
1801 actggagagt gtggggaata ggaagaagaa atttccttta gactaacgaa tatattgggg
1861 ggaggaatag aggggagggtg tgcaggaaac agcaatgaga aggccaggaa aagaaagagc
1921 tgaaaatgca gaaagccgaa gagttagaac ttttgatatac agcagaagaa acagcggctc
1981 cactaccgac ctgcccccg ttcgatgtcc ttccaagaat gaagtctttc cctgggtgatg
2041 gtccccctgc ctgtctttcc agcatccact ctgtcttgtc ctccctggaag tgtatctcag
2101 tcagccagtg gcttcttgat gatggcggtg gagggtgggtg ttgtagtgtg atggatcccc
2161 tttagggttat ttagggttat atgtccccct cttgaaccct gaaggccagg taatgagcca
2221 tggccattgt cccagctga ggaccagggt tctctaaaaa cccaaacatc ctggagagta
2281 tgcgagaacc taccagaaa aacagtctca ttactcatat acagcaggca aagagacaga
2341 aaattaactg aaaagcagtt tagagactgg gggaggccgg atctctagag ccatcctgct
2401 gagtgccttg tgtgtaagtc ctaataaact cacctactca ccaa

```

# APOL3 cDNA SEQUENCE 3 (SEQ ID NO: 4)

NM\_030644 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/b, mRNA

```

1 agcaggaggg tgggaccaag ggtgctgctg gaccaaggat gggactgggc caaggggtggg
61 gctgggaagc atcctgtttt gcatgtttga tcaggagctg ctgccaagtt gtgactttca
121 ctttcccttt tgggttccag ggtatatctc agagcctgga gaacgtgtct ggttattatg
181 cagatgcacg gctggagggtg ggatccacac agctcagaac agctggatct tgctcacact
241 ctttcaagag aagcttcctt ggacaaaagg accctgcctt ggtgtgagag tgagggcaga
301 gggagctgga gcaagtagaa tttctctaaa taccagctgg ctggggccca ggagattaaa
361 aaacaccggg ctaggtttaa gaaaaaaac gaacccttcc agtcagggtca gtgactggag
421 agctccatgg aaagtctctc agtgacctgg ctgctggcac catggactca gaaaagaaac
481 gctttactga agaggccacc aaatacttcc gggagagagt cagcccagtg catctgcaaa
541 tctgtctgac taacaatgaa gcctggaaga gattcgtgac tgcggtgaa ttgcccaggg
601 atgaggcaga tgctctctac gaagctctga agaagcttag aacatatgca gctattgagg
661 acgaatatgt gcagcagaaa gatgagcagt ttagggaaatg gtttttgaaa gagtttcccc
721 aagtcaagag gaagatccag gagtccatag aaaagcttcg tgcccttgca aatgggtattg
781 aagagggtcca cagaggctgc accatctcca atgtgggtgc cagctccact ggcgtgcctt
841 ctggcatcat gtcccttgct ggtctgtttt tggcaccatt tacagcaggg acgagtctgg
901 cccttactgc agctggggta gggctgggag cagcgtctgc tgtgactggg atcaccacca
961 gcatcgtgga gactcatac acatcatcag cagaagctga agccagcagg ctgactgcaa
1021 ccagcattga ccgattgaag gtatttaagg aagttatgcg tgacatcaca cccaacttac
1081 ttcccttctc taataattat tacgaagcca cacaaccat tgggagtga atccgtgcca
1141 tcaggcaagc cagagccagg gcccgactcc ctgtgaccac ctggcgaatc tcagctggaa

```

```

1201 gtggtggtca agcagagaga acgattgcag gcaccacccg ggcagtgagc agaggagccc
1261 ggatcctgag tgcgaccact tcaggcatct tccttgactt ggatgtgggtc aaccttgtat
1321 acgagtcaaa gcacttgcac gagggggcaa agtctgcatc tgctgaggag ctgaggcggc
1381 aggctcagga gctggaggag aatctaattg agctcactca gatctatcag cgtctgaatc
1441 catgccatac ccactgaccc cagaccagtg cagccagcag gggagggtgag ccatacacag
1501 gccacgacaa aatgcaggca ttttattagg gggataaaga gggcaaggta aagtttatgg
1561 agctgagtgat tagtgacttt ggcatttctg tagctgagca cagcagggga ggggttaatg
1621 cagatggcaa gtgcaccaag gagaaggcag gaatgctgga gcctggaata agggaggaga
1681 ggggactgga gagtgtgggg aataggaaga agaaatttcc ttagactaa cgaatatatt
1741 ggggggagga atagagggga ggtgtgcagg aaccagcaat gagaaggcca gaaaagaaa
1801 gagctgaaaa tgcagaaagc cgaagagtta gaacttttgg atacagcaga agaaacagcg
1861 gctccactac cgacctgcc cgggttcgat gtcttccaa gaatgaagtc tttccctggt
1921 gatggtcccc tgccctgtct tccagcatc cactctgtct tgctctcctg gaagtgtatc
1981 tcagtcagcc agtggcttct tgatgatggc ggtggagggtg gtggtttagt tgtgatggat
2041 cccctttagg ttatttaggg gtatatgtcc cctgcttgaa ccctgaaggc caggtaatga
2101 gccatggcca ttgtcccag ctgaggacca ggtgtctcta aaaacccaaa catcctggag
2161 agtatgcgag aacctacaa gaaaaacagt ctcttactc atatacagca ggcaaagaga
2221 cagaaaatta actgaaaagc agtttagaga ctgggggagg ccggatctct agagccatcc
2281 tgctgagtg cctgtgtgta agtcctaata aactcaccta ctcaccaa

```

# APOL3 cDNA SEQUENCE 4 (SEQ ID NO: 5)

NM\_030644 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant alpha/c, mRNA

```

1 agcaggaggg tgggaccaag ggtgctgctg gaccaaggat gggactgggc caagggtggg
61 gctgggaagc atcctgtttt gcatgtttga tcaggagctg ctgccaagtt gtgactttca
121 ctttcccttt tgggttccag ggtatatctc agagcctgga gaacgtgtct ggttattatg
181 cagatgcacg gctggagggt ggatccacac agctcagaac agctggatct tgctcacact
241 ctttcaagag aagcttccct gggttaagaa aaaaaacgaa cccttccagt caggtcagtg
301 actggagagc tccatgaaa gtctctcagt gacctggctg ctggcaccat ggactcagaa
361 aagaaacgct tcttgaaaga ggccacaaa tacttccggg agagagtcag cccagtgcac
421 ctgcaaatcc tgctgactaa caatgaagcc tgggaagagat tcgtgactgc ggtgaattg
481 cccagggatg aggcagatgc tctctacgaa gctctgaaga agcttagaac atatgcagct
541 attgaggacg aatatgtgca gcagaaagat gagcagttta gggaatgggt tttgaaagag
601 tttccccaag tcaagaggaa gatccaggag tccatagaaa agcttcgtgc ccttgcaaat
661 ggtattgaag aggtccacag aggtgcacc atctccaatg tgggtgtccag ctccactggc
721 gctgctctg gcacatgtgc ccttgcctgt cttgttttgg caccatttac agcagggacg
781 agtctgcccc ttactgcagc tggggtaggg ctgggagcag cgtctgctgt gactgggatc
841 accaccagca tcgtggagca ctcatcacaca tcatcagcag aagctgaagc cagcaggctg
901 actgcaacca gcattgaccg attgaaggta tttaaggaa ttagcgtga catcacaccc
961 aacttacttt cccttcttaa taattattac gaagccacac aaaccattgg gagtgaatc
1021 cgtgccatca ggcaagccag agccaggccc cgactccctg tgaccacctg gcgaattca
1081 gctggaagtg gtggtcaagc agagagaacg attgcaggca ccacccgggc agtgagcaga
1141 ggagcccagg tcctgagtg caccacttca ggcatcttcc ttgcaactga tgtggtcaac
1201 cttgtatagc agtcaaagca cttgcataag ggggcaaagt ctgcatctgc tgaggagctg
1261 aggcggcagg ctcaggagct ggaggagaat ctaatggagc tcactcagat ctatcagcgt
1321 ctgaatccat gccataccca ctgacccag accagtgcag ccagcagggg aggtgagcca
1381 tacacaggcc acgacaaaat gcaggcatct tattaggggg ataaagaggg caaggtaaag
1441 tttatggagc tgagtgttag tgactttggc atttctgtag ctgagcacag caggggaggg
1501 gttaatgcag atggcaagt caccaaggag aaggcaggaa tgctggagcc tggaaataag
1561 gaggagagg gactggagag tgtggggaat aggaagaaga aatttccttt agactaacga
1621 atatatggg gggaggaata gaggggaggt gtgcaggaa cagcaatgag aagggcagg
1681 aaagaaagag ctgaaaatgc agaaagccga agagttagaa cttttggata cagcagaaga
1741 aacagcggct ccactaccga cctgcccccg gttcgatgtc cttccaagaa tgaagtcttt
1801 ccctggtgat ggtcccctgc cctgtcttcc cagcatccac tctgtcttgt cctcctggaa
1861 gtgtatctca gtcaccagc ggtctcttga tgatggcggt ggagggtggt gttgtagtgt
1921 gatggatccc ctttaggtta ttagggggt tatgtcccct gcttgaacct tgaaggccag
1981 gtaatgagcc atggccattg tccccagctg aggaccaggt gtctctaaaa acccaaacat
2041 cctggagagt atgcgagaac ctaccaagaa aaacagctct attactcata tacagcaggc
2101 aaagagacag aaaattaact gaaaagcagt ttagagactg ggggaggccg gatctctaga
2161 gccatccctg tgagtgcctt gtgtgtaagt cctaataaac tcacctactc accaa

```

APOL3 cDNA SEQUENCE 5 (SEQ ID NO: 6)

NM\_145641 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant beta/a, mRNA

```

1  actctgggga aaggagggtg caaccacatg taaattttat tataatgatg gtataatgaa
61  cttgggggtg cctgagggca tgtttttgtg ttactgggca tgtgcccctt taggagactt
121 ccacctgtgc cttactttct ctttcttttg gatgtgctgg ccacagactt taccaaaaac
181 tccatccatt aggatggcat taggacggtt ctggggctaa acttaggttg gccaggggct
241 gtttcaactgt cagcctttct actctctttt cttaccactt cctagctgct aatgtctatt
301 taactaccta atatttcccc ctttagagaa aaaaagccaa atttttgggt agatcgggtg
361 caattaatct ggctacttcc tgctgacaag aggcagtggg aataattggg ttctcttttt
421 tgctctcttg tagctggtag gttgggcaga gaaaagtggg ggccatccaa gggggccacg
481 tagatatcag acatggttga gacctcgcgg taaccttgtg tagaatcatt tggagtttta
541 tggattctag gtgggaagaa acaaaaacac cttgtaaatc aaatgagcat cgtttgaaag
601 ctataagttg tataaagctg ttttaggacc aagaaagggg gctaaccagg aaaaccagga
661 ccagttgtta aatttccacc agtcaaagcc tcctgaaact ctgttttcca ttaacttgtt
721 ggccctgtct gtaatttttt taagttggtt tgcactttac ctgattggtt gatgaaaaca
781 gcaatgttta tcaagtgttg cacaagctcc cccttgattg gctgtgagca aattaaagc
841 tcatcaatth cataagacta tgcttgctaa tgaagcaatt tgttctgaaa ggggtattgac
901 ctggttagtt agattaataa tttgttgagt aatttttaag aagagtttct gggcagtaaa
961 aatggagtta agaggctcct ccagttcccg tgccaatacc agccagaacg ccaatttag
1021 tcagtgtctg taaaactcct ctttcagttt taccagattg agcgtgtata gggaggggaa
1081 tgctatcgat aagagtgagt ttggggatga tgtaaaactg ggccaaatcc ccgtttaatt
1141 agcagacaag cagagatatg ccttgtttct atacaaaaat gtgatttgtc atgttaagac
1201 aaatatcaac agtgatacta aagtagggtt tttccatgct gtgtaagtct gctttaatac
1261 cctcagaagt ggaagtcaag ctgagtctat gtaatggggg aacacaggca gtacttgaca
1321 gaatgaaaga ggaatcaaaa gcccaattag aggaaggagt gatgggatcc caaccaatat
1381 tgtgaaatta tggggagctg cagttttttg caatgatttt gccgaagtt gtgagactga
1441 aaccagaagt tgttatgttt aaaatgatat tctgggtgtg gtctggggaa aagggtagat
1501 ccagaatagc tggcttcttt ccacatagtg gttctgttgg ggggcttggg aaatgaataa
1561 aacacaagaa agaattagaa tatcagtgta aggtagcagg tgctcctggc agaagaacc
1621 acataaggaa gtgtccagaa gccacacagg gtatatctca gagcctggag aacgtgtctg
1681 gttattatgc agatgcacgg ctggaggttg gatccacaca gctcagaaca gctggatctt
1741 gctcacactc tttaagaga agcttccttg aaaagaaacg ctttactgaa gaggccacca
1801 aatacttccg ggagagagtc agccagtgct atctgcaaat cctgctgact aacaatgaag
1861 cctgggaagag attcgtgact gcggctgaaat tgcccaggga tgaggcagat gctctctacg
1921 aagctctgaa gaagcttaga acatatgcag ctattgagga cgaatatgtg cagcagaaag
1981 atgagcagtt tagggaatgg tttttgaaag agtttcccca agtcaagagg aagatccagg
2041 agtccataga aaagcttcgt gcccttgcaa atggtattga agaggtccac agaggctgca
2101 ccattctcaa tgtggtgtcc agctccactg gcgctgcctc tggcatcatg tcccttgctg
2161 gtcttgtttt ggcaccattt acagcaggga cgagtctggc ccttactgca gctgggttag
2221 ggctgggagc agcgtctgct gtgactggga tcaccaccag catcgtggag cactcataca
2281 catcatcagc agaagctgaa gccagcaggc tgactgcaac cagcattgac cgattgaagg
2341 tatttaagga agttatgcgt gacatcacac ccaacttact ttcccttctt aataattatt
2401 acgaagccac acaaaccatt gggagtgaaa tccgtgccat caggcaagcc agagccaggg
2461 cccgactccc tgtgaccacc tggcgaatct cagctggaag tgggtgtcaa gcagagagaa
2521 cgattgcagg caccaccccg gcagtgcgca gaggagcccg gatcctgagt gcgaccactt
2581 caggcatctt ccttgcaactg gatgtggtca accttgatata cgagtcaaag cacttgcatg
2641 aggggggcaa gtctgcatct gctgaggagc tgaggcgcca ggctcaggag ctggaggaga
2701 atctaattga gctcactcag atctatcagc gtctgaatcc atgccatacc cactgacccc
2761 agaccagtgc agccagcagg ggaggtgagc catcacacag ccacgacaaa atgcaggcat
2821 tttattaggg ggataaagag ggcaaggtaa agtttatgga gctgagtgtt agtgactttg
2881 gcatttctgt agctgagcac agcaggggag ggggttaatg agatggcaag tgcaccaagg
2941 agaaggcagg aatgctggag cctggaataa gggaggagag gggactggag agtggtggga
3001 ataggaagaa gaaatttcct ttagactaac gaatatattg gggggaggaa tagaggggag
3061 gtgtgcagga accagcaatg agaaggccag gaaaagaaag agctgaaaat gcagaaaacc
3121 gaagagttag aacttttgga tacagcagaa gaaacagcgg ctccactacc gacctgcccc
3181 cggttcgatg tccttccaag aatgaagtct ttccctgggt atgggtcccct gccctgtctt
3241 tccagcatcc actctgtctt gtctctctgg aagtgtatct cagtcagcca gtggcttctt
3301 gatgatggcg gtggagggtg tggttgtagt gtgatggatc ccctttaggt tatttagggg
3361 tatatgtccc ctgcttgaac cctgaaggcc aggtaatgag ccatggccat tgtcccagc
3421 tgaggaccag gtgtctctaa aaacccaaac atcctggaga gtatgcgaga acctaccaag
3481 aaaaacagtc tcattactca tatacagcag gcaaagagac agaaaattaa ctgaaaagca

```

3541 gtttagagac tgggggaggc cggatctcta gagccatcct gctgagtgcc ctgtgtgtaa  
3601 gtcctaataa actcacctac tcaccaa

# APOL3 cDNA SEQUENCE 6 (SEQ ID NO: 7)

NM\_145642 Homo sapiens apolipoprotein L, 3 (APOL3), transcript variant beta/a, mRNA

1 actctgggga aaggagggtg caaccacatg taaattttat tataatgatg gtataatgaa  
61 cttgggggtga cctgagggca tgtttttgtg ttactgggca tgtgcccctt taggagactt  
121 ccacctgtgc cttactttct ctttcttttg gatgtgctgg ccacagactt taccaaaaac  
181 tccatccatt aggatggcat taggacggtt ctggggctaa acttaggttg gccaggggct  
241 gtttcactgt cagcctttct actctctttt cttaccactt cctagctgct aatgtctatt  
301 taactaccta atatttcccc ctttagagaa aaaaagccaa atttttgggt agatcgggtg  
361 caattaatct ggctacttcc tgctgacaag aggcagtggg aataattggg ttctcttttt  
421 tgctctcttg tagctggtag gttgggcaga gaaaagtggg ggccatccaa gggggcccag  
481 tagatatcag acatggttga gacctcgagg taaccttgtg tagaatcatt tggagtttta  
541 tggattctag gtgggaagaa acaaaaacaac cttgtaaatc aaatgagcat cgtttgaaag  
601 ctataagttg tataaagctg ttttaggacc aagaaagggg gctaaccagg aaaaccagga  
661 ccagttgtta aatttccacc agtcaaagcc tcctgaaact ctgttttcca ttaacttggt  
721 ggccctgtct gtaatttttt taagtgtggt tgcactttac ctgattgggt gatgaaaaca  
781 gcaatgttta tcaagtgttg cacaagctcc cccttgattg gctgtgagca aattaaaagc  
841 tcatcaatct cataagacta tgcttgctaa tgaagcaatt tgttctgaaa gggattgac  
901 ctggttagtt agattaataa tttgttgagt aatttttaag aagagtctct gggcagtaaa  
961 aatggagtta aggaggtcct ccagttcccg tgccaatacc agccagaacg ccaattatag  
1021 tcagtgtctg taaaactcct ctttcagttt taccagattg agcgtgtata gggaggggaa  
1081 tgctatcgat aagagtggat ttggggatga tgtaaaactag ggccaaatcc ccgtttaatt  
1141 agcagacaag cagagatatg ccttgtttct atacaaaaat gtgatttgtc atgttaagac  
1201 aaatatcaac agtgatacta aagtaggggt tttccatgct gtgtaagtct gctttaatac  
1261 cctcagaagt ggaagtcaag gctagttcat gtaatggggg aacacaggca gtacttgaca  
1321 gaatgaaaga ggaatcaaaa gcccaattag aggaaggagt gatgggatcc caaccaatat  
1381 tgtgaaatta tggggagctg cagtttttat caatgatttt gcccgaggtt gtgagactga  
1441 taaccagaagt tgttatgttt aaaatgatat tctggtgtgg gtctggggaa aagggtagat  
1501 ccagaatagc tggcttcttt ccacatagtg gttctgttgg ggggcttggg aaatgaataa  
1561 aacacaaaga agaattagaa tatcagggtg tatctcagag cctggagaac gtgtctggtt  
1621 attatgcaga tgcacggctg gaggtgggat ccacacagct cagaacagct ggatcttgct  
1681 cacactcttt caagagaagc ttccttgaaa agaaacgctt tactgaagag gccaccaaat  
1741 acttccggga gaggtcagc ccagtgcac tgcaaatcct gctgactaac aatgaagcct  
1801 ggaagagatt cgtgactgag gctgaattgc ccagggatga ggcagatgct ctctacgaag  
1861 ctctgaagaa gcttagaaca tatgcagcta ttgaggacga atatgtgcag cagaaagatg  
1921 agcagtttag ggaatggttt ttgaaagagt ttccccaagt caagagggaag atccaggagt  
1981 ccatagaaaa gcttcgtgcc cttgcaaatg gtattgaaga ggtccacaga ggctgcacca  
2041 tctccaatgt ggttccagc tccactgcg ctcctctgtg catcatgtcc cttgtctggtc  
2101 ttgttttggc accatttaca gcagggacga gtctggccct tactgcagct ggggtagggc  
2161 tgggagcagc gtctgctgtg actgggatca ccaccagcat cgtggagcac tcatacacat  
2221 catcagcaga agctgaagcc agcaggctga ctgcaaccag cattgaccga ttgaaggtat  
2281 ttaaggaagt tatgctgac atcacaccga acttactttc cttctttaat aattattacg  
2341 aagccacaca aaccattggg agtgaaatcc gtgccatcag gcaagccaga gccagggcc  
2401 gactccctgt gaccacctgg cgaatctcag ctggaagtgg tggtaagca gagagaacga  
2461 ttgaggcac caccgggcca gtgagcagag gagcccggat cctgagtgcg accacttcag  
2521 gcatcttctt tgacttgat gtggtcaacc ttgtatacga gtcaaagcac ttgcatgagg  
2581 gggcaagtc tgactctgct gaggagctga ggcggcaggt tcaggagctg gaggagaatc  
2641 taatggagct cactcagatc tatcagctgc tgaatccatg ccataccac tgacccaga  
2701 ccagtgcagc cagcagggga ggtgagccat acacaggcca cgacaaaatg caggcatttt  
2761 attaggggga taaagagggc aaggtaaagt ttatggagct gagtgttagt gactttggca  
2821 tttctgtagc tgagcacagc aggggagggg ttaatgcaga tggcaagtgc accaaggaga  
2881 aggcaggaat gctggagcct ggaataaggg aggagagggg actggagagt gtggggaata  
2941 ggaagaagaa atttcttta gactaacgaa tatattgggg ggaggaatag aggggaggtg  
3001 tgcaggaacc agcaatgaga aggccaggaa aagaaagagc tgaaaatgca gaaagccgaa  
3061 gaggtagaac ttttgatac agcagaagaa acagcggctc cactaccgac ctgccccgg  
3121 ttcgatgtcc ttccaagaat gaagtctttc cctggtgatg gtcccctgcc ctgtctttcc  
3181 agcatccact ctgtcttgct ctcctgggag tgtatctcag tcagccagtg gcttcttgat  
3241 gatggcggtg gagggtgggtg ttgtagtgtg atggatcccc tttaggttat ttaggggtat

3301 atgtccctg cttgaacct gaaggccagg taatgagcca tggccattgt cccagctga  
3361 ggaccaggtg tctctaaaaa cccaaacatc ctggagagta tgcgagaacc taccaagaaa  
3421 aacagtctca ttactcatat acagcaggca aagagacaga aaattaactg aaaagcagtt  
3481 tagagactgg gggaggccgg atctctagag ccatactgct gagtgcctg tgtgtaagtc  
3541 ctaataaact cacctactca ccaa

[0243] The following are human polypeptide sequences for isoform 1, isoform 2 and isoform 3 of APOL3.

APOL3 AMINO ACID SEQUENCE 1 (SEQ ID NO: 8)

NP\_663615 Homo sapiens apolipoprotein L, 3 (APOL3), isoform 1, protein

MGLGQGWEASCFACLIRSCCQVVTFTFPFGFQGISQSLNVSGYYADARLEVSTQ  
LRTAGSCSHSFKRSFLEKKRFTEEATKYFRERVSPVHLQILLTNNEAWKRFVTAAELPR  
DEADALYEALKKLRTYAAIEDEYVQQKDEQFREWFLKEFPQVKRKIQESIEKLRALAN  
GIEEVHRGCTISNVSSSTGAASGIMSLAGLVLPFTAGTSLALTAAGVGLGAASAVTGI  
TTSIVEHSYTSSAEAEASRLTATSIDRLKVFKEVMRDITPNLLSLLNNYYEATQTIGSEIR  
AIRQARARARLPVTTWRISAGSGGQAERTIAGTTRAVSRGARILSATTSGIFLALDVVNL  
VYESKHLHEGAKSASAEELRRQAQEEENLMELTQIYQRLNPCHTH

APOL3 AMINO ACID SEQUENCE 2 (SEQ ID NO: 9)

NP\_055164 Homo sapiens apolipoprotein L, 3 (APOL3), isoform 2, protein

MDSEKKRFTEEATKYFRERVSPVHLQILLTNNEAWKRFVTAAELPRDEADALYEALKK  
LRTYAAIEDEYVQQKDEQFREWFLKEFPQVKRKIQESIEKLRALANGIEEVHRGCTISNV  
VSSSTGAASGIMSLAGLVLPFTAGTSLALTAAGVGLGAASAVTGITTSIVEHSYTSSAE  
AEASRLTATSIDRLKVFKEVMRDITPNLLSLLNNYYEATQTIGSEIRAIRQARARARLPVT  
TWRISAGSGGQAERTIAGTTRAVSRGARILSATTSGIFLALDVVNLVYESKHLHEGAKS  
ASAEELRRQAQEEENLMELTQIYQRLNPCHTH

APOL3 AMINO ACID SEQUENCE 3 (SEQ ID NO: 10)

NP\_663616 Homo sapiens apolipoprotein L, 3 (APOL3), isoform 3, protein

MSLAGLVLPFTAGTSLALTAAGVGLGAASAVTGITTSIVEHSYTSSAEAEASRLTATSI  
DRLKVFKEVMRDITPNLLSLLNNYYEATQTIGSEIRAIRQARARARLPVTTWRISAGSGG  
QAERTIAGTTRAVSRGARILSATTSGIFLALDVVNLVYESKHLHEGAKSASAEELRRQA  
QEEENLMELTQIYQRLNPCHTH

[0244] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are



within the scope and spirit of the invention, as set forth in the aspects which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0245] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

What is claimed is:

1. A method for identifying a subject at risk of osteoarthritis, which comprises detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby the presence of the polymorphic variation is indicative of the subject being at risk of osteoarthritis.

2. The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.

3. The method of claim 1, wherein the one or more polymorphic variations are detected within a region spanning chromosome positions 34828750 and 34833750 in human genomic DNA.

4. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions selected from the group consisting of 201, 425, 1095, 2201, 7879, 8395, 8461, 9503, 10304, 10695, 16300, 16444, 17591, 17988, 19116, 19358, 20300, 20669, 20891, 21451, 21978, 22785, 24248, 24770, 24844, 25066, 25096, 25309, 25344, 25529, 25537, 25554, 27963, 28134, 28356, 29648, 29986, 30217, 30267, 30315, 30585, 30724, 30897, 30931, 31080, 31246, 31373, 31463, 31467, 32188, 32288, 32520, 32594, 32657, 32677, 32764, 32784, 32830, 32872, 33121, 33348, 33952, 34184, 34361, 35026, 35192, 35600, 36033, 36289, 38869, 39629, 40530, 41621, 42379, 42802, 42865, 43644, 45051, 45828, 45829, 46257, 47286, 47427, 47963, 48013, 48229, 48282, 48376, 48404, 49900, 52699, 52897, 53414, 53487, 54112, 55492, 59766, 60307, 60701, 60952, 61401, 62379, 62870, 62879, 63499, 64284, 64408, 64760, 65230, 66127, , 6634, 66686, 66694, 67113, 67257, 67403, 67609, 68418, 68610, 69629, 70024, 70848, 71428, 71553, 71633, 71768, 71769, 73039, 73325, 73412, 73547, 73769, 73806, 74467, 74472, 74473, 74482, 74494, 74592, 74670, 74672, 74714, 74723, 74749, 74861, 74892, 74893, 75176, 75705, 75989, 76027, 77949, 77974, 78167, 78310, 78415, 78575, 78590, 78709, 78875, 79864, 81316, 81320, 81409, 81737, 81843, 82102, 82833, 83461, 83624, 83660, 83701, 83708, 83782, 85707, 85717,

86486, 86833, 87115, 87234, 87479, 87561, 87604, 87674, 87958, 87992, 88019, 88074, 88079, 88115, 88118, 88120, 88135, 88142, 88143, 88149, 88340, 88344, 88512, 88521, 88650, 88827, 89230, 89236, 90754, 90984, 91110, 92026, 92954, 93375, 93794, 94937, 95068, 96188, 97092 and 98812.

5. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in SEQ ID NO: 1 selected from the group consisting of 20300, 87958, 89236, 30267, 32657, 36289, 38869, 45051, 46257, 54112, 60307, 63499, 20891, 52699 and 71768.

6. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with one or more positions in claim 3, 4 or 5.

7. The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:

hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;

extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and

detecting the presence or absence of a polymorphic variation in the extension products.

8. The method of claim 1, wherein the subject is a human.

9. The method of claim 8, wherein the subject is a human female.

10. The method of claim 8, wherein the subject is a human male.

11. A method for identifying a polymorphic variation associated with osteoarthritis proximal to an incident polymorphic variation associated with osteoarthritis, which comprises:

identifying a polymorphic variation proximal to the incident polymorphic variation associated with osteoarthritis, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-7;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation;

determining the presence or absence of an association of the proximal polymorphic variant with osteoarthritis.

12. The method of claim 11, wherein the incident polymorphic variation is at one or more positions in claim 3, 4 or 5.

13. The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the incident polymorphic variation.

14. The method of claim 11, which further comprises determining whether the proximal polymorphic variation is in linkage disequilibrium with the incident polymorphic variation.

15. The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with osteoarthritis and determining if the second proximal polymorphic variation is associated with osteoarthritis.

16. The method of claim 15, wherein the second proximal polymorphic variant is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the proximal polymorphic variation associated with osteoarthritis.

17. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-7;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);

wherein the nucleotide sequence comprises a polymorphic variation associated with osteoarthritis selected from the group consisting of an adenine at position 20300, a thymine at position 46257, an adenine at position 89236, a guanine at position 30267, an adenine at position 32657, a cytosine at position 36289, a guanine at position 38869, a thymine at position 45051, a guanine at position 54112, an adenine at position 60307, a thymine at position 63499, a guanine at position 20891, a guanine at position 52699, and a cytosine at position 71768.

18. An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of (a), (b), (c), or (d) in claim 17, wherein the 3' end of the oligonucleotide is adjacent to a polymorphic variation associated with osteoarthritis.

19. A microarray comprising an isolated nucleic acid of claim 17 linked to a solid support.

20. An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 17.

21. A method for identifying a candidate therapeutic for treating osteoarthritis, which comprises:

(a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of:

- (i) a nucleotide sequence in SEQ ID NO: 1-7;
- (ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (iv) a fragment of a nucleotide sequence of (a), (b), or (c); or

introducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv); and

(b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein,

whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating osteoarthritis.

22. The method of claim 21, wherein the system is an animal.

23. The method of claim 21, wherein the system is a cell.

24. The method of claim 21, wherein the nucleotide sequence comprises one or more polymorphic variations associated with osteoarthritis.

25. The method of claim 24, wherein the one or more polymorphic variations associated with osteoarthritis are at one or more positions in claim 3, 4 or 5.

26. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
  - (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
  - (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
  - (d) a fragment of a nucleotide sequence of (a), (b), or (c); and
  - (e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);
- whereby contacting the one or more cells of the subject with the nucleic acid treats the osteoarthritis in the subject.

27. The method of claim 25, wherein the nucleic acid is RNA or PNA.

28. The method of claim 27, wherein the nucleic acid is duplex RNA.

29. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a protein, wherein the protein is encoded by a nucleotide sequence which comprises a polynucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
  - (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
  - (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
  - (d) a fragment of a nucleotide sequence of (a), (b), or (c);
- whereby contacting the one or more cells of the subject with the protein treats the osteoarthritis in the subject.

30. A method for treating osteoarthritis in a subject, which comprises:  
detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variation are detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis treatment to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

31. The method of claim 30, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

32. The method of claim 30, wherein the treatment is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondroitin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

33. A method for detecting or preventing osteoarthritis in a subject, which comprises:  
detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis prevention or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

34. The method of claim 33, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

35. The method of claim 33, wherein the osteoarthritis prevention is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

36. A method of targeting information for preventing or treating osteoarthritis to a subject in need thereof, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-7;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-7;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

directing information for preventing or treating osteoarthritis to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

37. The method of claim 36, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

38. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-7.




39. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO: 1-7.

40. The composition of claim 38, wherein the RNA molecule is a short inhibitory RNA molecule.

Abstract of the Disclosure

Provided herein are methods for identifying a risk of osteoarthritis in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating osteoarthritis, and therapeutic and preventative methods applicable to osteoarthritis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

FIGURE 1



## **Application Data Sheet**

### **Application Information**

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	Not Yet Assigned
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF
Attorney Docket Number::	524593009200
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets?::	1
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

### **Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Steven
Family Name::	MAH
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	12820 Via Nieve #74
City of mailing address::	San Diego
State or Province of mailing address::	CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Germany  
Status:: Full Capacity  
Given Name:: Andreas  
Family Name:: BRAUN  
City of Residence:: San Diego  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 3935 Lago Di Grata Circle  
City of mailing address:: San Diego  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Germany  
Status:: Full Capacity  
Given Name:: Stefan  
Middle Name:: M.  
Family Name:: KAMMERER  
City of Residence:: San Diego  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 3825 Elijah Court, Unit 334  
City of mailing address:: San Diego  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity

Initial 04/01/04

Given Name:: Matthew  
Middle Name:: Roberts  
Family Name:: NELSON  
City of Residence:: San Marcos  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 1250 Calle Prospero  
City of mailing address:: San Marcos  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92069

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Sweden  
Status:: Full Capacity  
Given Name:: Rikard  
Middle Name:: Henry  
Family Name:: RENELAND  
City of Residence:: San Diego  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 7555 Charmant Drive, #1114  
City of mailing address:: San Diego  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92122

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: United Kingdom  
Status:: Full Capacity  
Given Name:: Maria  
Middle Name:: L.  
Family Name:: LANGDOWN  
City of Residence:: San Diego

State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 3701 Yosemite Street  
City of mailing address:: San Diego  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92109

**Correspondence Information**

Correspondence Customer Number:: 25225

**Representative Information**

Representative Customer Number:: 25225